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Abstract 
Meckel-Gruber syndrome (MKS) is a universally lethal heritable human disease 
characterised by CNS malformations, cystic kidney, polydactyly, and liver 
fibrosis. MKS is classed as one of the ciliopathies due to its association with 
dysfunctional primary cilia, signalling organelles found on most cells in the 
human body. Some of the symptoms of MKS can be explained as a 
consequence of disrupted developmental signalling through the primary cilium, 
other defects are harder to explain, and evidence now exists for non-ciliary 
influences on ciliopathies. The nature of these influences, and the implications 
they may have for our understanding of ciliary function and the aetiology of 
MKS, remain unclear. In this thesis, defects in cell-extracellular matrix (ECM) 
interaction in MKS are investigated to determine whether MKS proteins have a 
role in this process, and if so, whether this role may be involved in MKS 
pathology. A combination of transcriptomic, proteomic, and cell imaging 
approaches are used to demonstrate that MKS patient cells produce a defective 
extracellular matrix, and that the MKS protein TMEM67 is present at the cell 
surface at sites of cell-ECM interaction. It is shown that the full-length TMEM67  
protein is required for correct ECM morphology, and it is further shown that the 
abnormal extracellular matrix morphology in MKS cells underlies other defects, 
including failure to build cilia and alterations to the actin cytoskeleton. This 
represents the first set of causal relationships identified between the cellular 
defects in this complex disease. It is further shown that treatment with 
developmental signalling pathway antagonists can rescue these defects, 
potentially revealing a new avenue of therapeutic intervention for MKS. Finally, 
possible upstream defects are investigated that might underlie the ECM defect, 
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including alterations to cell spreading behaviour and cell deformation 
resistance. 
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Chapter 1: Introduction 
 
1.1 Cilia and ciliopathies 
1.1.1 Introduction to cilia 
Cilia are organelles found in almost all cells of the vertebrates. Their basic 
structure (Figure 1.1) is a protrusion of the plasma membrane into the 
extracellular space, reinforced by an internal structure of specialised doublet 
microtubules – the axoneme (Figure 1.1, green). At the base of the cilium, a 
centriole (termed the “basal body” in this context) (Figure 1.1, orange) is 
responsible for organising these microtubules. The cilium is a highly specialised 
compartment with a large, distinct proteome, maintained by selective barriers to 
both cytoplasmic and membrane diffusion (Satir & Christensen, 2008). 
There are two major types of cilium: motile cilia and the non-motile primary cilia. 
In animals, motile cilia are found in specific tissues such as the tracheal 
epithelium, where they are frequently present in large numbers on a single cell 
and are responsible for driving fluid flow by directional beating. The eukaryotic 
flagellum, a structure responsible for the motility of many unicellular eukaryotes 
and the spermatocytes of diverse multicellular species, is an elongated motile 
cilium. Primary cilia are more widespread throughout the human body than 
motile cilia, with a single primary cilium found on most cells (Singla & Reiter, 
2006; Eggenschwiler & Anderson, 2007). The few non-ciliated human tissues 
include hepatocytes, differentiated cells of myeloid or lymphoid origin, and 
umbilical vein endothelia (reviewed by Wheatley, 1995). Cell types which 
usually live in suspension do not make primary cilia, suggesting that contact 
with a substratum is important for primary cilium formation (Albrecht-Buehler, 
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Figure 1.1: Structure of the cilium.
Left: Diagram of a longitudinal section through a cilium and basal body.
Right: Diagrams of transverse sections through a primary cilium and a motile 
cilium. The primary cilium has a 9-fold symmetrical arrangement of axoneme 
microtubule doublets (a 9+0 structure). A motile cilium contains the same 9-fold 
symmetrical MT doublets, but also various additional structures including a 
central pair of MTs (a 9+2 structure).
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1977; Wheatley, 1995). Primary cilia have a mainly sensory role, detecting and 
transducing signals from diverse inputs such as developmental signalling 
molecules, mechanical forces, light (in the modified cilia of rod and cone cells in 
the eye), and odorants in the olfactory sensory system (Singla & Reiter, 2006). 
Motile cilia have been recognised more recently to also function as sensors 
(Bloodgood, 2010; Satir & Christensen, 2008). 
Cilia are an ancient evolutionary adaptation, present in the last common 
ancestor of all extant eukaryotes (Cavalier-Smith, 2002; Mitchell, 2004; Satir et 
al, 2008). A small core set of ciliary proteins are widely conserved across 
ciliated eukaryotes (Broadhead et al, 2006; Satir & Christensen, 2007), though 
the full ciliary proteome, which in many species has been estimated to contain a 
number of proteins at least in the low hundreds (Ishikawa et al, 2012; Yuan & 
Sun, 2013; Arnaiz et al, 2009), is much more variable (Broadhead et al, 2006). 
This may indicate that while the basic architecture of the cilium is conserved, 
ciliary function has been subject to considerable evolutionary divergence. Some 
eukaryotes, including groups within the gymnosperms and the entire 
angiosperm lineage, have lost cilia (Finet et al, 2012; Bremer et al, 1987; 
Renzaglia & Garbary, 2001). However, some ciliary proteins remain conserved 
in these non-ciliated species, implying these proteins have (either ancestral or 
acquired) non-ciliary roles (Hodges et al, 2011). 
Ciliary signalling is important in a wide range of signal transduction pathways, 
including those of profound developmental importance such as Wnt and 
Hedgehog signalling (Goetz & Anderson, 2010; Singla & Reiter, 2006) (see 
section 1.1.5 for more details). The widespread importance of cilia has not 
always been recognised; for example, their role in the central nervous system 
was long ignored despite the ubiquity of neuronal primary cilia (Fuchs & 
19
  
Schwark, 2004). This was partly because of the difficulty of detecting primary 
cilia in ultrastructural studies (where they appear in only a small percentage of 
transmission electron micrographic sections), and partly due to a persistent 
false impression among researchers that non-motile cilia were vestigial 
structures without any function and thus not worthy of note (reviewed by Fuchs 
& Schwark, 2004).  
1.1.2 Ciliary structure 
Cilia are projections of the cell surface into the extracellular space, supported by 
an internal scaffold  of doublet microtubules (MTs) – the “axoneme” (Figure 1.1, 
green) These MTs are templated from the basal body (Figure 1.1, orange) at 
the ciliary base. The basal body is a modified centriole; centrioles function as 
foci for the MT cytoskeleton in mitosis and are part of the centrosome, which 
serves as a MT organising centre (Lüders & Stearns, 2007). See Figure 1.1 for 
an overview of ciliary structure. 
Motile cilia contain additional structures not present in primary cilia such as a 
central microtubule pair, dynein and nexin arms, and radial spokes, which 
contribute to their motility (Porter & Sale, 2000). 
1.1.3 Ciliogenesis 
Ciliogenesis, the process by which cilia are assembled, begins when the 
centrosome migrates to and “docks” with the cortical cytoskeleton at the apical 
cell surface, where the mother centriole acts as the basal body, which is 
required for ciliary assembly (Barker et al, 2015).  
Prior to ciliogenesis, the centrosome is typically found near the centre of the cell 
physically attached to the nucleus (Figure 1.2, panel 1). The suspected linker 
between the centrosome and nucleus is the LINC complex, composed of KASH 
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Figure 1.2: Centrosome migration prior to ciliogenesis.
Centrosome migration is a two-step process. Initially (1), the centrosome is 
attached to the nucleus (by the LINC complex), away from the apical cell 
surface. Without detaching, the centrosome moves around the nucleus (or the 
nucleus itself rotates) to bring the centrosome close to the apical cell surface 
(2). In the second step, the centrosome detaches from the nucleus and moves 
to the apical cell surface, where it docks and ciliogenesis takes place (3).
Apical cell surface
Nucleus
Centrosome
LINC 
complex
Apical cell surface
Nucleus
1. Centrosome moves to apical-adjacent side of nucleus
2. Centrosome moves from nucleus to apical cell surface
Nucleus
3. Centrosome docks at cell surface and cilium is 
assembled
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domain proteins on the outer nuclear membrane which are linked to SUN 
proteins on the inner nuclear membrane, and to the actin, MT, and intermediate 
filament cytoskeletons; LINC complexes are responsive to mechanical forces 
transduced through the cytoskeleton and are able to orchestrate global 
cytoskeletal organisation (reviewed by Starr & Fridolfsson, 2010). Centrosome 
migration for ciliogenesis is a two-step process where first, the centrosome 
moves around the nucleus until it is at the nearest point to its cell surface target 
site (Figure 1.2, panel 2), then disengages from the nucleus and migrates to the 
plasma membrane by a separate mechanism (Barker et al, 2015; Tsun et al, 
2011; Yi et al, 2013) (Figure 1.2, panel 3). It is not clear whether the nucleus 
itself rotates, or the centrosome moves around the nuclear envelope without 
nuclear rotation. 
While the process of migration and docking has been well-studied 
ultrastructurally, it was not well understood at a molecular level until recently. 
Even so, many studies report data only for motile cilia in multiciliated cells rather 
than primary cilia, for which ciliogenesis may differ in important mechanistic 
details (Dawe et al, 2007a; Barker et al, 2015). A large number of proteins are 
required for ciliogenesis including multiple actin-binding proteins (Kim et al, 
2010; Wheway et al, 2015), and the actin cytoskeleton, as well as myosin, are 
essential for migration and docking (Boisvieux-Ulrich et al, 1990; Boisvieux 
Ulrich et al, 1987; Kim et al, 2015, 2010; Klotz et al, 1986; Lemullois et al, 1988, 
1987; Pan et al, 2007; Park et al, 2008; Pitaval et al, 2010; Yan & Zhu, 2013). 
Microtubules (MTs) are not required (Bolvar et al, 2001; Boisvieux Ulrich et al, 
1987), even though MTs are responsible for centrosome positioning in other 
contexts (Plotnikova et al, 2008; Pugacheva et al, 2007; Burakov et al, 2003), 
implying that during ciliogenesis a different mechanism takes over control of 
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centrosome positioning. Wnt/PCP and RhoA signalling have been implicated in 
actin remodelling required for docking (Gray et al, 2009; Pan et al, 2007; Park et 
al, 2006, 2008; Carvajal-Gonzalez et al, 2016; Song et al, 2010; Gray et al, 
2011; Borovina et al, 2010; Epting et al, 2015). Kim et al. identified regulators of 
ciliogenesis and ciliary length, and found that actin regulators were commonly 
implicated; they also found that inhibition of actin polymerisation facilitated 
ciliary extension (Kim et al, 2010). This may indicate that ciliogenesis and ciliary 
extension is dependent on low levels of polymerised actin in the cilium’s 
immediate area. In human retinal pigment epithelial (RPE1) cells, lack of spatial 
confinement of the cell leads to an altered actin cytoskeleton, altered nucleus-
centrosome axis, and prevention of ciliogenesis that was rescued by actin 
depolymerisation (Pitaval et al, 2010). Assembly of denser actin bundles, and 
thus increased tension in the cytoskeleton, may therefore be expected to lead to 
ciliogenesis defects. 
Ciliogenesis is also linked to cytoskeletal tension through YAP/TAZ signalling. 
YAP and TAZ are transcriptional regulators that can act downstream of the 
Hippo kinase cascade, or independently of Hippo, though it is common in the 
literature to refer to all YAP/TAZ activity as Hippo signalling (Piccolo et al, 
2014). YAP/TAZ signalling is a conserved pathway that controls organ size and 
tissue homeostasis (Pan, 2010). YAP/TAZ activity is regulated by mechanical 
stimuli from the extracellular matrix (Halder et al, 2012), by actin stress fibres 
through the Hippo cascade (Wada et al, 2011; Zhao et al, 2012), or through 
tension in the actin cytoskeleton independently of Hippo (Dupont et al, 2011). 
Cells grown on pliant substrates have inhibited YAP/TAZ activity with 
localisation in the cytoplasm, whereas cells on rigid substrates have high 
YAP/TAZ activity, predominantly localised in the nucleus (Dupont et al, 2011). 
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Epithelial tissue architecture (characterised by basolaterally polarised cells and 
cell-cell adhesion) has a suppressive effect on YAP/TAZ signalling (Martin-
Belmonte & Perez-Moreno, 2012). YAP/TAZ knockdown induces ciliogenesis, 
and hyperactivation suppresses ciliogenesis (Kim et al, 2015). These finding 
imply that ciliogenesis is dependent on the mechanical microenvironment of the 
cell, and might be blocked by stimuli that increase cytoskeletal or extracellular 
substrate tension and thus activate YAP/TAZ signalling. 
The mother centriole must be modified with various accessory structures 
including distal and subdistal appendages before it is competent to template the 
axoneme; acquiring the full set of modifications takes one and a half cell cycles 
(Vorobjev & Chentsov, 1982). In the absence of distal appendages, centrioles 
successfully migrate to the cell surface but cannot orient correctly to the 
membrane and fail to dock (Tanos et al, 2013). Association of the mother 
centriole with a ciliary vesicle, which forms a double-membrane “sheath” around 
the distal end of the centriole, is dependent upon the presence of distal 
appendages (Schmidt et al, 2012; Joo et al, 2013) and may be involved in 
docking (Sorokin, 1962). While the role of the ciliary vesicle is not completely 
clear, it is thought that in at least some contexts the centriole/basal body 
elongates an axoneme within the sheath while the ciliary vesicle grows by 
fusion with secondary vesicles, then the ciliary vesicle fuses with the plasma 
membrane to form the ciliary pocket (an invagination of the plasma membrane 
around the base of the cilium), and the inner membrane of the sheath around 
the axoneme becomes the ciliary membrane (Ghossoub et al, 2011). In this 
model, vesicular trafficking to the site of ciliation is essential for docking, not just 
for elongation. The ciliary vesicle is thought to be derived from the Golgi 
(Sorokin, 1962), and ciliogenesis is dependent on a Rab8a-Rab11 cascade that 
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initiates trafficking of post-Golgi vesicles to the centrosome (Yoshimura et al, 
2007; Westlake et al, 2011). Rabin8 (an activator of Rab8) rapidly relocalises to 
the centrosome upon serum-starvation (Westlake et al, 2011) (serum-starvation 
initiates ciliogenesis), suggesting that this pathway is rapidly responsive to 
ciliogenesis initiation signalling. 
The protein CP110 caps the distal end of mature centrioles, and has been 
found to block ciliogenesis until it is removed (Tsang et al, 2008; Goetz et al, 
2012), but only in cultured cells; a study in vivo found that CP110 promotes 
cilium formation and is required for centriole docking (Yadav et al, 2016), 
suggesting context-dependent ciliogenesis suppression and promotion 
functions. TTBK2 promotes the removal of CP110 from the centriole as well as 
promoting recruitment of ciliary assembly factors (Goetz et al, 2012), but its 
upstream effectors are unclear; CEP110 removal may be triggered by docking 
of the centriole to the cell surface (Tanos et al, 2013). This is inconsistent with 
the ciliary vesicle model since axoneme extension should be blocked while 
CEP110 is present; in this case, it may be necessary that CEP110 is removed 
upon association of the centriole with the ciliary vesicle, prior to docking with the 
cell surface. The exact timing of these events is still to be determined. 
Once the centriole has docked and become the basal body, axoneme extension 
takes place to extend the cilium. The axonemal microtubules are elongated only 
at the distal ends (Johnson & Rosenbaum, 1992), at the tip of the growing 
cilium, the farthest point from the basal body and the cell. There is therefore a 
requirement for material to be transported along the entire length of the cilium 
(Hao et al, 2011). Nevertheless, this stage of ciliogenesis is fast: fully-formed 
cilia can be assembled within ten minutes after centriole docking (Dingle & 
Fulton, 1966). This implies rapid import and transport of ciliary building 
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materials. Transport along the cilium is achieved by a process called 
Intraflagellar Transport (IFT) , a kinesin-2- and dynein-dependent bidirectional 
transport mechanism running in “IFT trains” along the axonemal microtubules
(Figure 1.1, blue arrows) (Rosenbaum & Witman, 2002; Kozminski et al, 1993). 
Defective cilium assembly can result from mutations in IFT proteins (Adams et
al, 1982; Cole et al, 1998), indicating that IFT is required to build a cilium. IFT is 
also essential for maintenance of a cilium once assembled (Krock & Perkins, 
2008; Pazour et al, 2002), for ciliary disassembly (Ishikawa & Marshall, 2011; 
Pan & Snell, 2005), and for cilium-dependent signalling (May et al, 2005; 
Huangfu et al, 2003). The cilium therefore is a structure that relies on 
continuous, active turnover and maintenance, and is highly sensitive to 
disruption of these processes. 
1.1.4 Ciliary compartmentalisation 
Essential to the cilium’s role in signalling is its status as a specialised 
compartment. Most organelles are bounded by a membrane which prevents 
free diffusion of molecules between the organelle lumen and the cytoplasm. The 
cilium, by contrast, has no membrane barrier at the base, its membrane being 
continuous with the plasma membrane. However, there is thought to be a 
“ciliary gate” that serves as a barrier to diffusion near the base of the cilium, in a 
region termed the transition zone (TZ) (Figure 1.1, grey area). This barrier is 
size-dependent, allowing small molecules to diffuse freely but preventing 
passage of larger objects (Kee et al, 2012). Even among objects that can pass 
the barrier, larger objects are delayed in comparison to smaller objects (Breslow 
et al, 2013; Lin et al, 2013). The selectivity appears to be purely based on 
object size rather than mass, as fusion of the spatially compact but heavy GFP 
moiety to proteins did not limit their ability to enter the cilium (Kee & Verhey, 
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2013; Harris et al, 2016; Craft et al, 2015). IFT is believed to be necessary for 
import and export of large ciliary component proteins, as it is capable of 
transporting cargo past this barrier (Rosenbaum & Witman, 2002). In 
ultrastructural studies Y-shaped structures are seen in sections through the TZ 
(Figure 1.3); the protein composition of these “Y-links” is not yet clear, but 
evidence is summarised in section 1.3.2 below. Between the basal body (BB) 
and the TZ are structures termed the “transition fibres” (Figure 1.1, pink), 
arranged in a radial “pinwheel” around the BB. These appear to be derived from 
the distal appendages of the BB, and link the BB to the periciliary membrane at 
the base of the TZ. The close spacing of the transition fibres provides a further 
size-dependent barrier to diffusion, entirely excluding vesicles from the cilium 
(Doolin & Birge, 1966; Geimer & Melkonian, 2004; Hagiwara et al, 2008; Ringo, 
1967; Boquist, 1970; Reese, 1965). The transition fibres also serve as a 
docking site for IFT (Deane et al, 2001). The transition fibres are sometimes 
considered part of the TZ (Andersen et al, 1991), but are more often described 
as part of the BB (Reiter et al, 2012), though they are in close association with 
both.  
In addition to the diffusion barrier between the ciliary lumen and the cytoplasm, 
there is also a suspected barrier to free diffusion of membrane proteins between 
the ciliary membrane and the wider plasma membrane, even though the two are 
continuous. This barrier is suspected to involve the “ciliary necklace” in the TZ; 
a distinct membrane region visible in electron micrographs as a regular pattern 
of protrusions (Gilula & Satir, 1972), which are likely to be the outer ends of the 
Y-links, either protruding through or deforming the ciliary membrane. 
As a result of the gated entry to the cilium, both the ciliary membrane and 
cytoplasm are able to maintain a specialised composition; for example, 
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Figure 1.3: Y-links connect the axoneme to the ciliary membrane within 
the ciliary transition zone (TZ).
Left: Transmission electron micrograph showing a transverse section through a 
ciliary TZ.
Right: Schematic representation of the structure of the TZ.
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enrichment in signalling components (Rohatgi & Snell, 2010; Garcia-Gonzalo & 
Reiter, 2012). Activation or inhibition of signalling pathways may thus rely on 
selective import or export of signalling components to or from the cilium; for 
example, Ptch1 must be exported from the cilium as part of the activation of the 
Hh pathway (Rohatgi et al, 2007). When ciliary compartmentalisation is 
compromised, these signalling pathways can become aberrant. 
The precise nature of the diffusion barrier in the TZ is controversial. In addition 
to the TZ itself, evidence suggests that septins may form a barrier (Hu et al, 
2010), while some authors propose a “ciliary pore complex” with similarities to 
the nuclear pore complex (Kee et al, 2012), supported by the finding that ciliary 
entry of at least some cargo is controlled by importins (Dishinger et al, 2010; 
Hurd et al, 2011; Torrado et al, 2016) which are more familiar as nuclear import 
factors. At the other extreme, Francis et al (2011) proposed that there is no 
need for a selective barrier to explain ciliary enrichment or exclusion, 
suggesting this can be explained by cytoskeletal retention of specific 
components preventing free diffusion instead. 
1.1.5 Cilium-dependent signalling 
Primary cilia act as the cell’s “antennae”, receiving a wide variety of extracellular 
signals, including developmental signals, chemical signals, and mechanical 
signals (Figure 1.4). 
Developmental patterning in vertebrates is largely controlled by morphogens 
which activate developmental signalling pathways when they bind to receptors 
on the cell surface. Three of the most important developmental signalling 
pathways are Wnt, Hedgehog (Hh), and Notch. Cilia are known to be essential 
for Hh signalling (Eggenschwiler, 2012; Huangfu et al, 2003), important for 
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Figure 1.4: Signalling pathways proposed to be transduced through the 
cilium. The ciliary membrane is decorated with receptors for various pathways, 
all of which must be transduced via the TZ.
Cytoplasm
Plasma 
membrane
PD
G
FR
PDGF
signalling
Neighbouring cell
Delta
NOTCH
Notch
signalling
Pa
tc
he
d
Hedgehog 
signalling
Non-canonical 
Wnt signallling
Fr
iz
zl
ed
PC
1
PC
2
Mechanosignalling
Transition 
zone
30
  
some Notch signalling (Ezratty et al, 2011), and have a controversial 
relationship with Wnt signalling (Wallingford & Mitchell, 2011). 
Hedgehog signalling 
Mammals have three instances of the hedgehog (Hh) pathway initiated by three 
different ligands: Indian, Desert, and Sonic (Shh). Shh in particular establishes 
ventral polarity in the neural tube (Echelard et al, 1993; Ericson et al, 1997), and 
posterior polarity (Ehlen et al, 2006) in the limb bud (Ingham & McMahon, 2001; 
Laufer et al, 1994), making it responsible for the patterning of digits in a 
concentration-dependent manner: high levels of Shh produce additional digits 
(polydactyly), and deletion results in a single digit representing the most ventral 
digit (the thumb in humans), which is the only digit to not depend on Shh (Ehlen 
et al, 2006). During the development of the central nervous system (CNS), Shh 
is produced in the notochord to specify the ventral neural tube and neural stem 
cell fate (Han et al, 2008).  
On a molecular level, the Hh ligand binds to Patched1 (Ptch1), a 
transmembrane receptor protein found on the primary cilium membrane, 
resulting in the translocation of Ptch1 out of the cilium and the entry of 
Smoothened (Smo) (Rohatgi et al, 2007). Activated Smo prevents processing of 
the Glioma (Gli) transcription factor; in the absence of Hh, Gli is processed to a 
repressor form which prevents transcription of Hh target genes. When  the Hh 
pathway is activated, Gli is instead converted to an active form (GliA) and target 
gene transcription is promoted (Ruiz i Altaba, 1999). Processing of Gli into 
either active or repressor forms is dependent on IFT downstream of Ptch1/Smo 
(May et al, 2005; Huangfu & Anderson, 2005; Liu et al, 2005), so ciliary 
dysfunction can result in complex phenotypes where some alterations are due 
to hyperactivated Hh, and some due to hypoactivation. 
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Hh signalling depends on the cell being able to control the compartmentalisation 
of Hh pathway components to the cilium, and on the trafficking activity that 
translocates them in response to signalling (Rohatgi et al, 2007; Wong & Reiter, 
2008; Eggenschwiler, 2012). If this control became compromised, Hh defects 
such as altered digit number and altered CNS development would be expected. 
Equally, the presence of such symptoms implicates Hh signalling and ciliary 
function. Defects in ciliogenesis lead to multiple CNS malformations (Louvi & 
Grove, 2011). 
Wnt signalling 
Wnt signalling has wide responsibilities in cell fate determination and body axis 
patterning during embryonic development. Wnt is typically divided into three 
major pathways: one canonical (or β-catenin dependent) pathway, and the two 
non-canonical (β-catenin independent) pathways: the planar cell polarity (PCP) 
pathway, and the Wnt/calcium pathway. This is a simplification as there are a 
number of other Wnt pathways, and all Wnt pathways overlap via crosstalk to 
some degree (De, 2011). 
Canonical Wnt signalling is fairly well-characterised. In the absence of canonical 
Wnt, β-catenin is complexed with axin, APC, and GSK3-β (termed the 
“destruction complex”). This results in phosphorylation of β-catenin, which is 
targeted for degradation. Canonical Wnt signalling is activated when a Wnt 
ligand binds to a Frizzled cell surface receptor, which leads to uncoupling of the 
destruction complex and stabilisation of β-catenin, which is then able to enter 
the nucleus and activate transcription of Wnt target genes (Reya & Clevers, 
2005; van Amerongen & Nusse, 2009). Canonical Wnt is involved in cell 
proliferation, and hyperactivated Wnt is often seen in cancer (Anastas & Moon, 
32
  
2013), with APC mutations frequently implicated (Reya & Clevers, 2005; Sparks 
et al, 1998). 
The non-canonical PCP pathway is mediated by Rho family GTPases (including 
Rho, Rac, and Cdc42) (Schlessinger et al, 2009). PCP signalling controls cell 
polarity and the arrangement of the cytoskeleton (Winter et al, 2001), and thus 
controls overall cell morphology, but does not directly alter gene expression 
(Wallingford & Mitchell, 2011). Loss of core components of the PCP pathway 
leads to the development of kidney cysts (Cao et al, 2010). 
When the non-canonical Wnt/calcium pathway is activated, intracellular calcium 
ion levels are increased, which in turn activates calcium-sensitive enzymes, 
leading to downstream alterations in gene expression (Kestler & Kühl, 2008; 
De, 2011). This pathway is not as well-studied as the canonical or PCP 
pathways, but has been implicated in kidney development (Burn et al, 2011), 
convergent extension movement (Freisinger et al, 2010) (a process essential for 
neural tube closure and correct CNS development), and dorsoventral polarity 
(Kühl et al, 2000; De, 2011).  
The connections between Wnt and cilia are not yet clear. According to a 
number of studies, the canonical Wnt pathway is hyperactivated when cilia or 
ciliary proteins are disrupted (Gerdes et al, 2007; Corbit et al, 2008; McDermott 
et al, 2010; Voronina et al, 2009), implying that the cilium has a moderating role 
on canonical Wnt. However, other studies have found no alteration in canonical 
Wnt in the absence of cilia (Huang & Schier, 2009; Ocbina et al, 2009). This 
may suggest that ciliary involvement in canonical Wnt is specific to cell type; in 
any case, this relationship is still not well-understood (Wallingford & Mitchell, 
2011). A number of studies also implicate cilia in non-canonical PCP signalling; 
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in contrast to canonical Wnt, PCP is not hyperactivated but disrupted when cilia 
are disrupted (Simons et al, 2005; Ross et al, 2005; Ferrante et al, 2009; 
Wallingford & Mitchell, 2011), suggesting that the relationship between this 
pathway and cilia is quite different. This has led to the hypothesis that cilia 
contain a “switch” between canonical and non-canonical Wnt, mediated by 
increased expression of the ciliary Wnt component interactor Inversin in 
response to extracellular signals; correct activation of this switch may be 
essential for development of organs such as the kidney (Simons et al, 2005; 
Goetz & Anderson, 2010; Singla & Reiter, 2006).  
Though cilia are implicated in non-canonical Wnt signalling, non-canonical Wnt 
is conversely a prerequisite for correct organisation and function of motile cilia 
in some cell types, such as multiciliated epithelial cells (Del Bigio, 2010; 
Kishimoto & Sawamoto, 2012). This signalling dependency is most likely 
needed for correct ciliary polarisation; however, since motile cilia are also able 
to function in many of the signalling roles of primary cilia (Bloodgood, 2010), this 
could lead to further increases in signalling activity downstream, further 
complicating Wnt signalling response in these cells. 
Notch signalling 
The Notch pathway is mediated by Notch receptors on the cell surface which 
bind a number of ligands, prominently Delta and Jagged. These, and most other 
Notch ligands, are transmembrane proteins on the surface of neighbouring cells 
rather than secreted extracellular ligands (Bray, 2006). This means Notch 
signalling is generally only between cells in close physical contact rather than at 
a distance, as is common for other signalling pathways. Notch signalling is 
important in a number of developmental contexts, such as establishment of 
tissue boundaries and lineage determination; it is particularly involved in neural 
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cell fate specification (Lowell et al, 2006; Louvi & Artavanis-Tsakonas, 2006; 
Bray, 2006). Aberrant Notch can alter the development of the vasculature (Roca 
& Adams, 2007) or induce kidney cyst formation (Surendran et al, 2010). This 
indicates that Notch is important for correct overall organ development, even 
though most of its activity is local. 
Components of the Notch pathway, including Notch receptors, localise to cilia 
(among other localisations), and elimination of cilia produces defects in Notch 
response (Ezratty et al, 2011). As with non-canonical Wnt, Notch signalling can 
also regulate cilia; for example, controlling ciliary length at Kupffer’s vesicle (KV) 
in zebrafish (Lopes et al, 2010). KV is a structure homologous to the embryonic 
node in animals that establishes left/right asymmetry in a cilium-dependent 
process (Essner et al, 2002). Controlling the cilia in this structure confers Notch 
with broad developmental influence. 
Other ciliary signalling roles 
The platelet-derived growth factor (PDGF) pathway influences various 
proliferative and migration behaviours in many cell types. Components of this 
pathway localise to cilia, and cells with shortened cilia show abnormal PDGF 
response (Schneider et al, 2005; Eggenschwiler & Anderson, 2007), consistent 
with at least partial dependence on cilia. 
The role of cilia as sensors extends beyond developmental signalling. Cilia in 
olfactory cells are responsible for odour detection (Kleene, 2008; Castillo et al, 
2010), enabling the sense of smell; modified cilia in the rod and cone cells of 
the eye detect light (Lamb et al, 2007), enabling vision. Cilia in many tissues 
function as mechanosensors (Nguyen & Jacobs, 2013; Nauli et al, 2013). The 
major ciliary mechanotransduction pathway was thought to be calcium ion 
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dependent, in a pathway downstream of Ca2+ influx into the cilium in response 
to compression (Wann et al, 2012), but this model has recently been called into 
question by a study that found no evidence of the expected cilium-specific Ca2+ 
influx in observations of multiple tissues where cilium-dependent calcium 
signalling had been thought to be important, including kidney epithelia and 
embryonic nodal cells (Delling et al, 2016), so it may be that the reported 
changes in calcium signalling are actually reflective of cell body calcium flux 
downstream of another mechanosensory mechanism in cilia. An example of a 
possible alternative mechanism is the cilium-dependent mechanotransduction in 
osteocytes that has been reported to be calcium-independent (Malone et al, 
2007) in a pathway involving cAMP, downstream of ion channels in the cilium 
(Kwon et al, 2010), though there have also been observations of ciliary Ca2+ 
influx in the cilia of these cells (Lee et al, 2015), so it may be that calcium 
signalling in this case was not recognised because it was solely ciliary Ca2+ 
influx, and not associated with changes to calcium ion signalling in the cell 
body. The specific signalling pathways involved in ciliary mechanotransduction 
thus remain somewhat unclear, and some authors have proposed that 
mechanotransduction may not originate in the cilium at all, at least in certain 
contexts (Delling et al, 2016). Cilia are not absolutely essential to 
mechanotransduction as, for example, non-ciliated endothelial cells are still 
responsive to flow (though ciliated cells have increased flow sensitivity) (Hierck 
et al, 2008). Nevertheless, ciliary mechanotransduction has been regarded as 
essential to many processes including kidney development (Singla & Reiter, 
2006) and control of extracellular matrix secretion (Wann et al, 2012). Cilia are 
mechanically coupled to the extracellular matrix in cartilage (McGlashan et al, 
2006), which likely allows them to detect mechanical signals transmitted 
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through the ECM. This may also be true in other tissues, raising difficulties in 
the interpretation of studies conducted under non-physiological cell culture 
conditions where an organised ECM was not present.  
The cilium is thus a highly multifunctional sensory and signalling platform, able 
to integrate and transduce signals from a wide range of biological and non-
biological sources (Figure 1.3) to control gene expression, cell polarity and 
cytoskeletal dynamics (in the case of PCP signalling), and developmental 
patterning on the level of individual tissues, whole organs, or entire body axes. 
Transduction of these signals depends on control of ciliary entry and exit 
through the TZ (Figure 1.3), and therefore, disruption to the TZ is a plausible 
explanation for developmental disease associated with these pathways.   
1.1.6 Cilia in development 
As a consequence of their sensory and signalling roles, functional cilia are 
essential for correct development of multiple organ systems, including the 
central nervous system, heart and vasculature, kidney, liver, and skeleton 
(Tasouri & Tucker, 2011; Goetz & Anderson, 2010). 
1.1.7 Ciliopathies 
The importance of ciliary signalling in development is such that defects in 
ciliogenesis or ciliary function have profound developmental consequences. The 
ciliopathies are the category of diseases caused by disrupted ciliary function 
(Schwartz et al, 2011; Badano et al, 2006). In general, ciliopathies are 
hereditary diseases caused by mutations in genes encoding ciliary or basal 
body proteins (Logan et al, 2011). 
Currently identified ciliopathies include Bardet-Biedl syndrome (BBS) (Ansley et 
al, 2003), Alström syndrome (ALMS) (Karska-Basta et al, 2007; Collin et al, 
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2002), nephronophthisis (NPHP) (Hildebrandt et al, 2009), Joubert syndrome 
(JBTS) (Parisi, 2009), Jeune syndrome (JATD) (Beales et al, 2007), 
orofaciodigital syndrome (OFD) (Macca & Franco, 2009), and Meckel-Gruber 
syndrome (MKS) (Tobin & Beales, 2009).  
The ciliopathies exhibit overlapping phenotypes (Table 1.1), and in many cases 
a single gene is allelic for several of these diseases, with syndromic 
presentation dependent on the mutation (Valente et al, 2010; Leitch et al, 2008; 
Norris & Grimes, 2012), or affected by the presence of modifying alleles 
(Khanna et al, 2009). For example, mutations in the MKS gene TMEM67 can 
also cause JBTS (Baala et al, 2007b), NPHP (Otto et al, 2009), and COACH 
syndrome (Brancati et al, 2009) as well as modifying BBS (Leitch et al, 2008). 
The ciliopathies thus represent a collection of pathologies with similar 
presentation, linked by a common aetiology in ciliary dysfunction, suggesting 
that the phenotypes observed may all have a common root in disruption of 
cilium-dependent processes.  
Meckel-Gruber syndrome is the focus of this thesis, and will be discussed in 
more detail below (section 1.3). 
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 Alström BBS JBTS Jeune MKS NPHP OFD 
Cleft palate        
Cognitive 
defects 
    ?   
Deafness     ?   
Encephalocele        
Liver disease        
Obesity     ?   
Polydactyly        
Cystic kidney        
Retinopathy     ?   
Situs inversus        
Skeletal 
defects 
       
Table 1.1: Presentation of clinical symptoms in ciliopathy syndromes. 
Shaded boxes indicate the symptom is commonly reported. For MKS, question 
marks denote symptoms that are not reported, but may be masked by lethality. 
Data from Norris & Grimes (2012). 
Increasingly, components of the cilium have been found to play other roles in 
the cell outside the cilium and its environs (summarised in Figure 1.5). Even IFT 
proteins, once thought to constitute a highly specialised transport mechanism 
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Figure 1.5: Non-ciliary roles for ciliopathy proteins. Summary cartoon 
showing ciliopathy proteins that have been implicated in cellular processes 
outside the cilium (Benzing et al, 2001; Huan & van Adelsberg, 1999; Mangos 
et al, 2010; Adams et al, 2010; Gakovic et al, 2011; Hernandez-Hernandez et al, 
2013; Stephen et al, 2015).
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present only on ciliary axonemes, have been found to be involved in trafficking 
and exocytosis in non-ciliated cells (Finetti et al, 2009), in cell division and 
cytokinesis at sites outside the cilium/flagellum (Qin et al, 2007; Wood et al, 
2012), and to have a cilium-independent role in cell migration (Boehlke et al, 
2015); all indicating that IFT proteins have a wider role in various cellular 
processes than was previously thought. 
The actin cytoskeleton is a multifunctional scaffold that pervades the cell, 
responsible for control of cell shape, mechanical force generation, and cell 
motility (Le Clainche & Carlier, 2008; Pollard & Cooper, 2009). Many ciliary 
proteins, including TMEM67 (Dawe et al, 2009; Adams et al, 2012), BBS 
proteins (Hernandez & Beales, 2010; Hernandez-Hernandez et al, 2013), 
Talpid3 (Yin et al, 2009), and RPGR (mutations in which cause the ciliopathy 
retinitis pigmentosa) (Gakovic et al, 2011) interact with the actin cytoskeleton; 
BBS4, BBS6, and BBS8  regulate actin via the actin remodelling protein RhoA 
(Hernandez-Hernandez et al, 2013).  
One of the major types of structure that interact with actin are adhesions. These 
include focal adhesions, which physically connect cells to extracellular matrix 
substrates, and adherens junctions, which physically link neighbouring cells 
(see section 1.2 for details). Ciliary proteins are often found to interact with 
these adhesion sites: for example, TMEM67 interacts with filamin A, an actin-
binding and cell-substrate adhesion associated protein (Adams et al, 2012); and 
BBS proteins may regulate the actin cytoskeleton by stabilising focal adhesions 
(Hernandez-Hernandez et al, 2013). The NPHP proteins nephrocystin-1, 
polycystin-1, and polycystin-2 have all been associated with adhesions: 
nephrocystin-1 and polycystin-1 both localise to adherens junctions and focal 
adhesions (Donaldson et al, 2000, 2002; Wilson et al, 1999; Markoff et al, 
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2007), and polycystin-2 interacts with adhesion proteins (Li et al, 2005). 
Ciliopathy proteins may be required for formation of these adhesions (Voronina 
et al, 2009), suggesting a significant role for these proteins independent of cilia. 
While the ciliopathy proteins are mostly united by their relationship to cilia, 
recent work suggests their roles within the cell are more diverse. Important 
interactions with the cytoskeleton and with adhesion complexes suggest a wider 
role in regulation throughout the cell. The causal relationships between the 
ciliary and non-ciliary cellular phenotypes , however, remain unclear, as do their 
influence on disease pathology.  
1.2 Cell adhesion and the extracellular matrix 
1.2.1 Cell adhesion 
Cells form surface adhesion complexes to physically attach to other cells and to 
the extracellular matrix. This is a capability fundamental to multicellularity and of 
critical importance for development, which is likely to be altered in MKS and 
ciliopathies in general.  
The major structure for cell-substrate adhesion is the focal adhesion complex 
(Figure 1.6). This is composed of transmembrane integrin dimers which bind 
directly to extracellular ligands. Integrins are substrate-specific, only binding to a 
subset of the possible extracellular matrix (ECM) components in a cell’s 
environment (Barczyk et al, 2010). On the intracellular side of the adhesion, an 
immensely variable adhesion complex is assembled depending on many 
contextual cues including the substrate, the cell type, and various regulatory 
signals. Proteins often found in this complex include talin, vinculin, paxillin, and 
zyxin. The complex recruits and cross-links actin stress fibres. A mature focal 
adhesion forms a strong physical connection between the actin cytoskeleton 
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Figure 1.6: Structure of the focal adhesion complex and the ECM. Only the 
core components of the FA and the most prominent components of the ECM are 
shown.
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and the extracellular ligand, as well as serving as a mechanosensor, typically by 
increasing adhesion protein recruitment in response to increased tension, and 
disassembly in response to decreased tension (Xu et al, 2012; Wehrle-Haller, 
2012). 
Other adhesion structures exist, such as adherens junctions, desmosomes, and 
hemidesmosomes. While all the adhesion structures are functionally distinct, 
they have structural similarities and some shared protein components 
(Yeatman, 2004), suggesting some shared regulation. 
Adhesions are essential for the migration of cells on a 2D surface, as they 
represent the points of attachment through which cells exert tractional forces on 
the substrate. While this is well-established for cells migrating on a 2D surface, 
the importance of adhesions for cells undergoing amoeboid migration in 3D gels 
– generally a more physiologically relevant model – is more controversial. 
Amoeboid migration has been described as adhesion-independent (Harunaga & 
Yamada, 2011). However, Nagano et al (2010) proposed, based on the 
importance of adhesion proteins for amoeboid migration, that adhesions were 
present but too small and/or transient to be easily visualised. Subsequently, 
Kubow & Horwitz (2011), by further refining imaging conditions, were able to 
visualise paxillin-containing adhesions forming at cell-substrate interfaces in 
cells migrating in 3D gels, providing evidence that the focal adhesion complex is 
not an artefact of 2D migration, but is indeed employed by cells under 
physiological conditions. 
1.2.2 Focal adhesion morphology 
Focal adhesions (FAs) are protein complexes that assemble at the plasma 
membrane, where they form physical links between the extracellular matrix 
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(ECM) and the cytoskeleton. The major component of FAs which mediate 
attachment to the ECM are the integrins. 
Integrins 
The integrins are a family of transmembrane proteins that mediate adhesion 
and signalling between a cell and the extracellular matrix (Barczyk et al, 2010), 
as well as directly between cells in some situations, especially in the 
immunological synapse where a T cell makes adhesive contact with an antigen-
presenting cell as part of the immune response (Hynes, 1992; Dustin, 2002). 
Integrins are expressed on many cell types, and any one cell will generally 
express multiple integrins (Hynes, 1992). 
Together with other core components of the adhesion complex, integrins 
originated prior to the divergence of the opisthokonts and therefore ancestrally 
to the metazoans (and to the fungi and choanoflagellates, although they have 
been lost from those lineages) (Sebé-Pedrós et al, 2010). Integrins are found in 
all multicellular animals, and through gene duplication, appear to have evolved 
alongside complex body plans to fulfil the increasing need for control of cell 
positioning by adherence and migration both during development and 
regeneration (Johnson et al, 2009).  
Integrins form heterodimers involving one α- and one β-integrin. Both subunits 
are transmembrane proteins with a large region extending into the extracellular 
space. Most vertebrates, including humans, have a consistent number of 
conserved integrin genes (18 α- and 8 β-integrins), which associate (through 
non-covalent interactions) into 24 integrin dimers (Barczyk et al, 2010; Hynes, 
2002). The limited number of known integrin dimers implies highly specific 
dimerisation: if α- and β-integrins could bind one another indiscriminately, there 
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would be 144 such dimers. In contrast, many integrins bind exclusively to one 
partner; β1-integrin is the most prolific, binding to 11 of the 18 α-integrins.  
Some integrins have tightly limited distribution and a restricted set of binding 
partners, and thus are probably specialised for few or single functions. For 
example, the expression of αEβ7 integrin is near exclusive to T lymphocytes in 
mucosal tissue (Kilshaw, 1999), and it has only two known ligands: E-cadherin, 
an adhesion receptor present on epithelial cells, and mucosal addressin cell 
adhesion molecule 1 (MAdCAM-1), which is expressed predominantly in 
mucosal tissue at endothelial sites of leukocyte extravasation (Humphries et al, 
2006; Shyjan et al, 1996). This integrin, therefore, appears to be highly 
specialised for a role in leukocyte extravasation, the process that allows 
leukocytes circulating in the vasculature to exit into neighbouring tissues at sites 
requiring an immune response. Most integrins, however, have more widespread 
functionality. 
The major ligands of integrins are extracellular matrix (ECM) components. A 
number of integrins recognise and bind to the common RGD amino acid 
sequence found in ECM components including fibronectin and vitronectin 
(Pierschbacher & Ruoslahti, 1984; Ruoslahti & Pierschbacher, 1986; Pytela et
al, 1987; Cherny et al, 1993), which are widely distributed in the body. Others 
recognise laminins, collagens (often via the GFOGER motif (Knight et al, 1998, 
2000; Xu et al, 2000)), minor basement membrane components, or are involved 
in the immune response and so recognise cell-surface ligands instead of ECM 
components (LeBleu et al, 2007; Timpl et al, 1979). 
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Focal adhesions 
Focal adhesions (FAs) were first described by Abercrombie et al (1971), who 
observed them as close associations between the cell edge and the substratum 
in electron micrographs of migrating fibroblasts.  
A single focal adhesion is a large linked complex involving many integrins and 
other components.  Focal adhesion formation can be initiated when cell-surface 
integrins interact with extracellular ligands or are activated by signalling 
molecules. The integrins form clusters in the plasma membrane and recruit 
other adhesion components. Among the integrins, those dimers containing β1 
and β3 in particular are predominant in focal adhesions, whereas others, such 
as the leukocyte-specific integrins, or otherwise specialised integrins such as β4
and β5, are not usually found in FAs (Petit & Thiery, 2000). Early, small cell-
matrix adhesions are termed focal complexes, whereas more mature adhesions 
may be called focal contacts, adhesion plaques, or if elongated, fibrillar 
adhesions (Riveline et al, 2001; Geiger & Bershadsky, 2001). 
Active disassembly is required for FA turnover, especially in situations such as 
the rear of migrating cells. In such cells, many (~80%) of the integrins are 
physically broken free of the cell and the cytoskeleton, and left behind attached 
to the substratum as the cell moves forward. The remainder are taken up into 
vesicles and recycled (Palecek et al, 1996; Petit & Thiery, 2000). 
1.2.3 The extracellular matrix 
The extracellular matrix (ECM), present in all animals, is a complex, 
multifunctional structure that surrounds, protects, and supports cells. The ECM 
was once viewed as an inert scaffold with purely structural functions. In fact, the 
ECM is a dynamic structure that has many roles in development and tissue 
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maintenance. As well as providing a substrate for adhesion, components of the 
ECM are ligands for signalling interactions, and the ECM serves as a reservoir 
for growth factors, holding them in position and making them available for 
detection by cells (Singh et al, 2010).  
The ECM is a diverse structure composed of multiple protein networks as well 
as proteoglycans and other molecules (Schaefer & Schaefer, 2010; Hynes, 
2009) (Figure 1.6). A brief review of the major ECM proteins follows. 
Collagen 
Collagen is the major component of the ECM in most tissues. It is the most 
abundant of all proteins in the metazoa, and the most abundant protein on Earth 
(Buehler, 2006). (The plant biopolymers cellulose and lignin are more abundant, 
but are not classed as proteins). In the human body, collagen makes up one 
third of the protein content by mass (Shoulders & Raines, 2009). Twenty-eight 
collagens encoded by different genes have been identified so far; most recently 
collagen XXVIII was described by Veit et al (2006). Splice variants further 
expand the diversity of the collagen ECM: for example, Collagen IV has 6 
identified isoforms (LeBleu et al, 2007).  
The procollagen precursor has a characteristic repeating amino acid motif gly-
pro-x, where x can be any amino acid. This gives rise to a triple helical 
structure. Different types of collagen are mainly defined by interruptions to this 
triple helix (Pauling & Corey, 1951; Shoulders & Raines, 2009).  
Among the collagen types, the major distinction is between fibrillar and non-
fibrillar collagens. Collagens I, II and III, which make up 80-90% of all collagen 
in the body, are the major fibrillar collagens (Buehler, 2006). Fibrillar collagens 
are assembled from their triple-helical base units into fibrils, and then into fibres. 
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The non-fibrillar collagens have a number of different forms, including sheets; 
some serve to cross-link fibrillar collagens (Shoulders & Raines, 2009). 
Procollagens are assembled into macromolecules (probably in the ER prior to 
secretion), then fibrils and fibres are formed in the extracellular space (Canty & 
Kadler, 2002). 
Fibrillar collagens form a network throughout the ECM that provides its main 
source of mechanical strength, especially against stretching forces. For 
example, tendons, connective tissue structures specialised for withstanding 
tension, contain a highly organised array of collagen fibres (Canty & Kadler, 
2002). Defects in collagen formation lead to serious disease even after 
completion of development: for example, the major symptoms of scurvy are due 
to reduced ability to properly assemble collagen (Peterkofsky, 1991). 
Fibronectin 
Fibronectin (FN) is a ubiquitous fibrillar ECM glycoprotein, present in all tissues 
at all stages of life. It is encoded by a single gene, yielding an ~8 Kb mRNA 
transcript. Isoforms are generated by alternative splicing – in humans, 20 FN 
isoforms have been identified (Singh et al, 2010). 
FN molecules associate at their C-termini to form a dimer shaped like a 
wishbone, or a pair of tongs. The molecule contains many binding domains, 
including domains for binding other FN molecules , other ECM components 
such as collagen, and an RGD domain that binds to the cell surface via certain 
RGD-binding integrins; most prominently α5β1 integrin, but also αvβ3 and αvβ6 
integrins (Busk et al, 1992; Danen et al, 2002; Singh et al, 2010; Hynes, 1992). 
These binding activities are essential for the assembly of the FN network and its 
connection to the rest of the ECM.  
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FN assembly is a cell-mediated process (McDonald, 1988). Initially, a FN dimer 
is secreted into the extracellular space and then binds to a cell-surface integrin. 
This initiates interaction with other extracellular FN dimers via the N-terminal 
assembly domain. Subsequent changes in conformation expose yet more FN 
binding sites. Eventually, FN assembles into fibrils that form both linear and 
branched networks in the intercellular space, allowing FN to serve as a 
structural network in its own right (Singh et al, 2010), and as an intermediate 
that promotes the assembly of collagen networks and links those networks to 
cells (Velling et al, 2002). The FN matrix is physically flexible in comparison to 
other ECM networks (Zamir et al, 2000). 
Early fibroblast cultures show thin FN fibrils; later cultures with a more mature 
ECM have clustered bundles of FN fibrils. FN is ubiquitous, but levels can vary 
to some extent: for example, an increased level of FN is found around the 
neural tube during development (Martins-Green & Tokuyasu, 1988; George et 
al, 1993). Mice without fibronectin exhibit neural tube deformation and fail to 
complete embryogenesis (George et al, 1993). 
FN is also found in a soluble form, as a component of blood that is important in 
the clotting response. Soluble FN does not form fibrils, even at high 
concentrations, until activated by interaction with integrins (Singh et al, 2010; 
Wierzbicka-Patynowski & Schwarzbauer, 2003; Schwarzbauer & Sechler, 
1999). 
Laminin 
Laminin was first isolated by Timpl et al (1979). While basal metazoans such as 
Hydra have only one laminin, most species have many laminin isoforms with 
typically high similarity in all but a few protein domains (Domogatskaya et al, 
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2012). Laminins assemble into a cruciform heterotrimer, which then makes 
further connections to assemble an ECM network. It has no RGD binding sites, 
but possesses a non-RGD integrin-binding domain which is recognised by 
laminin-specific integrins (Tryggvason, 1993).  
Organisation of the ECM 
There are two major types of ECM: interstitial matrix and basement 
membrane. 
The interstitial matrix, or stroma, is the major form of ECM which surrounds 
cells in many tissues, and predominates in connective tissues. It is diverse, but 
typically contains high levels of collagens I, II, and III, as well as the ubiquitous 
fibronectin, alongside many other components (Hynes, 2009; McDonald, 1988). 
The basement membrane (BM), or basal lamina, is a specialised sheet of ECM 
that underlies and supports epithelia (Singh et al, 2010). Its major components 
are laminin, nidogen/entactin, perlecan, and collagens IV(LeBleu et al, 2007), 
XV, and XVIII (Hynes, 2009). This core set, or “toolkit”, of BM components is 
present in all sequenced metazoans, and were likely essential to the evolution 
of multi-layered body plans in the animals (Hynes, 2009; Whittaker et al, 2006). 
Collagen IV is the major collagen in BMs, and is not normally found elsewhere 
at significant concentrations (Whittaker et al, 2006), though it can accumulate in 
the interstitial matrix of fibrotic tissue (Vleming et al, 1995; Sharma et al, 1993). 
Every BM contains at least one laminin type, with the type(s) present being a 
major determining factor in the properties of the BM (Aumailley, 2013).  
The BM is formed by a self-assembling scaffold comprised of a collagen IV 
suprastructure and a network of polymerised laminin. Nidogen/entactin and 
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perlecans form stabilising bridges between these two structures (LeBleu et al, 
2007). 
One of the major functions of epithelia is to block free diffusion of molecules. 
The BM is not responsible for this function; the BM itself is highly permeable 
(Loewenstein & Kanno, 1964). Instead, the epithelial cell layer forms “tight” (or 
“occluding”) junctions to establish the barrier to diffusion (Madara & 
Dharmsathaphorn, 1985). 
The ECM in development 
Most cells are in continuous close contact with the ECM facilitated by 
adhesions. The ECM’s composition varies dramatically between different 
tissues; these serve as cues for cells to determine their position with the body, 
and thus how they should develop. The signals conveyed by the ECM are able 
to control cell survival, proliferation, differentiation, polarity, and migration 
(Nelson & Bissell, 2006; Roskelley et al, 1995; Lukashev & Werb, 1998).  
ECM components are secreted and assembled from a very early stage in 
embryogenesis (Rozario & DeSimone, 2010). This initial assembly of the ECM 
is still not a completely understood process, but incorrect or delayed ECM 
assembly is involved in diseases including fibrosis (overproduction of ECM), 
tumorigenesis, skeletal malformations and a range of birth defects (Singh et al, 
2010). 
The ECM is a major orchestrator of CNS development (Sobeih & Corfas, 2002), 
and ECM remodelling in the brain may be involved in memory consolidation 
(Wright et al, 2002).  
Mechanical forces transmitted through the ECM activate cellular 
mechanotransduction pathways, influencing cytoskeletal architecture and gene 
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expression (Jahed et al, 2014). This influences cellular dynamics but also feeds 
back into the maintenance of ECM homeostasis through integrin signalling 
(Humphrey et al, 2014).  
1.3 Meckel-Gruber syndrome 
1.3.1 MKS clinical presentation and genetics 
The focus of this thesis is the ciliopathy termed Meckel-Gruber syndrome, or 
Meckel syndrome (MKS; MIM 249000). MKS is an autosomally recessive 
heritable human disease universally lethal to patients, in whom death typically 
occurs before or shortly after birth (Alexiev et al, 2006). Incidence varies; MKS 
is relatively rare in Great Britain (1 in 140 000 births) (Seller, 1978) and 
uncommon in the general European population (1 in 39 000) (Barisic et al, 
2015) but more common in North African (1 in 3500), Belgian (1 in 3000), and 
Finnish (1 in 9000) populations (Salonen et al, 1984b; Roume et al, 1997; 
Salonen et al, 1984a; Chen, 2006; Myageri et al, 2013), though these figures 
may be distorted by differential diagnosis across different healthcare systems. 
As is generally the case for recessively inheritable diseases, a family history of 
consanguinity is often linked to incidence of MKS (Szymanska et al, 2012; 
Modell & Darr, 2002). 
MKS has variable presentation in patients, but is often characterised by a triad 
of symptoms as originally described by Meckel: kidney cystic dysplasia (100% 
of patients), occipital encephalocele (90%), and polydactyly (80%) (Salonen et 
al, 1984b; Salonen & Paavola, 1998). Symptoms such as liver fibrosis, fibrotic 
alterations to other organs, cleft palate and other midline defects, heart defects, 
defects of the eye, and various malformations of the central nervous system 
(CNS) are also often present and may contribute to a diagnosis of MKS 
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(Salonen et al, 1984b; Salonen & Paavola, 1998). Salonen et al (1984a) 
replaced polydactyly in the diagnostic triad with liver fibrosis, but this has not 
been universally followed by other authors. 
MKS exhibits a combination of most of the symptoms found in other ciliopathies, 
making it one of the most severe (Table 1.1). Symptoms such as obesity and 
deafness are common in other ciliopathies but are not reported for MKS. 
However, early lethality is universal in MKS; typically the proximal cause of 
death is pulmonary hypoplasia (Ramachandran et al, 2006; Eckmann-Scholz et 
al, 2012; Alexiev et al, 2006; Ickowicz et al, 2006). This early lethality would 
mask the presentation of late-onset symptoms, so the phenotypic overlap 
represented in Table 1.1 may underrepresent the true underlying similarity 
between these syndromes. 
To date, 14 genes have been identified (Table 1.2) in which mutations are 
causative for MKS. Three more (C5orf42, EVC2, and SEC8/EXOC4) are 
proposed as likely candidates on the basis of mutation analysis and exome 
sequencing (Shaheen et al, 2013b), but have not yet been confirmed outside 
the original study. TMEM67 (MKS3) and TMEM216 (MKS2) are the focus of this 
thesis and will be discussed in more depth below (see sections 1.3.4 and 1.3.5).   
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MKS 
locus 
Gene 
name(s) 
Protein name(s) 
Expression pattern 
(if reported) 
Reference for 
identification 
as an MKS 
gene 
MKS1 MKS1, 
BBS13 
MKS1  (Kyttälä et al, 2006) 
MKS2 
TMEM216, 
JBTS2, 
CORS2 
TMEM216 / MKS2  
 
CNS, limb bud, kidney, 
cartilage(Valente et al, 
2010) 
(Edvardson et al, 
2010; Valente et 
al, 2010) 
 
MKS3 
TMEM67, 
JBTS6, 
NPHP11 
TMEM67 / MKS3 / 
Meckelin 
CNS, limb bud, cartilage, 
intestine, stomach, 
kidney(Dawe et al, 2007b) 
(Smith et al, 
2006) 
 
MKS4 
CEP290, 
KIAA0373, 
3H11AG, 
JBTS5, 
SLSN6, 
LCA10, 
BBS14, 
NPHP6 
CEP290  (Baala et al, 2007a) 
MKS5 
RPGRIP1L, 
KIAA1005, 
JBTS7, 
NPHP8 
RPGRIP1L / 
Fantom  
(Delous et al, 
2007) 
MKS6 
CC2D2A, 
KIAA1345 
CC2D2A 
 
Expressed strongly in 
prostate, pancreas, 
kidney, lung, liver, retina, 
fetal brain, fetal 
kidney(Gorden et al, 
2008) 
 
(Tallila et al, 
2008; Noor et al, 
2008) 
 
MKS7 
NPHP3, 
NPH3, 
RHPD, 
KIAA2000 
Nephrocystin-3 
Very low expression in 
brain and lung(Wright et 
al, 2011) 
 
(Bergmann et al, 
2008) 
 
MKS8 
TCTN2, 
TECT2 
Tectonic 2  (Shaheen et al, 2011) 
MKS9 
B9D1, 
MKSR1 
B9 domain-
containing protein 
1 (B9D1). 
 (Hopp et al, 
2011) 
MKS10 
B9D2, 
MKSR2 
B9 domain-
containing protein 
2 (B9D2). 
 (Dowdle et al, 
2011) 
MKS11 JBTS20 TMEM231 
  
(Shaheen et al, 
2013a) 
MKS12 KIF14 KIF14 
 (Filges et al, 
2014) 
MKS13 TMEM107 TMEM107 
 (Shaheen et al, 
2015) 
 CSPP1 
Centrosome 
spindle pole-
associated protein 
1 
 
(Shaheen et al, 
2014) 
Table 1.2: MKS genes identified so far (UniProt Consortium, 2013; Hamosh 
et al, 2005) 
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1.3.2 Cell biology of MKS 
Ciliogenesis in ciliopathies 
The first stage of ciliogenesis is the migration of the centrosome to the apical 
cell surface in order to become the basal body; in the absence of a docked 
basal body the cilium cannot form. While this process is not well-understood, 
there is ample evidence that MKS proteins and other ciliopathy proteins are 
required. In mice, basal body docking and ciliogenesis are prevented by 
knockdown of Mks1 (Dawe et al, 2007b), Mks2 (Valente et al, 2010), or Mks3 
(Dawe et al, 2007b). Similar phenotypes are seen in human cells: functional 
MKS1 and TMEM67 (MKS3) are required for docking and ciliogenesis (Dawe et 
al, 2007b), and TMEM216 (MKS2) mutations cause failure of ciliogenesis (Lee 
et al, 2012) However, a study in Mks1krc mice, which are reported to abolish 
Mks1 at the transcript level, did not reproduce the failed ciliogenesis phenotype 
(Weatherbee et al, 2009). Similary, wpk (TMEM67 orthologue) rats did not show 
a ciliogenesis defect, though they did have altered cilium and flagellum lengths 
(Tammachote et al, 2009). These may be results peculiar to the models, or may 
indicate an alternate pathway to ciliogenesis that is activated under certain 
conditions. (See Table 1.3 for a list of published MKS models and their 
phenotypic presentation.) 
In the case of TMEM216, defective ciliogenesis is accompanied by, and likely a 
consequence of, blocked centrosome docking (Valente et al, 2010) and 
hyperactivation of RhoA, an actin regulator; inhibition of Rho rescued the 
centrosome docking defect (Valente et al, 2010), suggesting that Rho 
hyperactivation is upstream of ciliary dysfunction in TMEM216-deficient cells. 
These defects have many commonalities with non-MKS ciliopathies. An 
example of a non-MKS gene which abolishes ciliation when mutated or knocked 
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down is TALPID3. TALPID3 orthologues in mouse (Yin et al, 2009), chick 
(Davey et al, 2006), and zebrafish (Ben et al, 2011) models are implicated in 
pathologies including limb patterning and neural tube defects (Davey et al, 
2006; Bangs et al, 2011), and indeed TALPID3 mutations cause severe disease 
in humans with symptoms including short-rib polydactyly and abnormal neural 
tube dorsoventral patterning (Alby et al, 2015; Stephen et al, 2015; Malicdan et
al, 2015), often leading to a JBTS diagnosis, but not to MKS: retinal, renal, and 
liver defects are not reported (Bachmann‐ Gagescu et al, 2015; Hamosh et al, 
2005). TALPID3 orthologues localise to the centrosome and are essential for 
ciliogenesis in all these organisms (Yin et al, 2009; Bangs et al, 2011; Ben et al, 
2011). In mice Talpid3 has been shown to be essential for basal body docking 
(Bangs et al, 2011; Yin et al, 2009), suggesting failure of docking may be at the 
root of TALPID3 ciliogenesis phenotypes, as is suspected for MKS. This raises 
the question: why does TALPID3 mutation not cause all the symptoms seen in 
MKS, if it has the same effect on ciliation? Non-ciliary roles for MKS proteins 
would provide a possible explanation. 
Docking failure is not always implicated in ciliogenesis defects, however. 
TCTN1, a JBTS protein, is not required for docking but is required for 
ciliogenesis in some tissues (Garcia-Gonzalo et al, 2011). This suggests that 
ciliogenesis is regulated in a tissue-specific manner; since most studies 
investigate only one or a few tissues, the true complexity of this regulation may 
not yet be clear. Another example is Ofd1 (a protein associated with the 
ciliopathy orofaciodigital syndrome, OFD), a component of the centriole 
responsible for control of centriole length; in its absence, centrioles are 
abnormally elongated and defective in IFT protein recruitment, and ciliogenesis 
is impaired (Singla et al, 2010). After centrosome docking, correct ciliary protein 
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import via IFT is the next function required to correctly assemble a cilium, so in 
general, ciliogenesis defects not accompanied by docking failure are probably 
due to defective import, either due to defective IFT or defective recruitment of 
IFT and cargo to the ciliary base.  
Cilium length control 
The length of a cilium results from balanced assembly and disassembly 
depending on balanced anterograde and retrograde IFT. Disruption of ciliary 
import or IFT would be expected to result in shortened cilia as this balance is 
perturbed. This shortening has been reported for TMEM67: TMEM67/MKS3 
knockdown causes shortening and loss of cilia in mouse and human cells 
(Dawe et al, 2007b) and Paramecium (Picariello et al, 2014). However, some 
results do not agree with these findings. Wpk is the rat orthologue of TMEM67. 
Wpk rat spermatids have shortened flagella, but in renal collecting duct cysts, 
cilia are elongated (Tammachote et al, 2009). In the same study, TMEM67 
patient cells were found to have longer cilia. This appears to contradict the 
result obtained by Dawe et al (2007b), but the results were obtained under 
different conditions so are not directly comparable. C. elegans mks-3 mutants 
also show lengthened cilia (Williams et al, 2010). It can be concluded that 
TMEM67  has a role in cilium length control, but one that is complex and not 
fully understood. Given that the ciliary TZ is implicated in cilium length control 
(Roberson et al, 2015), this may be tied to TMEM67’s role in the TZ complex. 
Beyond MKS, other ciliopathy proteins influence cilium length; for example, BBS 
proteins have been reported to do so via alteration of RhoA levels, which leads 
to disruption of the actin cytoskeleton, including disruption of stress fibres 
(contractile actin bundles that provide intracellular tension and are important in 
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migration and adhesion) (Hernandez-Hernandez et al, 2013). However, these 
ciliopathy proteins are also associated with the TZ. 
Transition zone 
As described above (section 1.1.4), ciliary compartmentalisation is critical for 
ciliary signalling, and the barrier responsible for maintaining ciliary 
compartmentalisation is in the region of the cilium near the base, termed the 
ciliary transition zone (TZ). Proper cilium function depends on the TZ (Czarnecki 
& Shah, 2012; Reiter et al, 2012). A large number of ciliopathy proteins, 
including TMEM67 and TMEM216, have been found to localise to the TZ (Dawe 
et al, 2007b; Lee et al, 2012; Klinger et al, 2013; Gorden et al, 2008; Sang et al, 
2011; Wright et al, 2011; Bialas et al, 2009; Chih et al, 2012; Fliegauf et al, 
2006), many of them in a network of physically interacting proteins (Figure 1.7) 
(Garcia-Gonzalo et al, 2011). This network is composed of two functional 
modules; one “NPHP module” containing proteins mainly implicated in NPHP 
(Figure 1.7, orange), the other an “MKS module” containing MKS and JBTS 
proteins (Figure 1.7, green) (Chih et al, 2012; Garcia-Gonzalo & Reiter, 2012; 
Garcia-Gonzalo et al, 2011). 
As mentioned before, the TZ contains structures called “Y-links”, based on their 
Y-shaped appearance under electron microscopy (Figure 1.3), which link the 
axonemal microtubules to the surrounding membrane, and have been proposed 
to be involved in the barrier function of the TZ (Williams et al, 2011). This is 
supported by studies in Chlamydomonas  CEP290 (MKS4) mutants and C. 
elegans mutants which lack Y-links: proteins fail to accumulate in the ciliary 
membrane (Craige et al, 2010; Garcia-Gonzalo et al, 2011), suggesting that 
these structures are at least partly responsible for the diffusion barrier. The 
composition of the Y-links is unknown, but it is suspected to involve the TZ 
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Figure 1.7: The transition zone protein network. The network comprises two 
modules, one made up predominantly of NPHP proteins (orange), the other of 
MKS and JBTS proteins (green), including TMEM67 and TMEM216. The two 
networks are linked through the MKS/JBTS protein CEP290 (light green), as 
well as through an Inversin/AHI1 interaction. Grey lines indicate evidence for 
direct interaction. Data from Garcia-Gonzalo & Reiter (2012).
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complex of ciliopathy proteins. In this model, the transmembrane proteins such 
as TMEM67 and TMEM216 would be at the ends of the Y-links where they 
interact with the membrane, consistent with the predicted structure of the 
complex Figure 1.7). 
Evidence for the spatial relationships between ciliopathy proteins within the TZ 
has been mainly obtained by super-resolution imaging (Yang et al, 2015; Pratt 
et al, 2016). Yang et al showed that the human ciliary TZ contains at least two 
regions with different protein compositions: RPGRIP1L and MKS1 are found in 
a distal band and CEP290 in a more  proximal band (closer to the basal body) 
within the TZ (Yang et al, 2015). Based on this, Yang et al propose that the 
RPGRIP1L/MKS1 band may serve as a recruitment or storage site for TMEM67 
and TCTN2, which they found to be present at a similar axial level (on the 
proximal-distal axis from the base to the tip of the cilium) but a distinct radial 
position: while RPGRIP1 is localised close to the microtubules at the TZ core, 
TMEM67 and TCTN2 are close to the ciliary membrane (and ciliary necklace), 
consistent with the transmembrane anchoring role proposed for these proteins 
(Yang et al, 2015), suggesting they may be components of the membrane-
associated outer ends of the Y-links. MKS1 is found in between (Yang et al, 
2015) and may serve as a bridge between the membrane-associated and MT-
associated parts of the complex. Pratt et al found that deletion of an N-terminal 
region of Mks1 in Drosophila abolished TZ localisation of MKS protein 
orthologues B9D1, B9D2, TMEM216, CC2D2, and Tectonic, but did not affect 
localisation of CEP290 (Pratt et al, 2016), suggesting that MKS1 is critical for 
recruiting MKS module proteins to the TZ. Furthermore, deletion of B9D1 also 
led to abolishment of TZ localisation of MKS1 and B9D2 (and, while not 
specifically shown, presumably loss of the other proteins dependent on MKS1 
61
  
for recruitment) (Pratt et al, 2016), indicating that the MKS module is 
interdependent; loss of any one component may disrupt recruitment of the 
entire complex. These results also suggest that CEP290, while an MKS protein, 
is not involved in the MKS module (Figure 1.7) but in a separate CEP290 
module, which has been proposed to work partially redundantly with the NPHP 
and MKS modules to organise the TZ (Basiri et al, 2014; Schouteden et al, 
2015; Williams et al, 2011). 
If ciliopathy proteins are indeed partially redundant components of the Y-links, 
and the Y-links are essential for ciliary compartmentalisation, then much of the 
overlapping phenotypic presentation observed in ciliopathy patients can be 
explained as the result of partial disruption of the Y-link complex leading to 
failure to control levels of developmental signalling molecules in the cilium, and 
thus to aberrant developmental signalling. The different severities and 
symptoms resulting from different mutations would thus represent different 
degrees of compromised barrier function.  
Evidence for non-ciliary phenotypes in MKS 
As noted above, there is a growing body of evidence that many ciliopathy 
proteins have functions not localised to cilia. Within the MKS proteins, TMEM67 
is known to interact with filamin A, an actin regulatory protein, and localises to 
the actin cytoskeleton as well as the cell surface in polarised cells (Dawe et al, 
2007b, 2009; Adams et al, 2012). 
Alterations in cell migration can result from absence of ciliopathy proteins; in 
Inversin (Nephrocystin-2) deficient mouse cells migration is perturbed (Veland 
et al, 2013), potentially downstream of Wnt. In BBS, neural crest cell migration 
is perturbed leading to developmental abnormalities including mid-facial 
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hypoplasia and hypognathia (reduced jaw size) (Tobin et al, 2008). Since 
adhesions and the actin cytoskeleton are closely interlinked, and both are 
central to migration, the alterations in these structures seen frequently in 
ciliopathies may be at the root of migration defects. An example of such a 
defect in MKS patients may be occipital encephalocele, which results from 
failure to close the neural tube during early CNS development. MKS is the most 
common cause of neural tube defects (Leitch et al, 2008), which across all 
causes affect approximately 1 in 1000 births (Juriloff & Harris, 2000). Closure of 
the neural tube is a PCP (non-canonical Wnt) signalling dependent process 
(Wallingford et al, 2002; Hamblet et al, 2002; Murdoch et al, 2014; Juriloff & 
Harris, 2012; Ybot-Gonzalez et al, 2007; Murdoch et al, 2001, 2003; Curtin et al, 
2003; Robinson et al, 2012) involving directed mass cell migration by 
convergent extension, during which cell adhesion is key (Pyrgaki et al, 2011; 
Suzuki et al, 2012).  
1.3.3 MKS model organism studies 
A large number of studies have been published that investigate phenotypes 
associated with MKS gene homologues in other species. A full review of this 
work is beyond the scope of this thesis, but the results of these studies are 
summarised in Table 1.3. 
Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
MKS1 Mouse Mks1 Loss of 
function 
(Weatherbee 
et al, 2009) 
No alteration to 
BB positioning. 
Defective ciliation 
in most tissues. 
Altered Hh 
signalling. 
Defects in neural 
tube, biliary duct, 
limb patterning, 
skeletal 
development, 
kidney. 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
MKS1 C. elegans mks1 B9 domain 
disrupted 
(Bialas et al, 
2009) 
No ciliary 
structural defects. 
Mislocalisation of 
MKS1, MKSR1, 
MKSR2. 
 
Altered insulin 
signalling led to 
increased lifespan. 
MKS1 Drosophila 
melanogas
ter 
Mks1 Deletion of 
N-terminal 
region 
(Pratt et al, 
2016) 
Abolished TZ 
localisation of 
B9D1, B9D2, 
TMEM216, 
CC2D2, Tectonic. 
Did not affect 
localisation of 
CEP290. 
Cilium defects in 
early pupae, but 
cilia normal at 
later stage. 
Shortened 
spermatocyte 
axonemes. 
Subtle 
perturbation of 
IFT. 
Mutants are viable 
and fertile. 
No apparent effect 
on sensory cilia 
function. 
 
B9D1 Drosophila 
melanogas
ter 
B9D1 Deletion 
(Pratt et al, 
2016) 
Abolished TZ 
localisation of 
MKS1, B9D2. 
Mutants are viable 
and fertile. 
No apparent effect 
on sensory cilia 
function. 
TMEM6
7 
Rat Wpk Missense 
(Smith et al, 
2006; 
Tammachote 
et al, 2009) 
Shortened 
spermatid flagella 
Elongated liver 
ductal cilia 
Cystic kidney. 
Corpus callosum 
agenesis. 
Hydrocephalus. 
Retinal defects. 
 
TMEM6
7 
Mouse Tmem67 Null 
(Garcia-
Gonzalo et 
al, 2011) 
Reduced cilia 
number in kidney 
tubules 
Survived to birth 
but died soon after. 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
TMEM6
7 
Mouse Tmem67 Knockout 
(Abdelhame
d et al, 2013) 
Loss of primary 
cilia 
Diminished Shh 
signalling 
Deregulated Wnt. 
Hyperactive DVL1 
at BB. 
Exencephaly and 
encephalocele. 
Neural tube 
dorsalisation. 
 
TMEM6
7 
Zebrafish Mks3 Knockdown 
(Adams et al, 
2012) 
Basal body 
positioning 
disrupted 
Impaired 
ciliogenesis in 
neuroepithelium 
Axis defects. 
Cardiac edema. 
Auditory and eye 
defects. 
TMEM6
7 
Parameciu
m 
tetraurelia 
MKS3 Knockdown 
(Picariello, 
2015; 
Picariello et 
al, 2014) 
Global shortening 
and loss of cilia. 
No effect on BB 
structure, but 
alignment 
disrupted. 
 
TMEM2
16 
Zebrafish Tmem216 Knockout 
(Valente et 
al, 2010) 
 Gastrulation 
defects. 
Body axis 
shortening. 
Notochord 
broadening. 
Misshapen 
somites. 
TMEM2
16 
Zebrafish Tmem216 Knockdown 
(Lee et al, 
2012) 
 Pericardial effusion 
Curved/kinked tail 
Gastrulation 
defects. 
Hydrocephaly. 
CEP290 Mouse Cep290 In-frame 
deletion 
(Chang et al, 
2006) 
 Retinal 
degeneration. 
No CNS or kidney 
defect. 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
CEP290 Mouse Cep290 Hypo-
morphic 
mutation 
(McEwen et 
al, 2007) 
Defective ciliary 
localisation of G 
proteins Gna1, 
Gng13 
Olfactory 
dysfunction. 
CEP290 Cat Cep290 SNP causing 
termination 
(Menotti-
Raymond et 
al, 2007) 
 Progressive retinal 
degeneration. 
CEP290 Mouse Cep290 Null 
(Lancaster et 
al, 2011) 
 CNS defect: 
midline fusion 
RPGRI
P1L 
Mouse Rpgrip1l Null 
(Delous et al, 
2007) 
 CNS defects 
including 
exencephaly, 
hypoplasia, corpus 
callosum absence. 
Eye defects. 
Cleft lip. 
Some showed 
early signs of 
cystic kidney and 
liver fibrosis. 
RPGRI
P1L 
Mouse Rpgrip1l -/- 
(Laclef et al, 
2015) 
Neuroepithelia 
form cilia with no 
axonemes. 
Some cells failed 
to form cilia. 
Misexpression of 
guidance 
molecules. 
Some symptoms 
restored by Gli3r. 
Ventralisation of 
telencephalon 
leading to olfactory 
defects. 
 
CC2D2
A 
Zebrafish Cc2d2a Null 
(Gorden et 
al, 2008) 
No change in 
cilium number or 
morphology. 
Cystic kidney. 
Some had 
pericardial 
effusion. 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
CC2D2
A 
Mouse Cc2d2a Null 
(Garcia-
Gonzalo et 
al, 2011) 
Cilia defects, but 
not in embryonic 
fibroblasts. 
Randomised L-R 
axis. 
CNS defects. 
Curved body axis. 
NPHP3 Mouse Nphp3 Substitution 
in pcy locus 
(Olbrich et 
al, 2003; 
Omran et al, 
2001) 
Amenable to 
treatment with 
vasopressin-2 
receptor 
antagonist 
(Gattone et al, 
2003) 
Cystic kidney. 
Basement 
membrane defects. 
Nephropathy. 
NPHP3 Mouse Nphp3 Null 
(Bergmann 
et al, 2008) 
 Heterozygotes 
have no apparent 
defects, unless 
heterozygous with 
pcy. 
Homozygosity was 
lethal with 
lateralisation and 
situs defects. 
NPHP3 Zebrafish Nphp3 Knockdown 
(Hoff et al, 
2013) 
Common effect 
with KD of Anks6, 
Nek8 
Cystic kidney. 
Heart looping 
defect. 
NPHP3 Xenopus Nphp3 Knockdown 
(Hoff et al, 
2013) 
Common effect 
with KD of Aks6, 
Invs 
Kidney defect. 
TCTN2 Mouse Tctn2 Null 
(Garcia-
Gonzalo et 
al, 2011) 
No nodal cilia. 
Few, defective 
neural tube cilia. 
BB docking 
normal. 
 
B9D1 C. elegans mksr1 B9 domain 
disrupted 
(Bialas et al, 
2009) 
No ciliary defects. 
Mislocalisation 
when disrupted 
with mks1 and 
mksr2. 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
B9D1 Mouse B9d1 Null 
(Dowdle et 
al, 2011) 
Reduced number 
of cilia, shortened. 
Cilia in biliary 
ducts normal. 
Nodal cilia absent 
or defective. 
BB docking 
normal but 
axonemes not 
built in neural 
tube. Fibroblasts 
show normal 
ciliation, but 
defective Hh 
response. 
TZ complex 
proteins 
mislocalised. 
Cystic kidney, CNS 
defects including 
encephalocele, 
liver ductal plate 
malformation; 
resembles MKS. 
B9D1 Mouse B9d1 Knockout 
(Chih et al, 
2012) 
Loss of cilia. 
Altered Shh gene 
expression. 
Lethal. 
Vascular defects. 
Polydactyly. 
B9D2 Mouse stumpy Conditional 
knockout 
(Town et al, 
2008) 
Neural and kidney 
cilia absent or 
defective. 
Hydrocephalus. 
Cystic kidney. 
B9D2 C. elegans mksr2 B9 domain 
disrupted 
(Bialas et al, 
2009) 
No ciliary defects. 
Mislocalisation 
when disrupted 
with mks1 and 
mksr1. 
 
B9D1 Zebrafish B9d2 Knockdown 
(Dowdle et 
al, 2011) 
Defects rescued 
by human B9D2. 
Dosage-
dependent: 
Shortened body 
axes, elongated 
somites, notochord 
defects. 
JBTS20 Mouse Tmem231 Knockout 
(Chih et al, 
2012) 
Loss of cilia. 
Altered Shh gene 
expression. 
Lethal 
Vascular defects 
Polydactyly 
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Human 
gene 
Model 
species 
Homologou
s gene 
Alteration + 
ref 
Cellular 
phenotypes 
Developmental 
phenotypes 
KIF14 Mouse Kif14 Laggard 
(Fujikura et 
al, 2013) 
Reduced 
expression of 
brain 
development 
genes. 
Increased neural 
apoptosis. 
Growth retardation, 
Microcephaly. 
Homozygotes died 
within 3 weeks of 
birth with ataxia, 
tremors. 
CSPP1 Zebrafish cspp1a Knockdown 
(Tuz et al, 
2014) 
Cilia appear 
normal. 
Reduced ciliary 
localisation of 
Arl13b 
Curved body axis. 
Cystic kidney. 
CNS patterning 
defects. 
Table 1.3: Summary of MKS model studies 
This thesis focuses on the MKS genes TMEM67 (MKS3) and TMEM216 
(MKS2), which both encode proteins proposed to be involved in the MKS-JBTS 
module within the ciliary TZ as transmembrane linkers (Figure 1.7) (Garcia-
Gonzalo & Reiter, 2012). It is estimated that between them, mutations in these 
two genes account for over half of MKS cases (Szymanska et al, 2012). 
1.3.4 TMEM67 
TMEM67 was identified in 2006 (Smith et al, 2006), and is the most well-studied 
MKS gene.  
Genetics and clinical mutations 
TMEM67 is located on chromosome 8 in humans (Smith et al, 2006), in a 
corresponding region to the homologous rat Wpk locus, with which it shares 
>80% sequence identity. In a study of 38 families bearing MKS mutations, 50% 
of the families had changes to TMEM67, indicating that mutations in this gene 
are the most common cause of MKS (Szymanska et al, 2012). 
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There are multiple disease-causing mutations possible in TMEM67, which have 
variable syndromic presentation: different TMEM67 mutations have been 
reported to cause MKS (Smith et al, 2006), Joubert syndrome (JBTS) (Baala et 
al, 2007b), Nephronophthisis (NPHP) (Otto et al, 2009), and COACH syndrome 
(Brancati et al, 2009). Additionally, one mutation in TMEM67 was found to be a 
modifier of Bardet-Biedl syndrome; a zebrafish model showed that this modifier 
increases probability of gastrulation movement defects when in combination 
with a mutation in CEP290 (Leitch et al, 2008). 
Expression and function 
TMEM67 has a comparable expression pattern to other ciliopathy proteins. It 
has two reported major splice variants (UniProt Consortium, 2013), the more 
prominent of which encodes a protein of 995 amino acids, predicted to contain 7 
transmembrane domains. A number of smaller isoforms have also been 
reported but these have not been characterised (Dawe et al, 2007b). It localises 
to the ciliary membrane, the basal body, basolateral actin cables, the cell 
surface of polarised cells (Dawe et al, 2007b, 2009), and the endoplasmic 
reticulum, where it is proposed to function in protein degradation (Wang et al, 
2009). Direct evidence for functional roles outside the cilium and basal body is 
lacking. 
TMEM67 binds at the cytoplasmic C-terminus to filamin A (FLNA) (Adams et al, 
2012). Loss of either protein leads to alterations in basal body positioning, 
ciliogenesis, actin organisation, and deregulation of RhoA and Wnt signalling 
(Adams et al, 2012). This indicates that a TMEM67-FLNA complex is involved in 
Wnt signalling and regulates ciliogenesis, probably by influencing basal body 
migration or docking. In C. elegans, TMEM67, together with other MKS 
proteins, was found to establish connections between the basal body and TZ 
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(Williams et al, 2011); this process may be important for docking, or it may only 
be relevant after docking is complete. TMEM67 co-localises with and interacts 
with the Wnt receptor ROR2 at the TZ, and is required for ROR2 
phosphorylation (Abdelhamed et al, 2015b), implying that TMEM67 acts as a 
co-receptor in the Wnt pathway, perhaps influencing its other TZ roles in the 
MKS/JBTS module and with FLNA. 
Genotype/phenotype correlations 
The classical diagnostic symptoms of MKS (occipital encephalocele, 
polydactyly, cystic kidney, and liver fibrosis) may give the false impression that 
MKS is a single, well defined condition. This is not the case: among the 
diagnostic symptoms, only occipital encephalocele and cystic kidney are 
present near-universally in MKS patients (Salonen et al, 1984b; Salonen & 
Paavola, 1998).  
Incidence of polydactyly varies depending on genotype: Szymanska et al 
observed polydactyly in only 3 of 19 TMEM67 patients, a much lower incidence 
than seen in patients with MKS caused by RPGRIP1L or CC2D2A mutations 
(Szymanska et al, 2012). Since polydactyly is most easily explained as a 
consequence of disruption to the Hh signalling pathway, this implies that 
TMEM67 mutation is less disruptive to Hh than other MKS mutations. TMEM67 
patients in this sample also exhibited none of the situs or intestinal malrotation 
defects which are seen in other forms of MKS (Szymanska et al, 2012). These 
defects may result from lack of left-right patterning established by cilia during 
early development, though the aetiology of intestinal malrotation is not well 
understood (Stringer, 2009). Since TMEM67 patient cells are defective in 
ciliogenesis, it is difficult to explain lack of situs and malrotation defects in these 
patients. It may be that defective ciliogenesis is only present in certain cell types 
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or at certain developmental stages in patients with this genotype, or that other 
mechanisms of left-right patterning are able to compensate. Left-right patterning 
exhibits robust error-correcting mechanisms,  able to achieve correct axis 
determination despite serious disruptions such as reversed expression patterns 
of key genes (McDowell et al, 2016). Many of these mechanisms are cilium-
independent (reviewed by McDowell et al (2016); an example is serotonin 
asymmetry, which has been shown in Xenopus to establish left-right patterning 
early in development independent of cilia (Vandenberg et al, 2013).  
In NPHP, liver fibrosis is reported only in patients with TMEM67 mutations (Otto 
et al, 2009). Since most liver cells do not make cilia (Wheatley, 1995), this 
implies a non-ciliary role. TMEM67 MKS patients exhibit increased frequency of 
liver ductal plate malformation (Szymanska et al, 2012), usually caused by 
arrest of biliary system development as part of the common pattern of fibrotic 
changes to the liver (Sergi et al, 2000; Clotman et al, 2008). Bile duct epithelial 
cells, unlike most liver cells, are ciliated (Masyuk et al, 2008), so this does not 
necessarily require a non-ciliary explanation, but it is still difficult to explain why 
other MKS genotypes are less correlated with this symptom without invoking 
non-ciliary roles for TMEM67.  
It has been suggested that truncating mutations in TMEM67 tend to cause 
MKS, while missense mutations cause less severe phenotypes (Iannicelli et al, 
2010). This correlation has yet to be systematically verified, but appears to be 
consistent with the TZ hypothesis for MKS aetiology where the degree of 
disruption to the TZ complex correlates with the developmental consequences.  
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1.3.5 TMEM216 
TMEM216  was identified more recently than TMEM67 (Valente et al, 2010), 
and has been the subject of only limited published research thus far. 
Genetics and clinical mutations 
The TMEM216 gene is located on chromosome 11 in humans, and is 
associated with clinical mutations causing MKS2 and Joubert syndrome 2 
(JBTS2), both in an autosomally recessive inheritance pattern (Hamosh et al, 
2005). In a study of 38 families with MKS mutations, only one family had 
alterations in TMEM216, indicating that mutations in this gene are a 
comparatively rare cause of MKS (Szymanska et al, 2012). 
Seven distinct mutations in TMEM216 causing MKS2 have been identified 
(Valente et al, 2010), but these have not been studied in enough detail to make 
firm conclusions about genotype-phenotype correlations in MKS2.  
The R73L mutation, which has a high incidence in individuals of Ashkenazi 
heritage, is the most common TMEM216 mutation to cause JBTS2 (Edvardson 
et al, 2010; Hamosh et al, 2005). A different mutation in the same codon (R73H) 
was reported to cause a Joubert-related disorder in one sibling and MKS in 
another within the same family, implying a very closely related aetiology for the 
two syndromes. The different patient outcomes despite identical mutations can 
be assumed to have resulted from interactions with other genetic or 
environmental factors that have not been identified. Among other symptoms, 
JBTS2 is associated with CNS, retinal, and renal defects (Edvardson et al, 
2010), phenotypically overlapping with MKS. 
Mutations in TMEM216 are responsible for approximately half of  Joubert 
syndrome 2 (JBTS2) cases; the remainder, while phenotypically 
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indistinguishable, are caused by mutations in the neighbouring TMEM138 gene, 
which does not display sequence or domain similarity to TMEM216 but is part of 
a co-regulated expression module with TMEM216 that appears to have an 
evolutionary origin at the amphibian to reptile transition (Venkatesh et al, 2012), 
and has been conserved across the higher vertebrates (Lee et al, 2012), though 
the association was lost in Xenopus and zebrafish lineages (Venkatesh et al, 
2012). Lee et al investigated TMEM138 expression in multiple tissues and 
found it to parallel that of TMEM216 (Lee et al, 2012), confirming co-expression 
of the module. This pattern, where adjacent nonparalogous genes form a 
combined genetic locus with mutations in either gene causing phenotypically 
identical genetic disorders, is rare but not unique: another example is the cystic 
kidney disease (ADPKD) caused by mutation in either PKD1 or TSC2 
(Kleymenova et al, 2001). TMEM138 mutations can also cause OFD(Li et al, 
2016); two TMEM216 JBTS 2 patients presented with additional symptoms 
resembling OFD (Valente et al, 2010). Despite this evidence of close genetic 
association and complementarity of function between TMEM216 and 
TMEM138, mutations in TMEM138 have not been reported to cause MKS 
(Szymanska et al, 2014), though this may indicate only that it is an uncommon 
cause of the phenotype (Szymanska et al, 2012). The relevance of TMEM138 
to the pathology of MKS therefore remains unclear, though the protein product 
localises to the ciliary TZ, where it may form part of the MKS-JBTS module (Li 
et al, 2016) so it is likely to be at least a modifier of ciliopathies that have an 
aetiology involving TZ complex disruption. The lack of evidence for TMEM138 
involvement in MKS, in contrast to other ciliopathies, may therefore be an 
indication that TZ disruption is not sufficient to cause MKS. 
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Expression and function 
The human TMEM216 gene contains multiple exons; authors differ on their 
interpretation of the sequence data, reporting the presence of 3 (Edvardson et 
al, 2010), 5(Lee et al, 2012), or 6 (Valente et al, 2010) exons. The gene 
produces a transcript processed to at least four major splice variants, the 
longest and most prevalent of which encodes a protein predicted to contain 148 
amino acids and four transmembrane domains (Valente et al, 2010). In addition 
to the major variants, alternative splicing produces many very short protein 
products (Valente et al, 2010); the importance of these remains unclear. The 
expression pattern (Table 1.2) is broadly similar to that of other ciliopathy 
genes, and the protein localises to the base of the cilium, consistent with the TZ 
and/or the basal body, as well as to the mitotic spindle (Valente et al, 2010), 
implying an association with the microtubule cytoskeleton. TMEM216 is 
required for ciliogenesis and for basal body docking to the cell surface (Valente 
et al, 2010). 
In TMEM216 fibroblasts, filamin A localises to actin stress fibres, a localisation 
pattern not seen in control fibroblasts (Valente et al, 2010), implying TMEM216 
regulates the distribution of this important actin-binding protein. When 
TMEM216 expression is absent or attenuated, RhoA signalling becomes 
hyperactivated without an alteration in overall RhoA level (Valente et al, 2010). 
This is similar to the effect of TMEM67 on RhoA signalling, suggesting that the 
two proteins function non-redundantly to regulate this pathway. The Dishevelled 
(Dvl) pathway, responsible for mediation of Rho activation at the apical cell 
surface required for ciliogenesis, was also altered, with increased 
phosphorylation of Dvl (Valente et al, 2010), and Valente et al further suggest 
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that TMEM216, RhoA, and Dvl may be part of a single complex associated with 
the centrosome that regulates docking to the cell surface.  
1.3.6 Interaction between TMEM67 and TMEM216 
The TMEM67 protein physically interacts with TMEM216 to form a complex 
(Valente et al, 2010). It has been proposed that the two function together as a 
cell surface receptor/coreceptor complex in the non-canonical Wnt pathway 
(Valente et al, 2010), a model made more plausible by the evidence linking 
TMEM67 to ROR2 in the Wnt pathway (Abdelhamed et al, 2015b). Alterations 
to PCP/RhoA signalling downstream of this receptor activity may be responsible 
for organising apical actin cytoskeletal remodelling to enable basal body 
docking to the apical cell surface, and thus initiation of ciliogenesis (Valente et 
al, 2010). RhoA activity has been shown to be required for actin reorganisation 
during ciliogenesis (Pan et al, 2007), and Rho and Dvl are proposed to act 
together as part of a module of PCP signalling components, required for basal 
body docking and other ciliary regulatory functions (Park et al, 2008), so this 
signalling role could be an upstream explanation for ciliogenesis defects.  
A cell surface receptor role for the TMEM67/TMEM216 complex prior to 
ciliogenesis would imply plasma membrane localisation, which has been shown 
for TMEM67 (Dawe et al, 2007b, 2009), but not for TMEM216. This may be 
simply due to the lack of published research on TMEM216. 
1.4 Summary and aims 
As recently as five years ago, ciliopathy pathologies were thought to stem 
entirely from ciliary dysfunction. Recent studies have challenged this model: 
many ciliopathy proteins are now known to have roles away from the cilium in 
processes including actin organisation and cell adhesion. Adhesions and actin 
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interact and mutually regulate (Defilippi et al, 1999); and the organisation of the 
actin cytoskeleton is critical for ciliogenesis (Pitaval et al, 2010; Boisvieux-Ulrich 
et al, 1990; Boisvieux Ulrich et al, 1987; Kim et al, 2015, 2010; Klotz et al, 1986; 
Lemullois et al, 1988, 1987; Pan et al, 2007; Park et al, 2008; Yan & Zhu, 
2013). It is therefore unclear whether developmental malformations seen in 
ciliopathy patients are due to signalling defects downstream of cilium defects, or 
due to defects in other cellular processes such as cytoskeletal organisation, cell 
migration, and cell adhesion, which are also at the root of ciliogenesis defects. 
While much can be said about the genetic basis of MKS and the other 
ciliopathies, and their clinical presentation in patients, we still know very little 
about the causal relationships responsible on a cellular and developmental 
level. While the role of ciliopathy proteins in the ciliary transition zone provides a 
possible explanation for some patient phenotypes, especially given the 
importance of the cilium in developmental signalling, it is unsatisfactory to 
explain all symptoms. The observation of apparently unrelated cellular 
phenotypes, and roles for ciliopathy proteins outside the cilium that have been 
recently reported, as well as the findings suggesting MKS proteins act as 
receptors and are present on the plasma membrane, raise the question: is MKS 
truly a disease with an entirely ciliary aetiology, or is there a more complex 
causal relationship involving processes outside the cilium that has yet to be 
identified? 
This thesis will investigate the hypothesis that MKS proteins are involved in the 
regulation of cell-substrate interaction, which influences cytoskeletal 
organisation and developmental signalling, and may therefore provide an 
alternative explanation for MKS patient phenotypes and reveal new therapeutic 
approaches.  
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This thesis will demonstrate that the TMEM67 protein is involved in the cell-
substrate focal adhesion complex, and using a combination of transcriptomic 
and proteomic approaches, will show that TMEM67 patient cells have major 
alterations to cell-substrate interaction, including changes to the extracellular 
matrix and to focal adhesions. It will also be shown that defective extracellular 
matrix is upstream of both cytoskeletal alterations and failure to build cilia in 
TMEM67 patient cells, revealing for the first time a dependency relationship 
between cellular phenotypes in MKS. It will furthermore be shown that these 
alterations can be restored by antagonising the Wnt or TGF-β developmental 
signalling pathways, which may be viable drug targets with the potential to 
improve patient outcomes. Finally, ECM-independent alterations to MKS patient 
cells will be investigated to identify possible causes of the ECM defect. 
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Chapter 2: Materials and Methods 
2.1 Cell culture 
Neonatal patient fibroblasts (hTERT-immortalised MKS3/TMEM67 [c.653G>T 
p.R217X]+[c.785T>C p.M261T] and MKS2/TMEM216 c.253C>T p.R85X) and 
age-matched controls (also hTERT-immortalised) were obtained from Colin 
Johnson (Leeds Institute for Molecular Medicine). Cells were cultured in 
Dulbecco’s Modified Eagle’s Medium: Nutrient Mixture F-12 (DMEM-F12; 
Gibco) supplemented with 20% Fibroblast Growth Medium (FGM; AMS 
Biotech), 10% foetal calf serum (Gibco), and 500 µg ml-1 G418 to select for cells 
with the hTERT immortalisation plasmid. Cells were grown at 37°C with 5% 
CO2, and split to sub-passage in TrypLE Express cell dissociation reagent 
(Gibco) at approximately 70% confluency. All experiments were performed with 
cells between passages 11 and 22. 
2.2 Surface coating with extracellular matrix protein 
ECM protein was diluted to 10 μg ml-1 in PBS, or for collagens I and IV, in 0.02 
N acetic acid, then the solution was sterilised by passage through a 0.2 micron 
filter. Glass surfaces were coated by covering with a thin layer of ECM solution. 
The covered surface was then incubated for 1 hour at room temperature (for 
cell spreading microscopy) or overnight at 4°C (for all other experiments) before 
washing with PBS to remove excess protein.  
All ECM protein was obtained from Sigma-Aldrich. Collagen I solution from rat 
tail: product code C3867. Collagen IV derived from human placenta: product 
code C5533. Recombinant human vitronectin: product code SRP3186. Human 
plasma fibronectin: product code F2006. Laminin derived from human placenta: 
product code L6274. 
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2.3 Cell-derived matrix isolation 
To strip cells and purify cell-derived matrix (CDM), a method based on (Rashid 
et al, 2012) was used. Cells were grown to confluency in adherent culture, then 
left for 4 days post-confluency to synthesise mature ECM. Growth media was 
removed, cells were washed with PBS, then lysed for 4 minutes at room 
temperature in a solution of 20 mM ammonium hydroxide (Sigma-Aldrich), 0.5% 
Triton X-100 in PBS. After a final PBS wash to remove debris and residual lysis 
solution, the remaining ECM material (the CDM) was either used directly in 
further experiments, fixed in situ for SEM imaging (see below), or recovered into 
solution mechanically with a cell scraper (Fisher). For western blot analysis, the 
CDM was recovered in Laemmli reducing sample buffer and used immediately 
or stored at -20°C.  
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2.4 Antibodies and probes 
Antigen Host 
species 
Supplier Clone ID / 
cat no. 
IF fix IF 
dilution 
WB dilution 
Primary antibodies 
acetylated alpha 
tubulin  
mouse AbCam 6-11B-1 MeOH 1:200 N/A 
TMEM67 (MKS3) rabbit ProteinTech 13975-1-
AP 
2% FA 1:500 1:5000 
Vinculin mouse Millipore MAB3574 2% FA 1:400 1:5000 
VDAC1 rabbit Santa Cruz FL-283 N/A N/A 1:1000 
Filamin A goat AbCam ab11074 4% FA 1:100 1:1000 
Actin clone c4 mouse Sigma C4 MeOH 1:200 1:2000 
Laminin mouse DSHB 2E8 N/A N/A 1:25 
Collagen 4 mouse DSHB M3F7 N/A N/A 1:100 
Secondary antibodies 
anti-rabbit AlexaFluor 
488 Fab fragment 
goat Molecular 
Probes 
  1:1000  
anti-rabbit AlexaFluor 
594 Fab fragment 
goat Molecular 
Probes 
  1:1000  
anti-mouse AlexaFluor 
488 Fab fragment 
goat Molecular 
Probes 
  1:1000  
anti-mouse AlexaFluor 
594 Fab fragment 
goat Molecular 
Probes 
  1:1000  
anti-rabbit HRP donkey Jackson    1:20 000 
anti-mouse HRP donkey Jackson    1:20 000 
anti-goat HRP donkey Jackson    1:20 000 
 
Table 2.2: Primary and secondary antibodies used in this thesis 
 
The actin-binding phallotoxin phalloidin, conjugated to Alexa fluor 594 
(Molecular Probes), was used to label filamentous actin at a dilution of 1:500. 
Anti-collagen IV was deposited to the DSHB by Furthmayr, H. (DSHB 
Hybridoma Product M3F7), and anti-laminin was deposited to the DSHB by 
Engvall, E.S. (DSHB Hybridoma Product 2E8).  
2.5 Western blotting 
Polyacrylamide gels were made with 10% or 8% acrylamide depending on 
expected band size.  
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Samples were reduced by boiling in Laemmli reducing sample buffer at 95°C for 
5 minutes, then loaded alongside either ColourPlus prestained protein marker 
(New England Biosciences) or PageRuler Plus prestained protein ladder 
(Thermo Scientific). Protein was separated by electrophoresis at 75-150 volts 
for 1-2 hours, and transferred to a nitrocellulose membrane using either a wet 
transfer system (Mini-Protean 3, BioRad) at 150 mA for 1 hour, or a semi-dry 
transfer system (Trans-Blot SD, BioRad) at 25 volts for 1 hour. 
Membranes were blocked with continuous rotation at room temperature for 1 
hour in PBS with 0.1% Tween-20 (Fisher Scientific) and 5% Marvel milk powder 
(Premier Foods Group, UK), or in PBS with 0.1% Tween-20 and 5% BSA. To 
probe membranes, antibodies were diluted in blocking solution, and membranes 
were incubated in primary antibody with continuous rotation at room 
temperature for 1 hour or at 4°C overnight, washed for 3 x 20 minutes in PBS 
with 0.1% Tween-20, incubated in secondary antibody with rotation at room 
temperature for 30 minutes to 1 hour, and washed for 3 x 20 minutes in PBST. 
To visualise protein, the membrane was treated with ECL reagent and exposed 
to X-ray film (Super RX, FujiFilm). 
Membranes were stripped for re-probing by incubation in stripping buffer (100 
mM glycine, 2% SDS, pH 2.0) for 2 x 10 minutes at room temperature, washed 
with PBS for 3 x 10 minutes, then re-blocked, treated with ECL, and exposed to 
check for residual signal before re-probing. 
2.6 Immunofluorescence and phalloidin staining 
For formaldehyde fixation, cells were fixed in 2% or 4% formaldehyde in 
cytoskeleton buffer (10 mM MES pH 6.1, 138 mM KCl, 3 mM MgCl, 19 mM 
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EGTA pH 7.0) with sucrose at room temperature for 20 minutes, washed with 
PBS, then permeabilised in PBS with 0.5% Triton X-100 for 10 minutes.  
For methanol fixation, cells were fixed in -20°C methanol for 10 minutes, rehydrated 
in PBS at room temperature for 10 minutes, then further rehydrated in fresh PBS for 
another 10 minutes. 
Cells were blocked in AbDil (PBS with 2% BSA) for 15 minutes or more before 
incubation with the primary antibody for 1 hour. Cells were then incubated with 
the secondary antibody for 30 minutes, and for some experiments stained with 
DAPI (1 μg ml-1) for 1-2 minutes. After each incubation the cells were washed 
with PBS. Finally, the coverslips were mounted onto glass slides with 
Vectashield (Vector Laboratories) and sealed with clear nail polish (Boots, UK). 
While phalloidin is not an antibody, its staining protocol is similar to that for 
immunofluorescence. Labelled phalloidin is used in the place of a primary 
antibody and requires no secondary. 
2.7 Transfection 
Cells were transfected using an Amaxa Nucleofector electroporation device with 
transfection kit R (Lonza), according to the manufacturer’s instructions. For 
each transfection, a subconfluent T-25 flask of cells were dissociated from the 
culture surface, pelleted, and resuspended in 80 µl of transfection buffer. The 
transfection buffer contained 65 µl nucleofector solution R (Lonza), 15µl 
supplement 1 (Lonza), and 1 µg of plasmid DNA. The resulting cell suspension 
was loaded into an electroporation cuvette (Lonza) and electroporated with 
program D-023. After electroporation, the suspension was immediately 
transferred into a T-25 flask with 3 ml of fresh media. Since all transfections 
85
  
described here involved only transient expression, experiments were performed 
with cells between 48 and 96 hours post- transfection. 
2.8 Light microscopy 
For cell spreading, cell volume measurement, and immunofluorescence 
experiments, samples were imaged using a Zeiss Axio Observer Z1 inverted 
microscope, controlled by AxioVision (Carl Zeiss). Images were acquired by a 
CoolSnap HQ2 camera (Photometrics) and processed in AxioVision, 
ImageJ/FIJI (National Institutes of Health), and MetaMorph (Molecular Devices). 
The microscope was equipped with high-efficiency filters which have steep cut-
offs and high transmittance, and therefore represent the tightest excitation and 
emission efficiency available from the manufacturer. Single-fluorophore control 
experiments with fluorescent microbeads (Fisher) could detect no bleedthrough 
between the channels even at high exposures. 
Filter set Product ID Manufacturer 
Excitation 
(nm) 
Emission 
(nm) 
49 DAPI shift free 488049-9901-000 Carl Zeiss 365 445/50 
38 HE eGFP shift 
free 489038-9901-000 Carl Zeiss 470/40 525/50 
43 HE Cy 3 shift free 489043-9901-000 Carl Zeiss 550/25 605/70 
 
Table 2.1: Filter sets used in Zeiss Axio Observer Z1 microscope. Excitation and 
emission values are given as peak and spread – for example, filter set 38 has an 
excitation peak at 470 nm with a spread 20 nm to either side, for a total spread of 40 
nm. 
 
2.9 Scanning electron microscopy 
Samples for SEM were fixed in 2.5% glutaraldehyde, 1% formaldehyde, 0.1 M 
sodium cacodylate pH 7.1 or in 2.5% glutaraldehyde, 2% formaldehyde, 0.1% 
picric acid, 100 mM phosphate pH 6.5, then post-fixed in osmium tetroxide, 
dehydrated through a graded ethanol series, critical point dried and gold coated 
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with an Alto 2100 chamber (Gatan, Oxfordshire). Samples were imaged with a 
JSM-6390LV scanning electron microscope (JEOL, Tokyo). 
2.10 Cell spreading analysis 
For cell spreading experiments, imaging took place within a heated environment 
chamber at 37°C. Cells were dissociated from the cell culture surface then 
plated onto pre-warmed ECM-coated glass-bottom dishes 1-2 minutes before 
the time series began, and imaged at multiple z-axis planes every minute for 90 
minutes; or for logarithmic analysis, every 5 seconds for 20 minutes. When 
processing these time series, out-of-focus planes were discarded. Cell area was 
measured using the freehand drawing tool in ImageJ/FIJI. At least three cells 
were measured for each combination of cell line and substrate across at least 
two biological repeats. 
2.11 Cell volume measurement 
Control and TMEM67 cells were dissociated from the culture surface with 
trypLE Express, then plated still in dissociation buffer onto a glass-bottom dish. 
Under these conditions, the cells could not spread or form adhesions and 
remained spherical. The cells were imaged, and from these images, 
measurements were taken of the cell diameters with the line tool in ImageJ/FIJI, 
and the cell volumes were calculated. Over 100 cells were measured for each 
cell line across three biological repeats. 
2.12 Adhesion measurement 
Cells were plated on ECM-coated coverslips for 20 minutes at 37°C, 5% CO2, 
then fixed in 2% formaldehyde and immunostained for vinculin as described 
above to label adhesions. Images were acquired, then using ImageJ/FIJI’s 
rectangular selection tool, a 10 μm by 10 μm region at the right edge of the cell 
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was selected as the region of interest. Since the circular coverslip was randomly 
rotated during mounting, this was effectively a randomly chosen region of the 
cell periphery. The fluorescently labelled adhesions within this region were 
manually counted, and measured using the line and freehand measurement 
tools in ImageJ for area, length, and width. A figure for coverage was derived by 
dividing the sum of the areas of adhesions in the region by the total region size 
(100 μm2) to give the proportion of the region covered by adhesions. At least 25 
cells were imaged for each combination of cell line and substrate over two 
biological repeats. 
2.13 Micropipette aspiration 
Glass micropipettes were pulled from borosilicate glass capillaries (outer 
diameter 1.5 mm, inner diameter 0.86 mm, Clark Electromedical Instruments, 
Reading, UK) with an element puller (Model P-87, Sutter Instrument Co., 
California, USA), then mounted on a micromanipulator on the stage of a 
brightfield microscope (Laborlux 12HL, Ernst Leitz, Wetzlar, Germany) and 
manually forged with a heated filament until a smooth aperture was produced. 
Prior to use, the micropipette tips were incubated in 1% BSA overnight at 4°C. 
To create observation chambers, a glass slide and coverslip were assembled 
together, held approximately one millimetre apart by a parafilm spacer. The 
chambers were filled with cell suspension and observed with an inverted 
microscope (IX-51, Olympus, Hamburg, Germany) under DIC illumination.  
Micropipettes were back-filled with cell culture medium using a syringe with a 
fine-gauge needle, and attached to a pressure-generating apparatus controlled 
by the height of an adjustable water column. All water in the system was 
replaced at the start of each session with ultrapure water degassed in a vacuum 
chamber, and the system was checked for leaks or air bubbles. The 
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micropipette was mounted on a micromanipulator (PT3A/M, Thorlabs, New 
Jersey, USA) and the tip of the micropipette introduced into the chamber. An 
individual cell was captured and held at the aperture of the micropipette by 
minimal aspirating pressure (< 50 Pa). Aspirating pressure was increased to 
500 Pa and the resulting change in projection length as the cell moved into the 
micropipette barrel was imaged. Images were acquired by an AVT Stingray F-
145B CCD camera. From these movies, projection lengths were measured 
every 20 seconds relative to the length at t = 0. Measurements were taken with 
the line tool in ImageJ/FIJI. At least 7 cells were analysed per cell line across 
three biological repeats. Since micropipette apertures were inconsistent due to 
the manual forging method, each micropipette was used to aspirate at least one 
cell of each cell line to ensure a direct comparison was possible. 
2.14 Micropipette data analysis 
Projection lengths were analysed according to the standard linear solid (SLS) 
model. This models the cell as a viscoelastic solid (Jones et al, 1999; Sato et al, 
1990; Theret et al, 1988), and can be expressed: 
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and where L(t) is the length of the cellular projection into the micropipette at 
time t, φ is a dimensionless parameter representing the wall thickness effect 
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(derived from the ratio of inner radius to wall thickness), a is the inner radius of 
the micropipette, and ΔP is the step change in aspirating pressure.  
The elastic parameters k1 and k2, and the apparent viscosity µ, were 
determined for each cell using  Scilab (Scilab Enterprises). Parameter values 
were found by fitting each set of observed projection lengths to the SLS 
expression via Scilab’s lsqrsolve() function, which implements a Levenberg-
Marquardt algorithm to minimise the sum of squares of the difference between 
the enumeration of the expression and the experimental result for each data 
point (Gill & Murray, 1978). This yielded approximations to the parameter values 
k1, k2, and µ. A cellular equilibrium Young’s modulus E∞, which quantifies the 
mechanical stiffness of the cell, was thus derived from k1: 
    
 
 
   
 
2.15 Actin co-sedimentation 
This method was adapted from the method of Brainard et al (2005) with advice 
from James Wakefield. 
Approximately 107 human fibroblasts (10 confluent T-25 flasks) were 
resuspended in PBS after dissociation with TrypLE Express. The cells were 
pelleted by centrifugation at 2000 RPM for 3 minutes, washed by resuspension 
in PBS, and pelleted again. The pellet was snap-frozen in liquid nitrogen and 
stored at -80°C. 
Keeping all tubes and reagents on ice, the cell pellet was resuspended in 0.5 ml 
C-buffer (50 mM HEPES pH 7.4, 50 mM KCl, 1 mM MgCl, 1 mM EGTA, 0.1% 
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Triton X-100,  protease inhibitor). The suspension was transferred to a Dounce 
homogeniser tube (Wheaton, USA) and homogenised for 3 x 5 second bursts 
with a pestle attached to a power drill (KR500RE; Black & Decker, UK). The 
homogenate was transferred to an ultracentrifuge tube and centrifuged for 30 
minutes, at 4°C, 100 000 g (55 000 rpm) with a TLA-120.1 rotor in an Optima 
MAX Ultracentrifuge (Beckman Coulter, USA). The clear phase was recovered 
using a syringe and fine-gauge needle, and the pellet was discarded. 20 µl of 
the clear phase was taken and stored as a total lysis sample in Laemmli 
reducing sample buffer at -20°C. The remainder was split into positive and 
negative samples. The negative sample was treated with 100 µM nocodazole, 
50 µM latrunculin B, and kept on ice. The positive sample was treated with 100 
µM nocodazole and 2 mM ATP (Melford), incubated at 37°C for 10 minutes to 
promote polymerisation of actin, then treated with 20 nM phalloidin at 37°C for 
10 minutes to stabilise polymerised actin. 
Samples were layered in ultracentrifuge tubes above a 400 µl cushion of C-
buffer/glycerol (C-buffer as above, without inhibitors, with 40% glycerol) and 
centrifuged for 1 hour at 4°C, 100 000 g. The clear supernatant above the C-
buffer/glycerol layer was retrieved and stored at -20°C. The top of the C-
buffer/glycerol layer was washed with fresh C-buffer to remove residue of 
supernatant, then all remaining solution was removed. The pellet was 
resuspended in Laemmli reducing sample buffer and stored at -20°C. 
Total lysis, supernatant, and pellet samples were analysed for protein content 
via western blot. The experiment was repeated twice, giving the same result 
both times. 
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2.16 Total mRNA isolation 
For RNA-sequencing differential expression analysis, total mRNA was isolated 
from control and TMEM67 fibroblasts using a Dynabeads mRNA DIRECT Kit 
(Ambion/Life Technologies) according to the manufacturer’s instructions. A 
DynaMag-2 magnetic rack (Life Technologies) was used to pellet the 
Dynabeads. After the final wash, mRNA was eluted and recovered in 13 µl 
elution buffer (10 mM Tris-HCl pH 7.5). The mRNA was split into a 3 µl quality 
control sample and a 10 µl sample for sequencing. Both samples were snap-
frozen in liquid nitrogen and stored at -80°C before RNA-sequencing. 
2.17 Differential expression analysis and gene set enrichment 
analysis 
Differential expression analysis was performed on an Illumina RNA-seq 
platform. The mRNA was reverse transcribed and quality assessed with a 
BioAnalyzer (Agilent). Illumina barcoding was performed using the ScriptSeq v2 
RNA-seq Library Preparation Kit (Epicentre) and sequencing was performed 
using a HiSeq 2500 sequencer (Illumina). Data quality was assessed using 
FastQCReads, low-quality reads filtered out and adaptor sequences removed 
using RobiNA. Trimmed reads were aligned against the human genome using 
Tophat2 (Center for Computational Biology, Johns Hopkins University), and 
Cufflinks (Cole Trapnell, University of Washington) was used for initial 
processing and automated annotation of data. The online DAVID resource was 
employed for gene set enrichment and functional annotation clustering analysis. 
2.18 Focal adhesion isolation 
Adapting the method of Kuo et al (2012), cells were grown to confluency in 10 
cm diameter cell culture dishes then left for 4 days post-confluency to 
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synthesise ECM and form mature adhesions. Culture medium was removed by 
aspiration and PBS washing. Cells were hypotonically shocked with 
triethanolamine-containing low ionic strength buffer (2.5 mM triethanolamine, 
pH 7.0) for 15 minutes to induce rounding, then washed off the surface with 
hydrodynamic force applied by a WaterPik dental water jet (Interplak dental 
water jet WJ6RW, Conair) at pressure setting 3. The WaterPik was loaded with 
PBS supplemented with broad-spectrum protease inhibitor tablets (Fisher) to 
minimise degradation of material. The jet was applied to the culture surface 
from a distance of approximately 1 centimetre, at a 90° angle, and moved 
around the surface in repeated cross-hatch and spiral patterns over 
approximately 30 seconds per dish to ensure even coverage. The remaining 
material containing adhesion and ECM protein was then recovered from the 
surface by scraping in RIPA buffer with mass-spectrometry grade protease and 
phosphatase inhibitors (MS-SAFE; Sigma-Aldrich), snap frozen in liquid 
nitrogen, and stored at -80°C. 
2.19 Tandem mass tag mass spectrometry 
Six 100 µl samples of adhesion fraction (isolated as described above), 
representing three biological repeats of control and TMEM67 cells, were 
submitted to TMT MS/MS analysis. The samples were digested with trypsin and 
labelled with Tandem Mass Tag reagents according to the manufacturer’s 
protocol (Thermo Fisher Scientific). After labelling, the samples were combined, 
and the pooled sample was fractionated with an Ettan LC system (GE 
Healthcare). NanoLC-MS/MS analysis was performed using a Thermo LTQ-
Orbitrap Velos mass spectrometer.  Data was processed and quantified with 
Proteome Discoverer 1.2 (Thermo Scientific) and searched against the Uniprot 
human proteome and analysed for quality with Mascot (Matrix Science).  
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2.20 Statistical analysis  
Numerical and statistical analyses were performed using Excel (Microsoft 
Corporation), QuickCalcs (GraphPad), Prism (GraphPad), and Scilab (Scilab 
Enterprises). For all data, D’Agostino’s K2 test was used to assess normality.  
Differential expression datasets were aligned to the human genome with 
Tophat2 and quantification and statistical analysis performed with Cufflinks. 
Significantly altered transcripts were identified in Cufflinks by multiple-
comparison t-tests corrected for false discovery rate to account for the large 
number of tests. Functional annotation clustering was performed using the 
online DAVID resource. 
Mass spectrometry data was analysed by a similar approach, where 
significantly altered abundance of proteins was assessed by multiple-
comparison t-tests corrected for false-discovery rate. 
Data for adhesion size, number, and coverage were analysed in a one-way 
ANOVA test comparing each measurement between control and MKS cells, 
with Bonferroni post-hoc analysis to determine which factor was significantly 
altered. A parametric test was preferred for this analysis because the data was 
normally distributed. 
Cell volume measurements and ciliogenesis of cells in experiments with only 
two groups were analysed with Student’s t test, appropriate for simple 
comparison of two groups which are normally distributed, as was the case in 
these datasets. Ciliogenesis of cells in experiments with more than two groups 
was analysed with Pearson’s χ2 test. This test is appropriate for comparison of 
non-continuous data such as counts of population (in this case, ciliated cells vs 
non-ciliated cells). Ciliogenesis of cells plated on collagen IV or laminin involved 
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a large number of factors that could be responsible for any observed effect 
(three cell lines and six substrates), so was analysed by one-way ANOVA with 
Bonferroni post-hoc analysis for multiple comparisons. Parametric tests were 
chosen because the data was normally distributed.  
For analysis of actin organisation in MEFs, since the data was not normally 
distributed, the non-parametric Kruskal-Wallis test was used. Since four groups 
were to be compared to a single control, Dunn’s post-hoc correction for multiple 
comparisons was used to determine which groups were significantly altered. 
For analysis of micropipette-derived cellular equilibrium Young’s moduli, a one-
way ANOVA was used with Dunnet’s post-hoc analysis, which is appropriate 
when data is normally distributed and multiple groups are to be compared with a 
single control group. 
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Chapter 3: TMEM67 is a focal adhesion protein required for 
adhesion complex and extracellular matrix morphology and 
composition 
3.1 Introduction 
TMEM67 has been reported in many subcellular localisations including 
basolateral actin (Adams et al, 2012). Basolateral actin is typically in close 
association with adhesions. Given that TMEM67 is a predicted transmembrane 
protein proposed to serve a role in membrane tethering as part of the 
MKS/JBTS module in the cilium (Craige et al, 2010; Smith et al, 2006), it is 
plausible that TMEM67 may also be involved in cell surface interactions at focal 
adhesions.  
Adhesions are complex signalling platforms involving a large number of 
proteins; recent studies have proposed numbers of candidate adhesion proteins 
in the thousands (Kuo et al, 2011; Zaidel-Bar et al, 2007; Horton et al, 2015). 
Adhesion-dependent interactions and signalling are key to the organisation of 
the extracellular matrix (ECM), and to the transduction of ECM-mediated signals 
which are essential for development (Boudreau & Jones, 1999). Therefore, 
alterations to adhesions in TMEM67 patient cells could underlie patient 
phenotypes, such as the excess ECM secretion in liver fibrosis. 
In this chapter, quantitative transcriptomics reveals that mRNA transcripts 
associated with ECM and adhesion functions are significantly altered in patient 
cells compared to controls, suggesting a possible role for TMEM67 in ECM 
organisation that could be important for disease aetiology. The association of 
TMEM67 with actin and focal adhesions is investigated, and changes to the 
TMEM67 patient cell adhesion proteome (adhesome) and extracellular matrix 
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proteome (matrisome) are quantified. Finally, the morphology of adhesions and 
ECM of MKS patient cells are shown to be altered. 
3.2 TMEM67 patient cells exhibit altered expression of ECM-
associated genes 
To investigate the global changes to cellular processes in MKS, Illumina RNA-
seq differential transcriptional profiling of TMEM67 patient fibroblasts, together 
with age-matched control fibroblasts, was performed. The experiment was 
replicated across two biological repeats for each cell line. 1376 transcripts were 
found to be significantly altered in abundance, with q < 0.05 (t-tests with 
multiple comparisons: q is a false discovery rate-adjusted p that corrects for 
large multiple comparisons). For a full list of significantly altered transcripts, see 
Appendix 1, table 1. The list of differentially expressed transcripts was 
submitted for gene set enrichment analysis with functional annotation clustering 
using the online DAVID resource, revealing disproportionately altered 
expression of ECM and adhesion genes (Figure 3.1 A).  In particular, the single 
most enriched cluster detected by DAVID represented genes associated with 
the extracellular matrix, and among the most enriched was a cluster associated 
with cell-substrate junctions (Figure 3.1 A). Moving from this high-level analysis 
to investigating individual genes, it was found that among the genes within the 
dataset annotated as ECM-associated (Figure 3.1 B), laminin (Figure 3.1 B, 
purple) and collagen transcripts were altered, with expression of laminin α2 in 
particular almost abolished, and two collagen IV transcripts (Figure 3.1 B, 
yellow) substantially under-expressed compared to control cells. Additionally, 
metallopeptidases (Figure 3.1 B, green), which degrade and remodel the 
extracellular matrix, had predominantly increased expression. 
100
Figure 3.1: TMEM67 patient cells exhibit altered expression of ECM- and 
adhesion-associated genes.
A: The top 20 enriched clusters identified by functional annotation clustering 
analysis (based on Cellular Component GO annotations) of Illumina RNA-seq 
differential expression data from TMEM67 patient cells (with respect to age-
matched control cells). 
B: Fold change in expression of ECM-associated genes in TMEM67 patient 
cells from the same dataset.
0 1 2 3 4 5 6 7
Extracellular matrix
Plasma membrane
Cell-substrate junction
Insoluble/membrane fraction
Cytoskeleton
Adherens junction
Tight junction
Vesicle
Centrosome
Golgi
Sarcomere/myofibril
Vesicle lumen
Synapse
Clathrin coated vesicle/trans-Golgi
Lytic vacuole
Chromosome
Organelle/nuclear lumen
Kinetochore
Golgi/ER membrane
Nucleoplasm/TF part
Enrichment scoreA
B
101
  
To determine whether these expression changes were reflected in changes to 
actual protein levels in the ECM, cell-derived matrix (CDM) was purified from 
control and TMEM67  patient cells at 2, 4, 6, 8, and 10 days after plating. These 
samples were probed via Western blot for collagen IV and laminin (Figure 3.2, 
A), showing that while control CDM had high levels of collagen IV from day 6 
onward, and high levels of laminin on day 2 that diminished in subsequent days, 
TMEM67 patient CDM contained reduced levels of both in comparison at each 
timepoint. A Coomassie stain showed that the samples contained comparable 
total protein levels (Figure 3.2 B). 
3.3 TMEM67 is a focal adhesion protein 
Regulation of ECM synthesis and composition is dependent on signalling 
through the focal adhesion complex (Humphrey et al, 2014). Disruption of both 
ECM and adhesion gene expression in TMEM67 patient cells might be 
explained if TMEM67 has a function in the focal adhesion complex. To 
investigate the localisation of TMEM67, human fibroblasts were fixed and 
labelled to visualise TMEM67 and actin via immunofluorescence (Figure 3.3 A). 
In agreement with the findings of Adams et al (2012), TMEM67 co-localised with 
F-actin near the basolateral cell surface. To confirm a physical association 
between TMEM67 and F-actin, a co-sedimentation assay was performed with 
human fibroblast cell homogenate in the presence and absence of phalloidin to 
stabilise F-actin (Figure 3.3 B). TMEM67 was found to co-sediment with the F-
actin pellet, consistent with a (direct or indirect) physical interaction. Three 
TMEM67 bands were observed, of approximate molecular mass 45, 50, and 55, 
possibly representing the smaller, uncharacterised TMEM67 isoforms identified 
by Dawe et al (2009) that are found only in subconfluent, non-ciliated cells.  
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Figure 3.2: TMEM67 patient cell-derived ECM contains reduced levels of 
collagen IV and laminin protein.
A: Western blots of purified ECM deposited over time by control and TMEM67 
patient cell cultures, probed for collagen IV and laminin. B: Coomassie stains 
showing total protein over the same time series.
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Figure 3.3: TMEM67 localises to basolateral actin filaments and co-
sediments with stabilised F-actin.
A: TMEM67 localises to basolateral actin filaments. Human fibroblasts were 
immunolabelled for TMEM67 (green), stained for actin with phalloidin (red), 
and for nuclei with DAPI. Bar: 20 μm. Single fluorophore control experiments 
showed no bleedthough between these channels even at high exposures. 
B: Western blot of samples from an actin co-sedimentation assay, showing 
TMEM67 physically associates with F-actin in human fibroblasts.
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Given that basolateral actin cables often directly overlay and connect to 
adhesions (Xu et al, 2012), it was next investigated whether TMEM67 was 
present in the focal adhesion complex. Human fibroblasts were fixed and 
immunolabelled for TMEM67 and the adhesion marker vinculin (Figure 3.4 A). 
TMEM67 was found to co-localise with vinculin adhesion patches (Figure 3.4 A, 
blue arrows). To confirm the presence of TMEM67 at cell surface adhesions, 
two different focal adhesion preparations were performed (Figure 3.4 B). Prep 1 
was based on the method of Kuo et al (2012) using hypotonic treatment and 
hydrodynamic force. Prep 2 was based on the method of Rashid et al, (2012), 
using high alkaline treatment. In both preparations, vinculin was detected by 
western blot alongside TMEM67 and filamin A, a known direct TMEM67 
interactor (Adams et al, 2012) and focal adhesion protein (Kuo et al, 2011). 
VDAC1, a mitochondrial porin not associated with adhesions or the cell surface, 
was found to be excluded from the preparations, indicating successful removal 
of cytoplasmic material. In contrast to the three TMEM67 bands observed in 
whole cell lysate (Figure 3.4 B) and actin co-sedimentation assays (Figure 3.3 
B), only a single band was observed in focal adhesions prepared by either 
method, suggesting isoform-specific  functions. 
3.4 Tandem mass tag proteomics reveal major alterations to the 
TMEM67 patient cell adhesome 
To determine the effect of the absent TMEM67 protein on adhesions in 
TMEM67 patient cells, tandem mass tag comparative mass spectrometry (TMT-
MS/MS) was performed (Figure 3.5) to quantitatively determine differences in 
the adhesome and matrisome in patient cells compared with age-matched 
controls grown under identical conditions. The adhesion/ECM fraction was 
isolated from control and TMEM67 patient cells, and relative protein content 
105
Figure 3.4: TMEM67 is a focal adhesion protein. 
A: TMEM67 co-localises with the focal adhesion marker vinculin. Human 
fibroblasts were immunolabelled for TMEM67 (green) and vinculin (red). 
Single fluorophore control experiments showed no bleedthough between these 
channels even at high exposures. Arrows: an area of co-localisation. Bar: 
20 μm. B: Western blot showing TMEM67 and filamin A present along with 
vinculin in two different focal adhesion preparations, while VDAC1 is excluded.
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Figure 3.5: Workflow for Tandem Mass Tag (TMT) quantitative mass 
spectrometry of the adhesion/ECM fraction.
TMEM67 patient cells and age-matched controls were plated until mature 
adhesions had been formed, then the cells were removed by hypotonic 
treatment and hydrodynamic force. The residue remaining after cell removal 
is enriched in adhesion and ECM proteins. This fraction is recovered and 
processed for mass spectrometry. Each sample is labelled with a different 
tandem mass tag, after which the samples are combined and analysed in a 
single liquid chromatography mass spectrometry (LC-MS) experiment. 
Control cells TMEM67 patient cells
Cells removed leaving adhesion/ECM proteins on surfaceAdhesion/ECM fraction recovered and processed for mass spectrometry
Samples labelled with tandem mass tags
All samples combined
Analysis by LC-MS
TMT-126 TMT-128 TMT-130TMT-127 TMT-129 TMT-131
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quantified over three biological repeats for each cell line. A Mascot score was 
assigned to each detected protein, derived from a combination of criteria 
including number and size of matching peptides against the expected human 
proteome. Since lower Mascot score represents proteins with higher probability 
of erroneous detection, results with Mascot score < 30 (representing a 
probability of erroneous detection > 10-3) were excluded from further analysis. 
This threshold is arbitrary, but is widely used in the literature (for example, 
(Hughes et al, 2008; Hauck et al, 2010)).  
The remaining 1394 proteins were compared to previously published proteomic 
datasets to assess quality. A previous, methodologically similar study of the 
adhesion proteome by Kuo et al. identified 1917 candidate adhesion proteins 
(Figure 3.6 A, purple circle), 754 of which were found reproducibly across 
multiple experimental repeats (Figure 3.6 A, light blue circle) (Kuo et al, 2011). 
Pairwise comparisons showed that the present study had considerable overlap 
with these results (Figure 3.6 A); of the 1394 proteins detected (Figure 3.6 A, 
red circle), 797 (57%) matched Kuo et al’s full adhesome list. Of their list of 754 
reproducible adhesome proteins, 417 were detected in the present study (55%). 
This overlap, consistent with that found between Kuo et al’s three datasets, 
indicates recovery of the adhesion fraction was successful. (See Appendix 1 for 
lists of raw data and matching proteins). 
The matrisome is less well-studied than the adhesome, but a recent study used 
a combination of in silico and in vivo approaches to identify candidate proteins 
(Naba et al, 2011). Working in silico (Figure 3.6 B, left),  Naba et al identified 
1062 candidate proteins (Figure 3.6 B left, teal circle), including a “core 
matrisome” of 281 proteins (Figure 3.6 B left, green circle). Pairwise 
comparisons with the present study had some overlap with these; of the 1394 
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Figure 3.6: The protein content of the recovered adhesion/ECM fraction is 
consistent with current knowledge of the adhesion and ECM proteomes.
Venn diagrams showing overlap between proteins identified by this study and 
(A) those identified in a methodologically similar adhesome study by Kuo et al.; 
(B) proteins identified in matrisome studies performed both in silico and in vivo 
by Naba et al.
Kuo et al.Full adhesome1917 proteins
Kuo et al. Reproducible adhesome754 proteins
417380597 337 783
A: Adhesome
This study1394 proteins
Naba et al.Total matrisome (in silico) 1062 proteins Naba et al. Core matrisome (in silico) 281 proteins
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proteins detected, 108 (8%) matched Naba et al’s total matrisome. Of their 281 
core matrisome proteins, 51 were detected in the present study (18%). Working 
in vivo (Figure 3.6 B, right), Naba et al found 143 and 107 candidate proteins in 
lung (Figure 3.6 B right, blue circle) and colon (Figure 3.6 B right, green circle) 
ECM respectively, totalling 166 distinct candidate proteins (with overlap). Of 
these, 53 were also detected in the present study (32%). This level of overlap 
indicates that the present study’s recovery of ECM proteins, while not as 
reliable as the recovery of adhesion proteins, is sufficient for analysis.  
To analyse the alterations to adhesion and ECM proteins in the recovered 
fraction, the TMEM67 patient cell protein levels were compared to those of 
controls. Widespread changes in abundance were found. Of the 1394 proteins 
detected, 638 had significantly altered abundance. Of these 638, only 30 had 
increased abundance, with the vast majority (608) reduced. The 608 proteins 
with reduced abundance included 198 of the “reproducible” adhesome proteins 
identified by Kuo et al, representing 26% of the reproducible adhesome and  
47% of the reproducible adhesome proteins also detected in the present study. 
Only 3 of the 30 proteins with increased abundance were reproducible 
adhesome proteins (MAP4, P4HB, and tenascin C). In comparison to Kuo et 
al’s full adhesome, 344 proteins were lower in abundance (representing 18% of 
the full adhesome), while only 14 were increased. These results indicate major 
reductions in the protein content of adhesions in TMEM67 patient cells.  
To investigate the changes to the adhesome and matrisome, knowledge-based 
annotation of the list of significantly altered proteins was undertaken. Proteins of 
interest were identified within six exclusive functional categories (Figures 3.7-
3.9): core adhesion components (excluding proteins that fell into any other 
category) (Figure 3.7 A), transmembrane receptors (including integrins) (Figure 
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Figure 3.7: Abundance of core adhesion, transmembrane receptor, and 
structural ECM components are altered in the adhesion/ECM fraction of 
TMEM67 patient cells.
Graphs show abundance fold change (on a logarithmic scale) for individual 
proteins within category, with respect to control cells. Proteins were categorised 
via knowledge-based annotation.
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3.7 B), structural ECM components (including major ECM proteins such as 
collagen and laminin) (Figure 3.7 C), membrane trafficking proteins (Figure 3.7 
A), ECM-associated signalling molecules (which are secreted into and typically 
sequestered by the ECM) (Figure 3.7 B), ECM remodelling factors (such as 
matrix metallopeptidases) (Figure 3.7 C), actin binding proteins (Figure 3.9 A), 
and non-actin-binding actin regulatory proteins (Figure 3.9 B).  
Only a few core adhesion components were identified (Figure 3.7 A), which 
were all present with lower abundance in TMEM67 patient cells, with fold 
changes between 0.6 and 0.9. 
A total of 22 significantly altered transmembrane receptors were identified, all 
but one of which were reduced (Figure 3.7 B). Eleven of these were highly 
reduced with fold changes below 0.5; the most reduced were alpha-4 integrin 
and CD44, though several other integrins were also represented including beta-
1 integrin. 
The 20 structural ECM components identified were all reduced in abundance 
(Figure 3.7 C). This included six collagens and four laminins. 
Membrane trafficking proteins were the most highly represented group; 41 were 
identified, all of which were reduced (Figure 3.8 A). This category included the 
most reduced protein in the dataset, caveolin-1, with fold change < 0.1. An 
additional isoform of caveolin-1 was also detected with reduced abundance. 
A total of 17 ECM-associated signalling molecules were significantly altered 
(Figure 3.8 B). However,  the alterations here were mixed, with 11 proteins 
decreased and 6 increased, across a wide range of fold changes from 0.14 to 
2.4. 
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Figure 3.8: Abundance of membrane trafficking, ECM-associated 
signalling, and ECM remodelling proteins in the adhesion/ECM fraction 
are altered in TMEM67 patient cells.
Graphs show abundance fold change (on a logarithmic scale) for individual 
proteins within category, with respect to control cells. Proteins were categorised 
via knowledge-based annotation.
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Figure 3.9: Abundance of actin binding and actin regulatory proteins is 
altered in the adhesion/ECM fraction of TMEM67 patient cells.
Graphs show abundance fold change (on a logarithmic scale) for individual 
proteins within category, with respect to control cells. Proteins were categorised 
via knowledge-based annotation.
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ECM remodelling proteins showed a similar mixed pattern, with six decreased 
and three increased (Figure 3.8 C).  
Actin-binding proteins and actin regulatory proteins were a large component of 
the dataset, with 68 proteins represented between them. Of the 38 actin-binding 
proteins significantly altered, all but one was reduced in abundance (Figure 3.9 
A). The sole increased actin-binding protein was alpha-B crystallin, which was 
the most increased protein in the dataset with a fold change of 13.6. The 30 
actin regulatory proteins were all decreased in abundance (Figure 3.9 B). 
3.5 Adhesion morphology is altered in MKS patient fibroblasts 
Given the evidence of alterations to adhesion transcripts and proteins in MKS 
patient cells, the next question addressed was whether these changes led to 
alterations in the morphology and distribution of adhesions in MKS cells. To 
investigate changes in distribution of adhesions within spreading cells, control, 
TMEM67, and TMEM216 cells were plated for 20 minutes on ECM substrates, 
then fixed and immunolabelled for vinculin, a major component of the cell-
substrate adhesion complex. For all cell lines, the population at this timepoint 
was morphologically heterogeneous. Six categories of combined overall cellular 
and vinculin adhesion morphology were observed, with examples of each 
morphology category seen in all three cell lines (Figure 3.10).  
These morphology categories (Figure 3.10 A) were: 
Early: cells that had not initiated lamellipodial spreading, which were small and 
usually close to circular. These cells had a ring of vinculin staining, either 
continuous or punctate, around their periphery but few or no elongated “fibrillar” 
adhesions. These cells often showed brighter, diffuse vinculin staining within the 
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Figure 3.10: MKS patient cells exhibit alterations to adhesion patterning. 
Cells were plated for 20 minutes on ECM substrates, then fixed and 
immunostained with anti-vinculin to label focal adhesions. Based on observed 
adhesion distribution, cells were assigned to one of six categories. A: example 
cells representing each category. Bar: 20 µm. B: Percentages of control and 
MKS patient calls that match each category (n = at least 56 cells per line).
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cell body than other morphologies, likely indicating cytoplasmic reserves of 
vinculin not yet assembled into adhesion complexes. 
Fringed: cells that were spread and highly circular, with a fringe of vinculin 
staining near the periphery, consisting of a continuous ring of staining at the 
very edge of the lamella and a region of constant width inward from the cell 
edge decorated by punctate adhesions. These cells had few or no fibrillar 
adhesions. 
Concentric: cells that were spread and moderately circular, with multiple rings of 
vinculin staining not confined to the cell periphery. These cells exhibited larger 
adhesion patches than fringed cells, but still few or no fibrillar adhesions. 
Spiky: cells that were highly irregular and stellated in shape, with strongly 
fibrillar adhesions typically extending along the interior of the stellations. These 
adhesion “spikes” were prominent and elongated in comparison to the fibrillar 
adhesions of other morphologies, and few smaller or more punctate adhesions 
were present. 
Ringed: cells that were irregular, but less so than “spiky” cells, and showed a 
ring of moderately fibrillar adhesions and punctate adhesions around the cell 
body, but also some large regions of lamella undecorated by adhesions. 
Pervasive: cells that were as irregular in shape as “ringed” cells, but which 
showed adhesions pervading the entire lamella, leaving no undecorated regions 
other than the cell body. These adhesions ranged from punctate to fibrillar. 
Having identified descriptive adhesion morphology categories, prevalence of 
these morphologies was quantified. For each cell line the percentage of cells 
that conformed to each category was recorded (Figure 3.10 B). The most 
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prevalent morphologies in control cells were “Early” and “Pervasive”. In 
comparison to controls, in the TMEM67 and TMEM216 cell lines fewer cells 
matched the “Early” category, and more cells were seen which matched the 
“Pervasive” category; with TMEM216 cells in both cases showing greater 
deviation from control cells. 
Having observed differing cell-wide adhesion patterning, next the patterning of 
individual adhesions was investigated in more detail. In cells immunolabelled for 
vinculin after plating for 20 minutes, a 10 µm by 10 µm square region of interest 
was chosen (without bias) at the cell periphery adjacent to the cell edge (Figure 
3.11 A). This region was manually examined to identify individual adhesions 
(Figure 3.11 B, C) which were counted, and measured for perimeter, area, 
length, and width (Figure 3.11 D). A ratio of length to width was calculated for 
each adhesion to quantify roundness, and the total coverage of the area was 
determined by the percentage of adhesion area to total area. These 
measurements were taken for cells on fibronectin, collagen I, collagen IV, 
laminin, and vitronectin substrates. It was found that TMEM67 patient cells 
spreading on a collagen IV substrate had significantly fewer adhesions per area 
than control cells (Figure 3.12), and that TMEM216 cells spreading on a laminin 
substrate had significantly more adhesions per area, and greater coverage of 
the region with adhesions, than control cells (Figure 3.13). Neither MKS cell line 
exhibited significant alterations to adhesion size (Figures 3.12, 3.13), or to 
length, width, roundness, or perimeter (data not shown). 
3.6 MKS patient cells have defective extracellular matrix 
Given the changes to ECM gene expression (Figure 3.1) and ECM protein 
content (Figures 3.2, 3.7, 3.8, 3.9) found in TMEM67 cells, together with the 
alterations to cell-ECM interaction implied by the focal adhesion alterations in 
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Figure 3.11: Workflow for measurement 
of vinculin adhesions in cells. 
Cells were plated for 20 minutes on ECM 
substrates, then fixed and immunostained 
with anti-vinculin to label focal adhesions. 
A: A cell labelled with anti-vinculin. Bar: 
20 μm. B: A 10 μm by 10 μm region of 
interest is designated. C: Adhesions are 
selected visually and measured by hand. 
D: Adhesions are measured by drawing 
around the outside of the adhesion 
(perimeter), by measuring the longest axis 
(length), and by measuring the shortest 
axis (width).
B
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Figure 3.12: TMEM67 patient cells exhibit reduced adhesion number on a 
Collagen IV substrate. Error bars: SEM. *: p < 0.05, ANOVA with Bonferroni 
post-tests; n = 25 cells per line per condition over 2 experiments.
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Figure 3.13: TMEM67 patient cells exhibit increased adhesion number and 
coverage on a laminin substrate. Error bars: SEM. *: p < 0.05, **: p < 0.01; 
ANOVA with Bonferroni post-tests; n = 25 cells per line per condition over 2 
experiments.
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TMEM67  (Figure 3.12) and TMEM216 cells (Figure 3.13), the next question 
investigated was whether the MKS patient cell ECM was morphologically 
defective. MKS patient cells were allowed to synthesise ECM on glass 
coverslips for four days, then the cell layer was stripped via high alkaline 
treatment and the remaining cell-derived matrix (CDM) layer was fixed and 
processed for  scanning electron microscopy (SEM). The electron micrographs 
(Figure 3.14) revealed that TMEM67 CDM was markedly less dense, contained 
fewer fibrillar structures, and was less interconnected than the CDM of control 
cells. TMEM216 CDM showed an even more severe phenotype: there was little 
material of any kind, and no evidence of an interconnected ECM network.  
3.7 Discussion 
In this chapter it has been shown that TMEM67 is a focal adhesion protein, and 
that the absence of TMEM67 is associated with major alterations to the 
expression of genes, and to the abundance of proteins, associated with 
adhesions and the extracellular matrix; as well as a marked morphological 
alteration to the extracellular matrix and substrate-specific alterations to 
adhesion patterning. TMEM216 patient cells showed a more extreme version of 
the ECM phenotype, as well as an alteration in substrate-specific adhesion 
patterning. 
The proteomics of the focal adhesion complex have been studied for some 
time, so the identification of TMEM67 as an adhesion protein in this chapter 
(Figure 3.4) raises the question: why was TMEM67 not detected at adhesions 
before now? Methods for isolating adhesion proteins for proteomic studies have 
varied: Plopper et al used trypsin treatment and resuspension of the whole 
culture followed by incubation with RGD-coated beads (Plopper & Ingber, 
1993), which was likely to degrade many proteins and only recover those 
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strongly bound to the subset of integrins with RGD-binding activity; whereas 
Kuo et al introduced a method (used in the present chapter) to recover 
adhesion proteins via isotonic treatment and hydrodynamic force (Kuo et al, 
2012), which, while less chemically aggressive than Plopper et al’s method, is 
liable to wash away loosely attached proteins. Furthermore, proteomic studies 
generally have low repeatability; for example, a meta-analysis of flagellar 
proteomes found only 25 proteins shared between three different proteomic 
studies which had each detected >100 proteins (Broadhead et al, 2006). Within 
studies of the adhesome, Horton et al defined a consensus adhesome and 
found that it excluded 90% of the candidate adhesion proteins suggested in a 
previous analysis (Geiger & Zaidel-Bar, 2012; Horton et al, 2015), which they 
attributed to tissue and isoform specificity of some protein adhesion 
associations. In Kuo et al’s study of the adhesome, only 754 proteins were 
shared between three methodologically identical repeats which identified a total 
of 1917 proteins (summarised in Figure 3.6) (Kuo et al, 2011). The adhesome 
presented in this chapter, which was methodologically similar to Kuo et al’s but 
employed different cell lines, had an overlap of 797 proteins (Figure 3.6) with 
Kuo et al’s total out of 1394 detected; and likewise failed to detect TMEM67. 
Given the high variability of these studies, it is likely that many adhesion 
associated proteins remain to be detected, especially if their abundance is low 
or their association with the adhesion is conditional, tissue specific, or transient, 
any of which may be true for TMEM67. 
A cell-substrate adhesion role for TMEM67 places it alongside a number of 
other ciliopathy proteins that have recently been found to associate with 
adhesions. NPHP1 localises to cell-matrix and cell-cell adhesions (Benzing et 
al, 2001), and the polycystic kidney disease protein PKD1 is a transmembrane 
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protein with adhesion domains that is involved in integrin recycling to nascent 
adhesions (Palsson et al, 1996; Woods et al, 2004), and also has an essential 
role in cell-cell adhesion at adherens junctions (Streets et al, 2003; Huan & van 
Adelsberg, 1999; Ibraghimov-Beskrovnaya et al, 2000). PKD2 is predicted to be 
an adhesion protein, and PKD1 and PKD2 regulate extracellular matrix 
formation (Mangos et al, 2010). Since cystic kidney is a common pathology in 
MKS patients there may be a shared aetiology in dysregulation of the ECM. 
The widespread disruption to focal adhesion protein content (Figures 3.7-3.9) 
may have many downstream effects. Loss of core adhesion components 
(Figure 3.7 A) such as the talins, major integrin-actin linking and tension-
sensing proteins, could further disrupt cell adhesion and actin organisation by 
preventing the establishment of the ECM-adhesion-actin mechanotransduction 
axis. Reduction in levels of transmembrane receptors (Figure 3.7 B), including 
multiple integrins which are essential adhesion receptors, could impact the 
ability of the cell to sense and respond to its environment; this disruption could 
be upstream of the ECM defect, since the ECM is regulated through an integrin-
mediated feedback mechanism (Gjorevski & Nelson, 2009). ECM structural 
components are also depleted (Figure 3.7 C), with collagens and laminins 
prominent, although interestingly collagen IV is not detected as reduced in 
abundance despite this being indicated by Western blot (Figure 3.2 A); in fact, it 
was not detected in the fraction at all, even in control cells (Appendix 1, Table 
2). Given the unreliable detection of specific proteins by this experimental 
approach, however (see above), this is not necessarily meaningful. 
Widespread disruption to the membrane trafficking machinery is also in 
evidence (Figure 3.8 A), with two isoforms of caveolin-1 especially reduced in 
abundance. A defect in trafficking could indicate a loss of delivery and recycling 
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to the adhesion complex, which might explain the protein depletion observed, 
and a reduction in ECM secretion. This is reminiscent of the finding that PKD1 
promotes recycling of components to the adhesion, including integrins (Woods 
et al, 2004): TMEM67 may have a similar function. 
No overall pattern of change to ECM-associated signalling molecules (Figure 
3.8 B) or ECM remodelling factors (Figure 3.8 C) was observed, though there 
were disruptions to individual proteins. Actin binding (Figure 3.9 A) and 
regulatory proteins (3.9 B) were (with a single exception discussed below) all 
depleted. This may reflect a loss of actin filament association with the 
adhesions, which given the bidirectional feedback that drives adhesion and 
actin cable assembly (Kuo et al, 2011; Defilippi et al, 1999; Hynes, 2002), could 
originate in either structure.  
Given these large changes to the protein content of adhesions, it is surprising 
that when visualised and measured (Figures 3.10-3.13), the changes to 
morphology of adhesions are relatively minor, with only small substrate-specific 
alterations that barely pass a statistical significance test. However, these results 
were obtained in cells shortly after plating, whereas the proteomic dataset was 
acquired from cells that had been plated for >4 days (which was necessary for 
ECM to be synthesised). By this point an actin defect characterised by dense 
actin bundles appears in TMEM67 patient cells (McIntosh, 2016; Adams et al, 
2012; Dawe et al, 2007b; Valente et al, 2010) (discussed in more detail below). 
The defective ECM phenotype likely emerges at some point in between; it may 
be informative to repeat the adhesion measurements in cells at 4 days to 
determine what the effect of a mature cell-derived ECM is on adhesion 
morphology in MKS patient cells. 
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Adhesions and actin filaments are physically connected and work cooperatively 
to transduce mechanical signals along the ECM-adhesion-actin axis, which 
regulates adhesion assembly and turnover as well as influencing actin stress 
fibre formation (Xu et al, 2012; Wehrle-Haller, 2012; Tomasek et al, 2002; 
Grinnell, 2003), depending on ECM stiffness and Rho GTPase signalling 
(Ridley & Hall, 1992). Given the findings in this chapter that in TMEM67 patient 
cells, adhesion protein content is widely diminished, with many actin-binding 
and actin regulatory factors among those reduced in abundance including 
members of the Rho family (Rho A, Rho G, Rac1, and Cdc42) (Figure 3.9), and 
that the ECM secreted by these cells is defective (Figure 3.14), effects on the 
organisation of the actin cytoskeleton are almost inevitable. Actin organisation 
defects have been reported in TMEM67 and TMEM216 patient cells (Adams et 
al, 2012; Dawe et al, 2009; Valente et al, 2010; McIntosh, 2016). In TMEM67, 
actin bundle density is significantly increased 4 days after plating, with bundles 
appearing thicker and more intense via immunofluorescence, accompanied by a 
decreased G- to F-actin ratio (McIntosh, 2016). TMEM216 cells exhibit earlier 
dense actin formation arising as quickly as 40 minutes after plating, and, 
contrary to TMEM67, an increased G- to F-actin ratio (McIntosh, 2016). Actin 
defects have also been reported in other ciliopathies (Gakovic et al, 2011; 
Hernandez-Hernandez et al, 2013; Yin et al, 2009; Kim et al, 2010; Pitaval et al, 
2010), and other ciliopathy proteins that localise to actin have been identified, 
including BBS proteins (Hernandez-Hernandez et al, 2013; May-Simera et al, 
2015). Disruption of BBS4, BBS6, or BBS8 proteins lead to abnormal actin 
morphology (Hernandez-Hernandez et al, 2013). This evidence all suggests a 
general role for ciliopathy proteins in regulation of the actin cytoskeleton. 
Specifically in the case of TMEM67, its interaction with the adhesion protein and 
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actin regulator Filamin A (FLNA) (Adams et al, 2012) is particularly interesting; 
the two proteins may cooperate to organise actin both in the cytoplasm and at 
adhesions; and the absence of TMEM67 in patient cells may lead to aberrant 
localisation or function of FLNA. Loss of FLNA causes many of the same 
cellular phenotypes as loss of TMEM67, including actin organisation defects, 
basal body positioning and ciliogenesis defects, and deregulation of signalling 
(Adams et al, 2012), and has been linked to patient pathologies including 
pulmonary cysts (Emiralioglu et al, 2015), and pulmonary dysplasia (Lord et al, 
2014), which is the cause of death in most MKS patients (Kenny & Beales, 
2013). 
In light of this relationship between TMEM67 and FLNA, the massive increase 
in abundance of the small heat shock protein alpha-B crystallin (CRYAB) in the 
adhesion/ECM fraction (Figure 3.9 A, green bar) is especially interesting: 
CRYAB has a conserved actin-binding domain, and also binds to FLNA 
(Wójtowicz et al, 2015). CRYAB’s abundance was increased by a factor of 13; it 
was the single most increased protein in the dataset, and was the only actin-
binding or actin-regulatory protein to be increased. Whether this represents a 
cell-wide increase in CRYAB levels, or merely a redistribution of CRYAB to the 
ECM, adhesions or adhesion-associated actin is not clear. CRYAB is mostly 
known as one of the highly stable crystallins that make up the lens of the eye, 
but it has widespread expression outside the eye, and its actin-binding activity is 
known to be important for the stabilisation of myofibrils in muscle tissue 
(Wójtowicz et al, 2015; Goldfarb & Dalakas, 2009). This actin stabilising function 
may have a role in the aberrant dense actin bundles seen in TMEM67 cells 
(Adams et al, 2012; Dawe et al, 2009; Valente et al, 2010; McIntosh, 2016). 
Given the interaction between actin, FLNA, and TMEM67 (Adams et al, 2012), a 
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possible model to explain the increased abundance of CRYAB in the 
adhesion/ECM fraction is that in the absence of TMEM67, FLNA is free to be 
bound by CRYAB, leading to increased recruitment of CRYAB to the adhesion 
complex in place of TMEM67. Alternatively, the increased level of CRYAB may 
be a stress response to one of the various defects in TMEM67 patient cells; as 
a molecular chaperone, this is one of its predicted functions (Morimoto, 1998). 
Alterations to the actin cytoskeleton have knock-on effects on ciliogenesis, 
since actin remodelling is required for basal body migration and docking (Gray 
et al, 2009; Pan et al, 2007; Park et al, 2006; Carvajal-Gonzalez et al, 2016; 
Song et al, 2010; Gray et al, 2011; Borovina et al, 2010; Epting et al, 2015; 
Boisvieux-Ulrich et al, 1990; Boisvieux‐ Ulrich et al, 1987; Kim et al, 2015, 
2010; Klotz et al, 1986; Lemullois et al, 1988, 1987; Pitaval et al, 2010; Yan & 
Zhu, 2013). Disruption to actin regulation downstream of the defects found in 
this chapter may therefore explain ciliation defects leading to signalling 
disruption and patient phenotypes. This may take place through activated 
YAP/TAZ signalling downstream of ECM rigidity and stress fibre formation, 
which inhibits ciliogenesis by preventing actin reorganisation (Kim et al, 2015; 
Halder et al, 2012; Wada et al, 2011; Zhao et al, 2012; Dupont et al, 2011). This 
suggests a model where in MKS patient cells, defective ECM synthesis leads to 
a more rigid substrate, which activates YAP/TAZ signalling and therefore 
inhibits ciliogenesis. A cautionary note regarding the relationship between 
substrate stiffness and ciliation is merited, however: cell culture glass and 
plastic are several orders of magnitude more stiff than most tissue (Lu et al, 
2012). It is possible that defective ciliogenesis in MKS cells may be partially 
caused by the artificial cell culture surface which they are unable to coat with a 
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functional pliant ECM of their own, and therefore might not represent a fully 
physiological phenotype. 
The influence of adhesions on the microtubule (MT) cytoskeleton is less clear 
than for actin. MTs can enter the lamella and interact with the actin cytoskeleton 
to regulate migration (Lindberg et al, 1981; Theisen & Straube, 2016). MTs 
appear to target adhesions, and can regulate adhesions, since contact of a MT 
plus-end with an adhesion is a stimulus for adhesion disassembly (Stehbens & 
Wittmann, 2012; Ezratty et al, 2005; Kaverina et al, 1999). However, adhesions 
also capture and stabilise MTs (Kaverina et al, 1998), leading to regulation of 
MT dynamics, so causal relationships could run in either direction (Akhmanova 
et al, 2009). It is plausible that the general loss of adhesion protein content 
found in this chapter would influence these interactions, but it is not clear how. 
There is a MT defect in MKS cells involving loss of a single focus for the MT 
cytoskeleton and altered MT maturation (McIntosh, 2016), however this defect 
is consistent with defective tethering at the minus ends (possibly downstream of 
a role for TMEM67 as an organiser or linker at the centrosome), and appears 
rapidly (within 20 minutes) after plating (McIntosh, 2016), so presumably cannot 
be downstream of an ECM defect (which would not arise in such a short time), 
and is unlikely to be downstream of an interaction of MT plus-ends with 
adhesions. The causal relationship may run the other way: could the MT defect 
underlie changes to adhesions and the ECM by disrupting adhesions, perhaps 
due to aberrant stimulation of adhesion disassembly, leading to the depleted 
adhesion proteome found in this chapter? The MT defect was found not to 
underlie the actin defect or other cellular defects in MKS cells (McIntosh, 2016), 
but this has not yet been tested for the adhesion or ECM defects found in the 
present study, so this remains a possibility. Given the influence of MTs on 
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migration, an alteration to the interaction between MTs and adhesions could be 
responsible for migration defects in MKS cells, which may underlie patient 
phenotypes which arise from failure of neural crest cells to migrate to correct 
sites during development, such as midline defects and heart defects.  
The increased expression of matrix metallopeptidases (MMPs) found in this 
chapter (Figure 3.1 B) might be expected to result in increased ECM 
degradation, which could explain the reduced ECM density observed in MKS 
cells (Figure 3.14). However, matrix remodelling enzymes are typically closely 
regulated at the translational and post-translational levels, via mechanisms such 
as inhibitory domains, likely due to their potentially destructive effect on tissue if 
they were to become dysregulated (Page-McCaw et al, 2007; Aitken & Bägli, 
2009). Therefore a change in expression of these proteins is, even more than 
for most proteins, not necessarily evidence for a change in abundance or 
activity. None of the upregulated matrix remodelling transcripts identified in 
Figure 3.1 were found to have increased abundance in the adhesion/ECM 
fraction (Figure 3.8 C), though since these proteins are typically soluble they 
would not be expected to have been retained in this sample. Elevated MMP 
activity is implicated in inflammatory and vascular disease (Hu et al, 2007); 
these are not reminiscent of any MKS phenotypes,  although, in the wider 
ciliopathies, vascular lesions are seen in PKD (Griffin et al, 1997) and airway 
inflammation is a feature of primary ciliary dyskinesia (Bush et al, 2007). 
Experimentally testing the MMP activity in MKS patient cell cultures would help 
to determine the importance of this factor in the ECM defect. 
ECM stiffness determines cell fate; for example, the differentiation of 
mesenchymal stem cells into brain (determined by soft ECM), muscle 
(intermediate ECM), or bone tissue (stiff ECM) (Engler et al, 2006). ECM 
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stiffness is not sufficient for specification, however, as some tissues have 
similar ECM elasticity (Watt & Hogan, 2000).The ECM has a major influence on 
cell shape (Ingber, 1991), which is in turn a regulator of growth and 
differentiation (Folkman & Moscona, 1978) responsible for development of, for 
example, myocardial organisation (Manasek et al, 1972). Correct ECM protein 
composition also affects cell fate: it is essential for differentiation of endothelia 
(Wang et al, 2013), and control of hepatic stellate cell activation in the liver, 
which may underlie liver fibrosis in MKS (for more detail on this point, see 
Chapter 6). Alterations to ECM composition can thus lead to widespread tissue 
specification defects. 
The ECM defect (Figure 3.14) found in this chapter is the most prominent defect 
yet observed in MKS patient cells and is likely to have profound cellular and 
developmental consequences. The next chapter will investigate this defect and 
its downstream effects on cellular phenotypes in MKS patient cells. 
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Chapter 4 
The extracellular matrix defect in MKS is upstream of 
defective ciliation 
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Chapter 4: The extracellular matrix defect in MKS is upstream 
of defective ciliation 
4.1 Introduction 
Multiple MKS proteins have been shown to be required for ciliogenesis and for 
docking of the basal body to the cell surface, including TMEM67 (Lee et al, 
2012; Dawe et al, 2007b). Since basal body docking is required for ciliogenesis, 
it has been suggested that failure to build a cilium in MKS cells is a 
consequence of disrupted docking. However, docking failure is not always 
implicated in ciliogenesis defects (Garcia-Gonzalo et al, 2011; Singla et al, 
2010), and MKS proteins including TMEM67 are known to have extra-ciliary 
roles; among other localisations, TMEM67 has been shown to localise to actin 
cables (Dawe et al, 2009). A number of ciliopathy proteins have been reported 
to regulate or interact with adhesions (Donaldson et al, 2000, 2002; Wilson et 
al, 1999; Markoff et al, 2007; Li et al, 2005; Hernandez-Hernandez et al, 2013), 
and adhesion and cytoskeletal signalling have been implicated in control of 
ciliogenesis. It is thus plausible that alterations elsewhere in MKS cells are 
upstream of ciliogenesis defects. 
In this chapter, the causal relationships between absence of the TMEM67 
protein, defective ECM, defective ciliogenesis, and disrupted signalling in 
TMEM67 cells are investigated. 
Both the ciliation and actin defect in TMEM67 patient cells are shown to be a 
downstream consequence of defective ECM, and ciliation can be rescued by 
expression of full-length TMEM67 protein or by inhibition of the TGF-β or 
canonical Wnt signalling pathways. 
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4.2 Plating on TMEM67 cell-derived ECM is necessary and sufficient 
for defective ciliogenesis 
To investigate the role of defective extracellular matrix in ciliogenesis, cell-
derived matrix (CDM) from both control and TMEM67 patient cells was 
prepared, then control and TMEM67 patient cells were plated reciprocally on 
each CDM substrate. The cells were grown under serum-starvation conditions 
that induce ciliation in normal cells, then cilia were imaged (Figure 4.1 A). 
Approximately 30% of control cells on control matrix were ciliated, and fewer (< 
15%) TMEM67 cells plated on TMEM67 CDM were ciliated (Figure 4.1 B), in 
line with the results of previous studies (Adams et al, 2012; Dawe et al, 2009). 
However, when TMEM67 cells were plated onto control CDM, ciliation was 
rescued; when control cells were plated on TMEM67 CDM, ciliation was 
reduced to a percentage similar to that of TMEM67 cells on TMEM67 CDM 
(Figure 4.1 B).  These results indicate that the ciliation defect in TMEM67 cells 
is a downstream consequence of defective ECM. To determine whether this 
was specific to TMEM67 or might be general to MKS, TMEM216  patient cells 
were plated on control and TMEM216 CDM; control CDM was found to rescue 
ciliogenesis of TMEM216 cells (Figure 4.1 C). 
4.3 TMEM67 protein is required for a morphologically normal 
extracellular matrix 
Having determined that the ECM defect is upstream of ciliation defects in 
TMEM67 cells, it was next asked whether defective ECM morphology (shown in 
Chapter 3, Figure 3.14) could be attributed to a function of  the TMEM67 
protein. Cell-derived matrices were prepared from controls, TMEM67 cells 
expressing full-length TMEM67, and cells expressing TMEM67-919delF (a 
deletion in the C-terminal region which abolishes filamin A binding (Adams et al, 
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Figure 4.1: Plating on MKS cell-derived matrix is necessary and sufficient 
for defective ciliogenesis. A: Cells were replated onto control or TMEM67 
cell-derived matrix (CDM), serum-starved for 48 hours to induce ciliation, then 
fixed and labelled for cilia (acetylated alpha-tubulin, green) and nuclei (DAPI, 
blue). Micrographs showing representative cells. Arrows: cilia. Bar: 20 μm. 
B: Percentage of cells ciliated under each condition. Error bars: SEM. ***: p 
< 0.001, χ2 test, n = at least 200 cells per condition over 4 experiments. C: 
TMEM216 cell ciliogenesis was also rescued by replating on control CDM.
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2012)). These CDMs were imaged via SEM and the morphology of the ECM 
examined (Figure 4.2). As previously shown (Figure 3.14), TMEM67 cells 
(Figure 4.2, left middle) produce matrix that is sparse in comparison to control 
cells (Figure 4.2, top). This defect was rescued in cells transfected with full 
length TMEM67 (Figure 4.2, right middle). Cells transfected with TMEM67-
919delF, however, did not rescue matrix morphology (Figure 4.2, bottom row), 
indicating that the C-terminal region of TMEM67 required for filamin A binding 
activity is also required for normal matrix morphology. 
4.4 Wnt and TGF-β pathway antagonists rescue defective ECM 
morphology, ciliogenesis, and actin organisation in TMEM67 patient 
cells 
It has been shown in this chapter that loss of TMEM67 leads to defective ECM 
morphology, which leads to defective ciliogenesis; however, the causal chain 
linking these defects, and the connection to the actin defect, is not clear. TGF-β 
signalling is required for ciliary localisation of MKS proteins (Tozser et al, 2015), 
and Wnt signalling is disrupted in TMEM67 patient cells and TMEM67 models 
(Abdelhamed et al, 2013; Adams et al, 2012; Dawe et al, 2009). To investigate 
whether these signalling pathways have a role in the cellular defects, TMEM67 
cells were treated with antagonists to the TGF-β and Wnt signalling pathways, 
and the effect on ECM morphology (Figure 4.3 A), ciliation (Figure 4.3 B), and 
actin bundle density (Figure 4.3 C) were assessed. 
Inhibition of TGF-β signalling with TGF-β receptor 1 kinase inhibitor II (TRIKinII) 
completely restored matrix morphology (Figure 4.3 A) and ciliogenesis (Figure 
4.3 B), but had no effect on actin morphology (Figure 4.3 C). Inhibition of the 
same pathway with SIS3 partially restored matrix morphology (Figure 4.3 A), 
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Figure 4.2: TMEM67 patient cell-derived matrix morphology is rescued by 
expression of full-length TMEM67, but not by the TMEM67-919delF mutant.
Cells were plated (untreated samples) or transfected then plated (all other 
samples) and allowed to synthesise ECM for 48 hours. Cells were then stripped 
and CDMs were processed and imaged via scanning electron microscopy. Bar: 
5 μm.
Untreated control
Untreated TMEM67 TMEM67 + empty vector
TMEM67 + HA-TMEM67-919delF
TMEM67 + full length HA-TMEM67
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Figure 4.3: TMEM67 patient cell-derived matrix morphology, ciliogenesis, 
and actin organisation are restored by treatment with Wnt or TGF-β 
pathway antagonists. Cells were drug-treated for 48 hours. A: SEM of CDMs. 
Bar: 2 μm. B: Cells were serum-starved, fixed and labelled for acetylated alpha-
tubulin and nuclei, and cilia were counted. Error bars: SEM. ***: p < 0.001, χ2 
test; n = 5 experiments (at least 200 cells per experiment) C: Cells were fixed 
and labelled for actin and actin bundle fluorescence intensity was measured. 
Error bars: interquartile range. **: p < 0.01; ***: p < 0.001, χ2 test. n = 3 
experiments (at least 100 cells per experiment).
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and restored ciliogenesis (Figure 4.3 B), but again had no rescue effect on actin 
morphology (Figure 4.3 C). 
The canonical Wnt antagonist FH535 fully restored matrix morphology (Figure 
4.3 A), restored ciliogenesis (Figure 4.3 B), and partially restored actin bundle 
density (Figure 4.3 C). However, the Wnt/planar cell polarity (PCP) pathway 
inhibitor Box5 had no effect on either ECM morphology (Figure 4.3 A) or 
ciliogenesis (Figure 4.3 B), though it did partially restore the actin defect (Figure 
4.3 C).  
These results suggest that signalling through the TGF-β  and canonical Wnt 
pathways, but not the Wnt/PCP pathway, are upstream of defective ECM and 
ciliogenesis in TMEM67 cells, while both canonical and non-canonical Wnt/PCP 
may be involved in the actin defect. 
4.5 TMEM67 knockout mouse cells can be rescued via the same 
interventions as TMEM67 patient cells 
Having shown that the ciliation and actin defects in TMEM67 patient cells could 
be rescued, it was next asked whether these interventions would be effective 
beyond a single patient cell line. To this end, mouse embryonic fibroblasts 
(MEFs) with both copies of the TMEM67 gene knocked out were subjected to 
the same analyses. These cells exhibited the same sparse ECM phenotype 
seen in TMEM67 patient cells (Figure 4.4 A), and their ciliation defect could be 
rescued by plating on control CDM (Figure 4.4 B). Treatment with pathway 
antagonists rescued ciliogenesis in a similar pattern to TMEM67 patient cells: 
TRIKiinII again produced the largest response, but unlike in patient cells, Box5 
did partially restore ciliation (Figure 4.4 C). Unlike the patient cells, treatment 
141
Figure 4.4: TMEM67 -/- mouse embyronic fibroblasts exhibit the same 
phenotypes and rescue responses as MKS patient fibrolasts. Cells were 
treated as for previous experiments. A: SEM of TMEM67 -/- mouse embryonic 
fibroblast (MEF) CDM shows sparse ECM. B: TMEM67 -/- MEF ciliation can be 
rescued by plating on control CDM (Error bars: SEM; ***: p < 0.001, t-test), or 
(C) by treating with Wnt or TGF-β pathway antagonists (Error bars: SEM; **: p 
< 0.01; ***: p < 0.001; χ² test). C: TMEM67 -/- MEF actin organisation can be 
rescued by Wnt or TGF-β antagonists (Error bars: interquartile range. ****: p < 
0.0001, Kruskal-Wallis test with Dunn’s correction for multiple comparisons).
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with any of the pathway antagonists reduced the density of actin bundles within 
the knockout MEFs (Figure 4.4 D).  
4.6 TMEM67 patient cell ciliation can be rescued by plating on 
collagen IV or laminin 
Having shown that plating on a morphologically normal ECM is sufficient to 
restore MKS patient cell ciliogenesis (Figure 4.1 B), and that drug intervention 
was sufficient to restore ECM morphology and ciliogenesis in TMEM67 patient 
cells, it was next asked: is there a specific component of the ECM which is 
deficient in MKS patient cells? To investigate this, TMEM67  and TMEM216 
patient cells were plated onto purified ECM component substrates, or their own 
CDM as a control, and ciliation was induced by serum-starvation, then cilia were 
counted as before. TMEM67  cells had significantly increased ciliation on 
collagen IV and laminin (Figure 4.5). TMEM216 cells showed some rescue of 
ciliation on collagen IV, but this was not statistically significant. For both cell 
lines, plating on collagen I, fibronectin, or vitronectin had negligible impact on 
ciliation. 
4.5 Discussion 
In this chapter, it has been shown that absence of the TMEM67 protein, or its C-
terminal filamin A binding region, leads to a chain of events in which, possibly 
downstream of disrupted TGF-β and/or Wnt signalling, defective ECM causes 
defective actin organisation and defective ciliogenesis.  
The extracellular matrix has diverse roles as both a mechanical substrate and a 
site for sequestration of signalling molecules , so there are multiple plausible 
mechanisms whereby defective ECM could lead to defective ciliogenesis. 
Multiple signalling pathways regulate ciliogenesis (Santos & Reiter, 2008), but 
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Figure 4.5: Plating on collagen IV or laminin substrates rescues the 
ciliation defect in TMEM67 patient cells. Cells were plated onto purified 
ECM or their own CDM and serum-starved after adhesion. Cilia were counted 
after 48 hours. Error bars: SEM; *: p < 0.05, one-way ANOVA with multiple 
comparisons post-test. n = at least 100 cells per line per condition over 2 
experiments.
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ciliation also depends on cell shape control: RPE1 cells grown on small 
fibronectin-coated micropatterns built cilia readily, while those on wide 
micropatterns did not, leading to the conclusion that spatial confinement is 
necessary for ciliogenesis (Pitaval et al, 2010). However, there is no obvious 
cell morphology defect in adherent TMEM67 patient cells, and plating TMEM67 
cells on fibronectin micropatterns did not rescue the ciliation defect (H. Dawe, 
unpublished observations), so altered spatial confinement of the cell does not 
appear to be an explanation for the failure of these cells to ciliate. Ciliation is 
also dependent on cortical contractility (Pitaval et al, 2010); aberrant cortical 
tension could arise due to alterations in adhesion-actin cytoskeleton interaction 
downstream of cell-ECM interaction. The finding that plating TMEM67 cells on 
collagen IV or laminin partially rescues ciliogenesis (Figure 4.5) could therefore 
indicate that the ECM defect is primarily absence of these components, rather 
than the other components tested (collagen I, fibronectin, vitronectin). This is 
consistent with the findings in Chapter 3 that laminin and collagen IV expression 
(Figure 3.1 B) and protein level in the ECM (Figure 3.2 A) are reduced. A further 
development of the experiment in Figure 4.5 would be to plate MKS cells on a 
substrate coated with both laminin and collagen IV; this might completely 
rescue ciliogenesis. 
Restoration of the ECM defect by full-length TMEM67, but not by the TMEM67-
919delF mutant that abolishes the filamin A (FLNA)-binding C-terminal region 
(Figure 4.2), indicates that this region is of critical importance for normal ECM 
morphology. TMEM67-919delF has previously been shown to not rescue 
ciliogenesis (Adams et al, 2012), which is consistent with the present finding 
that this defect is downstream of the ECM. The 919delF mutation results in 
deletion of the last 77 residues of the 995 amino acid protein sequence of 
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TMEM67, a relatively small sequence with no known domains or function 
except FLNA binding. It must be presumed therefore that it is the TMEM67-
FLNA interaction that is necessary for correct ECM morphology.  
FLNA is an actin-binding and adhesion protein, but also binds to integrins, and 
to TMEM67 in an interaction essential for ciliogenesis (Adams et al, 2012). As 
shown in Chapter 3 (Figure 3.4 B), TMEM67 and FLNA both physically 
associate with the adhesion fraction. In the absence of TMEM67, FLNA’s 
recruitment to adhesions at the cell surface may be disrupted leading to altered 
signalling. FLNA has been linked to ECM regulation through control of matrix 
metallopeptidases (Baldassarre et al, 2012), and influences tension response 
by interacting with β1 integrin (Gehler et al, 2009), so its role in the adhesion 
complex may be key to MKS defects; this will be discussed fully in chapter 6. 
The finding that antagonists to the TGF-β and Wnt signalling pathways rescue 
defects in TMEM67 patient cells is consistent with a model where disruption to 
TGF-β and Wnt signalling is an upstream contributor to defective ciliogenesis. It 
is difficult to interpret the influence of these pathways on ciliogenesis since most 
studies have investigated the inverse: the effect of disruption to cilia on 
signalling pathways (Gerdes et al, 2007; Corbit et al, 2008; McDermott et al, 
2010; Voronina et al, 2009; Huang & Schier, 2009; Ocbina et al, 2009).  
Signalling via the TGF-β family has broad roles controlling development and 
homeostasis of tissues throughout the body, including adhesion, cytoskeleton 
organisation (Weiss & Attisano, 2013), and extracellular matrix production 
(Sugiyama et al, 2013). The effects of TGF-β signalling can differ depending on 
cell type and context: for example, in wound healing, TGF-β induces 
proliferation of fibroblasts but inhibits proliferation of keratinocytes (Ashcroft et 
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al, 1999; Zambruno et al, 1995). In the absence of TGF-β signalling, the MKS 
protein B9D1 fails to localise to the ciliary TZ and cilia are shortened (Tozser et 
al, 2015). The finding in this chapter that attenuation of TGF-β restores 
ciliogenesis in TMEM67 patient cells (Figure 4.3 B) implies therefore that the 
native levels of TGF-β are aberrantly high, to the point that inhibition serves to 
restore a balance of TGF-β signalling required for proper ciliary assembly. In the 
differential expression and mass spectrometry data shown in Chapter 3, TGFB1 
was detected to be increased in both expression (Appendix 1, Table 1) and 
abundance in the adhesion/ECM fraction (Figure 3.8 B) in TMEM67 patient 
cells, supporting this model.  
Normally when TGF-β signalling is activated, the core of the signalling pathway 
is transduced when TGF-β receptor 1 (TGFβRI) phosphorylates Smad3, which 
enters the nucleus (in conjunction with Smad4) to affect gene expression. TGF-
β receptor 1 kinase inhibitor II (TRIKinII) inhibits the TGF-β pathway at the 
receptor level, while SIS3 selectively inhibits Smad3 phosporylation and 
interaction with Smad4 (Jinnin et al, 2006). The different degrees of rescue 
observed between these two inhibitors (Figures 4.3, 4.4 C) indicate that when 
the whole pathway is inhibited from TGFβRI, defects are more strongly 
alleviated than when just the part of the pathway downstream of Smad3 is 
inhibited; this implies that TMEM67 patient cell defects are not solely 
downstream of Smad3, but other parts of the TGF-β pathway or crosstalk to 
other pathways branching from TGFβRI are involved; other branches from 
TGFβRI include Ras and RhoA pathways (Derynck & Zhang, 2003).  
TGF-β signalling generally increases production of ECM (Sugiyama et al, 2013), 
so it is strange that inhibition of TGF-β in TMEM67 patient cells would rescue a 
lack of ECM production. This may be another example of context-sensitive 
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regulatory roles for TGF-β, or of restoring a balance of signalling. TGF-β does 
not universally stimulate ECM synthesis: while treatment of fibroblasts with 
TGF-β stimulates production of various ECM components including collagen 
(Roberts et al, 1986), vitronectin, fibronectin, and tenascin C, it was reported to 
have no effect on production of laminins (Sugiyama et al, 2013). In fact, 
presence of basement membrane (BM) proteins such as laminin or collagen IV 
inhibit TGF-β activity (Streuli et al, 1993; Roskelley et al, 1995). It was shown in 
Chapter 3 that TMEM67 patient cells have lower expression (Figure 3.1 B) and 
secretion (Figure 3.2 A) of collagen IV and laminin. This could suggest a model 
where, downstream of low levels of collagen IV and laminin in TMEM67 ECM, 
TGF-β signalling is aberrantly activated.  
FH535 antagonises the nuclear receptors PPARγ and PPARδ and inhibits 
GRIP1 and β-catenin recruitment, thus inhibiting canonical Wnt (Handeli & 
Simon, 2008). Caron et al  reported that in zebrafish, attenuation of canonical 
Wnt signalling was upstream of ciliogenesis via foxj1, with defects leading to 
cystic kidney reminiscent of MKS (Caron et al, 2012), so activation of this 
pathway may block ciliogenesis. TMEM67 patient cells exhibit a hyperactivation 
response to Wnt ligand (Adams et al, 2012). This is consistent with the finding 
in this chapter that inhibition of canonical Wnt with FH535 rescues ciliogenesis 
(Figure 4.4 B). FH535 treatment also rescued ECM morphology, which is 
difficult to interpret given the role of canonical Wnt activation in stimulating ECM 
deposition in fibrosis (Wei et al, 2011; Bergmann et al, 2011), which can be in 
cooperation with TGF-β signalling (Akhmetshina et al, 2012); if these pathways 
are aberrantly activated in TMEM67 patient cells, the presence of the ECM 
defect indicates they not stimulating ECM deposition in this context. 
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Box5 is a stabilised peptide derived from Wnt5a that inhibits the non-canonical 
Wnt5a/planar cell polarity (PCP) pathway (Jenei et al, 2009), upstream of Rho 
family signalling that controls cell polarity and cytoskeletal rearrangement 
(Veeman et al, 2003). The PCP protein Wdpcp (which is also a BBS protein) is 
required for ciliogenesis, and modulates the actin cytoskeleton (Cui et al, 2013). 
Box5 treatment did not rescue ECM morphology (Figure 4.3 A) or significantly 
rescue ciliogenensis in TMEM67 patient cells (Figure 4.3 B), while both were 
rescued by inhibition of canonical Wnt with FH535. Wnt/PCP signalling has 
been linked to control of fibronectin ECM organisation (Dzamba et al, 2009), but 
evidently this is not a major factor in the TMEM67 ECM defect. Failure to rescue 
ciliation indicates that this pathway to ciliogenesis may not be disrupted (or as 
severely disrupted), though a significant rescue (albeit still with smaller effect 
than other inhibitors) was found in TMEM67 knockout MEFs (Figure 4.4 C). 
Box5 treatment did rescue actin morphology (Figure 4.3 C), suggesting that 
PCP mediated control of the cytoskeleton is disrupted, but this is not as major 
an influence on ciliation as the pathways affected by other inhibitors. 
Analysing the impact of these pathways is complicated by widespread cross-
talk between Wnt and TGF-β signalling, as well as other pathways such as 
YAP/TAZ (Attisano & Wrana, 2013). For example, non-canonical Wnt5a has 
been shown to be both activated by and a regulator of TGF-β-dependent 
production of collagen and fibronectin (Kumawat et al, 2013). The two pathways 
converge on RhoA, which in TMEM67 patient cells is upregulated, influencing 
actin organisation (Adams et al, 2012; Dawe et al, 2009). The finding that Wnt 
antagonists were able to restore actin density, while TGF-β antagonists did not, 
may reflect greater influence of Wnt on the RhoA pathway; however, the sample 
size was much lower for the TGF-β component of this experiment, so this result 
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must be regarded with some caution, especially since when the experiment was 
repeated in TMEM67 knockout MEFs all inhibitors had highly significant effects. 
The possible roles of RhoA in MKS will be discussed in more detail in Chapter 
6. 
This chapter has shown that the ECM defect is upstream of multiple cellular 
defects in MKS. However, it is not sufficient to explain all cellular defects found 
in MKS patient cells. The next chapter will investigate defects that are 
independent of the ECM, in order to shed further light on the possible causes of 
the ECM defect and the pattern of causation in MKS.  
  
150
  
Chapter 5 
Alterations to cell spreading dynamics in MKS patient 
cells  
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undergraduate project student who worked under my supervision to assist in 
analysis of logarithmic cell spreading data. Where included, this has been 
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Chapter 5: Alterations to cell spreading dynamics in MKS 
patient cells 
5.1 Introduction 
Cell adhesion to extracellular substrates is dependent on interactions between 
cell surface adhesion receptors and their extracellular binding partners. 
Integrins, the major adhesion receptors, are transmembrane proteins with 
extracellular domains that couple primarily to the extracellular matrix (Hynes, 
1987, 2002). Within the cell, integrins link to a proteomically diverse adhesion 
complex which couples primarily to the actin cytoskeleton, though it also 
interacts with microtubules, intermediate filaments, and other structural cell 
components. 
A mature focal adhesion forms a strong physical connection between the actin 
cytoskeleton and the extracellular ligand, and integrates multiple bidirectional 
signals as well as serving as a mechanosensor, typically by increasing 
adhesion protein recruitment in response to increased tension, and disassembly 
in response to decreased tension (Xu et al, 2012; Wehrle-Haller, 2012). Integrin 
adhesion complex formation requires the presence of extracellular matrix 
ligands, and Rho family GTPase signalling at the membrane (Hotchin & Hall, 
1995). 
Adhesions are essential for the migration of cells on both 2D substrates and in 
physiological 3D environments (Nagano et al, 2010; Kubow & Horwitz, 2011) as 
they represent the points at which cells attach to and exert traction forces on the 
substrate. Cell spreading follows the initial attachment of a cell to a substrate. 
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During spreading, a leading edge followed by a thin sheet of membrane and 
cytoplasm (the lamella) extends from the cell body over the substrate, often 
initially in an isotropic (unpolarised) pattern giving the cell a circular shape when 
viewed from above. This process is similar in underlying mechanism to cell 
migration, except that the leading edge in migration is polarised (Vasiliev, 
1982). 
The advancement of the leading edge is driven by polymerisation of actin into 
bundled arrays which undergo retrograde flow away from the leading edge 
(Small et al, 2016). This process is regulated by Rac, one of the Rho family 
GTPases (Hall, 1998; Ridley, 2001; Brancolini et al, 1999). Actin also drives 
early formation of adhesions at the leading edge. Slower spreading has been 
observed in cells treated with microtubule-destabilising drugs (Ivanova et al, 
1976), implying some role for the microtubule cytoskeleton in spreading. 
However, this role is minimal compared to that of actin. Fragments of lamella 
disconnected from a cell are capable of leading-edge formation and motility 
(Euteneuer & Schliwa, 1984), indicating that this process is autonomous to the 
machinery within the lamella and does not require cell-wide cytoskeletal 
organisation or signalling. 
Biophysical studies of the dynamics of cell spreading have identified three 
phases of spreading, each characterised by a spreading rate governed by a 
logarithmic power law, separated by dynamic phase transitions (Döbereiner et 
al, 2004), with each phase proposed to represent a different underlying 
biological mechanism, and the phase transitions the points at which the cell 
“switches” from one mechanism to another. Dubin-Thaler et al (2008) propose 
that these three phases correspond to 1: initial contact formation; 2: rapid 
spreading; and 3: periodic actin-dependent contractions and stable adhesion 
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formation. The actin cytoskeleton may only be involved in force generation 
during the third phase, but cortical actin flow is likely rate-limiting throughout 
(Cuvelier et al, 2007). An alteration to the spreading behaviour of a cell may 
impact any one of these phases or multiple phases, depending on the 
underlying mechanisms that are disrupted. 
In this chapter, the spreading behaviour and pattern of adhesion formation of 
MKS patient cells is investigated in relation to different extracellular matrix 
substrates. Having previously shown that MKS patient cells have altered 
adhesion composition (Chapter 3, Figures 3.7-3.9), including depletion of many 
key adhesion components, and that the TMEM67 protein is a component of 
adhesions in non-diseased cells, it was hypothesised that MKS patient cells 
would exhibit defective adhesion formation and, consequentially, defective cell-
ECM interaction. Since adhesion formation is influenced by the extracellular 
matrix environment, cells were plated onto surfaces artificially coated with 
individual ECM component proteins so that comparisons could be made of 
adhesion formation in the same extracellular environment. To minimise 
secretion and remodelling of the ECM by cells within the timeframe of 
observation, these experiments were necessarily conducted shortly after 
seeding cells onto the artificial ECM substrate, and therefore were focused on 
the cell spreading process. 
It was found that MKS patient cells have altered spreading behaviour 
characterised by faster spreading, greater cell area, and alterations to 
spreading dynamics, with substrate-dependence. 
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5.2 Cell spreading is altered in MKS patient fibroblasts 
To investigate the morphology of spreading MKS patient cells, TMEM67,  
TMEM216,  and age-matched control fibroblasts were plated onto a collagen I 
substrate, and imaged under phase contrast illumination for up to 90 minutes 
(Figure 5.1).  
Control cells (Figure 5.1, left column) exhibited morphology typical of fibroblasts 
in 2D cell culture, characterised by an irregular shape with long (10 µm or 
greater) cytoplasmic protrusions emanating from a  main cell body containing 
the nucleus and the bulk of intracellular compartments visible under phase 
contrast. 
TMEM67 patient fibroblasts exhibited similar morphology to control fibroblasts 
(Figure 5.1, centre column). TMEM216 fibroblasts (Figure 5.1, right column) 
were morphologically altered in a number of ways: the vast majority were 
spread over a larger surface area; many cells had large lamella-like thin, 
smooth regions, and a number of cells (approximately 10 to 15%) were 
observed to fragment, leaving multiple patches of membrane disconnected from 
the cell body.  
Having observed altered morphology in MKS patient fibroblasts spreading on a 
collagen I substrate, quantitative investigation of how spreading progresses 
over time on this substrate was undertaken. Phase contrast movies were 
acquired of  cells spreading on collagen I (Figure 5.2 A). Cell area was 
measured at regular timepoints. Since not all cells initiated spreading at the 
same time, for the purposes of analysis t = 0 was assigned for each cell 
individually. This was defined as the frame prior to the first observation of 
smooth, lamellipodial spreading. Small changes in cell area due to formation of 
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Control TMEM67 TMEM216
Figure 5.1: TMEM216 patient fibroblast morphology is altered. 
Control fibroblasts (left) exhibit normal morphology. TMEM67 patient fibroblasts 
(centre) exhibit similar morphology to controls. TMEM216 fibroblasts (right) 
spread over a larger area, and some cells were observed to fragment (top right). 
Cells shown are representative of the population observed. Cells were plated 
for 90 minutes on a collagen I substrate and imaged under phase contrast 
illumination. Bar: 40 μm.
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transient protrusions such as blebs and microspikes were often observed earlier 
than this point; these were not included in this analysis. Cells were measured 
across 30 minutes of the time series from their individual t = 0. Cells that began 
to spread, but then retracted and rounded up within this timeframe were 
excluded from the analysis. A mean area was calculated for each cell line at 
each timepoint (Figure 5.2 B). In line with the first observations, TMEM216 
fibroblasts had a greater area at all timepoints and showed faster spreading, 
while control and TMEM67 fibroblasts had very similar areas at all timepoints. 
Most spreading occurred during the first 10 minutes, with only minor change in 
cell area between the 10 minute and 30 minute timepoints. 
Having observed altered spreading behaviour for MKS patient cells on one 
substrate, we proceeded to investigate other substrates to determine whether 
these alterations were substrate-specific. Phase-contrast movies were acquired 
and analysed as before, for cells spreading on collagen IV (Figure 5.3), 
fibronectin (Figure 5.4), and laminin (Figure 5.5). 
On collagen IV, fewer of the plated cells spread; of over 20 TMEM67 cells 
imaged, only3 spread without retracting for the 30 minutes required to be 
included in the analysis. Those TMEM67 cells that did spread exhibited faster 
spreading and a larger area than controls (Figure 5.3 B), even outpacing 
TMEM216 cells. This is in contrast to TMEM67 cells on collagen I, which spread 
in a similar manner to controls. TMEM216 cells on collagen IV, as on collagen I, 
spread over a larger area than controls; however, the area of TMEM216 cells at 
30 minutes was lower than the same cell line on collagen I, and spreading 
continued after the 10 minute timepoint, unlike on collagen I where most 
spreading occurred during the first 10 minutes. TMEM67 and control cells on 
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Figure 5.2: TMEM216 fibroblasts exhibit greater cell area when spreading 
on collagen I.
A: Images from phase contrast time-lapse movies of cells spreading on a 
collagen I substrate. Bar: 40 μm. B: Spreading area over time on collagen I. 
Solid lines: Mean cell area; Dotted lines: SEM; n = at least 8 cells per cell line.
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Figure 5.3: TMEM67 and TMEM216 fibroblasts exhibit greater cell area 
when spreading on collagen IV.
(A) Images from phase contrast time-lapse movies of cells spreading on a 
collagen IV substrate. Bar: 40 μm. (B) Spreading area over time on collagen IV. 
Solid lines: Mean cell area; Dotted lines: SEM; n = at least 3 cells per cell line.
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Figure 5.4: TMEM216 fibroblasts exhibit greater cell area when spreading 
on fibronectin.
(A) Images from phase contrast time-lapse movies of cells spreading on a 
fibronectin substrate. Bar: 40 μm. (B) Spreading area over time on fibronectin. 
Solid lines: Mean cell area; Dotted lines: SEM; n = at least 8 cells per cell line.
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Figure 5.5: TMEM216 fibroblasts exhibit greater cell area when spreading 
on laminin.
(A) Images from phase contrast time-lapse movies of cells spreading on a 
laminin substrate. Bar: 40 μm. (B) Spreading area over time on laminin. Solid 
lines: Mean cell area; Dotted lines: SEM; n = at least 3 cells per cell line.
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collagen IV, as on collagen I, reached near maximum area within 10 minutes of 
spreading initiation. 
On fibronectin (Figure 5.4), the overall pattern of spreading observed was 
similar to that on collagen I, with control and TMEM67 cells exhibiting very 
similar morphology (Figure 5.4 A) and area at all timepoints (Figure 5.4 B), 
while TMEM216 cells spread faster and over a wider area. In comparison to 
their spreading area on collagen I, TMEM216 cells had spread even further on 
fibronectin at the 30 minute timepoint, and continued to spread beyond the 10 
minute timepoint. 
On laminin (Figure 5.5), control cells spread at a similar rate to the other 
substrates, and TMEM216 cells again spread faster and further than controls, 
though they showed a small lag period within the first two minutes where their 
rate of spreading was similar to that of controls. Out of 20 TMEM67 cells 
imaged, none were observed to spread even transiently on a laminin substrate; 
therefore TMEM67 cells were not included in this analysis. 
A limitation of cell spreading analysis is that measurement of planar cell area in 
two-dimensional images does not provide information about cell shape changes 
in the z-axis. It may be that MKS patient cells have a larger volume, and this 
contributes to their ability to spread over a wider area. A previous study 
assessed the volume of control, TMEM67, and TMEM216 cells via confocal 
imaging and detected no obvious difference in cell volume (McIntosh, 2016), 
however this was based on a small sample size and amorphous, highly spread 
cells which makes measurement of volume difficult. An experiment was 
designed to improve on this methodology: control and TMEM67 cells were 
dissociated from the culture surface with TrypLE Express cell dissociation 
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reagent and, while still suspended in the reagent, imaged. Under these 
conditions the cells would be prevented from spreading or forming adhesions 
and remain spheroid, and therefore their volume could be estimated from 
diameter measurements. No significant difference was found between the 
volumes of control and TMEM67 cells (Student’s t-test, p > 0.05, n = 3 biological 
repeats, at least 100 cells per line). 
5.3 Logarithmic analysis of cell spreading 
Having found altered spreading area and rate in MKS patient cells, next the 
spreading process was examined in more depth via logarithmic analysis of 
spreading rates. Control and MKS fibroblasts were plated as before, on 
collagen I, collagen IV, and laminin substrates, and imaged at a higher 
frequency (one image every five seconds for 30 minutes) to generate a dataset 
with improved temporal resolution. Cell area was measured over time and 
plotted on double-logarithmic graphs so spreading conforming to exponential 
power laws could be visualised as straight lines, and dynamic phase transitions 
between such exponential spreading phases visualised as changes in gradient 
(Figure 5.6), following the approach of  Döbereiner et al (2004). 
The majority (>70%, n = 7) of control cells exhibited three phases of spreading 
on collagen I; the remainder exhibited two phases. On collagen IV  (n = 3) and 
laminin (n = 3), control cells all exhibited three spreading phases. A double 
logarithmic plot of a representative cell for each substrate is shown in Figure 5.7 
A.  
TMEM67 cells spreading on collagen I all exhibited three phases of spreading 
(n = 5) (Figure 5.7 B, top). On collagen IV, 80% (n = 5) exhibited three phases 
of spreading, while the remainder spread in two phases (Figure 5.7 B, middle). 
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Figure 5.6: The three phases of isotropic cell spreading. A: A control 
fibroblast spreading normally on a collagen I substrate (phase contrast). The 
three spreading phases are denoted by colour (red: intial contact formation; 
green: rapid spreading;, blue: actin contractions and stable adhesions). 
Images labelled with time in seconds. Bar: 20 μm. B: Spreading area over 
time represented on a double logarithmic plot reveals the three phases (red, 
green, blue) governed by different power laws, recognisable as phases of 
approximately constant gradient. (Figure prepared by A. Toynbee).
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Figure 5.7: TMEM67 patient cells exhibit disrupted spreading dynamics on 
collagen IV and laminin. Each line on a double logarithmic plot represents a 
single cell; cells representative of the observed population have been chosen. 
A: control cells undergo spreading with similar power laws, especially for the 
second, rapid spreading phase, on all three substrates. B: TMEM67 cells exhibit 
three phases of spreading on collagen I, but on collagen IV some cells spread 
in only two phases, and on laminin cells only appear to spread in two phases. 
(Measurements taken by A. Toynbee).
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TMEM67 cells would not readily spread on laminin, resulting in sparse data – 
over four separate experiments, only two cells were observed spreading, with 
neither showing three phases (Figure 5.7 B, bottom). 
A slight majority of TMEM216 cells on collagen I exhibited three phases (54%, n 
= 13), while the remainder spread in two phases (Figure 5.8 B, top). All 
TMEM216 cells spread on collagen IV in only two phases (n = 4) (Figure 5.8 B, 
middle). On laminin, only two cells were observed, but both spread with three 
phases (Figure 5.8 B, bottom). 
5.4 TMEM67 cells are less resistant to deformation 
Spreading speed, especially during the second, fast phase (Cuvelier et al, 
2007), is limited by the mechanical properties of a cell, especially the resistance 
to deformation of the cortex and the cytoskeleton. The alterations to spreading 
behaviour in MKS cells could be explained by changes in the tension or 
stiffness of the cell caused by alterations in these cellular components.   
Micropipette aspiration can be used to determine the mechanical properties of 
cells under the assumption that cells behave as viscoelastic solids (Jones et al, 
1999; Sato et al, 1990; Theret et al, 1988). To investigate whether MKS patient 
cells had altered mechanical properties, micropipette aspiration of individual 
cells was undertaken. In this process, aspirating pressure is applied to a cell 
through a glass micropipette with an aperture smaller than the diameter of the 
cell, forcing a change in shape as the cell is aspirated inside the micropipette 
barrel (Figure 5.9 A). The increase in projection length over time in response to 
500 Pa of aspirating pressure was measured and used to determine the 
equilibrium Young’s modulus (mechanical stiffness) E∞ of the cell via a standard 
linear solid (SLS) viscoelastic model. This model assumes intrinsic 
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Figure 5.8: TMEM216 patient cells exhibit disrupted spreading dynamics 
on collagen I, IV, and laminin. Each line represents a single cell; cells 
representative of the observed population have been chosen. A: Reproduced 
from Figure 5.7 for ease of comparison. Control cells undergo spreading 
with similar power laws, especially for the second, rapid spreading phase, 
on all three substrates. B: TMEM216 cells exhibit two patterns of spreading 
on collagen I; either in three or two phases. On collagen IV only two phases 
are observed, while on laminin TMEM216 cells spread in three phases. 
(Measurements taken by A. Toynbee).
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Figure 5.9: TMEM67 patient cells are less resistant to deformation under 
aspirating pressure than control or TMEM216 cells. A: Example of a cell 
being aspirated into a micropipette, imaged under DIC. Note the projection 
of membrane into the micropipette barrel (black arrowheads). Blue arrows: 
aspiration direction. Bar: 20 µm. B: Mean equilibrium modulus calculated via 
the standard linear solid (SLS) viscoelastic model for control and MKS cell lines 
based on response to micropipette aspiration. Error bars: SEM; n = at least 7 
cells per cell line; *: p < 0.05 (One-way ANOVA with Dunnet’s post-test).
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incompressibility of the cell and instantaneously applied aspiration pressure 
(Jones et al, 1999; Guilak et al, 1999). (For technical details of the SLS model, 
see Chapter 3.) Control and TMEM216 cells exhibited similar mechanical 
stiffness, but TMEM67 cells were found to have significantly reduced 
mechanical stiffness in comparison to controls (Figure 5.9 B). 
5.5 Discussion 
MKS patient cells are defective in ciliation, and cells that are highly spread are 
prevented from forming cilia (Pitaval et al, 2010), so defective control of cell 
spreading is a possible explanation for ciliation defects. As previously shown 
(Chapter 3, Figure 3.14), MKS patient cells are defective in extracellular matrix 
synthesis. Due to the complex, bidirectional nature of integrin adhesion 
signalling, this may either cause alterations in cell spreading or be a 
downstream consequence of an alteration in cell spreading. Examining the cell-
ECM interaction of cells on artificially coated substrates, therefore, might reveal 
defects that could underlie ECM synthesis defects. 
TMEM67 patient cells were found to have altered spreading on collagen IV 
(Figure 5.3), one of the ECM components for which they exhibited reduced 
expression and secretion (Chapter 3, Figures 3.1 B, 3.2 A). This may reflect a 
defective cell-ECM signalling response in collagen IV-binding integrins. A 
possible model to explain both findings would be that collagen IV-binding 
integrins are non-competent to bind extracellular collagen IV, and 
simultaneously, send aberrant signalling to the cell indicating the presence of 
extracellular collagen IV (and therefore negatively regulating its synthesis). 
TMEM216 patient cells exhibited altered spreading on all substrates (Figures 
5.2-5.5). This probably indicates that the spreading defect in TMEM216 is not 
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dependent on substrate-specific integrin interactions, but on a dysregulation of 
the cell spreading process itself. 
Investigating the dynamics of cell spreading revealed that spreading of non-
diseased control fibroblasts proceeds in three phases of growth driven by 
distinct power laws, in agreement with the findings of Cuvelier et al (2007). 
Where Cuvelier et al investigated spreading on fibronectin, here spreading was 
examined on collagen I, collagen IV, and laminin substrates, but on all three, 
control cells exhibited the expected three distinct growth phases (Figure 5.7 A). 
In contrast, MKS patient cells exhibited altered spreading dynamics (Figures 5.7 
B, 5.8 B). 
Actin defects has been observed in MKS patient cells and models (Dawe et al, 
2009; Valente et al, 2010; Adams et al, 2012; McIntosh, 2016). Since the actin 
cytoskeleton is a key regulator of cell shape and force generator during cell 
spreading, Cuvelier et al predicted that disruption to actin would lead to 
disrupted spreading (Cuvelier et al, 2007). However, the initiation and progress 
of spreading is also contingent on recognition of the substrate by integrins and 
subsequent signalling (Maheshwari et al, 2000), so a disruption to integrins or 
integrin signalling could also underlie spreading defects in MKS patient cells. 
Since the influence of actin and integrins are at least partially temporally 
separated during the spreading process, it is possible to infer which process 
might be defective on the basis of the precise timing of alterations to the 
spreading process. 
Control cells exhibited similar power law growth for phase 2 on each of the 
three ECM substrates (Figure 5.7 A). This suggests that spreading during 
phase 2 is driven by a substrate-independent mechanism. Morphologically, 
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during phase 2 a smooth lamella undergoes rapid isotropic growth (Figure 5.6 
A, green). Talin-1 is a protein that couples integrins to contractile actin in the 
adhesion complex and thus mediates traction force transmission through the 
ECM-adhesion-actin physical assembly. Knockdown of Talin-1 has been shown 
to reduce formation of adhesions and development of traction force in spreading 
cells, but does not prevent initial spreading (Zhang et al, 2008). This indicates 
that the early stage of spreading, corresponding to the first and/or second 
exponential spreading phase as identified by Döbereiner et al, is independent of 
mechanical traction forces generated by actin. Phase 2 is still likely to be 
dependent on remodelling of of cortical actin (Cuvelier et al, 2007). If there are 
alterations to spreading control in MKS patient cells during this phase, a 
different power law would be expected. However, when gradients were 
measured no differences to the power law in phase two were found between 
MKS and control cells; this suggests that the mechanism driving substrate-
independent spreading in phase 2 is not disrupted in MKS, though the loss of 
phase 2 in some of the observed cells (Figures 5.7 B, 5.8 B) may indicate a 
failure to initiate this mechanism. 
In the logarithmic analysis of TMEM216 patient cells, greater spreading rate and 
cell area was not seen (Figure 5.8), in contrast to the dramatic increase in 
spreading rate found for these cells earlier (Figures 5.2, 5.3, 5.4, 5.5). However, 
the analysis was different: with the higher temporal resolution of the logarithmic 
analysis, the spreading initiation point could be determined more accurately, 
which may tend to place it earlier. Additionally, the logarithmic analysis did not 
image cells for longer than 30 minutes, whereas the earlier cell spreading 
analysis covered up to 90 minutes. 30 minutes was sufficient for control cells to 
undergo all three spreading phases, but TMEM216 patient cells have prolonged 
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phase one spreading (Figure 5.8 B), so it may be that TMEM216 cells take so 
long to transition to phase 2 after initiation of spreading that it was not seen 
within the timespan analysed. If the logarithmic analysis was extended further 
they might eventually be seen to enter phase 2; longer time series imaging 
should be considered as an extension of this work. 
A limitation of the cell spreading analysis presented here is that differences in 
initial cell volume may contribute to differences in cell spreading behaviour 
without requiring any other alterations to the spreading machinery. A previous 
study found no difference in volume between control and MKS cells (McIntosh, 
2016), and this was supported by the finding in this chapter that there was no 
significant difference in cell volume between rounded control and TMEM67 
cells. However, since the lamella represents a very small proportion of the cell 
by volume, even a small difference in initial volume could have a large impact 
on spreading behaviour, so it is still possible that a difference in volume below 
the sensitivity of these experiments may explain some of the altered spreading 
in MKS cells. Nevertheless, an alteration to spreading behaviour purely driven 
by different initial volume would be unlikely to exhibit substrate-dependence, 
which is seen in the present study.  
The timing of spreading phase 1 has been established as approximately two 
minutes in non-diseased cells (Döbereiner et al, 2004), and the control cells 
used here conform to this. Phase one in both MKS cell lines spreading on 
collagen IV and laminin was extended, however, delaying initiation of phase 2. 
Phase 2 initiation is contingent on ECM-dependent integrin signalling reaching a 
threshold (Dubin-Thaler et al, 2004), so extension of phase 1 may indicate that 
MKS patient cells are deficient in cell-ECM signalling. An actin cytoskeleton 
dependent spreading defect would be expected to delay spreading evenly 
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across different substrates, whereas the alterations observed in this chapter 
have been substrate-dependent; integrins are substrate-specific receptors. 
These factors suggest that the spreading defect is a result of defective cell-ECM 
interaction through integrin signalling rather than a direct consequence of 
altered actin dynamics. 
Cell-surface integrin density is a critical factor in initiation and progress of rapid 
phase 2 spreading (Maheshwari et al, 2000; Cavalcanti-Adam et al, 2007). 
Reduced integrin density (and therefore increased integrin spacing) delays 
adhesion complex formation and transition to phase 2 spreading (Cavalcanti-
Adam et al, 2007). This delay has also been linked to ECM concentration: lower 
ECM density results in less integrin engagement with the ECM, increased 
spacing between integrins, and slower integrin clustering, adhesion complex 
formation, and spreading phase 2 initiation (Dubin-Thaler et al, 2004). Since 
integrins are substrate-specific, the substrate-specific spreading defects could 
thus be due to lower concentration of only certain integrins on the cell surface, 
or a failure to cluster these types of integrins. 
The existing literature on the cell spreading process either takes a top-down 
biophysical approach to modelling the dynamics of spreading without 
considering underlying biology (Dubin-Thaler et al, 2004; Döbereiner et al, 
2004; Cuvelier et al, 2007; Dubin-Thaler et al, 2008; Döbereiner et al, 2005), or 
focuses on biological mechanisms (Defilippi et al, 1999; Maheshwari et al, 
2000; Loosli et al, 2010; Xiong et al, 2010), but there is little research that 
makes links between the two. The molecular and cell biological processes that 
actually drive the dynamic spreading phases therefore remain somewhat 
unclear, and the low replication of the experiments presented in this chapter 
mean that caution must be used when interpreting the results. However, this 
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evidence does suggest that alterations to integrin-based adhesions may be at 
the root of the MKS cell spreading defect. Given the placement of TMEM67 at 
the adhesion (Chapter 1, Figure 3.4), this may represent one of the core 
phenotypic alterations in TMEM67 patient cells. 
The rate of cell spreading is determined by a combination of active force 
generation by actin polymerisation, cell-ECM interactions, and the mechanical 
resistance of the cell to shape change influenced primarily by the stiffness of the 
cortex (Cuvelier et al, 2007; Carvalho et al, 2013; Clark et al, 2013). TMEM67 
cells exhibit a reduced resistance to shape change when aspirated by 
micropipette (Figure 5.9 B), suggesting that their cortical stiffness is lower than 
that of control cells. TMEM216 patient cells exhibited no alteration to 
deformation resistance, a surprising result since TMEM216 cells have shown a 
more extreme phenotype than TMEM67 cells in almost every other experiment. 
To assess the role of the actin cytoskeleton in cortical stiffness in these cells, 
imaging of fluorescently labelled f-actin at the cortex in rounded cells would be 
informative. It might also be informative to repeat the micropipette experiments 
with cells containing fluorescently labelled actin. Alterations to the actin cortex 
or failure of the actin cortex to adhere to the plasma membrane when subjected 
to micropipette aspiration, as observed in MKS1-deficient Paramecium 
(Campillo et al, 2012), could indicate a defective connection between the cortex 
and the membrane,  which may explain cell shape control defects. Ciliopathy 
proteins such as TMEM67 may be involved in this connection. 
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Chapter 6: General discussion 
6.1 Summary 
Despite a well-established genetic basis, the aetiology of MKS, in common with 
many other ciliopathies, is poorly understood. It is unclear how patient or 
cellular phenotypes emerge from single gene mutations, and even the function 
of many of the affected proteins remains unknown. MKS cells are defective in 
ciliogenesis; however, while MKS proteins have been linked to a functional 
complex in the cilium, they are also often reported in cellular locations distant 
from the cilium, and both ciliopathy models and patient cells show many cellular 
defects that are not easily explained if the primary defect is in ciliation. In this 
thesis, it has been shown that defective extracellular matrix made by MKS 
patient cells is the cause of the ciliation defect. This altered extracellular matrix 
is accompanied by depleted focal adhesion protein content and alterations to 
the actin cytoskeleton; alterations which can be rescued in TMEM67 patient 
cells by treatment with Wnt or TGF-β pathway antagonists.  
6.2 Known and proposed functions of MKS proteins 
MKS proteins function as part of a diffusion barrier at the ciliary TZ 
The MKS protein TMEM67 is a transmembrane protein that functions as part of 
a network of MKS and other ciliopathy proteins at the ciliary transition zone 
(TZ), where it is involved in the connection between the basal body and the TZ 
(Williams et al, 2011). This network is composed of two large modules: the 
NPHP module, and the MKS/JBTS module which includes TMEM67. The 
ciliopathy protein network is a component of the Y-links which connect the 
ciliary axoneme doublet microtubules to the ciliary membrane within the TZ, and 
contribute to a diffusion barrier which maintains separation between the ciliary 
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lumen and the cytoplasm, as well as between the ciliary membrane and the 
plasma membrane (Williams et al, 2011; Sang et al, 2011; Reiter et al, 2012; 
Garcia-Gonzalo et al, 2011). Compartmentalisation is essential for correct 
signalling through the cilium (Reiter et al, 2012; Hu et al, 2010). Since TMEM67 
is a transmembrane protein, and is found within the MKS/JBTS module in close 
physical association with TCTN1 and TMEM216 (Garcia-Gonzalo & Reiter, 
2012), which are also transmembrane proteins, it is likely that these have 
shared responsibility for connecting the outer ends of the Y-links to the ciliary 
membrane.  
While TMEM216 is less-studied than TMEM67, it is placed within the transition 
zone complex alongside TMEM67 (Garcia-Gonzalo et al, 2011; Garcia-Gonzalo 
& Reiter, 2012), with which it physically interacts (Valente et al, 2010). It likely 
also serves as a membrane linker since it has been predicted to contain four 
transmembrane domains (Valente et al, 2010).  
MKS proteins may be adhesion proteins 
In this thesis, it has been shown that TMEM67 is an adhesion protein, and that 
the focal adhesions of TMEM67 patient cells are depleted of many proteins. 
These results suggest that MKS cells have defective control of adhesion 
formation in response to the substrate, perhaps due to failure of recruitment or 
retention. The molecular pathways controlling adhesion formation are complex, 
with the conserved “adhesome” associated with integrin consisting of over 100 
proteins (Zaidel-Bar, 2009). Among these are a number of ciliopathy proteins. 
Fibrocystin-1 is normally present in focal adhesions, but in the ciliopathy 
polycystic kidney disease, fibrocystin-1 is lost from adhesions. Fibrocystin-1 
knockdown cells show longer paxillin-labelled adhesions, which were 
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associated with actin rearrangement and increased levels of β1-integrin and Src 
(Israeli et al, 2010). Other NPHP proteins have been found to localise to 
adhesion complexes or to interact with proteins that are components of 
adhesion complexes (Donaldson et al, 2000, 2002; Wilson et al, 1999; Markoff 
et al, 2007; Li et al, 2005). Polycystin-1 may function as an ECM receptor at 
focal adhesions, in a role similar to that of integrin (Wilson, 2001). Ciliopathy 
proteins can therefore be directly involved in regulation of the focal adhesion 
complex, its composition, and its morphology – MKS proteins may be 
performing a similar role, which would explain the alterations in adhesion 
morphology observed in MKS cells. Given its physical interaction with TMEM67, 
TMEM216 may also be a focal adhesion protein as part of a functional complex 
with TMEM67, as may other as yet undetected MKS and ciliopathy proteins, 
perhaps in a large complex with some similarities to the TZ ciliopathy network.  
MKS proteins function as cell-surface receptors 
TMEM67 has structural resemblance to the Frizzled family of transmembrane 
receptors, and it has been identified as a receptor in non-canonical Wnt 
signalling mediated by Wnt5a and ROR2 (Abdelhamed et al, 2015b). ROR2 co-
localises and physically interacts with TMEM67 at the TZ (Abdelhamed et al, 
2015b). Consequences of this signalling include inhibition of Shh and canonical 
Wnt and downstream changes reminiscent of pulmonary dysplasia (a frequent 
MKS patient symptom), which could be rescued by RhoA activation 
(Abdelhamed et al, 2015b). The finding in this thesis that inhibition of canonical 
Wnt can restore patient cell phenotypes can be understood in this context: in 
the absence of TMEM67, canonical Wnt is not inhibited and so becomes 
aberrantly activated, leading to various downstream defects which inhibition 
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rescues. This model does not explain why inhibition of Wnt/PCP was able to 
rescue some phenotypes.  
TMEM67 has been reported to localise to the basal body/centrosome, 
basolateral actin cables, the cell surface of polarised cells (Dawe et al, 2007b, 
2009), and the endoplasmic reticulum (Wang et al, 2009). Its function in these 
locations is not clear, though Wang et al propose a role in protein degradation 
at the ER. In this thesis, TMEM67 was additionally shown to localise to focal 
adhesions. The role of TMEM67 at the focal adhesion complex is also unclear. 
One of the proposed roles for TMEM67 in the ciliary transition zone is as a 
membrane anchor (Garcia-Gonzalo et al, 2011; Williams et al, 2011), so it may 
serve a similar function at the adhesion complex: as a membrane-bound 
recruiter of other proteins, including filamin A (FLNA). FLNA is not a 
transmembrane protein, so to be retained at the cell surface it must bind to 
some other factor. TMEM67’s receptor function in cooperation with ROR2 for 
Wnt/PCP (Abdelhamed et al, 2015a) may also take place at adhesions. Cilia 
are considered to be important for Wnt/PCP signalling, but this is based on the 
involvement of BBS proteins and IFT88. These are cilium-associated, but BBS 
and IFT proteins have roles elsewhere in the cell (Hernandez-Hernandez et al, 
2013; Finetti et al, 2009; Qin et al, 2007; Wood et al, 2012; Boehlke et al, 2015), 
so the involvement of the cilium itself is not necessarily supported by this 
evidence. Core PCP proteins including Dvl are required for actin reorganisation 
preceding ciliogenesis (Valente et al, 2010; Park et al, 2008), so the relationship 
may be that the cilium depends on PCP components rather than the other way 
around. 
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MKS proteins may act as membrane linkers 
One of the proposed roles for TMEM67 in the ciliary transition zone is as a 
membrane anchor (Garcia-Gonzalo et al, 2011; Williams et al, 2011), so it may 
serve a similar function elsewhere in the cell. When MKS1 expression is 
silenced in Paramecium, the cortical cytoskeleton detached from the plasma 
membrane (Campillo et al, 2012), and in this thesis it was shown that TMEM67, 
but not TMEM216, patient cells have reduced deformation resistance, which 
could be a consequence of less stable cortical actin attachment. This appears 
to support a role for some MKS proteins as membrane-cortex linkers, and is 
consistent with the interaction between TMEM67 and filamin A, which has a 
tethering activity to actin but no transmembrane domains (Calderwood et al, 
2001). It may be that the two act together as a complex in tethering roles in 
multiple contexts. TMEM67 may also act as an actin-dependent tether during 
ciliogenesis, when attenuation of TMEM67 causes basal body misalignment 
(Boisvieux-Ulrich et al, 1990; Dawe et al, 2007a; Lemullois et al, 1987; Picariello 
et al, 2014). 
6.3 Proposed model for MKS cellular defects 
Figure 6.1 shows a model for the causal relationships that might exist between 
the cellular processes that are defective in TMEM67 cells, on the basis of the 
evidence shown in this thesis and previously published work. In non-diseased 
cells (Figure 6.1 A), TMEM67 and filamin A interact at cell surface focal 
adhesions, modulating cell-ECM interaction and ECM organisation. Adhesions 
modulate the actin cytoskeleton through recruitment of actin and actin binding 
proteins, and mechanotransduction. Correct cell-ECM interaction at the 
adhesion triggers signalling leading to basal body recruitment to the cell surface 
and ciliogenesis, possibly through tension signalling along the ECM-actin-
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Figure 6.1: Model of possible alterations underlying defects in TMEM67 
patient cells.
A: In a non-diseased cell, TMEM67 interacts with FLNA at sites of cell-substrate 
adhesion, recruiting adhesion proteins and initiating tension signalling through 
the actin-nesprin 2G axis to promote basal body migration, docking, and 
ciliogenesis.
B: In a TMEM67 patient cell, absence of TMEM67 leads to broad loss of protein 
at the cell-matrix adhesion, reduced ECM density, and dense actin bundles 
(downstream of substrate rigidity and/or Wnt/TGF-β/Rho/ROCK signalling). 
Actin density and/or substrate rigidity may activate YAP/TAZ signalling, which 
inhibits BB migration/docking and ciliogenesis.
A: Non-diseased cell
B: TMEM67 patient cell
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nucleus axis involving nesprin 2G, which is a known TMEM67 binding partner 
(Dawe et al, 2009; Arsenovic et al, 2016). In TMEM67 patient cells (Figure 6.1 
B), the absence of TMEM67 at adhesions results in reduced activation of 
integrins, aberrant assembly of adhesions, and sparse ECM. Downstream of 
the changes to the ECM, or downstream of TGF-β or Wnt/Rho/ROCK signalling, 
actin bundles become denser, and either downstream of the reduced ECM 
pliancy (Dupont et al, 2011) or the actin stress fibre formation, the YAP/TAZ 
pathway may activate and negatively regulate ciliogenesis (Kim et al, 2015). 
Possible roles of Wnt signalling 
Wnt5a has a highly context-dependent effect on canonical Wnt signalling: in the 
presence of ROR2, Wnt5a inhibits canonical Wnt; however in the absence of 
ROR2 and the presence of frizzled 4, Wnt5a can activate canonical Wnt 
signalling (Mikels & Nusse, 2006). Therefore, a possible extension to the model 
in figure 6.1 would be that in TMEM67 patient cells, the absence of TMEM67 
leads to a failure to recruit its binding partner ROR2 to the cell surface, and as a 
consequence canonical Wnt is aberrantly activated. Aberrant Wnt activation has 
been reported previously in TMEM67 mouse models (Abdelhamed et al, 2013), 
and as shown in this thesis (Figure 5.3), inhibition of canonical Wnt rescues 
multiple TMEM67 patient cell phenotypes, lending credence to this model. 
Aberrant ROR2/Wnt5a signalling could explain multiple defects as ROR2/Wnt5a 
is involved in regulation of centrosome positioning, lammelipodia formation, cell 
migration, and convergent extension (Nomachi et al, 2008). Abdelhamed et al. 
only report TMEM67 and ROR2 co-localising at the ciliary transition zone, so it 
is possible that disruption to this signalling pathway is downstream of failure to 
build cilia, and therefore the loss of the receptor site, rather than directly due to 
absence of TMEM67. However, inhibition of canonical Wnt rescues ciliation 
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(Figure 5.3 B), which indicates that aberrant activation of canonical Wnt is an 
upstream cause of the ciliation defect and thus must be cilium-independent. 
This implies that ROR2/Wnt5a interaction is disrupted elsewhere in TMEM67 
patient cells. Since TMEM67 is found at multiple cellular sites including 
adhesions, it is quite plausible that the TMEM67/ROR2 interaction may also 
occur at adhesions. In this case aberrant activation of the canonical Wnt 
pathway could be a primary defect, in line with the successful rescue by 
inhibition. This model is further complicated as ROR2/Wnt5a interaction also 
activates filamin A by direct physical interaction between ROR2 and filamin A 
(Nomachi et al, 2008). As both of these proteins are reported to bind to 
TMEM67, it may be that TMEM67 plays a key role in regulating this interaction 
as well. 
Possible roles of the filamins 
What is the role of filamins at adhesions? Filamins are a family of 
multifunctional actin-binding proteins with over 30 known binding partners, 
many of which are cell surface receptors involved in adhesion (Stossel et al, 
2001; Feng & Walsh, 2004). Filamins can recruit proteins to the plasma 
membrane, and are involved in the linking of adhesions to actin, modulating the 
actin cytoskeleton’s spatial organisation and thus influencing cell shape and cell 
migration (Calderwood et al, 2001; Tu et al, 2003).  
Knockdown of filamins has been shown to impair cell spreading and initiation of 
motility, which is rescued by full length filamin A but not by a filamin A mutant 
lacking IgG domains 19 to 21 (Baldassarre et al, 2009). Baldassare et al. further 
propose that interaction of FLNA with other proteins mediated by the 19-21 
region is important for spreading and migration initiation. Conversely, increased 
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filamin binding to β-integrin at the adhesion complex inhibits cell migration and 
matrix protrusions (Calderwood et al, 2001). These apparently contradictory 
results indicate that filamins have complex roles controlling cell shape change 
that are likely to be regulated by tight control of localisation and specific binding 
partners. Filamin A is known to physically interact with TMEM67, and this 
interaction is required for ciliogenesis (Adams et al, 2012). It was proposed that 
this interaction took place at the centrosome; however, in this thesis it has been 
shown that TMEM67 is also present at adhesions.  
The interaction with TMEM67 may be important for recruitment of FLNA to the 
adhesion complex; however, in the adhesion/ECM fraction investigated by mass 
spectrometry in Chapter 3, FLNA was detected but was not significantly altered 
in abundance in TMEM67 patient cells (Appendix 1, Table 2). It may instead be 
that TMEM67 is a necessary cofactor or linker to recruit other proteins into a 
functional complex or subcomplex with FLNA at the adhesion, perhaps involving 
other MKS/JBTS module proteins which are known binding partners of 
TMEM67 such as TMEM216, and in the absence of these factors FLNA’s 
activity is dysregulated. 
FLNA knockdown has been shown to increase matrix metallopeptidase (MMP) 
activity and consequent degradation of the ECM (Baldassarre et al, 2012). 
Mutations in FLNA’s CHD2 domain can cause otopalatodigital (OPD) spectrum 
disorders, which typically present symptoms including cleft palate, deafness, 
skeletal dysplasia, digital malformations, and microcephaly (Robertson et al, 
2003; Dudding et al, 1967; Stratton & Bluestone, 1991; Stoll & Alembik, 1993). 
These symptoms are reminiscent of those seen in ciliopathies. The CHD2 
domain mutations in FLNA are predicted to alter actin binding; mutations in the 
homologous CHD2 domain of alpha-actinin have been found to increase actin 
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binding activity (Kaplan et al, 2000), suggesting that the ciliopathy-like 
symptoms of OPD may be downstream of increased actin binding by FLNA. 
Furthermore, when FLNA expression is knocked down, the observed cellular 
phenotypes are identical to those caused by TMEM67 knockdown (Adams et al, 
2012).  Some data also suggest that FLNA mutation is associated with 
connective tissue fragility (Feng & Walsh, 2004), potentially as a result of 
alterations to the ECM. These phenotypes are consistent with a role for filamin 
A as a component or upstream effector of the same signalling pathways that are 
disrupted in ciliopathies. Adams et al (2012) showed that interaction between 
filamin A and TMEM67 is essential for ciliogenesis, and in this thesis it has been 
shown to be essential for correct extracellular matrix morphology upstream of 
ciliation. In Chapter 5 it was shown that cell spreading is disrupted in MKS cells. 
A possible model to explain multiple MKS cellular defects is that the absence of 
MKS proteins leads to altered localisation or activity of filamins, disrupting 
control of actin, spreading, and the extracellular matrix, with the ciliation defect 
downstream. 
Possible roles of TGF-β signalling 
How is TGF-β signalling involved in MKS? It has been reported that in the 
absence of TGF-β signalling, at least one MKS protein, B9D1, fails to localise to 
the ciliary transition zone (Tozser et al, 2015), suggesting that TGF-β signalling 
may be necessary for the recruitment of components of the transition zone 
complex. This mis-localisation does not help to explain the non-ciliary 
phenotypes in patient cells, however. In this thesis, inhibition of TGF-β 
signalling was shown to rescue ECM morphology in TMEM67 patient cells 
upstream of ciliogenesis independently of rescue by inhibition of canonical Wnt. 
This suggests that defective ECM synthesis in MKS is downstream of combined 
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activation of both canonical Wnt and TGF-β. TGF-β1 was among the few 
proteins to have significantly increased abundance in the adhesion/ECM 
fraction of TMEM67 patient cells (Figure 4.6 B), further evidencing upregulation 
of this pathway. TGF-β activation is associated with increased ECM synthesis 
and reduced matrix metallopeptidase ECM degradation (Gressner et al, 2002); 
thus TGF-β pathway activation is difficult to reconcile with the sparse ECM 
made by MKS patient cells. A possible explanation could be that while loss of 
TMEM67 leads to activation of TGF-β signalling, it also blocks the pathways 
that would increase ECM synthesis downstream of TGF-β. TGF-β itself can also 
become activated downstream of the ECM: when cells are cultured on a normal 
matrix, TGF-β1 expression is downregulated, but cells cultured without 
endogenous or exogenous matrix have elevated TGF-β1 expression (Streuli et 
al, 1993). This cannot explain an elevation of TGF-β in TMEM67 cells, however, 
as ECM morphology was rescued by inhibition of TGF-β signalling (figure 5.3 
A), placing the ECM defect downstream of elevated TGF-β signalling, in 
defiance of the normal role of TGF-β in ECM synthesis. 
Possible roles of the Rho family GTPases 
The Rho family, of which the most well-studied members are RhoA, Rac1, and 
Cdc42, control various cellular processes including actin organisation and cell 
shape (Hall, 1998; Schmitz et al, 2000). 
A number of signalling pathways converge on the GTPase RhoA, including both 
the TGF-β pathway and the Wnt pathway (Derynck & Zhang, 2003), as well as 
force transmission via cell-matrix and cell-cell interactions (Lessey et al, 2012). 
RhoA promotes contractility of actomyosin leading to stress fibre and focal 
adhesion formation, with consequent effects on cell shape and cell-substrate 
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adhesion (Wennerberg & Der, 2004). ROCK is one of the major downstream 
effectors of Rho signalling (Leung et al, 1995). 
In TMEM216 patient cells, RhoA is hyperactivated, leading to increased ROCK 
which may be upstream of dense actin bundle formation (Valente et al, 2010; 
McIntosh, 2016), and of the cell spreading defect described in this thesis. 
RhoA is downstream of both the pathways which have been shown to rescue 
defects in TMEM67 patient cells when inhibited, and various MKS cellular 
phenotypes are plausibly downstream of altered Rho signalling, including dense 
actin bundle formation and cell spreading alterations. RhoA in TMEM67 patient 
cells has previously been found to be hyperactivated (Adams et al, 2012; Dawe 
et al, 2009). While RhoA activation was not investigated in the present study, in 
Chapter 3 of this thesis, total levels of RhoA were found to be somewhat 
diminished in the adhesion/ECM fraction, while levels of Rho family members 
Cdc42, Rac1, RhoG, ARHGEF1, and FARP1 were even more attenuated, as 
part of the overall pattern of loss of actin regulatory protein from the adhesion. 
This may reflect a redistribution of these proteins away from adhesions in 
TMEM67 patient cells rather than a cell-wide loss of abundance. Given the 
confluence of signalling and regulatory roles it still seems likely that RhoA has 
an impact on TMEM67 patient cell defects, but no clear evidence for such a role 
was acquired in this thesis. 
6.4 Causal relationships in MKS 
What is the primary defect in TMEM67 patient cells? It remains unclear how 
exactly ciliogenesis is impaired in TMEM67 cells. Previous studies have 
proposed factors upstream of ciliogenesis including TMEM67/filamin A 
interaction-dependent failure to migrate or dock the basal body to initiate 
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ciliogenesis, which may be due to failure of nucleus rotation, failure to transfer 
the basal body to the vicinity of the cell surface, or failure to clear a path through 
the cortical actin to effect docking (Adams et al, 2012; Dawe et al, 2009). 
Given the finding that cellular phenotypes including ECM synthesis and ciliation 
are rescued by inhibition of developmental signalling pathways, it is tempting to 
conclude that aberrant activation of these pathways is one of the earlier steps in 
the causal chain. This may be directly downstream of alterations to cell-surface 
receptors, especially in the light of TMEM67’s proposed role as a Wnt pathway 
receptor (Abdelhamed et al, 2013, 2015a). While developmental signalling 
pathways have profound effects on multiple cellular components, it is not 
necessarily the case that alterations in signalling cause all TMEM67 cell 
phenotypes directly, since ciliogenesis was rescued by plating on non-disease 
ECM; at the very least, signalling is taking place through the ECM. 
The causal chain linking absence of TMEM67 to patient symptoms is still 
unclear. Developmental defects may be caused directly by the activation of Wnt 
and/or TGF-β signalling, or downstream of these, by alterations to the ECM, or 
further downstream, by failure to build cilia and thus transduce cilium-dependent 
developmental signalling. Studying a disease with organism-wide 
consequences in individual cells, derived from a single tissue in a single 
individual, inherently limits confidence in the data acquired. To investigate these 
causal links more thoroughly, tissue-level or whole-organism developmental 
models would be valuable in future work. 
While the ECM defect is upstream of ciliary and actin defects, there remain 
multiple alterations in TMEM67 patient cells independent of the ECM, as has 
been shown in Chapter 5 of this thesis. The altered cell spreading dynamics 
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and deformation resistance may result from multiple underlying alterations, but 
if interpreted in line with the model in Figure 6.1, are probably a result of altered 
actin cytoskeleton regulation or tension sensing, either throughout the cell or 
specifically in the cortex. These results suggest that these defects are not a 
result of altered ECM leading to reduced tension or adhesion signalling, but that 
the causal relationship runs the other way: altered tension/adhesion signalling 
leads the cell to make an aberrant ECM. This is plausible given that ECM 
synthesis and maintenance is an actively regulated process dependent on the 
cell correctly sensing the condition of the ECM in its vicinity, through outside-in 
integrin signalling and tension sensing by adhesion components. 
6.5 Impact on MKS patient symptoms 
Cystic kidney dysplasia 
Cystic kidney is seen in 100% of MKS patients (Salonen et al, 1984a; Salonen 
& Paavola, 1998). Kidney cysts can be attributed to impaired canonical or non-
canonical (PCP) Wnt signalling (Pinson et al, 2000; Lancaster et al, 2009), and 
non-canonical Wnt/calcium signalling has been implicated in kidney 
development (Burn et al, 2011) so may also have an impact. Since TMEM67 is 
a Wnt/PCP receptor, its loss likely impacts the Wnt/PCP pathway upstream of 
cystic kidney. It is not clear how Wnt/PCP impacts kidney development, but it 
may involve convergent extension or oriented cell division, both of which are 
involved in kidney tubule development and are dependent on Wnt/PCP 
(Lancaster & Gleeson, 2010; Ybot-Gonzalez et al, 2007; Jessen et al, 2002).  
Kidney branching morphogenesis is dependent on precise expression of ECM 
and MMPs, both of which have been shown in this thesis to have altered 
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abundance in TMEM67 patient cells; these changes may be a more proximal 
cause of the cysts (Shah et al, 2004). 
The reduced laminin production in TMEM67 patient cells found in this thesis 
may indicate another possible mechanism driving kidney cysts, as laminin α5 
(LAMA5) regulates kidney cell proliferation, and mutation in LAMA5 can cause 
PKD (Shannon et al, 2006; Joly et al, 2006) (although LAMA5 was not one of 
the laminins that was significantly lower in abundance in the present study). The 
alterations found in collagen IV secretion are not likely to be involved in cystic 
kidney because collagen IV overexpression, rather than underexpression, is 
implicated in PKD (Schäfer et al, 1993). 
Occipital encephalocele 
The major CNS defect occipital encephalocele is seen in 85-90% of MKS 
patients (Salonen et al, 1984a, 1984b). Encephalocele results from failure to 
close the neural tube, which is a process requiring convergent extension of the 
midline dependent on Wnt/PCP signalling (Wallingford et al, 2002; Hamblet et 
al, 2002; Murdoch et al, 2014; Juriloff & Harris, 2012; Ybot-Gonzalez et al, 
2007; Murdoch et al, 2001, 2003; Curtin et al, 2003; Robinson et al, 2012). 
Again, the role of TMEM67 as a Wnt/PCP receptor is likely to be important in 
this pathology. Cell-cell adhesion is key during convergent extension (Pyrgaki et 
al, 2011; Suzuki et al, 2012). While in this thesis the focus has been on cell-
ECM adhesion, cell-cell adhesion through the adherens junction is also of 
interest since the ciliopathy proteins NPHP1 (Donaldson et al, 2000) and PKD1 
(Streets et al, 2003) are involved in adherens junctions, as well as both being 
focal adhesion proteins. It is possible that MKS proteins have roles in these 
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structures as well, which may influence the convergent extension phenotypes in 
MKS. 
Polydactyly 
Polydactyly, a limb patterning defect that results in supernumerary digits, is 
found in 80% of patients (Salonen & Paavola, 1998). Of all symptoms of MKS, 
polydactyly may be the simplest to explain, as the developmental patterning of 
the digits is well understood. Sonic hedgehog (Shh) signalling establishes 
posterior polarity in the limb bud, with digits specified by Shh concentration. 
Cilia and IFT are required for Hh signalling (Eggenschwiler, 2012), so this 
patient symptom is very likely a result of the ciliation defect leading to disrupted 
Shh signalling in the limb bud. 
Liver fibrosis 
Liver fibrosis has been estimated to be present in 100% of MKS cases (Salonen 
& Paavola, 1998). Liver fibrosis is an aberrant overproduction of ECM, while in 
this thesis it has been shown that MKS patient fibroblasts synthesise a less 
dense ECM (Figure 3.14), a finding that at first glance is difficult to reconcile. 
However, liver fibrosis is proximally caused when hepatic stellate cells (HSCs) 
become activated, transdifferentiating into myofibroblast-like cells, which then 
initiate ECM production (Puche et al, 2013). The HSCs reside in the spaces of 
Disse within the liver, which contain a selection of basement membrane (BM)-
associated ECM proteins (though no apparent structural BM) including collagen 
IV and laminin, which are thought to be essential for maintaining HSC 
quiescence (Bissell et al, 1987; Burt et al, 1990; Friedman et al, 1989). The 
reduced expression and abundance of collagen IV and laminin in TMEM67 
patient cell ECM shown in Chapter 3 (Figures 3.1 B, 3.2), therefore, suggest a 
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possible aetiology for liver fibrosis in MKS where reduced levels of BM proteins 
in the spaces of Disse lead to HSC activation and consequent fibrotic 
overproduction of ECM in the liver. 
Elevated levels of TGF-β in MKS would also explain liver fibrosis, as TGF-β 
activates HSCs and stimulates secretion of ECM. TGF-β activity is implicated in 
many forms of fibrosis (Leask & Abraham, 2004) 
6.6 Evolutionary context 
Why would ciliopathy proteins have dual roles at cell-substrate adhesions and 
at cilia? Many classical adhesion proteins such as paxillin and vinculin have 
been detected associated with the ciliary basal body, connecting to the actin 
cytoskeleton, leading Antoniades et al (2014) to propose that the adhesion 
complex may have originated in primitive eukaryotes as a linking module at the 
ciliary base, and later became co-opted to serve a similar role at cell-substrate 
adhesions. Ciliopathy proteins such as TMEM67 would have been closely 
associated, as they have served as highly conserved components of the ciliary 
TZ for at least as long (Barker et al, 2014). An evolutionary model may therefore 
be proposed where the ciliary base adhesion complex interacted with the TZ 
ciliopathy protein complex to serve as a cytoskeleton/cilium interface early in 
eukaryotic evolution, and when the majority of this structure was co-opted to 
serve as a cytoskeleton/ECM interface (a proto-focal adhesion), TMEM67 and 
other ciliopathy proteins were included, retaining their function at a new location 
and becoming integrated into the signalling networks at adhesions. It is possible 
that TMEM67 has diverged into functional isoforms which are differentially 
localised to these different sites; indeed, in this thesis, only one isoform of 
TMEM67 was recovered from focal adhesions (Figure 3.4 B) whereas three 
isoforms of distinct molecular weight were detected in whole cell lysate and 
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associated with actin (Figure 3.3 B). These are potentially the same small 
isoforms of TMEM67 that only appear in subconfluent, non-ciliated cells 
reported by Dawe et al (2009). Investigation of the functional differences 
between these isoforms may further inform conclusions about the evolutionary 
relationship between different roles for ciliopathy proteins. It is quite plausible 
that the single gene mutations that underlie MKS have such complex effects on 
a cellular and developmental level because they actually abolish a set of 
homologous but functionally divergent isoforms, each of which may have a 
tethering or receptor role at a different cellular site.  
6.7 Therapeutic outlook 
The findings presented here that inhibition of Wnt or TGF-β signalling can 
rescue major cellular phenotypes may indicate potential for antagonists of these 
pathways to be used therapeutically. Some such drugs are already licensed; for 
example, losartan, which antagonises the TGF-β pathway through AT1, is used 
to treat high blood pressure and slow kidney damage, and it has been proposed 
as a therapeutic intervention in Marfan syndrome, a connective tissue disorder 
(Matt et al, 2008). Neural tube defects, of which MKS is the most common 
cause (Leitch et al, 2008), are an active area of medical research. Although folic 
acid supplementation can alleviate symptoms in some patients, many neural 
tube defects do not respond to this intervention, leading to trials of other 
therapeutics such as inositol (Greene et al, 2016). Since in this thesis many of 
the defects in TMEM67 patient cells have been shown to be amenable to 
rescue via TGFβ or Wnt antagonists, it is possible that the MKS neural tube 
defect could also be rescued by similar interventions, opening a new category 
of treatments for neural tube defects. 
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Further identification of disrupted upstream effectors of the pathways in MKS 
patient cells would also be relevant to identification of drug targets. Since 
inhibition of either pathway appeared to independently rescue phenotypes, it 
may be that multiple different therapeutic strategies are viable. As this thesis 
was concerned with defects on a cellular level, no direct evidence is shown here 
for rescue of developmental defects; however the developmental pathways 
leading to many of the common MKS clinical symptoms are plausibly 
downstream of altered Wnt and TGF-β signalling, ECM synthesis, or disruption 
to ciliary signalling, all of which have been shown to be amenable to drug 
treatment. An obvious next step would be to test these interventions in an 
animal model. 
6.8 Conclusion 
This thesis presents the first comprehensive analysis of cell adhesion and the 
extracellular matrix in a ciliopathy, the first evidence of dependency 
relationships between cellular defects in Meckel-Gruber syndrome, and 
therefore a key step forward in our understanding of the aetiology of this 
phenotypically complex disease. The finding that developmental signalling 
pathway antagonists can rescue cellular defects raises the hope that new 
therapeutic approaches may be found following this work, and point toward 
future work which could further unravel the defects in ciliopathies. If a thorough 
understanding of the intra- and extracellular signalling pathways that impact on 
ciliopathies can be achieved, not only could we gain new insight into these 
complex processes, but also work towards effective treatment for deleterious 
and lethal diseases. 
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Supplementary Table 1: Illumina differential expession analysis
Official gene Name Full gene name log2(fold_change)
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 1.27666
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 1.54252
ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 2.39777
ABHD13 abhydrolase domain containing 13 1.16719
ABHD2 abhydrolase domain containing 2 1.33772
ABHD5 abhydrolase domain containing 5 -1.55508
ABI3BP ABI family, member 3 (NESH) binding protein -2.23738
ABLIM1 actin binding LIM protein 1 -2.61344
ACAA2 hypothetical LOC648603; acetyl-Coenzyme A acyltransferase 2 1.38283
ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 1.00416
ACLY ATP citrate lyase 0.830769
ACOX1 acyl-Coenzyme A oxidase 1, palmitoyl 1.24279
ACPL2 acid phosphatase-like 2 2.85809
ACSS3 acyl-CoA synthetase short-chain family member 3 -1.86537
ACTA2 actin, alpha 2, smooth muscle, aorta -2.27376
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 1.09742
ACVRL1 activin A receptor type II-like 1 -4.22295
ACYP1 acylphosphatase 1, erythrocyte (common) type -1.56813
ADAM10 ADAM metallopeptidase domain 10 1.27091
ADAM12 ADAM metallopeptidase domain 12 1.58166
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 3.151
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 -1.02107
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 1.58827
ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif, 6 -1.0243
ADAMTSL1 ADAMTS-like 1 1.56946
ADCY7 adenylate cyclase 7 1.36317
ADK adenosine kinase -1.47022
ADM adrenomedullin -1.20007
ADM2 adrenomedullin 2 -2.57051
AGAP11-C10orf116 ankyrin repeat and GTPase domain Arf GTPase activating protein 11 - chromosome 28 open reading frame 116-3.17174
AGFG2 ArfGAP with FG repeats 2 2.51403
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)-1.57242
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic acid acyltransferase, epsilon)0.762837
AGPS alkylglycerone phosphate synthase 1.55564
AGTR1 angiotensin II receptor, type 1 1.19111
AGTRAP angiotensin II receptor-associated protein -2.13317
AHNAK2 AHNAK nucleoprotein 2 1.18451
AIM1 absent in melanoma 1 0.870181
AJUBA ajuba LIM protein -1.0314
AK4 adenylate kinase 4 1.22614
AK5 adenylate kinase 5 -0.874911
AKAP12 A kinase (PRKA) anchor protein 12 3.57012
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 4.01852
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 1.83607
ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 1.49948
ALG10B asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog B (yeast)1.53345
ALMS1 Alstrom syndrome 1 0.943234
ALPK1 alpha-kinase 1 -2.00555
ALPK2 alpha-kinase 2 -2.04979
AMOT angiomotin 2.51657
AMOTL1 angiomotin like 1 1.12105
AMPD3 adenosine monophosphate deaminase (isoform E) 1.10696
AMZ2 archaelysin family metallopeptidase 2 -0.917297
ANAPC1 anaphase promoting complex subunit 1; similar to anaphase promoting complex subunit 10.957962
ANGPTL4 angiopoietin-like 4 2.77765
ANKDD1A ankyrin repeat and death domain containing 1A -1.80711
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 3.13106
ANKRD33B ankyrin repeat domain 33B 3.04791
ANO2 anoctamin 2 inf
ANO3 anoctamin 3 2.43375
ANP32A hepatopoietin PCn127; acidic (leucine-rich) nuclear phosphoprotein 32 family, member A0.772422
ANPEP alanyl (membrane) aminopeptidase -2.66581
ANXA2P2 annexin A2 pseudogene 2 -1.21108
ANXA5 annexin A5 0.869039
AP1AR chromosome 4 open reading frame 16 -0.876568
AP1S2 adaptor-related protein complex 1, sigma 2 subunit pseudogene; adaptor-related protein complex 1, sigma 2 subunit1.86544
AP1S3 adaptor-related protein complex 1, sigma 3 subunit 3.26998
APAF1 apoptotic peptidase activating factor 1 1.19259
APLP2 amyloid beta (A4) precursor-like protein 2 1.37227
APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B-1.47971
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APOL6 apolipoprotein L, 6 -1.66824
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 10.797917
AR androgen receptor -2.59733
ARAP2 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 inf
ARHGAP29 Rho GTPase activating protein 29 -2.35549
ARHGAP31 Cdc42 GTPase-activating protein 31 1.11631
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 3.48463
ARL4C ADP-ribosylation factor-like 4C 3.42277
ARL6IP4 ADP-ribosylation-like factor 6 interacting protein 4 -0.931122
ARMCX3 armadillo repeat containing, X-linked 3 0.984325
ARMCX4 similar to hCG1792883 -1.18477
ARPP19 cAMP-regulated phosphoprotein 19 pseudogene; cAMP-regulated phosphoprotein, 19kDa0.94993
ARRDC3 arrestin domain containing 3 1.8463
ARSJ arylsulfatase family, member J 1.22271
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 1.15117
ASIC1 acid-sensing (proton-gated) ion channel 1 1.75785
ASNS asparagine synthetase -1.58743
ASS1 argininosuccinate synthetase 1 -3.6714
ATF1 activating transcription factor 1 -1.13851
ATF3 activating transcription factor 3 -2.32275
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67); activating transcription factor 4C-1. 6969
ATOH8 atonal homolog 8 (Drosophila) 2.95746
ATP13A3 ATPase type 13A3 1.43556
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 -1.01892
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 0.755718
ATP5E-SLMO2 ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit - slowmo homolog 2 (Drosophila)-1.22283
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 1.12318
ATRX alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae)0.867452
ATXN7L3B ataxin 7-like 3B 1.6881
AURKA aurora kinase A; aurora kinase A pseudogene 1 -1.04372
AUTS2 autism susceptibility candidate 2 5.51109
AVPI1 arginine vasopressin-induced 1 -1.23663
B2M beta-2-microglobulin -1.27575
B3GALTL beta 1,3-galactosyltransferase-like 1.21691
B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 1.06871
B4GALNT4 beta-1,4-N-acetyl-galactosaminyl transferase 4 2.72013
B4GALT4 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4-0.836808
BAALC brain and acute leukemia, cytoplasmic 4.1237
BBS2 Bardet-Biedl syndrome 2 1.11735
BCAT1 branched chain aminotransferase 1, cytosolic 2.3425
BCOR BCL6 co-repressor 1.2503
BCYRN1 brain cytoplasmic RNA 1 (non-protein coding) -0.949748
BEX1 brain expressed, X-linked 1 1.02303
BEX4 brain expressed, X-linked 4 -1.65998
BGN biglycan 2.13611
BHLHE41 basic helix-loop-helix family, member e41 0.970513
BHMT2 betaine-homocysteine methyltransferase 2 -2.47987
BICC1 bicaudal C homolog 1 (Drosophila) -1.03906
BIRC6 baculoviral IAP repeat-containing 6 0.759303
BLCAP bladder cancer associated protein 0.920888
BNC1 basonuclin 1 -5.01044
BTN2A1 butyrophilin, subfamily 2, member A1 -0.943724
BTN2A2 butyrophilin, subfamily 2, member A2 -1.11174
BTN3A1 butyrophilin, subfamily 3, member A1 -2.15881
BTN3A2 butyrophilin, subfamily 3, member A2 -2.30666
BTN3A3 butyrophilin, subfamily 3, member A3 -3.10287
BZW1 basic leucine zipper and W2 domains 1 pseudogene 1; basic leucine zipper and W2 domains 1 like 1; basic leucine zipper and W2 domains 11.11785
C11orf63 chromosome 11 open reading frame 63 -3.1193
C11orf9 chromosome 11 open reading frame 9 1.79537
C14orf132 chromosome 14 open reading frame 132 1.67056
C14orf37 chromosome 14 open reading frame 37 2.39154
C1GALT1C1 C1GALT1-specific chaperone 1 1.28177
C1QL4 complement component 1, q subcomponent-like 4 inf
C20orf111 chromosome 20 open reading frame 111 -1.2429
C22orf29-GNB1L C22orf29 - guanine nucleotide binding protein (G protein), beta polypeptide 1-like-1.26494
C2orf44 chromosome 2 open reading frame 44 1.44273
C3orf55 chromosome 3 open reading frame 55 -1.73223
C3orf67 chromosome 3 open reading frame 67 -2.22964
C7orf10 chromosome 7 open reading frame 10 1.1556
C7orf41 chromosome 7 open reading frame 41 1.24305
C9orf64 chromosome 9 open reading frame 64 -2.30051
CA12 carbonic anhydrase XII 1.47224
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CABYR calcium binding tyrosine-(Y)-phosphorylation regulated -1.47529
CADM3 cell adhesion molecule 3 inf
CALCRL calcitonin receptor-like -1.89875
CALHM2 calcium homeostasis modulator 2 -1.27149
CAMK1D calcium/calmodulin-dependent protein kinase ID 2.84135
CAND1 cullin-associated and neddylation-dissociated 1 1.34477
CARD16 caspase recruitment domain family, member 16 -3.28496
CARD6 caspase recruitment domain family, member 6 -2.03093
CARD9 caspase recruitment domain family, member 9 -inf
CARS cysteinyl-tRNA synthetase -1.05459
CASP1 caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase)-3.3351
CASS4 Cas scaffolding protein family member 4 -3.53058
CAST calpastatin -1.06626
CBS cystathionine-beta-synthase -1.00927
CBX5 chromobox homolog 5 (HP1 alpha homolog, Drosophila) 1.09598
CBX7 chromobox homolog 7 -2.96316
CBY1 chibby homolog 1 (Drosophila) -1.10738
CCDC113 coiled-coil domain containing 113 -1.76335
CCDC130 coiled-coil domain containing 130 -1.56788
CCDC152 coiled-coil domain containing 152 inf
CCDC71L coiled-coil domain containing 71-like -1.8226
CCDC8 coiled-coil domain containing 8 1.72829
CCDC85A coiled-coil domain containing 85A 3.99673
CCNB1 cyclin B1 -0.937324
CCNB2 cyclin B2 -0.887692
CCND1 cyclin D1 1.03973
CCND2 cyclin D2 2.48238
CCT2 chaperonin containing TCP1, subunit 2 (beta) 0.799956
CD109 CD109 molecule 1.27569
CD164 CD164 molecule, sialomucin 0.799539
CD248 CD248 molecule, endosialin 1.29987
CD274 CD274 molecule 0.915163
CD2AP CD2-associated protein 1.04862
CD55 CD55 molecule, decay accelerating factor for complement (Cromer blood group)-2.1411
CD58 CD58 molecule -2.14454
CD59 CD59 molecule, complement regulatory protein 0.898397
CD68 CD68 molecule -1.09217
CD82 CD82 molecule -3.15769
CD83 CD83 molecule -3.815
CD97 CD97 molecule -1.01691
CDC20 cell division cycle 20 homolog (S. cerevisiae) -1.31356
CDC25B cell division cycle 25 homolog B (S. pombe) -1.3198
CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 -1.53983
CDCA3 cell division cycle associated 3 -1.45681
CDCA8 cell division cycle associated 8 -0.862716
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) 1.26243
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 0.947065
CDK11A similar to cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 1 (PITSLRE proteins); cell division cycle 2-like 2 (PITSLRE proteins)-0.940209
CDK15 PFTAIRE protein kinase 2 -1.56201
CDK17 PCTAIRE protein kinase 2 1.09715
CDK20 cell cycle related kinase -2.05691
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) -1.11063
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) -1.36325
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) -1.45961
CDKN3 cyclin-dependent kinase inhibitor 3 -2.28507
CDR1 cerebellar degeneration-related protein 1, 34kDa 1.72713
CDR2 cerebellar degeneration-related protein 2, 62kDa -0.880281
CDYL chromodomain protein, Y-like -0.921214
CEBPB CCAAT/enhancer binding protein (C/EBP), beta -1.2911
CEBPD CCAAT/enhancer binding protein (C/EBP), delta -1.80966
CEBPG CCAAT/enhancer binding protein (C/EBP), gamma -1.24876
CELF2 CUG triplet repeat, RNA binding protein 2 2.73062
CEP170 centrosomal protein 170kDa 1.8749
CEP19 centrosomal protein 19kDa -1.88973
CEP250 centrosomal protein 250kDa / CNAP1 1.41592
CETN3 centrin, EF-hand protein, 3 (CDC31 homolog, yeast) -1.09736
CFH complement factor H -1.18438
CFL2 cofilin 2 (muscle) -0.860912
CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) -2.79477
CHD9 chromodomain helicase DNA binding protein 9 0.780368
CHIC1 cysteine-rich hydrophobic domain 1 0.999948
CHN1 chimerin (chimaerin) 1 -2.47714
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CHORDC1 cysteine and histidine-rich domain (CHORD)-containing 1; cysteine and histidine-rich domain (CHORD)-containing 1 pseudogene0.852996
CHPF chondroitin polymerizing factor 1.14338
CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 152.59689
CHSY3 chondroitin sulfate synthase 3 2.50189
CISD1 CDGSH iron sulfur domain 1 1.18842
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2-2.02062
CKAP2 cytoskeleton associated protein 2 -0.707997
CKAP4 cytoskeleton-associated protein 4 0.706704
CKS2 CDC28 protein kinase regulatory subunit 2 -0.892051
CLCN5 chloride channel 5 1.36993
CLDN1 claudin 1 1.84605
CLDN11 claudin 11 4.18892
CLPP ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (E. coli)-1.23401
CLTB clathrin, light chain (Lcb) -1.09621
CLTCL1 clathrin, heavy chain-like 1 -1.7184
CLU clusterin 3.96023
CMIP c-Maf-inducing protein 1.06442
CMTM4 CKLF-like MARVEL transmembrane domain containing 4 1.64097
CNIH3 cornichon homolog 3 (Drosophila) 2.99667
CNN1 calponin 1, basic, smooth muscle 4.18816
CNTNAP2 contactin associated protein-like 2 inf
CNTNAP3B contactin associated protein-like 3; contactin associated protein-like 3Binf
COA6 cytochrome c oxidase assembly factor 6 homolog (S. Cerevisiae) -1.23795
COBLL1 COBL-like 1 1.01567
COL16A1 collagen, type XVI, alpha 1 1.57505
COL1A1 collagen, type I, alpha 1 1.2435
COL4A2 collagen, type IV, alpha 2 -0.98649
COL4A6 collagen, type IV, alpha 6 -1.8766
COL6A1 collagen, type VI, alpha 1 0.843068
COLEC12 collectin sub-family member 12 inf
COPS8 COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis)0.817848
CORIN corin, serine peptidase -2.18769
CORO2B coronin, actin binding protein, 2B -1.52726
CPA4 carboxypeptidase A4 2.55071
CPEB2 cytoplasmic polyadenylation element binding protein 2 2.35014
CPED1 cadherin-like and PC-esterase domain containing 1 -1.82691
CPM carboxypeptidase M -1.2285
CPNE8 copine VIII -inf
CPS1 carbamoyl-phosphate synthetase 1, mitochondrial 3.07178
CPT1A carnitine palmitoyltransferase 1A (liver) 1.55128
CPXM2 carboxypeptidase X (M14 family), member 2 inf
CRABP2 cellular retinoic acid binding protein 2 3.18615
CRADD CASP2 and RIPK1 domain containing adaptor with death domain -2.3475
CREB5 cAMP responsive element binding protein 5 2.4193
CREG1 cellular repressor of E1A-stimulated genes 1 -1.75744
CRELD1 cysteine-rich with EGF-like domains 1 -1.49636
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 -3.89405
CRNDE hCG1815491 -1.47427
CRYAB crystallin, alpha B 2.2337
CSRP2 cysteine and glycine-rich protein 2 -1.63107
CST3 cystatin C -1.08921
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 0.868635
CTNND2 catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein)inf
CTSC cathepsin C -1.63365
CTSL1 cathepsin L1 -1.37689
CTSZ cathepsin Z -0.857053
CUL4B cullin 4B 1.69546
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)-2.69854
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 7.47892
CXCL5 chemokine (C-X-C motif) ligand 5 -1.88329
CXXC5 CXXC finger 5 -2.33221
CYB5R2 cytochrome b5 reductase 2 -3.63906
CYFIP2 cytoplasmic FMR1 interacting protein 2 3.16387
CYGB cytoglobin -1.29924
CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2 -1.96144
CYR61 cysteine-rich, angiogenic inducer, 61 -1.31188
CYYR1 cysteine/tyrosine-rich 1 3.03389
DBNDD1 dysbindin (dystrobrevin binding protein 1) domain containing 1 2.38699
DCBLD2 discoidin, CUB and LCCL domain containing 2 1.84057
DCHS1 dachsous 1 (Drosophila) 1.34521
DCLK2 doublecortin-like kinase 2 -2.3465
DCP1B DCP1 decapping enzyme homolog B (S. cerevisiae) -0.91217
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DCTN3 dynactin 3 (p22) -0.903299
DDIT4 DNA-damage-inducible transcript 4 -2.39062
DDIT4L DNA-damage-inducible transcript 4-like -3.11374
DDX19B DEAD (Asp-Glu-Ala-As) box polypeptide 19B -0.877952
DDX6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 0.800345
DEGS1 degenerative spermatocyte homolog 1, lipid desaturase (Drosophila)0.874168
DENND1A DENN/MADD domain containing 1A -1.14827
DGKB diacylglycerol kinase, beta 90kDa -4.20003
DGKI diacylglycerol kinase, iota -1.88613
DHRS3 dehydrogenase/reductase (SDR family) member 3 inf
DHRS7 dehydrogenase/reductase (SDR family) member 7 -1.384
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 1.12236
DKK3 dickkopf homolog 3 (Xenopus laevis) -0.772393
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 0.849068
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 -2.15521
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, member 15 -3.21689
DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 -1.51549
DNM3OS DNM3 opposite strand/antisense RNA 1.91143
DNMBP dynamin binding protein 1.06954
DOCK7 dedicator of cytokinesis 7 1.23904
DOK5 docking protein 5 inf
DPM3 dolichyl-phosphate mannosyltransferase polypeptide 3 -1.36268
DPP6 dipeptidyl-peptidase 6 inf
DPY19L1 dpy-19-like 1 (C. elegans); similar to hCG1645499 1.25509
DPYSL3 dihydropyrimidinase-like 3 -1.8657
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) -1.45234
DRP2 dystrophin related protein 2 3.49499
DSP desmoplakin 1.43308
DTNA dystrobrevin, alpha 1.49901
DUSP7 dual specificity phosphatase 7 -0.872847
DYRK3 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 -1.13724
EBF1 early B-cell factor 1 2.69508
ECE1 endothelin converting enzyme 1 -1.4237
ECH1 enoyl Coenzyme A hydratase 1, peroxisomal 1.06097
ECM1 extracellular matrix protein 1 -1.59787
EDEM3 ER degradation enhancer, mannosidase alpha-like 3 1.18644
EDIL3 EGF-like repeats and discoidin I-like domains 3 3.58966
EDN1 endothelin 1 2.69965
EDNRA endothelin receptor type A 3.02633
EEA1 early endosome antigen 1 0.748717
EEF2K eukaryotic elongation factor-2 kinase 1.19295
EFCAB2 EF-hand calcium binding domain 2 -1.14182
EFHA2 EF-hand domain family, member A2 1.37444
EFS embryonal Fyn-associated substrate 2.32565
EGLN1 egl nine homolog 1 (C. elegans) 0.91977
EGR1 early growth response 1 -2.80541
EIF1 similar to eukaryotic translation initiation factor 1; eukaryotic translation initiation factor 1-0.886446
EIF2B2 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa -1.14541
EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 -0.798792
EIF5B eukaryotic translation initiation factor 5B 0.884016
ELOVL6 ELOVL family member 6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast).09481
EMB embigin homolog (mouse) 4.4359
EMILIN1 elastin microfibril interfacer 1 0.91782
EMILIN2 elastin microfibril interfacer 2 -3.85787
EML1 echinoderm microtubule associated protein like 1 -1.3169
EML2 echinoderm microtubule associated protein like 2 -1.35044
EMP1 epithelial membrane protein 1 1.17646
EMR2 egf-like module containing, mucin-like, hormone receptor-like 2 -1.9149
EMX2 empty spiracles homeobox 2 3.05693
ENAH enabled homolog (Drosophila) 0.750457
ENC1 ectodermal-neural cortex (with BTB-like domain) 1.6565
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 -1.47876
ENY2 enhancer of yellow 2 homolog (Drosophila) 0.79612
EPAS1 endothelial PAS domain protein 1 -2.84778
EPB41L1 erythrocyte membrane protein band 4.1-like 1 1.40027
EPHA5 EPH receptor A5 5.09744
EPHB2 EPH receptor B2 4.86398
EPHB4 EPH receptor B4 1.48017
EPM2AIP1 EPM2A (laforin) interacting protein 1 1.1658
EPSTI1 epithelial stromal interaction 1 (breast) -1.98292
EPT1 selenoprotein I 0.977814
ERCC1 excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)-1.02249
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ERN1 endoplasmic reticulum to nucleus signaling 1 -2.61485
ESAM endothelial cell adhesion molecule -inf
ESM1 endothelial cell-specific molecule 1 -2.48189
EVA1C eva-1 homolog C (C. Elegans) -1.90607
EVL Enah/Vasp-like 3.28693
EXOC5 exocyst complex component 5 0.826216
EXTL3 exostoses (multiple)-like 3 1.27224
EYA3 eyes absent homolog 3 (Drosophila) 0.932061
F2RL2 coagulation factor II (thrombin) receptor-like 2 2.71598
F3 coagulation factor III (thromboplastin, tissue factor) -4.65222
F8A1 coagulation factor VIII-associated (intronic transcript) 2; coagulation factor VIII-associated (intronic transcript) 3; coagulation factor VIII-associated (intronic transcript) 11.80648
FABP5 fatty acid binding protein 5-like 2; fatty acid binding protein 5 (psoriasis-associated); fatty acid binding protein 5-like 8; fatty acid binding protein 5-like 7; fatty acid binding protein 5-like 90.909151
FADS2 fatty acid desaturase 2 -0.910657
FADS3 fatty acid desaturase 3 -2.46254
FAHD2B fumarylacetoacetate hydrolase domain containing 2B -2.41446
FAM100B family with sequence similarity 100, member B -1.62775
FAM101B hypothetical protein LOC100133632; family with sequence similarity 101, member B0.829994
FAM102B family with sequence similarity 102, member B -2.12812
FAM105A family with sequence similarity 105, member A -5.04816
FAM115C family with sequence similarity 115, member C; family with sequence similarity 115, member D (pseudogene)1.45379
FAM127C family with sequence similarity 127, member C; hypothetical LOC1001289491.08 22
FAM149B1 family with sequence similarity 149, member B1 -0.915872
FAM156A family with sequence similarity 156, member A; family with sequence similarity 156, member B3.62284
FAM160B1 family with sequence similarity 160, member B1 0.853713
FAM162B family with sequence similarity 162, member B -3.55294
FAM171A1 family with sequence similarity 171, member A1 1.96446
FAM173B family with sequence similarity 173, member B 1.27539
FAM19A5 family with sequence similarity 19 (chemokine (C-C motif)-like), member A5inf
FAM206A family with sequence similarity 206, member A -1.35426
FAM20B family with sequence similarity 20, member B 0.992194
FAM210B family with sequence similarity 210, member B 0.815229
FAM21B family with sequence similarity 21, member B; family with sequence similarity 21, member A-inf
FAM3C family with sequence similarity 3, member C 1.1279
FAM63B family with sequence similarity 63, member B 1.43031
FAM65A family with sequence similarity 65, member A -0.812135
FAM83D family with sequence similarity 83, member D -1.1053
FAM98A family with sequence similarity 98, member A 0.852854
FAM98B family with sequence similarity 98, member B 0.87878
FANCM Fanconi anemia, complementation group M 1.23376
FAP fibroblast activation protein, alpha 2.15828
FARP1 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)-1.09358
FBLN1 fibulin 1 2.24302
FBLN2 fibulin 2 -1.97545
FBLN5 fibulin 5 1.23585
FBN1 fibrillin 1 0.767791
FBXL2 F-box and leucine-rich repeat protein 2 -1.33678
FBXL7 F-box and leucine-rich repeat protein 7 -1.08072
FBXO4 F-box protein 4 -1.46901
FBXW5 F-box and WD repeat domain containing 5 -1.20055
FCHO1 FCH domain only 1 -3.80109
FCHSD1 FCH and double SH3 domains 1 -1.15864
FCHSD2 FCH and double SH3 domains 2 -0.957955
FDXR ferredoxin reductase -1.56914
FEN1 flap structure-specific endonuclease 1 1.03001
FER1L4 fer-1-like 4 (C. elegans) -1.36104
FERMT1 fermitin family homolog 1 (Drosophila) -2.7883
FGD4 FYVE, RhoGEF and PH domain containing 4 1.29177
FGF2 fibroblast growth factor 2 (basic) -1.2029
FHL1 four and a half LIM domains 1 -1.74194
FHOD3 formin homology 2 domain containing 3 1.94733
FIBIN fin bud initiation factor homolog (zebrafish) 2.87582
FILIP1 filamin A interacting protein 1 -3.05188
FKBP9L FK506 binding protein 9-like 1.44545
FLJ42627 hypothetical LOC645644 3.74231
FLJ45340 hypothetical LOC402483; similar to capicua-like protein/double homeodomain 4 fusion protein1.39366
FLNC filamin C, gamma (actin binding protein 280) 0.909861
FLOT1 flotillin 1 -0.980214
FLRT3 fibronectin leucine rich transmembrane protein 3 5.01167
FMN2 formin 2 1.36628
FNBP1L formin binding protein 1-like 2.49282
FOLR3 folate receptor 3 (gamma) -inf
FOSL2 FOS-like antigen 2 -1.10946
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FOXD1 forkhead box D1 1.278
FOXF2 forkhead box F2 -2.96617
FOXN3 forkhead box N3 1.47012
FOXO3 forkhead box O3; forkhead box O3B pseudogene 1.03703
FRAS1 Fraser syndrome 1 6.00799
FRMD3 FERM domain containing 3 1.00267
FRMD4A FERM domain containing 4A 0.952147
FRMPD4 FERM and PDZ domain containing 4 -2.14447
FRYL FRY-like 0.942554
FUS fusion (involved in t(12;16) in malignant liposarcoma) 0.807373
FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 1.55209
FXYD5 FXYD domain containing ion transport regulator 5 -1.14422
FYCO1 FYVE and coiled-coil domain containing 1 0.986025
FZD1 frizzled homolog 1 (Drosophila) 1.71073
FZD4 frizzled homolog 4 (Drosophila) -1.71385
G0S2 G0/G1switch 2 -6.69607
G3BP1 GTPase activating protein (SH3 domain) binding protein 1 1.04477
GABBR2 gamma-aminobutyric acid (GABA) B receptor, 2 4.68423
GADD45A growth arrest and DNA-damage-inducible, alpha -1.09578
GADD45B growth arrest and DNA-damage-inducible, beta -1.47781
GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13); UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1)1.00392
GALNT10 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 10 (GalNAc-T10)1.52515
GALNT2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2)0.94851
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3)3.96136
GALNT5 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5)1.00265
GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T7)1.78008
GALNTL2 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 21.89482
GANC glucosidase, alpha; neutral C 1.4026
GAP43 growth associated protein 43 inf
GAS2L3 growth arrest-specific 2 like 3 -1.92197
GAS5 growth arrest-specific 5 (non-protein coding) -0.926889
GAS6 similar to growth arrest-specific 6; growth arrest-specific 6 -0.78806
GATAD2B GATA zinc finger domain containing 2B 0.985028
GBP3 guanylate binding protein 3 -1.10648
GDF15 growth differentiation factor 15 -1.94194
GDNF glial cell derived neurotrophic factor 3.31722
GGA2 golgi associated, gamma adaptin ear containing, ARF binding protein 20.995662
GHR growth hormone receptor 3.52875
GJA1 gap junction protein, alpha 1, 43kDa 1.52568
GLCCI1 glucocorticoid induced transcript 1 1.06217
GLIPR1 GLI pathogenesis-related 1 3.09151
GLIS2 GLIS family zinc finger 2 -1.32179
GLRB glycine receptor, beta -1.25349
GLS glutaminase 0.967195
GLUL glutamate-ammonia ligase (glutamine synthetase) -1.20263
GM2A GM2 ganglioside activator -0.9274
GMFB glia maturation factor, beta 1.17835
GNA12 guanine nucleotide binding protein (G protein) alpha 12 -1.07038
GNAQ guanine nucleotide binding protein (G protein), q polypeptide 0.879318
GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 1.22141
GNG2 guanine nucleotide binding protein (G protein), gamma 2 2.4221
GOLGA8A golgi autoantigen, golgin subfamily a, 8B; golgi autoantigen, golgin subfamily a, 8A1.07817
GOLM1 golgi membrane protein 1 1.79907
GOT1 glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)-1.88783
GPBP1 GC-rich promoter binding protein 1 -0.780635
GPC1 glypican 1 -1.05326
GPC6 glypican 6 1.271
GPM6B glycoprotein M6B 3.14969
GPR155 G protein-coupled receptor 155 1.31649
GPR176 G protein-coupled receptor 176 -0.80256
GPX4 glutathione peroxidase 4 (phospholipid hydroperoxidase) -0.976611
GRAMD3 GRAM domain containing 3 -0.92356
GRB14 growth factor receptor-bound protein 14 2.96493
GREM1 gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) -2.99277
GRHPR glyoxylate reductase/hydroxypyruvate reductase -0.88368
GRIA1 glutamate receptor, ionotropic, AMPA 1 1.72969
GRSF1 G-rich RNA sequence binding factor 1 0.817898
GSTA4 glutathione S-transferase alpha 4 1.02708
GSTM4 glutathione S-transferase mu 4 -1.72633
GULP1 GULP, engulfment adaptor PTB domain containing 1 -2.47147
GUSB glucuronidase, beta -1.05278
GXYLT1 glycosyltransferase 8 domain containing 3 1.04251
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GYG2 glycogenin 2 2.5253
H1F0 H1 histone family, member 0 -2.48234
H1FX H1 histone family, member X -1.90722
HCFC1R1 host cell factor C1 regulator 1 (XPO1 dependent) -1.08458
HCLS1 hematopoietic cell-specific Lyn substrate 1 -6.6458
HECTD2 HECT domain containing 2 1.30276
HELZ helicase with zinc finger 0.995185
HERC2P7 hect domain and RLD 2 pseudogene 7 inf
HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1-0.984702
HEY1 hairy/enhancer-of-split related with YRPW motif 1 -2.36771
HFE hemochromatosis -1.21649
HHIP hedgehog interacting protein 3.63982
HHIP-AS1 HHIP antisense RNA 1 2.30151
HIC1 hypermethylated in cancer 1 -1.4375
HINT1 histidine triad nucleotide binding protein 1 -1.09043
HIPK2 homeodomain interacting protein kinase 2; similar to homeodomain interacting protein kinase 20.84467
HJURP Holliday junction recognition protein -1.22585
HLA-A major histocompatibility complex, class I, A -0.821578
HLA-C major histocompatibility complex, class I, C; major histocompatibility complex, class I, B1.82993
HLA-E major histocompatibility complex, class I, E -1.20576
HLX H2.0-like homeobox -2.038
HMGA2 high mobility group AT-hook 2 1.89086
HMGB1 high-mobility group box 1; high-mobility group box 1-like 10 0.797918
HNMT histamine N-methyltransferase -3.0376
HNRNPL similar to heterogeneous nuclear ribonucleoprotein L-like; heterogeneous nuclear ribonucleoprotein L1.05643
HNRNPM heterogeneous nuclear ribonucleoprotein M 1.12647
HNRNPU heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)0.977889
HNRPLL heterogeneous nuclear ribonucleoprotein L-like 1.0212
HOMER1 homer homolog 1 (Drosophila) 1.47924
HOMER3 homer homolog 3 (Drosophila) -0.988472
HOOK3 hook homolog 3 (Drosophila) 0.992316
HOPX HOP homeobox 1.89295
HOXA10-HOXA9 homeobox A10 - homeobox A9 -7.13909
HOXA11-AS HOXA11 antisense RNA -inf
HOXB-AS3 HOXB cluster antisense RNA 3 inf
HOXB4 homeobox B4 inf
HOXB5 homeobox B5 inf
HOXB6 homeobox B6 inf
HOXB8 homeobox B8 inf
HOXC10 homeobox C10 2.44632
HOXC4-5-6 homeobox C4 - homeobox C5 - homeobox C6 3.82751
HOXC8 homeobox C8 6.85905
HOXC9 homeobox C9 1.22503
HOXD-AS1 HOXD cluster antisense RNA 1 3.33391
HOXD12 homeobox D12 -inf
HOXD13 homeobox D13 -inf
HOXD9 homeobox D9 -2.10587
HPCAL1 hippocalcin-like 1 -2.91195
HSBP1L1 heat shock factor binding protein 1-like -2.77585
HSPA1A heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 2.25994
HSPA1B heat shock 70kDa protein 1A; heat shock 70kDa protein 1B 1.85133
HSPA2 heat shock 70kDa protein 2 -2.1368
HSPD1 heat shock 60kDa protein 1 (chaperonin) pseudogene 5; heat shock 60kDa protein 1 (chaperonin) pseudogene 6; heat shock 60kDa protein 1 (chaperonin) pseudogene 1; heat shock 60kDa protein 1 (chaperonin) pseudogene 4; heat shock 60kDa protein 1 (chaperonin)0.916597
HSPH1 heat shock 105kDa/110kDa protein 1 1.02258
HTATSF1P2 HIV-1 Tat specific factor 1 pseudogene 2 -4.01519
HTR7P1 5-hydroxytryptamine (serotonin) receptor 7 pseudogene 2.50236
HTRA1 HtrA serine peptidase 1 -1.20197
HYAL3-NAT6 Hyaluronoglucosaminidase 3  - N-acetyltransferase 6 (GCN5-related)-1.47789
HYLS1 hydrolethalus syndrome 1 -2.25236
IAH1 isoamyl acetate-hydrolyzing esterase 1 homolog (S. cerevisiae) -0.999219
ICAM1 intercellular adhesion molecule 1 -4.01889
ICAM5 intercellular adhesion molecule 5, telencephalin -2.07951
ICK intestinal cell (MAK-like) kinase 1.14282
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein3.01118
IDE insulin-degrading enzyme 1.13843
IER3 immediate early response 3 -1.50332
IFI27L2 interferon, alpha-inducible protein 27-like 2 -1.28116
IFI35 interferon-induced protein 35 -1.85921
IFI44 interferon-induced protein 44 1.99545
IFIH1 interferon induced with helicase C domain 1 -2.12642
IFITM1 interferon induced transmembrane protein 1 (9-27) -1.5045
IFITM2 interferon induced transmembrane protein 2 (1-8D) -1.64381
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IFITM3 interferon induced transmembrane protein 3 (1-8U) -1.38122
IFNAR1 interferon (alpha, beta and omega) receptor 1 1.02002
IFNGR1 interferon gamma receptor 1 -0.984212
IFRD1 interferon-related developmental regulator 1 -0.927675
IGF1R insulin-like growth factor 1 receptor 0.902806
IGF2BP1 insulin-like growth factor 2 mRNA binding protein 1 2.00907
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 -0.79061
IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 1.06442
IGFBP3 insulin-like growth factor binding protein 3 3.92219
IGFBP5 insulin-like growth factor binding protein 5 3.1166
IGFBP7 insulin-like growth factor binding protein 7 -1.54497
IKZF2 IKAROS family zinc finger 2 (Helios) 1.27753
IL10RB interleukin 10 receptor, beta -1.05597
IL32 interleukin 32 -3.03102
IL7R interleukin 7 receptor -3.34722
IL8 interleukin 8 -4.37071
IMPAD1 inositol monophosphatase domain containing 1 0.991612
INA internexin neuronal intermediate filament protein, alpha 4.45129
ING2 inhibitor of growth family, member 2 -1.34412
INPP1 inositol polyphosphate-1-phosphatase -1.32143
INPP4B inositol polyphosphate-4-phosphatase, type II, 105kDa -2.01152
INSIG1 insulin induced gene 1 -1.69197
IPW imprinted in Prader-Willi syndrome (non-protein coding) 2.33296
IQCB1 IQ motif containing B1 -1.22219
IQGAP1 IQ motif containing GTPase activating protein 1 0.837213
IQGAP3 IQ motif containing GTPase activating protein 3 -1.42997
IRAK3 interleukin-1 receptor-associated kinase 3 -5.15571
IRAK4 interleukin-1 receptor-associated kinase 4 1.30373
IRF1 interferon regulatory factor 1 -1.60238
IRF2 interferon regulatory factor 2 -1.21716
IRX2 iroquois homeobox 2 2.97669
IRX5 iroquois homeobox 5 -2.78844
ITGA1-PELO integrin, alpha 1 - pelota homolog (Drosophila) -0.996068
ITGA10 integrin, alpha 10 2.32336
ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 2.63657
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)-1.32241
ITGA5 integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 0.852733
ITGAV integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51)0.981272
ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains) 2.22384
ITPR2 inositol 1,4,5-triphosphate receptor, type 2 1.34505
JAM2 junctional adhesion molecule 2 2.75744
JDP2 Jun dimerization protein 2 -1.36843
JRKL jerky homolog-like (mouse) 1.05758
JUNB jun B proto-oncogene -1.58681
JUND jun D proto-oncogene -1.16647
KBTBD6 kelch repeat and BTB (POZ) domain containing 6 1.06208
KBTBD8 kelch repeat and BTB (POZ) domain containing 8 2.92384
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 2.42894
KCNJ8 potassium inwardly-rectifying channel, subfamily J, member 8 1.73682
KCNK2 potassium channel, subfamily K, member 2 0.888359
KCNQ3 potassium voltage-gated channel, KQT-like subfamily, member 3 4.23663
KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 1.4318
KCTD12 potassium channel tetramerisation domain containing 12 2.71563
KCTD16 potassium channel tetramerisation domain containing 16 2.40081
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) inf
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3-1.84926
KIAA0391 KIAA0391 0.997664
KIAA0408-SOGA3 KIAA0408 - SOGA family member 3 -1.12752
KIAA1147 KIAA1147 1.31772
KIAA1217 KIAA1217 3.64925
KIAA1456 KIAA1456 -2.33334
KIAA1462 KIAA1462 1.65147
KIAA1549L KIAA1549L 0.94839
KIAA1598 KIAA1598 2.45778
KIF14 kinesin family member 14 -0.897447
KIF2C kinesin family member 2C -0.888528
KIFC3 kinesin family member C3 -1.92175
KIT similar to Mast/stem cell growth factor receptor precursor (SCFR) (Proto-oncogene tyrosine-protein kinase Kit) (c-kit) (CD117 antigen); v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog2.04094
KITLG KIT ligand 0.76707
KLF10 Kruppel-like factor 10 0.866038
KLF4 Kruppel-like factor 4 (gut) -1.87634
KLF5 Kruppel-like factor 5 (intestinal) -2.44426
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KLHL29 kelch-like 29 (Drosophila) 1.4157
KLHL9 kelch-like 9 (Drosophila) 1.35535
KRBOX1 KRAB box domain containing 1 -1.77955
KRCC1 lysine-rich coiled-coil 1 -0.887558
KRR1 KRR1, small subunit (SSU) processome component, homolog (yeast)1.62807
KRT19 keratin 19 0.890488
KRT34 keratin 34 -3.08787
KRTAP2-3 keratin associated protein 2-1; keratin associated protein 2-4; keratin associated protein 2-3; similar to keratin associated protein 2-4; keratin associated protein 2-2-2.47193
KRTAP3-1 keratin associated protein 3-1 -inf
KRTCAP2 keratinocyte associated protein 2 -0.940404
L3MBTL3 l(3)mbt-like 3 (Drosophila) 1.46059
LAMA1 laminin, alpha 1 1.35974
LAMA2 laminin, alpha 2 -5.47237
LANCL1 LanC lantibiotic synthetase component C-like 1 (bacterial) 1.19459
LCE2A late cornified envelope 2A -2.07037
LDOC1 leucine zipper, down-regulated in cancer 1 3.22106
LGALS1 lectin, galactoside-binding, soluble, 1 -1.53186
LHFP lipoma HMGIC fusion partner -1.94153
LHPP phospholysine phosphohistidine inorganic pyrophosphate phosphatase-2.96725
LIFR leukemia inhibitory factor receptor alpha 1.63513
LINC00467 long intergenic non-protein coding RNA 467 -2.04789
LINC00657 long intergenic non-protein coding RNA 657 1.02389
LITAF lipopolysaccharide-induced TNF factor -4.53655
LOC100134259 similar to hCG1987718 -2.31247
LOC100144602 hypothetical inf
LOC100190986 hypothetical LOC100190986 inf
LOC100294145 hypothetical protein LOC100294145 1.49293
LOC100505491 4.69634
LOC100506123 1.44719
LOC100506453 inf
LOC100506518 -1.80099
LOC100506548 1.06119
LOC100506844 -1.00058
LOC100506948 1.57331
LOC100507053 3.02992
LOC100507127 -3.28069
LOC100507165 -2.70221
LOC100507420-LOC100507439 1.69455
LOC100996242 inf
LOC100996277 inf
LOC152742 hypothetical protein LOC152742 -3.5702
LOC344595 hypothetical LOC344595 1.71968
LOC375295 hypothetical protein LOC375295 2.21159
LOC388796 hypothetical LOC388796 -2.57018
LOC400027 hypothetical protein LOC400027 1.45189
LOC441528 hypothetical protein LOC441528; similar to hCG1981372; similar to Serine/threonine-protein kinase PRKX (Protein kinase PKX1)inf
LOC646329 hypothetical LOC646329 1.27377
LOC646719 hypothetical LOC646719 1.93115
LOC728392 hypothetical protein LOC728392 3.55366
LOC728730 hypothetical LOC728730 -1.46861
LOC730101 hypothetical LOC730101 -0.829729
LOC730102 hypothetical protein LOC730102 -2.44679
LOC90246 hypothetical protein LOC90246 2.43129
LONRF1 LON peptidase N-terminal domain and ring finger 1 -2.13581
LOX lysyl oxidase 1.43598
LPCAT2 lysophosphatidylcholine acyltransferase 2 2.70662
LPCAT4 lysophosphatidylcholine acyltransferase 4 -1.16844
LPHN2 latrophilin 2 3.35194
LPP LIM domain containing preferred translocation partner in lipoma 1.14905
LRBA LPS-responsive vesicle trafficking, beach and anchor containing 1.3983
LRFN5 leucine rich repeat and fibronectin type III domain containing 5 -inf
LRIF1 ligand dependent nuclear receptor interacting factor 1 -1.38102
LRP4 low density lipoprotein receptor-related protein 4 2.68745
LRRC17 leucine rich repeat containing 17 2.62118
LRRC37A4P leucine rich repeat containing 37, member A4, pseudogene 2.13854
LRRC8B leucine rich repeat containing 8 family, member B 3.5717
LRRFIP2 leucine rich repeat (in FLII) interacting protein 2 -0.901066
LTBP2 latent transforming growth factor beta binding protein 2 1.44772
LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) -1.08803
LUM lumican -2.91782
LY6E lymphocyte antigen 6 complex, locus E -0.900249
LY75-CD302 lymphocyte antigen 75  - CD302 molecule -1.24544
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MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) -1.68487
MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)-1.14794
MAGED1 melanoma antigen family D, 1 0.776822
MAGI1 membrane associated guanylate kinase, WW and PDZ domain containing 1; CNKSR family member 31.22238
MAGI2-AS3 MAGI2 antisense RNA 3 -1.62109
MAMDC2 MAM domain containing 2 -2.85811
MAN1A1 mannosidase, alpha, class 1A, member 1 2.09409
MAP1A microtubule-associated protein 1A 1.30931
MAP1B microtubule-associated protein 1B 0.944347
MAP2K3 mitogen-activated protein kinase kinase 3 -1.01027
MAP7D3 MAP7 domain containing 3 2.80351
MAPK13 mitogen-activated protein kinase 13 -2.9206
MAPK8 mitogen-activated protein kinase 8 -1.01305
MARC2 mitochondrial amidoxime reducing component 2 -3.02562
MARCKS myristoylated alanine-rich protein kinase C substrate 1.67687
MARCKSL1 MARCKS-like 1 3.36511
MARK1 MAP/microtubule affinity-regulating kinase 1 inf
MARS methionyl-tRNA synthetase -0.805528
MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)-3.02318
MAT2A methionine adenosyltransferase II, alpha -1.83962
MATN2 matrilin 2 -3.51999
MBOAT2 membrane bound O-acyltransferase domain containing 2 1.02863
MCAM melanoma cell adhesion molecule 1.71038
MCTP1 multiple C2 domains, transmembrane 1 -3.05574
MCTP2 multiple C2 domains, transmembrane 2 -2.29342
MDK midkine (neurite growth-promoting factor 2) 2.49801
MDN1 MDN1, midasin homolog (yeast) 0.862162
MECOM ecotropic viral integration site 1 1.30286
MED28 mediator complex subunit 28 1.15803
MEF2A myocyte enhancer factor 2A 0.825775
MEST mesoderm specific transcript homolog (mouse) 1.58624
METRNL meteorin, glial cell differentiation regulator-like; similar to meteorin, glial cell differentiation regulator-like-2.01577
METTL9 methyltransferase like 9 0.987785
MEX3A mex-3 homolog A (C. elegans) 1.55964
MFAP4 microfibrillar-associated protein 4 3.01033
MGARP mitochondria-localized glutamic acid-rich protein -2.25983
MGC45800 hypothetical LOC90768 2.47778
MGMT O-6-methylguanine-DNA methyltransferase -3.3289
MGP matrix Gla protein inf
MGST1 microsomal glutathione S-transferase 1 -1.88079
MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 homolog (zebrafish))-1.2981
MID2 midline 2 -2.50339
MIOS missing oocyte, meiosis regulator, homolog (Drosophila) 0.86629
MITF microphthalmia-associated transcription factor -5.48937
MKI67 antigen identified by monoclonal antibody Ki-67 -1.00064
MKNK1 MAP kinase interacting serine/threonine kinase 1 -1.0802
MKNK2 MAP kinase interacting serine/threonine kinase 2 -1.24334
MKX mohawk homeobox -5.70329
MLH3 mutL homolog 3 (E. coli) 2.80764
MLLT11 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 112.4135
MLLT3 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3-1.70287
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.75702
MMP16 matrix metallopeptidase 16 (membrane-inserted) 1.66101
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)2.33847
MMP24 matrix metallopeptidase 24 (membrane-inserted) 3.49951
MOAP1 modulator of apoptosis 1 1.26046
MOB3C MOB kinase activator 3C -1.29113
MOCOS molybdenum cofactor sulfurase -3.38138
MOK MOK protein kinase -2.63255
MOXD1 monooxygenase, DBH-like 1 -0.854693
MPP1 membrane protein, palmitoylated 1, 55kDa -1.77838
MR1 major histocompatibility complex, class I-related -2.02344
MRPL23 mitochondrial ribosomal protein L23 -1.19076
MRPL4 mitochondrial ribosomal protein L4 -1.08451
MRPL42 mitochondrial ribosomal protein L42 0.827851
MRPS6-SLC5A3 mitochondrial ribosomal protein S6  - solute carrier family 5 (inositol transporters), member 31.79322
MSL3P1 male-specific lethal 3 homolog (Drosophila) pseudogene 1 -1.37712
MSN moesin 0.741884
MT1E metallothionein 1L (gene/pseudogene); metallothionein 1E; metallothionein 1 pseudogene 3; metallothionein 1J (pseudogene)1.01068
MT1L metallothionein 1L (gene/pseudogene); metallothionein 1E; metallothionein 1 pseudogene 3; metallothionein 1J (pseudogene)-1.02695
MT3 metallothionein 3 inf
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase-1.11692
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MTPN myotrophin; leucine zipper protein 6 0.883325
MTRNR2L1 MT-RNR2-like 1 1.22132
MTRNR2L10 MT-RNR2-like 10 inf
MTRNR2L8 MT-RNR2-like 8 8.61338
MTSS1 metastasis suppressor 1 -1.65331
MTSS1L metastasis suppressor 1-like -1.24368
MYBL1 v-myb myeloblastosis viral oncogene homolog (avian)-like 1 -1.21896
MYEF2 myelin expression factor 2 -1.4748
MYO10 myosin X 1.04454
MYO1B myosin IB 0.997485
MYOZ2 myozenin 2 4.62989
N4BP2 NEDD4 binding protein 2 1.35009
NAA15 NMDA receptor regulated 1 0.891006
NALCN sodium leak channel, non-selective 2.13203
NAT1 N-acetyltransferase 1 (arylamine N-acetyltransferase) -1.60318
NAV1 neuron navigator 1 1.15644
NBLA00301 Nbla00301 inf
NBPF3 neuroblastoma breakpoint family, member 3 -1.25687
NCAM1 neural cell adhesion molecule 1 -2.75511
NCAM2 neural cell adhesion molecule 2 inf
NCBP1 nuclear cap binding protein subunit 1, 80kDa 0.924867
NCEH1 arylacetamide deacetylase-like 1 -1.00781
NCK1 NCK adaptor protein 1 -1.155
NDE1 nudE nuclear distribution gene E homolog 1 (A. nidulans) -1.08489
NDN necdin homolog (mouse) 3.12353
NDNF neuron-derived neurotrophic factor 2.78448
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 0.812278
NEAT1 non-protein coding RNA 84 1.61578
NEK11 NIMA (never in mitosis gene a)- related kinase 11 -1.37715
NEK2 NIMA (never in mitosis gene a)-related kinase 2 -1.2498
NET1 neuroepithelial cell transforming 1 0.847237
NETO1 neuropilin (NRP) and tolloid (TLL)-like 1 -2.15051
NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 6.14029
NEURL1B neuralized homolog 1B (Drosophila) -1.61782
NFE2L2 nuclear factor (erythroid-derived 2)-like 2 -1.09039
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1-1.06052
NFKB2 nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)-1.41833
NFKBIE nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon-2.50551
NFXL1 nuclear transcription factor, X-box binding-like 1 -1.6987
NFYA nuclear transcription factor Y, alpha 1.07557
NID2 nidogen 2 (osteonidogen) 0.934174
NIPAL2 NIPA-like domain containing 2 -1.70044
NLGN1 neuroligin 1 -1.79861
NLGN4Y neuroligin 4, Y-linked 1.84538
NMT2 N-myristoyltransferase 2 1.12792
NNMT nicotinamide N-methyltransferase -1.7006
NOB1 NIN1/RPN12 binding protein 1 homolog (S. cerevisiae); hypothetical LOC100132364-0.96998
NOTCH2 Notch homolog 2 (Drosophila) 0.864433
NOTCH2NL Notch homolog 2 (Drosophila) N-terminal like 1.14348
NOTCH3 Notch homolog 3 (Drosophila) -1.67148
NPIPL3 nuclear pore complex interacting protein-like 3; similar to Uncharacterized protein KIAA02202.56145
NQO1 NAD(P)H dehydrogenase, quinone 1 -3.15695
NR1D2 nuclear receptor subfamily 1, group D, member 2 -1.04063
NR2F1 nuclear receptor subfamily 2, group F, member 1 -1.42756
NRCAM neuronal cell adhesion molecule 4.2517
NREP neuronal regeneration related protein 1.96124
NRG1 neuregulin 1 -2.2647
NRGN neurogranin (protein kinase C substrate, RC3) -3.11498
NRK Nik related kinase 10.2053
NRN1 neuritin 1 7.91488
NRP2 neuropilin 2 1.6744
NT5E 5'-nucleotidase, ecto (CD73) -1.15946
NTF3 neurotrophin 3 2.11497
NTNG1 netrin G1 2.26727
NUDT11 nudix (nucleoside diphosphate linked moiety X)-type motif 11 1.47389
NUDT12 nudix (nucleoside diphosphate linked moiety X)-type motif 12 -1.62258
NUF2 NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae)-0.879882
NUPR1 nuclear protein, transcriptional regulator, 1 -3.4198
NYNRIN KIAA1305 1.36406
OAF OAF homolog (Drosophila) -2.70124
OAZ1 ornithine decarboxylase antizyme 1 -1.1338
OGFRL1 opioid growth factor receptor-like 1 -2.43307
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OLAH oleoyl-ACP hydrolase inf
OLFML3 olfactomedin-like 3 2.01766
OPTN optineurin -1.35844
OSBPL6 oxysterol binding protein-like 6 -1.19287
OSR1 odd-skipped related 1 (Drosophila) 1.93259
OSR2 odd-skipped related 2 (Drosophila) -4.18878
OXTR oxytocin receptor -2.45369
PAG1 phosphoprotein associated with glycosphingolipid microdomains 1-2.00815
PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 -1.28142
PAPPA PAPPA antisense RNA (non-protein coding); pregnancy-associated plasma protein A, pappalysin 12.40688
PAR5 Prader-Willi/Angelman syndrome-5 1.72947
PARD3B par-3 partitioning defective 3 homolog B (C. elegans) -1.43165
PARG similar to poly (ADP-ribose) glycohydrolase; poly (ADP-ribose) glycohydrolase1.60789
PARP1 poly (ADP-ribose) polymerase 1 0.809193
PARP4 poly (ADP-ribose) polymerase family, member 4 0.786836
PARVB parvin, beta -1.27771
PBRM1 polybromo 1 1.21802
PCDH10 protocadherin 10 3.49047
PCDH18 protocadherin 18 -0.779012
PCDHGA1-12 protocadherin gamma subfamily A, 1 – 12 1.11457
PCGF5 polycomb group ring finger 5 1.73758
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) -1.73228
PCOLCE procollagen C-endopeptidase enhancer 1.13719
PCOLCE2 procollagen C-endopeptidase enhancer 2 inf
PDE12 phosphodiesterase 12 1.16224
PDE1C phosphodiesterase 1C, calmodulin-dependent 70kDa -2.71687
PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila)-0.892858
PDE7B phosphodiesterase 7B 4.06662
PDGFC platelet derived growth factor C -0.810702
PDGFRA platelet-derived growth factor receptor, alpha polypeptide 2.1335
PDK1 pyruvate dehydrogenase kinase, isozyme 1 1.74615
PDLIM4 PDZ and LIM domain 4 1.37014
PDZRN3 PDZ domain containing ring finger 3 2.82411
PEA15 phosphoprotein enriched in astrocytes 15 -0.77804
PEAR1 platelet endothelial aggregation receptor 1 4.22289
PER1 period homolog 1 (Drosophila) -1.90519
PFN2 profilin 2 0.737425
PGLS 6-phosphogluconolactonase -1.18503
PGM2 phosphoglucomutase 2 -1.54733
PGM2L1 phosphoglucomutase 2-like 1 3.06574
PHACTR2 phosphatase and actin regulator 2 1.6092
PHB2 prohibitin 2 -0.963147
PHGDH phosphoglycerate dehydrogenase -1.18643
PHIP pleckstrin homology domain interacting protein 0.782513
PHKA1 phosphorylase kinase, alpha 1 pseudogene 1; phosphorylase kinase, alpha 1 (muscle)0.881072
PHLDA1 pleckstrin homology-like domain, family A, member 1 -2.05333
PHLDB1 pleckstrin homology-like domain, family B, member 1 1.52
PHLDB2-PLCXD2 pleckstrin homology-like domain, family B, member 2 - phosphatidylinositol-specific phospholipase C, X domain containing 21.08416
PHTF2 putative homeodomain transcription factor 2 -0.826681
PIANP PILR alpha associated neural protein 2.05068
PIGL phosphatidylinositol glycan anchor biosynthesis, class L -1.31192
PIGM phosphatidylinositol glycan anchor biosynthesis, class M 1.2771
PIGW phosphatidylinositol glycan anchor biosynthesis, class W 1.15497
PIK3C2A phosphoinositide-3-kinase, class 2, alpha polypeptide 1.17419
PIK3IP1 phosphoinositide-3-kinase interacting protein 1 1.59234
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 1.89917
PION pigeon homolog (Drosophila) -2.1709
PIP prolactin-induced protein inf
PITX2 paired-like homeodomain 2 inf
PJA2 praja ring finger 2 0.855053
PKD1P1 polycystic kidney disease 1 (autosomal dominant) pseudogene 1 4.09202
PKI55 DKFZp434H1419 2.25562
PLAU plasminogen activator, urokinase 1.74962
PLCB1 phospholipase C, beta 1 (phosphoinositide-specific) 2.36883
PLCB4 phospholipase C, beta 4 1.26312
PLCD1 phospholipase C, delta 1 -1.4013
PLK1 polo-like kinase 1 (Drosophila) -0.833125
PLK1S1 non-protein coding RNA 153 -1.07136
PLSCR4 phospholipid scramblase 4 -2.20324
PLXNA2 plexin A2 2.30799
PLXNB1 plexin B1 1.55739
PM20D2 peptidase M20 domain containing 2 0.984651
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PMF1-BGLAP polyamine-modulated factor 1 - bone gamma-carboxyglutamate (gla) protein-1.1237
PMM1 phosphomannomutase 1 -1.23388
PMP22 peripheral myelin protein 22 2.72747
PMS2L2 postmeiotic segregation increased 2-like 5; postmeiotic segregation increased 2-like 5-like; similar to postmeiotic segregation increased 2-like 2; postmeiotic segregation increased 2-like 2 pseudogeneinf
PNMAL1 PNMA-like 1 -4.84834
PODXL podocalyxin-like 5.50039
POLM polymerase (DNA directed), mu -1.46933
POLQ polymerase (DNA directed), theta -1.00347
POLR2J polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa -0.971444
POLR3A polymerase (RNA) III (DNA directed) polypeptide A, 155kDa 1.13642
POLR3G polymerase (RNA) III (DNA directed) polypeptide G (32kD) 1.08014
PPA2 pyrophosphatase (inorganic) 2 -1.1693
PPAP2B phosphatidic acid phosphatase type 2B 2.65679
PPAPDC3 phosphatidic acid phosphatase type 2 domain containing 3 -inf
PPARA peroxisome proliferator-activated receptor alpha -1.57216
PPAT phosphoribosyl pyrophosphate amidotransferase 1.04012
PPCS phosphopantothenoylcysteine synthetase -1.1091
PPIF peptidylprolyl isomerase F -0.948192
PPM1D protein phosphatase 1D magnesium-dependent, delta isoform -1.48589
PPM1M protein phosphatase 1M (PP2C domain containing) -1.29229
PPP1CB protein phosphatase 1, catalytic subunit, beta isoform; speedy homolog A (Xenopus laevis)0.921916
PPP1R15A protein phosphatase 1, regulatory (inhibitor) subunit 15A -1.7575
PPP1R18 protein phosphatase 1, regulatory subunit 18 -0.745421
PPP1R3B protein phosphatase 1, regulatory (inhibitor) subunit 3B 1.13274
PPP2R2C protein phosphatase 2 (formerly 2A), regulatory subunit B, gamma isoform3.488
PPP2R3B protein phosphatase 2 (formerly 2A), regulatory subunit B'', beta -2.053
PPP3CB protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform0.78672
PRAF2 PRA1 domain family, member 2 -0.874153
PRDM1 PR domain containing 1, with ZNF domain -1.54567
PRDM8 PR domain containing 8 -3.25745
PREX1 phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 11.56677
PRKCA protein kinase C, alpha 1.07293
PRKCD protein kinase C, delta -1.17234
PRKCDBP protein kinase C, delta binding protein -1.39898
PRKDC similar to protein kinase, DNA-activated, catalytic polypeptide; protein kinase, DNA-activated, catalytic polypeptide1.02512
PRKG1 protein kinase, cGMP-dependent, type I 3.05612
PRPS1 phosphoribosyl pyrophosphate synthetase 1; phosphoribosyl pyrophosphate synthetase 1-like 10.921169
PRR16 proline rich 16 -1.45895
PRRT2 proline-rich transmembrane protein 2 -2.37809
PRRX1 paired related homeobox 1 1.93215
PRSS12 protease, serine, 12 (neurotrypsin, motopsin) 1.13383
PRSS23 protease, serine, 23 -0.892186
PRUNE2 prune homolog 2 (Drosophila) 7.33773
PSAT1 chromosome 8 open reading frame 62; phosphoserine aminotransferase 1-1.00273
PSD3 pleckstrin and Sec7 domain containing 3 3.17911
PSG4 pregnancy specific beta-1-glycoprotein 7; pregnancy specific beta-1-glycoprotein 8; pregnancy specific beta-1-glycoprotein 4-4.22696
PSG5 pregnancy specific beta-1-glycoprotein 5 -1.02658
PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2)-4.04439
PSME4 proteasome (prosome, macropain) activator subunit 4 1.08466
PSRC1 proline/serine-rich coiled-coil 1 -1.96313
PTMS parathymosin -0.922531
PTP4A1 protein tyrosine phosphatase type IVA, member 1 0.824712
PTPLAD2 protein tyrosine phosphatase-like A domain containing 2 -0.927615
PTPN14 protein tyrosine phosphatase, non-receptor type 14 0.849229
PTPRD protein tyrosine phosphatase, receptor type, D -1.69447
PTPRN protein tyrosine phosphatase, receptor type, N 4.82647
PTPRQ protein tyrosine phosphatase, receptor type, Q -3.12196
PTTG1 pituitary tumor-transforming 1; pituitary tumor-transforming 2 -1.23832
PUS7L pseudouridylate synthase 7 homolog (S. cerevisiae)-like 1.08501
PXK PX domain containing serine/threonine kinase -1.48559
PYCARD PYD and CARD domain containing -2.82352
R3HDM2 R3H domain containing 2 -0.801332
RAB27B RAB27B, member RAS oncogene family -1.55176
RAB31 RAB31, member RAS oncogene family 0.98328
RAB32 RAB32, member RAS oncogene family -0.99443
RAB38 RAB38, member RAS oncogene family -3.23119
RAP1GAP2 GTPase activating Rap/RanGAP domain-like 4 -4.89796
RBBP6 retinoblastoma binding protein 6 -1.25973
RBM12B RNA binding motif protein 12B 1.59281
RBM24 RNA binding motif protein 24 -1.1389
RBPJ recombination signal binding protein for immunoglobulin kappa J region1.77958
RCHY1 ring finger and CHY zinc finger domain containing 1 0.936505
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RCN1 reticulocalbin 1, EF-hand calcium binding domain -0.815832
RDH10 retinol dehydrogenase 10 (all-trans) 2.33539
RECQL RecQ protein-like (DNA helicase Q1-like) 1.01029
RELB v-rel reticuloendotheliosis viral oncogene homolog B -2.29375
RGS20 regulator of G-protein signaling 20 -1.66187
RGS3 regulator of G-protein signaling 3 -1.35278
RGS4 regulator of G-protein signaling 4 0.815643
RHBDF2 rhomboid 5 homolog 2 (Drosophila) -1.71802
RHOU ras homolog gene family, member U 1.09227
RIMS2 regulating synaptic membrane exocytosis 2 -2.12718
RIN2 Ras and Rab interactor 2 -0.88595
RIPK2 receptor-interacting serine-threonine kinase 2 -1.79775
RN7SK RNA, 7SK small nuclear -1.77664
RN7SL1 RNA, 7SL, cytoplasmic 2; RNA, 7SL, cytoplasmic 1 inf
RNASEL ribonuclease L (2',5'-oligoisoadenylate synthetase-dependent) -2.17675
RNF130 ring finger protein 130 4.06696
RNF141 ring finger protein 141 0.929311
RNF144B ring finger protein 144B 2.39479
RNF6 ring finger protein (C3H2C3 type) 6 -0.836501
ROR1 receptor tyrosine kinase-like orphan receptor 1 1.80759
RORA RAR-related orphan receptor A 2.87465
RPA2 replication protein A2, 32kDa 0.847011
RPL23A ribosomal protein L23a pseudogene 63; ribosomal protein L23a pseudogene 75; ribosomal protein L23a pseudogene 37; ribosomal protein L23a pseudogene 65; ribosomal protein L23a pseudogene 43; ribosomal protein L23a pseudogene 44; ribosomal protein L23a0.99521
RPL28 ribosomal protein L28 -0.993039
RPL39 ribosomal protein L39 pseudogene 10; ribosomal protein L39 pseudogene 20; ribosomal protein L39 pseudogene 27; ribosomal protein L39; ribosomal protein L39 pseudogene 13; ribosomal protein L39 pseudogene 32-1.24042
RPL39L ribosomal protein L39-like -1.67747
RPL9 ribosomal protein L9; ribosomal protein L9 pseudogene 25 -0.794515
RPLP2 ribosomal protein, large, P2 pseudogene 3; ribosomal protein, large, P2-0.99474
RPS19 ribosomal protein S19 pseudogene 3; ribosomal protein S19 -0.98473
RPS26 ribosomal protein S26 pseudogene 38; ribosomal protein S26 pseudogene 39; ribosomal protein S26 pseudogene 35; ribosomal protein S26 pseudogene 31; ribosomal protein S26 pseudogene 20; ribosomal protein S26 pseudogene 54; ribosomal protein S26 pseudogene 2; ribosomal protein S26 pseudogene 53; ribosomal protein S26 pseudogene 25; ribosomal protein S26 pseudogene 50; ribosomal protein S26 pseudogene 6; ribosomal protein S26 pseudogene 8; ribosomal protein S26-1.18058
RPS5 ribosomal protein S5 -1.12957
RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2; hypothetical LOC1001279842.85769
RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 -2.67941
RPSAP58 ribosomal protein SA pseudogene 9; ribosomal protein SA pseudogene 8; ribosomal protein SA pseudogene 58; ribosomal protein SA pseudogene 19; ribosomal protein SA pseudogene 18; ribosomal protein SA; ribosomal protein SA pseudogene 15; ribosomal protein SA pseudogene 61; ribosomal protein SA pseudogene 29; ribosomal protein SA pseudogene 121.11579
RRAS related RAS viral (r-ras) oncogene homolog -1.13557
RTEL1-TNFRSF6B regulator of telomere elongation helicase 1  - tumor necrosis factor receptor superfamily, member 6b, decoy-2.50158
RTN2 reticulon 2 -1.77364
RTTN rotatin -1.29541
RUNX1T1 runt-related transcription factor 1; translocated to, 1 (cyclin D-related)-1.44643
RUNX2 runt-related transcription factor 2 -1.19392
RXRA retinoid X receptor, alpha 1.14779
S100A13 S100 calcium binding protein A13 1.05335
S100A16 S100 calcium binding protein A16 -1.5239
S100A6 S100 calcium binding protein A6 -1.16099
S1PR1 sphingosine-1-phosphate receptor 1 -1.83939
SALL1 sal-like 1 (Drosophila) -5.38719
SALL2 sal-like 2 (Drosophila) 1.58757
SAMD3 sterile alpha motif domain containing 3 1.79017
SAMD9L sterile alpha motif domain containing 9-like -3.62208
SARS seryl-tRNA synthetase -1.10212
SAV1 salvador homolog 1 (Drosophila) -1.20382
SCARA3 scavenger receptor class A, member 3 2.78831
SCD5 stearoyl-CoA desaturase 5 3.07152
SCN9A sodium channel, voltage-gated, type IX, alpha subunit 0.815452
SDC2 syndecan 2 3.60882
SDC3 syndecan 3 1.97575
SDK1 sidekick homolog 1, cell adhesion molecule (chicken); hypothetical LOC7303513.5373
SELM selenoprotein M -1.36848
SEMA5A sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A1.67369
SEPP1 selenoprotein P, plasma, 1 inf
SEPT6 septin 6 2.31958
SEPT9 septin 9 0.811132
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 -1.74972
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 -3.63219
SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 7 -3.77104
SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 20.943321
SESN2 sestrin 2 -1.91658
SGOL1 shugoshin-like 1 (S. pombe) -1.24328
SH3BP2 SH3-domain binding protein 2 -0.996869
SH3BP5 SH3-domain binding protein 5 (BTK-associated) 1.36917
SH3D19 SH3 domain containing 19 0.88353
SH3KBP1 SH3-domain kinase binding protein 1 0.96157
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SH3PXD2B SH3 and PX domains 2B 1.3853
SH3RF1 SH3 domain containing ring finger 1 1.27164
SHC3 SHC (Src homology 2 domain containing) transforming protein 3 1.89107
SHISA9 hypothetical protein LOC729993 3.83112
SHMT2 serine hydroxymethyltransferase 2 (mitochondrial) -1.0405
SHOX2 short stature homeobox 2 0.965961
SHROOM2 shroom family member 2 -4.70224
SHROOM3 shroom family member 3 -3.04883
SIRPA signal-regulatory protein alpha 1.8253
SIX1 SIX homeobox 1 1.21462
SKAP2 src kinase associated phosphoprotein 2 -0.976246
SLC11A2 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 21.03777
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 21.04783
SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group)4.83963
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1)0.889572
SLC16A12 solute carrier family 16, member 12 (monocarboxylic acid transporter 12)3.10135
SLC17A9 solute carrier family 17, member 9 -1.81065
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 -1.48801
SLC20A1 solute carrier family 20 (phosphate transporter), member 1 1.33865
SLC22A15 solute carrier family 22, member 15 -4.05798
SLC25A5 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 pseudogene 8-0.847198
SLC25A6 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6-1.35326
SLC26A2 solute carrier family 26 (sulfate transporter), member 2 0.949979
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 0.86242
SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12 1.69976
SLC2A13 solute carrier family 2 (facilitated glucose transporter), member 13 -3.87055
SLC35F2 solute carrier family 35, member F2 1.56731
SLC37A2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2-2.22524
SLC38A5 solute carrier family 38, member 5 1.46496
SLC39A1 solute carrier family 39 (zinc transporter), member 1 -0.759829
SLC39A4 solute carrier family 39 (zinc transporter), member 4 -2.22172
SLC44A1 solute carrier family 44, member 1 1.31978
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 42.86533
SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9-2.9411
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11-1.25931
SLC7A2 solute carrier family 7 (cationic amino acid transporter, y+ system), member 21.51301
SLC7A5 solute carrier family 7 (cationic amino acid transporter, y+ system), member 5-1.2195
SLC7A6 solute carrier family 7 (cationic amino acid transporter, y+ system), member 61.76614
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 0.824504
SLC9A7 solute carrier family 9 (sodium/hydrogen exchanger), member 7 1.73759
SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 -2.4099
SLFN11 schlafen family member 11 -1.86687
SLIT2 slit homolog 2 (Drosophila) -1.5438
SLIT3 slit homolog 3 (Drosophila) 2.54296
SMAD9 SMAD family member 9 1.50927
SMARCA1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 10.847674
SMARCC1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 11.28314
SMC1A structural maintenance of chromosomes 1A 0.878832
SMCP sperm mitochondria-associated cysteine-rich protein inf
SMYD3 SET and MYND domain containing 3 -0.944649
SNAI2 snail homolog 2 (Drosophila) -0.927921
SNAPC1 small nuclear RNA activating complex, polypeptide 1, 43kDa -0.886334
SNCAIP synuclein, alpha interacting protein -4.77817
SNHG5 small nucleolar RNA host gene 5 (non-protein coding) 1.34399
SNRNP27 small nuclear ribonucleoprotein 27kDa (U4/U6.U5) -1.0426
SNRPG hypothetical protein LOC100132425; similar to small nuclear ribonucleoprotein polypeptide G; small nuclear ribonucleoprotein polypeptide G; small nuclear ribonucleoprotein G-like protein-0.886559
SNTB1 syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1)1.57992
SOCS2 suppressor of cytokine signaling 2 -2.83476
SORT1 sortilin 1 1.5178
SOX11 SRY (sex determining region Y)-box 11 6.24776
SOX9 SRY (sex determining region Y)-box 9 2.88432
SPAG7 sperm associated antigen 7 0.832696
SPATA18 spermatogenesis associated 18 homolog (rat) -1.08419
SPATA6 spermatogenesis associated 6 -3.38969
SPATS2 spermatogenesis associated, serine-rich 2 1.06616
SPCS3 signal peptidase complex subunit 3 homolog (S. cerevisiae) 1.18504
SPDYE7P speedy homolog E7 (Xenopus laevis), pseudogene inf
SPOCD1 SPOC domain containing 1 1.45262
SPOCK3 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3inf
SPON2 spondin 2, extracellular matrix protein -1.31959
SPRED1 sprouty-related, EVH1 domain containing 1 0.878543
SPRY1 sprouty homolog 1, antagonist of FGF signaling (Drosophila) 3.09049
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SPRY2 sprouty homolog 2 (Drosophila) 0.800871
SPSB1 splA/ryanodine receptor domain and SOCS box containing 1 -1.31557
SPTBN1 spectrin, beta, non-erythrocytic 1 0.91976
SPTLC2 serine palmitoyltransferase, long chain base subunit 2 0.797591
SRD5A3 steroid 5 alpha-reductase 3 1.25099
SREBF2 sterol regulatory element binding transcription factor 2 -0.896079
SRGN serglycin -0.792521
SRPX2 sushi-repeat-containing protein, X-linked 2 1.67759
SSFA2 sperm specific antigen 2 -0.808965
SSTR1 somatostatin receptor 1 -1.68759
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein -1.9618
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 1.93286
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 1.64772
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 2.64226
ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 33.31466
ST6GALNAC5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5inf
STAG2 stromal antigen 2 0.992699
STARD8 StAR-related lipid transfer (START) domain containing 8 -2.43045
STC1 stanniocalcin 1 1.00946
STEAP1 six transmembrane epithelial antigen of the prostate 1 1.299
STEAP1B STEAP family member 1B 1.7123
STEAP2 six transmembrane epithelial antigen of the prostate 2 1.68847
STEAP3 STEAP family member 3 2.4173
STPG1 sperm tail PG rich repeat containing 1 -1.38079
STRBP spermatid perinuclear RNA binding protein -1.70057
STX1A syntaxin 1A (brain) 2.39918
STX1B syntaxin 1B 1.71436
STX6 syntaxin 6 1.00002
STX8 syntaxin 8 -0.851769
STXBP6 syntaxin binding protein 6 (amisyn) -1.58601
STYK1 serine/threonine/tyrosine kinase 1 2.26607
SUCLG2 similar to sucb; succinate-CoA ligase, GDP-forming, beta subunit -0.959139
SULF1 sulfatase 1 4.47284
SV2A synaptic vesicle glycoprotein 2A 2.73271
SVIL supervillin 2.69325
SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting protein 0.8697
SYNGR2 synaptogyrin 2 -1.17636
SYNJ2 synaptojanin 2 1.20962
SYNPO synaptopodin -2.25653
SYT1 synaptotagmin I -1.49838
SYT11 synaptotagmin XI 1.62607
SYT14 synaptotagmin XIV 2.45707
SYTL2 synaptotagmin-like 2 -1.04314
SYTL4 synaptotagmin-like 4 1.15812
TACC1 transforming, acidic coiled-coil containing protein 1 -1.23128
TACC2 transforming, acidic coiled-coil containing protein 2 -2.26038
TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 68kDa0.733706
TAGLN transgelin 1.73003
TANC1 tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 11.15196
TAOK3 TAO kinase 3 -0.875339
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) -1.97902
TBC1D1 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 -0.933769
TBC1D2 TBC1 domain family, member 2 -2.39482
TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 0.911988
TBX15 T-box 15 2.81275
TBX2 T-box 2 -1.15613
TBX3 T-box 3 -0.817011
TBX5 T-box 5 -6.23781
TCEA3 transcription elongation factor A (SII), 3 -1.96269
TCEAL3 transcription elongation factor A (SII)-like 3 -1.13643
TCEAL4 transcription elongation factor A (SII)-like 4 -0.955688
TCF4 transcription factor 4 0.91443
TEF thyrotrophic embryonic factor -1.80252
TENM2 teneurin transmembrane protein 2 1.93732
TENM3 teneurin transmembrane protein 3 2.08983
TES testis derived transcript (3 LIM domains) 1.70915
TFAP2A transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)-4.11888
TFAP2C transcription factor AP-2 gamma (activating enhancer binding protein 2 gamma)-2.17584
TGFB1 transforming growth factor, beta 1 1.17719
TGFBI transforming growth factor, beta-induced, 68kDa 1.81639
TGIF1 TGFB-induced factor homeobox 1 -1.54141
THBS1 thrombospondin 1 -0.848488
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THBS2 thrombospondin 2 -3.80012
THNSL1 threonine synthase-like 1 (S. cerevisiae) 1.24158
THSD4 thrombospondin, type I, domain containing 4 0.743909
TIA1 TIA1 cytotoxic granule-associated RNA binding protein 0.872304
TIAM1 T-cell lymphoma invasion and metastasis 1 4.32921
TICAM1 toll-like receptor adaptor molecule 1 -1.2296
TIFA TRAF-interacting protein with forkhead-associated domain -1.43022
TIMM9 translocase of inner mitochondrial membrane 9 homolog (yeast) -1.2812
TIMP1 TIMP metallopeptidase inhibitor 1 0.937005
TKT transketolase -1.20248
TLE4 transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) -1.1314
TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 22.74258
TMEM106C transmembrane protein 106C -1.21627
TMEM11 transmembrane protein 11 -1.14327
TMEM119 transmembrane protein 119 2.92113
TMEM120A transmembrane protein 120A -1.58016
TMEM132B transmembrane protein 132B; hypothetical LOC121296 4.28403
TMEM154 transmembrane protein 154 -2.6736
TMEM158 transmembrane protein 158 -1.02546
TMEM200A transmembrane protein 200A 1.94637
TMEM237 transmembrane protein 237 0.930043
TMEM35 transmembrane protein 35 3.11315
TMEM50A transmembrane protein 50A 1.05245
TMEM51 transmembrane protein 51 -2.90031
TMEM64 transmembrane protein 64 1.22591
TMEM67 transmembrane protein 67 -1.33112
TMOD2 tropomodulin 2 (neuronal) 3.64525
TMTC3 transmembrane and tetratricopeptide repeat containing 3 1.03175
TNC tenascin C 1.66344
TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-like 1 -0.936313
TNFAIP8L3 tumor necrosis factor, alpha-induced protein 8-like 3 1.95989
TNFRSF10D tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain2.33643
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b -3.7712
TNFRSF19 tumor necrosis factor receptor superfamily, member 19 -3.48802
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A -0.8253
TNFSF12-TNFSF13 TNFSF12-TNFSF13 readthrough transcript; tumor necrosis factor (ligand) superfamily, member 12; tumor necrosis factor (ligand) superfamily, member 13-2.56666
TNIK TRAF2 and NCK interacting kinase 1.8141
TNPO1 transportin 1 1.0967
TNS1 tensin 1 4.96371
TNS3 tensin 3 -0.974262
TOM1L1 target of myb1 (chicken)-like 1 -1.95748
TOM1L2 target of myb1-like 2 (chicken) 0.874764
TOP1 topoisomerase (DNA) I 1.03574
TP53INP1 tumor protein p53 inducible nuclear protein 1 1.01709
TPCN1 two pore segment channel 1 -1.36474
TPST1 tyrosylprotein sulfotransferase 1 -1.33546
TRIB2 tribbles homolog 2 (Drosophila) 2.35668
TRIB3 tribbles homolog 3 (Drosophila) -3.16038
TRIM22 tripartite motif-containing 22 -1.17258
TRIM44 tripartite motif-containing 44 0.886195
TRIM66 tripartite motif-containing 66 -1.8556
TRIP10 thyroid hormone receptor interactor 10 -0.836833
TRNT1 tRNA nucleotidyl transferase, CCA-adding, 1 1.16743
TRO trophinin 2.98963
TRPA1 transient receptor potential cation channel, subfamily A, member 1-3.46927
TRPS1 trichorhinophalangeal syndrome I 1.34827
TRPV2 transient receptor potential cation channel, subfamily V, member 22.18497
TSC22D3 TSC22 domain family, member 3; GRAM domain containing 4 -1.87447
TSKU tsukushin 2.30116
TSPAN14 tetraspanin 14 0.883013
TSPYL1 TSPY-like 1 0.953928
TSPYL4 TSPY-like 4 1.5868
TSPYL5 TSPY-like 5 2.1947
TSTA3 tissue specific transplantation antigen P35B -1.42023
TTYH3 tweety homolog 3 (Drosophila) 1.11325
TUB tubby homolog (mouse) 2.334
TUBA1A tubulin, alpha 1a 1.54122
TUBE1 tubulin, epsilon 1 -1.88458
TUG1 taurine upregulated 1 (non-protein coding) 1.48394
TYW1B tRNA-yW synthesizing protein 1 homolog B (non-protein coding) -3.12428
UACA uveal autoantigen with coiled-coil domains and ankyrin repeats -0.961539
UBASH3B ubiquitin associated and SH3 domain containing, B 0.92835
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UBE2J2 ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast) -0.929691
UBE2L6 ubiquitin-conjugating enzyme E2L 6 -1.07945
UBE2S ubiquitin-conjugating enzyme E2S -1.82296
UBR3 ubiquitin protein ligase E3 component n-recognin 3 (putative) 0.87952
UBR5 similar to E3 ubiquitin protein ligase, HECT domain containing, 1; ubiquitin protein ligase E3 component n-recognin 50.959679
UBXN11 UBX domain protein 11 -2.17847
UBXN6 UBX domain protein 6 -0.963097
UHRF1 ubiquitin-like with PHD and ring finger domains 1 1.05284
ULBP1 UL16 binding protein 1 -3.32718
UNC119B unc-119 homolog B (C. elegans) -0.944141
USP12 ubiquitin specific peptidase 12 0.820724
VAT1 vesicle amine transport protein 1 homolog (T. californica) -0.811281
VAT1L vesicle amine transport protein 1 homolog (T. californica)-like 3.75996
VCAN versican 5.49773
VCL vinculin 0.899026
VEGFA vascular endothelial growth factor A 0.803307
VPS13A vacuolar protein sorting 13 homolog A (S. cerevisiae) 1.40538
VPS41 vacuolar protein sorting 41 homolog (S. cerevisiae) 0.921365
VRK1 vaccinia related kinase 1 0.99521
VSNL1 visinin-like 1 inf
WAC-AS1 WAC antisense RNA 1 (head to head) 1.86077
WASF3 WAS protein family, member 3 0.992719
WASH5P WAS protein family homolog 3 pseudogene; WAS protein family homolog 2 pseudogene; WAS protein family homolog 1; WAS protein family homolog 5 pseudogeneinf
WASL Wiskott-Aldrich syndrome-like 0.855422
WDFY1 WD repeat and FYVE domain containing 1 0.93064
WDR62 WD repeat domain 62 -1.34223
WDR66 WD repeat domain 66 -1.21335
WDR91 WD repeat domain 91 -2.11467
WHAMMP1 WAS protein homolog associated with actin, golgi membranes and microtubules pseudogene 13.42404
WIPI1 WD repeat domain, phosphoinositide interacting 1 -0.935348
WNK4 WNK lysine deficient protein kinase 4 -0.970018
WNT5A wingless-type MMTV integration site family, member 5A 0.793361
WNT5B wingless-type MMTV integration site family, member 5B -1.11355
WWC1 WW and C2 domain containing 1 3.85493
XAF1 XIAP associated factor 1 -3.64019
XBP1 X-box binding protein 1 -0.92707
XIAP X-linked inhibitor of apoptosis 0.95733
XPC xeroderma pigmentosum, complementation group C -1.0346
XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)0.892379
XXYLT1 xyloside xylosyltransferase 1 1.14752
XYLT1 xylosyltransferase I 1.7115
YAP1 Yes-associated protein 1, 65kDa 1.02891
YY1AP1 YY1 associated protein 1; gon-4-like (C. elegans) -0.851649
ZBED5 zinc finger, BED-type containing 5 1.3742
ZBTB10 zinc finger and BTB domain containing 10 1.42762
ZBTB33 zinc finger and BTB domain containing 33 1.08311
ZBTB38 zinc finger and BTB domain containing 38 -0.883911
ZC3H13 zinc finger CCCH-type containing 13 0.809431
ZDHHC18 zinc finger, DHHC-type containing 18 -1.11042
ZFAND2B zinc finger, AN1-type domain 2B -1.10758
ZFHX4 zinc finger homeobox 4 1.27071
ZFP36 zinc finger protein 36, C3H type, homolog (mouse) -1.29417
ZFP36L1 zinc finger protein 36, C3H type-like 1 -1.96425
ZFP62 zinc finger protein 62 homolog (mouse) 1.01741
ZFPM2 zinc finger protein, multitype 2 -1.86603
ZMAT1 zinc finger, matrin type 1 3.30172
ZNF12 postmeiotic segregation increased 2-like 3; zinc finger protein 12 1.20374
ZNF140 zinc finger protein 140 -1.07575
ZNF185 zinc finger protein 185 (LIM domain) 0.996787
ZNF213 zinc finger protein 213 -1.17566
ZNF260 zinc finger protein 260 1.29989
ZNF322 zinc finger protein 322 1.73702
ZNF326 zinc finger protein 326 1.66665
ZNF331 zinc finger protein 331 -1.1428
ZNF33A zinc finger protein 33A 1.74224
ZNF33B zinc finger protein 33B 2.52811
ZNF365 zinc finger protein 365 -3.05316
ZNF407 zinc finger protein 407 1.23816
ZNF415 zinc finger protein 415 -2.70783
ZNF434 zinc finger protein 434 -1.05333
ZNF438 zinc finger protein 438 -1.55854
ZNF503 zinc finger protein 503 1.82613
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ZNF536 zinc finger protein 536 inf
ZNF593 zinc finger protein 593 -1.57727
ZNF600 zinc finger protein 600 -1.24994
ZNF618 zinc finger protein 618 0.994489
ZNF664-FAM101A zinc finger protein 664 - family with sequence similarity 101, member A0.897909
ZNF703 zinc finger protein 703 -2.01008
ZNF711 zinc finger protein 711 4.78613
ZNF780B zinc finger protein 780B 1.55014
ZNF84 zinc finger protein 84 1.05586
ZNRF2 zinc and ring finger 2 -2.1475
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Supplementary Table 2: TMT-MS (1394 proteins with score > 30)
Accession Gene name Score Coverage # Unique Peptides# P ptides
Fold change 
(control/ 
TEMEM67)
p-value 
(t-test) Significant
Q09666 AHNAK 2548.291346 77.83 367 372 0.550299976 6.1656E-05 ***
P62736 ACTA2 2102.808761 59.42 8 24 1
P35579 MYH9 1880.956313 69.39 144 181 0.938076642 0.25607624 ns
P21333 FLNA 1661.802431 61.69 121 164 0.871347163 0.07132594 ns
Q15149 PLEC 1618.3484 61.25 309 320 0.591085406 0.00050806 ***
K7EM38 ACTG1 1469.717712 86.47 2 12 1
P02751 FN1 1234.425823 47.53 86 100 0.597819172 0.00087466 ***
P08670 VIM 1211.491325 82.4 48 52 1
Q562R1 ACTBL2 1118.182656 28.46 3 11 1
V9HVZ7 HEL-176 883.2879592 56.95 1 15 0.732308745 0.03787219 *
Q9Y490 TLN1 876.4000921 61.87 127 153 0.812600631 0.02456296 *
A0A024R884 TNC 732.0419426 44.62 3 91 2.163394224 3.5931E-05 ***
Q14315 FLNC 726.4536204 48.77 105 127 1.035549346 0.37390097 ns
A7BI36 RRBP1 721.140589 77.08 5 113 0.569310668 0.00247826 **
Q9P2E9 RRBP1 698.3166647 74.04 1 107 0.37390097 ns
P07355 ANXA2 666.6238135 73.75 4 36 0.605345387 0.05467716 ns
J3QSU6 TNC 665.199635 45.62 1 86 1
O43707 ACTN4 658.120904 68.61 47 72 0.690474684 0.01181065 *
P02452 COL1A1 641.6736932 64.07 27 78 0.841352423 0.00598474 **
A7MBN2 TNC 634.0634744 47.33 1 81 1
P12814 ACTN1 601.9220594 68.27 6 65 1.024595437 0.7078428 ns
Q9NZM1 MYOF 598.8537889 52.3 109 109 0.696477111 0.00103697 **
A0A024RAB6 HSPG2 594.6339364 33.87 118 118 0.83294794 0.02155118 *
P02545 LMNA 593.7931058 71.69 58 60 0.632706168 0.00180691 **
A3KC71 okuribin 571.1877854 45.79 54 54 1.3931369 0.08674285 ns
A7XZE4 TPM2b 561.1105729 79.23 0 42 0.37390097 ns
V9HW25 HEL-S-273 560.9230582 79.23 0 42 0.37390097 ns
H9KV75 ACTN1 557.7364188 68.49 2 58 1
P35555 FBN1 555.4908155 37.58 88 97 0.84174742 0.00463287 **
E7EX44 CALD1 547.7379301 66.07 2 48 0.762641409 0.06701541 ns
P04406 GAPDH 531.0058281 63.58 18 24 1
O75369 FLNB 522.8687154 49.96 104 120 0.927212849 0.32998714 ns
Q14204 DYNC1H1 519.8988945 31.68 151 154 0.987846459 0.37390097 ns
Q13813 SPTAN1 519.8065332 50.44 128 131 0.92611441 0.291638 ns
A0A024QZN4 VCL 517.4315126 69.23 82 82 0.837731683 0.01554463 *
P07951 TPM2 513.3293515 79.93 0 41 0.37390097 ns
Q5TCU3 TPM2 513.1418368 79.93 0 41 0.37390097 ns
A0A087WTA8 COL1A2 494.0386064 58.43 65 66 1
A1A5C4 RRBP1 467.6552649 74.09 1 81 0.549480479 0.06428488 ns
Q01082 SPTBN1 457.7369539 48.94 95 113 0.709403508 0.00357674 **
P35580 MYH10 451.1570888 41.75 69 101 0.910526341 0.2028309 ns
Q9NYG1 CALD1 450.7610346 65.9 1 43 0.493158018 0.03887113 *
Q6ZN40 TPM1 448.9174283 82.82 0 47 0.37390097 ns
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P12111 COL6A3 445.930968 35.76 91 111 0.691426307 0.00130278 **
P09493 TPM1 436.2237647 78.17 3 43 0.523483864 0.00184149 **
D3DTX7 COL1A1 434.9648905 65.2 2 50 1
P11021 HSPA5 424.8001866 58.87 42 45 0.785115258 0.01419472 *
D6RGG3 COL12A1 421.1263083 37.43 83 105 0.341581009 0.00010642 ***
Q01995 TAGLN 402.038233 88.06 23 24 1
P11142 HSPA8 397.828596 67.03 27 45 0.835867066 0.14170051 ns
Q9Y6C2 EMILIN1 397.3190974 41.24 40 41 1.107206504 0.12630456 ns
P46939 UTRN 392.6341412 35.22 124 128 0.493121532 0.00017494 ***
H3BPE1 MACF1 391.9020389 19.21 119 142 0.867691593 0.00161102 **
E7EVA0 MAP4 388.751092 30.78 42 79 1
P07437 TUBB 386.5880187 58.33 1 23 0.995536199 0.77219546 ns
A0A024R5W6 TPM1 384.8602352 84.15 2 42 0.910414402 0.37524163 ns
P06733 ENO1 377.330439 61.29 22 32 1
P68371 TUBB4B 376.8059994 58.2 3 23 0.45733371 0.00081374 ***
F8J2B5 LMO7 368.4897411 48.8 15 81 0.781259377 0.00014803 ***
Q562L9 ACT 361.6715438 62.14 1 5 0.796645023 0.35608301 ns
P50454 SERPINH1 356.5576262 64.11 29 29 0.965260328 0.12673625 ns
Q6NZI2 PTRF 354.4344435 48.97 25 25 0.257716867 1.0035E-05 ***
H0YL33 ANXA2 348.5871323 94.37 1 20 0.998536231 0.99276992 ns
Q07954 LRP1 347.2111082 22.58 97 99 0.556713386 0.00018004 ***
Q13885 TUBB2A 347.0562832 48.76 2 21 0.649844794 0.00860867 **
P35556 FBN2 343.9252758 30.39 71 80 0.767000531 0.00067495 ***
K7ENT6 TPM4 339.5298222 72.07 4 23 0.966213677 0.11611652 ns
A0A024R5Z9 PKM2 339.2878151 65.35 4 39 1.309466263 0.10839275 ns
P14618 PKM 336.3497125 68.93 4 39 1
Q9BVA1 TUBB2B 335.5305188 47.87 1 20 1
P26038 MSN 334.6859671 64.99 39 53 0.856598426 0.06815586 ns
P07900 HSP90AA1 329.1727566 47.4 25 42 0.923318177 0.17734462 ns
H7BYY1 TPM1 328.8078473 77.82 5 33 0.510033044 9.1748E-05 ***
P08238 HSP90AB1 324.117381 46.82 20 39 0.99949352 0.97982142 ns
B7Z722 TPM1 314.8596587 76.21 0 33 0.37390097 ns
Q07065 CKAP4 311.6385463 75.25 47 51 0.811086991 0.00813192 **
P07237 P4HB 311.0591892 62.2 19 41 0.659529182 0.00574831 **
A0A087WWU8 TPM3 304.6919378 76.65 0 29 0.37390097 ns
Q00610 CLTC 302.3552299 40.48 46 66 0.720153887 0.02337615 *
F8WE98 FLNA 298.8545407 49.5 1 37 0.358828626 0.1826965 ns
J3KN67 TPM3 298.8268863 74.39 0 35 0.37390097 ns
E9PMP7 LMO7 296.1819879 62.72 1 67 1
P05556 ITGB1 294.2261002 34.46 32 32 0.568053086 0.00054908 ***
P0CG38 POTEI 292.8573812 6.7 2 9 0.385835791 0.00292175 **
Q562Z4 ACT 292.3050373 43.69 2 5 0.521964622 0.00981352 **
P00558 PGK1 287.879802 80.1 31 37 0.969466692 0.45450322 ns
Q5CAQ5 TRA1 286.4381999 49.63 48 50 0.710498413 0.00393027 **
P15144 ANPEP 285.4914589 36.4 40 40 0.358430957 2.0143E-05 ***
Q8N6G6 ADAMTSL1 284.8162529 33.14 53 53 5.131836577 0.00689487 **
P04075 ALDOA 275.8095648 52.47 20 26 0.90751017 0.18671031 ns
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P08133 ANXA6 274.5942166 69.99 17 54 0.959173066 0.23908694 ns
P68871 HBB 273.1425576 80.27 9 10 1
Q15746 MYLK 271.9642065 38.45 75 76 0.244756638 2.8425E-08 ***
Q15075 EEA1 269.9820769 56.84 85 86 0.814187691 0.02195571 *
P06753 TPM3 266.1630107 58.6 0 29 0.37390097 ns
Q6UVK1 CSPG4 262.7662312 30.62 60 60 0.676220325 6.5054E-05 ***
P13639 EEF2 262.6470323 47.55 44 46 0.959360058 0.31285028 ns
P46940 IQGAP1 261.2991457 39.29 65 71 0.830185526 0.09524408 ns
Q13509 TUBB3 251.4441684 46.67 3 19 1
P07814 EPRS 248.7080508 44.11 66 66 0.921798276 0.29846771 ns
A0A024R4E5 HDLBP 247.0384294 46.29 67 68 0.81753132 0.1086258 ns
Q5VU61 TPM3 246.7296144 73.09 0 27 0.37390097 ns
P07996 THBS1 244.497406 35.3 45 47 0.595028283 0.00094269 ***
P78527 PRKDC 241.4075385 22.65 89 90 0.950916787 0.28954462 ns
P37802 TAGLN2 241.0602553 60.8 16 16 1
H6VRF8 KRT1 240.2438672 53.88 31 37 1.62718057 0.12997129 ns
Q9Y4G6 TLN2 239.5484822 26 40 64 0.780224006 0.00124288 **
Q14766 LTBP1 239.2944666 30.68 16 49 0.863410867 0.0011778 **
B4DDF4 CNN2 236.6205363 64.09 7 19 0.699775552 8.984E-05 ***
H0YMT9 ANXA2 236.3209443 74.44 1 12 1
P05121 SERPINE1 236.1432859 49.75 20 20 2.752676045 0.04821869 *
F5H6E2 MYO1C 232.736766 48.41 10 56 0.707338333
A0A024RAM4 MAP1B 232.7246077 31.12 71 73 1.697069333 0.04010525 *
P04083 ANXA1 230.1643298 69.08 25 25 0.679745816 0.00295271 **
P68104 EEF1A1 228.2592816 53.25 17 29 0.950384643 0.31745178 ns
O95782 AP2A1 214.3199095 44.01 32 46 0.793206291 0.00637162 **
P00338 LDHA 213.5945603 50.9 18 22 1
P09382 LGALS1 209.7425601 61.48 9 9 0.873708746 0.02939249 *
P13645 KRT10 206.4215987 48.29 24 29 1.204207305 0.00434723 **
F8W1R7 PDE6H 205.2020943 73.1 10 14 0.66548598 0.01524969 *
Q14847 LASP1 204.1760097 62.84 21 21 0.702306731 0.00013824 ***
P13667 PDIA4 202.5469694 56.74 42 42 0.824601601 0.02482868 *
A0A024R316 WNT5A 202.1867456 65.48 21 28 1
E5RK69 ANXA6 200.6484622 68.91 2 38 1.448222867 0.20235332 ns
P55072 VCP 199.0352004 46.03 37 38 0.732903819 0.0080365 **
Q15582 TGFBI 198.3452414 37.34 28 28 2.260095341 0.03624746 *
P35241 RDX 196.7058394 48.2 23 41 0.675501275 0.00637906 **
P19338 NCL 196.3796581 49.15 52 54 0.764211172 0.00072966 ***
P35908 KRT2 195.2749681 59.62 25 36 1.129208342 0.03628783 *
P68366 TUBA4A 195.1068015 51.12 7 22 1
P23528 CFL1 194.884449 57.23 13 17 0.892138546 0.09048513 ns
P54652 HSPA2 193.9694864 49.45 19 36 0.162704618 1.641E-05 ***
P78559 MAP1A 193.2342867 23.72 59 60 1.345043661 0.086733 ns
G3V511 LTBP2 191.0526236 21.14 32 33 1.033457262 0.37390097 ns
A0A024RBC7 ATP2B1 190.6042435 30.98 23 43 0.187261445 3.9452E-05 ***
P10412 HIST1H1E 189.460579 50.68 7 21 0.80397553 0.10883412 ns
P63104 YWHAZ 188.4819531 70.61 14 22 0.637164873 0.00606452 **
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Q13308 PTK7 188.0309761 41.4 31 39 0.520474371 0.00420134 **
Q14764 MVP 187.6864544 45.58 38 38 1
Q92743 HTRA1 187.153482 41.67 23 24 0.727502567 0.00179837 **
A0A024R8V0 SEPT9 185.2142369 48.94 30 31 0.871243058 0.08732122 ns
P35527 KRT9 183.7064301 46.07 24 27 1.046352678 0.37390097 ns
H0Y3Z3 P4HB 182.0657699 63.14 1 22 2.05199365 1.4528E-05 ***
O00622 CYR61 179.9928662 59.06 8 26 1.322912655 0.09031084 ns
P08758 ANXA5 179.104543 64.38 23 24 0.996805142 0.37390097 ns
H0YNH8 UACA 179.0918717 37.76 58 60 0.214672826 6.8332E-07 ***
P69905 HBA1 178.8468475 67.61 1 7 1
Q99880 HIST1H2BL 177.7797129 75.4 3 12 0.599885351 0.0136029 *
D3DTH7 MYO1C 177.4313129 46.87 1 47 0.829269712 0.22034168 ns
P62258 YWHAE 173.6921875 63.14 16 19 0.991087565 0.37390097 ns
H0UID5 AP2B1 173.0101945 34.8 17 40 0.789548867 0.00711105 **
P04792 HSPB1 172.8352734 68.29 15 15 1
P34932 HSPA4 172.5974011 60 46 51 0.930702707 0.37390097 ns
A5YM53 ITGAV 172.1697701 39.12 43 43 0.694045701 0.00639968 **
E1NZA1 PRIC295 171.7274282 22.91 59 59 1
Q9P0K7 RAI14 171.2898729 47.96 15 55 0.61262396 0.10325788 ns
H3BVI6 CNN2 171.189696 55.5 1 12 1
P12270 TPR 170.6305518 27.3 60 62 0.966004203 0.37390097 ns
Q86UP2 KTN1 170.0112429 38.69 55 55 0.522855356 0.00249309 **
Q16643 DBN1 169.3715217 30.2 19 19 0.984214704 0.16578221 ns
Q15417 CNN3 169.3560406 51.67 12 17 0.892970587 1.2558E-06 ***
C9JD84 LTBP1 169.0533299 28.13 2 35 1.182815899 0.19696483 ns
Q16181 SEPT7 169.0110484 56.98 1 32 0.604957685 0.09618452 ns
Q9C0C2 TNKS1BP1 168.9289422 34.82 47 47 0.750989657 0.00182711 **
P06576 ATP5B 168.8537085 43.67 19 19 1
D3DVC4 NES 168.2278731 36.09 54 55 0.43503887 0.00023324 ***
P50990 CCT8 166.9869953 61.5 38 38 1.007056549 0.50216216 ns
A4GYY8 DKFZp686F17268 166.7033601 57.27 1 32 1
P07737 PFN1 166.4012851 75 14 14 1
D6RGI3 SEPT11 165.2654428 53.88 21 26 0.936004919 0.23697042 ns
H7C4C5 MAP4 164.8512311 57.61 1 33 1.23850677 0.02352006 *
Q9NZN4 EHD2 163.8736092 55.8 31 36 0.251549884 3.2558E-06 ***
Q03001 DST 163.8669878 10.26 18 73 0.936899764 0.21769326 ns
A0A024R968 ATP2B4 163.5945637 31.54 19 39 0.645383043 0.00380248 **
Q14517 FAT1 163.297958 13.58 60 61 0.394805853 0.00032022 ***
Q06830 PRDX1 163.1730397 67.84 13 17 0.896887056 0.23218901 ns
P53396 ACLY 162.9876926 42.6 2 43 1
V9HWK1 HEL-S-49 162.6966738 64.26 16 16 1.039272013 0.37390097 ns
P36578 RPL4 161.7100201 58.31 34 34 0.784286174 0.02405164 *
P23527 HIST1H2BO 160.9403104 75.4 0 12 0.37390097 ns
P42224 STAT1 159.8770468 45.73 33 33 2.166535553 0.08589961 ns
P49588 AARS 159.5166144 37.81 37 38 0.97235105 0.37390097 ns
Q15942 ZYX 159.4029963 38.11 18 18 0.777149879 0.08383182 ns
P12109 COL6A1 159.2365223 33.95 32 32 0.729606246 0.00431815 **
254
Q14697 GANAB 159.1921918 34.96 6 33 0.691971245 0.00982615 **
Q14247 CTTN 159.1920178 53.09 35 35 0.572716956 0.00021378 ***
P16403 HIST1H1C 159.1845506 51.17 6 19 0.674677552 0.00021671 ***
Q16555 DPYSL2 158.8813334 47.2 12 25 0.745739574 0.00696558 **
P25705 ATP5A1 158.724646 46.65 27 27 0.818476915 0.12599899 ns
P06899 HIST1H2BJ 158.6156653 75.4 1 12 1
P62979 RPS27A 158.457484 66.67 3 11 0.875770179 0.10216263 ns
P78371 CCT2 157.7462435 57.57 29 29 0.936226791 0.46434211 ns
O60664 PLIN3 157.69199 47.93 20 20 0.941559051 0.37390097 ns
P33176 KIF5B 156.9906948 47.46 38 47 0.955974352 0.35672256 ns
A0A024R972 LAMC1 156.6201007 28.99 48 48 0.608690509 0.00024581 ***
Q15019 SEPT2 155.3444058 64.82 1 18 1.055694582 0.37390097 ns
Q8WX93 PALLD 155.0870602 26.25 29 30 1
P29401 TKT 154.7412307 43.98 30 30 0.700062357 0.009044 **
P16401 HIST1H1B 154.5475035 46.02 12 18 0.581744128 0.0008482 ***
P08107 HSPA1A 154.4033821 42.59 25 31 0.624745661 0.00242907 **
P22314 UBA1 154.173106 32.23 34 34 0.853595007 0.04981382 *
P22626 HNRNPA2B1 154.1225662 62.32 18 21 1
Q75MT9 MDH2 153.8939714 68.67 20 20 0.877504155 0.00153648 **
Q9Y617 PSAT1 153.1415509 62.7 23 25 0.951885391 0.17798032 ns
P35221 CTNNA1 152.9984876 42.16 40 41 0.930022675 0.15118623 ns
P10809 HSPD1 152.8527744 54.62 34 34 0.862045574 0.04550256 *
P52272 HNRNPM 152.7092085 56.58 41 41 0.739650741 0.00634019 **
Q7Z406 MYH14 150.5499064 7.92 1 21 0.77325912 0.59023817 ns
Q9NR12 PDLIM7 148.8551916 60.61 22 26 0.620734662 0.00108061 **
B5MCX3 SEPT2 148.8292395 67.91 1 18 2.301628569 0.10015173 ns
Q9UMS6 SYNPO2 148.1076521 33.03 2 30 1.356947831 0.10968932 ns
F1T0J2 GOLGB1 147.5332184 18.4 53 58 0.995950288 0.37390097 ns
A0A024R1Y2 ACLY 146.8171654 42.53 1 42 1.090961672 0.37390097 ns
B9EG60 SYNPO2 146.4652463 28.87 2 30 0.624065153 0.0368964 *
Q4W4Y1 DRIP4 145.8285236 42.63 13 41 0.887601181 0.2180873 ns
Q4LE64 NUMA1 145.5194148 23.95 49 51 0.992990326 0.37390097 ns
B1AK87 CAPZB 144.8130934 60 19 19 0.718399859 0.00169186 **
U3PXP0 HBA2 144.4545075 66.67 1 3 1.108423991 0.30417802 ns
Q96AY3 FKBP10 144.1849332 39.86 8 21 0.99751601 0.37390097 ns
J9R021 eIF3a 143.1834774 31.33 46 46 0.857462844 0.15792758 ns
Q562M3 ACT 142.8758645 63.11 1 4 1
P16402 HIST1H1D 142.34615 55.66 9 21 0.608452782 5.3839E-05 ***
P16615 ATP2A2 142.2563137 33.97 23 36 0.886150383 6.5429E-06 ***
Q9UBG0 MRC2 141.2125521 22.65 32 32 0.979019885 0.03339527 *
O75083 WDR1 141.1094668 53.96 2 30 0.676098694 0.08138391 ns
P04259 KRT6B 140.9515443 48.23 2 29 8.106084218 0.34159634 ns
P15924 DSP 140.143989 15.67 53 54 1.881798851 0.16705582 ns
Q0ZGT2 NEXN 139.8744437 40.74 8 38 0.549970498 0.00736104 **
P05023 ATP1A1 139.6666487 35.97 37 37 0.586358395 0.00030901 ***
Q53GN4 WDR1 139.1673987 53.96 1 29 0.526954373 0.03247766 *
P49327 FASN 139.1655601 19.95 43 44 0.948541019 0.48363166 ns
255
Q05639 EEF1A2 138.4625857 23.33 1 13 3.831314217 0.00474054 **
P62987 UBA52 138.152216 58.59 1 9 0.502742521 0.00546223 **
B9EGI2 MPRIP 136.9463496 40.79 13 38 0.911360911 0.13667744 ns
Q5VSQ6 P4HA1 136.9330615 44.94 3 30 1.001006803 0.99381623 ns
L0R849 EDARADD 136.6105492 17.01 1 9 0.67248539 0.41945802 ns
Q16891 IMMT 135.3568089 44.06 24 36 0.783639761 1.1026E-07 ***
P60981 DSTN 134.8958205 60.61 14 16 0.754255877 0.08708322 ns
P61981 YWHAG 134.6530833 57.89 11 18 0.930446357 0.47399171 ns
C9JZR2 CTNND1 134.6313362 41.58 3 36 0.788917666 0.09391941 ns
B7Z468 CAST 134.2900164 44.16 1 29 0.431365654 0.04250405 *
P09936 UCHL1 134.0906191 55.61 13 13 1.009604458 0.37390097 ns
P61160 ACTR2 132.9217631 40.61 15 16 0.871180146 0.00306342 **
P80723 BASP1 132.9019195 90.75 18 18 1.06482871 0.44862993 ns
Q96FS1 CTNND1 132.7694018 44.94 2 35 0.520736621 0.11945106 ns
F8W9U4 MAP4 132.5353867 23.67 1 24 0.37390097 ns
A0A024RDE8 PDLIM5 132.4792871 44.8 26 26 0.782528053 0.0101845 *
O43175 PHGDH 132.4610718 44.28 23 23 1
E9PDF6 MYO1B 132.3769262 30.98 31 34 1.004179959 0.9323451 ns
P42704 LRPPRC 132.33355 31.85 48 48 0.652003969 0.02302581 *
P62805 HIST1H4A 132.1132618 59.22 8 8 0.875558779 0.25985011 ns
P11940 PABPC1 132.0747147 36.95 8 27 0.731075341 0.03202648 *
Q9BXX0 EMILIN2 131.7607465 38.27 36 36 0.592634009 0.00151198 **
H3BLZ8 DDX17 131.3434603 39.95 21 30 0.781984795 0.01891577 *
P13674 P4HA1 131.3028356 44.94 1 28 0.836904531 0.75151654 ns
P30041 PRDX6 130.9547349 65.18 14 20 0.512929788 4.8121E-07 ***
E9PHM6 DST 130.7590989 10.71 1 56 1
P13797 PLS3 130.5439528 43.97 28 28 0.936940408 0.43636682 ns
O43491 EPB41L2 130.0160707 36.32 25 37 0.348943113 3.2092E-05 ***
P46783 RPS10 129.8825579 61.21 13 14 0.852999138 0.21721834 ns
P40939 HADHA 128.960264 42.07 35 35 0.828693697 0.07988641 ns
Q0VG55 TNS1 128.9290791 27.48 24 39 1.477018259 0.11716346 ns
P23396 RPS3 128.7227206 82.72 21 21 1.123436122 0.16369883 ns
P61158 ACTR3 128.4069434 44.02 21 21 0.796324447 0.02820602 *
P50991 CCT4 127.9244182 50.65 23 24 0.933258935 0.37390097 ns
P54577 YARS 127.8571453 60.98 36 37 0.714808766 0.01434562 *
Q14192 FHL2 127.6310918 69.18 24 24 0.576018491 0.00740547 **
F8W6I7 HNRNPA1 127.1105659 49.51 11 15 1
E9PKU7 GANAB 127.0304532 33.57 1 28 0.615390063 0.20838233 ns
A0A024RAC0 LUZP1 126.2594339 33.64 36 38 0.744115429 0.02105395 *
P53621 COPA 125.6068113 31.13 39 39 0.883450744 0.30196192 ns
P23246 SFPQ 125.468215 33.24 22 23 0.91933363 0.01624401 *
P51911 CNN1 124.890978 51.18 13 17 1.224789917 0.11830904 ns
P08473 MME 124.8862733 36.13 30 30 0.386951042
Q04917 YWHAH 124.7699639 61.79 12 19 0.942109911 0.33710753 ns
P12110 COL6A2 123.7901797 26.01 29 29 0.842006315 0.04950592 *
Q13428 TCOF1 123.6172953 26.81 39 40 0.971185432 0.37390097 ns
P46777 RPL5 123.3136277 59.26 24 24 0.684052177 0.01475471 *
256
P12956 XRCC6 122.537093 47.45 31 32 0.715984763 0.0074175 **
Q92626 PXDN 122.3245876 26.71 37 37 1
Q6ZMP0 THSD4 121.9858315 32.61 31 31 1.233594018 0.11815306 ns
Q9H4M9 EHD1 121.5936142 49.44 17 25 0.679386672 0.01543007 *
P27348 YWHAQ 121.3325688 55.92 13 21 0.973813013 0.37390097 ns
P98095 FBLN2 120.7940519 22.97 21 21 0.246503518
Q9Y4L1 HYOU1 120.4799857 32.03 24 34 0.641753491 0.00689286 **
B5BU24 YWHAB 119.317009 49.59 6 15 0.909918912 0.2319738 ns
P61247 RPS3A 119.2561367 59.47 21 21 0.936471066 0.25708173 ns
A0A024R7F1 PRKCSH 118.8073331 34.91 21 22 0.92796777 0.00077078 ***
Q9NR99 MXRA5 118.6306386 15.74 42 43 0.206665617 1.4329E-09 ***
Q9NYU2 UGGT1 118.0733888 21.67 32 33 0.855884948 0.18423421 ns
V9HWC6 HEL-S-39 117.457016 66.35 16 17 0.629871012 0.00160822 **
P07195 LDHB 117.3477082 43.71 15 17 0.839404235 0.09993236 ns
A0A024RBR1 RSN 117.3324572 28.8 6 42 0.906652315 0.48797657 ns
Q5ZEY3 GAPD 117.3277793 82.56 1 7 1.299733685 0.65076261 ns
Q9Y281 CFL2 117.1565025 53.61 8 12 0.76272253 0.08155423 ns
A0A024R152 hCG_28765 116.9731456 28.2 7 32 0.919182588 0.01016658 *
P08729 KRT7 116.9231068 50.32 19 27 0.499987295 0.00054884 ***
A0A087WZH7 MARCKS 116.3047463 37.88 11 11 0.979231104 0.28866214 ns
Q15084 PDIA6 115.7789886 46.36 22 22 1
P62906 RPL10A 115.5641451 54.84 15 15 0.863494207 0.08750442 ns
P11216 PYGB 115.203419 43.3 31 36 1.023819507 0.50508696 ns
A0A087WTP3 KHSRP 115.2032006 48.1 29 34 0.680161794 0.00469485 **
P08779 KRT16 114.4794499 62.37 18 31 2.395929688 0.37390097 ns
Q10567 AP1B1 113.5890634 27.71 4 33 0.564120778 0.01088418 *
O00468 AGRN 113.3961686 23.51 38 38 1
Q9H1J7 WNT5B 113.366237 51.25 12 20 1.311476292 0.11886264 ns
P49792 RANBP2 113.0460924 17.21 42 45 0.993696103 0.37390097 ns
B2ZZ86 COL5A1 113.0095174 17.9 2 32 0.873288645 0.26289096 ns
P52209 PGD 112.0586804 41.2 22 22 0.728607945 0.00091616 ***
P26640 VARS 111.8930584 28.48 33 34 0.944840466 0.37390097 ns
J3KTA4 DDX5 111.8308004 41.04 19 27 0.948061794 0.1261551 ns
P13647 KRT5 111.7110255 38.81 15 25 1.884037842 0.37390097 ns
P04843 RPN1 111.67961 42.5 27 27 0.68997072 0.00166499 **
O60506 SYNCRIP 111.6434879 36.76 3 25 1
E7EX90 DCTN1 111.2703466 30.81 29 39 0.985705149 0.24045445 ns
P18669 PGAM1 111.207642 51.18 7 12 0.953396049 0.18255768 ns
P39019 RPS19 110.9174967 62.76 13 13 1
Q8IX30 SCUBE3 110.7792724 27.39 26 26 0.936476623 0.18124504 ns
Q14008 CKAP5 110.3784194 20.37 42 42 1
A0A087WXW9 COL5A1 110.291368 17.85 1 31 1.743305974 0.25021365 ns
Q9UID7 CYR61 110.123684 51.8 1 19 1.088048077 0.73001024 ns
A0A024R755 CALU 109.9674361 42.86 2 14 1.16980138 0.60593353 ns
K4DI93 CUL4B 109.9444809 38.22 26 37 0.751655651 0.00886359 **
P55268 LAMB2 109.5432255 22.36 33 34 0.767846399 4.5402E-05 ***
E7EPN9 PRRC2C 108.6890309 14.05 20 37 1
257
P24844 MYL9 108.4822969 54.65 4 10 1
A0A024R652 MTHFD1 108.0902104 33.37 32 33 0.737757315 0.02073715 *
Q8N2S1 LTBP4 107.5885618 23.58 32 33 1.142211077 0.00798273 **
Q5T4S7 UBR4 107.2926911 7.81 40 41 1
P63244 GNB2L1 107.0053422 66.56 21 21 1.007943506 0.37390097 ns
Q01813 PFKP 106.8734899 35.97 24 32 1.368885983 0.0392236 *
Q13418 ILK 106.4220018 48.23 22 22 0.621032374 0.00080987 ***
Q03252 LMNB2 105.7580711 48.5 28 33 0.63494303 0.00309776 **
P62424 RPL7A 105.7038603 55.26 19 20 0.756996442 0.06126472 ns
Q13423 NNT 105.2907741 26.7 31 31 0.41526868 3.5721E-05 ***
P19105 MYL12A 105.2013487 66.67 5 11 1
A6XND0 IGFBP3 105.1730219 72.59 19 19 0.898670007 0.11104011 ns
J3KP58 CLIP1 104.7454406 28.42 1 37 1.031706061 0.75975074 ns
P14649 MYL6B 104.0745589 42.79 7 11 0.991927108 0.84154448 ns
P00352 ALDH1A1 103.7933685 43.51 19 21 0.675096897 1.7548E-06 ***
Q8WUJ3 CEMIP 103.7649856 26.45 34 34 1.47912209 0.08416036 ns
F5GZS6 SLC3A2 103.7404037 33.89 20 21 0.770250587 0.01611655 *
E9PLK3 NPEPPS 103.7036138 38.25 35 35 0.908742335 0.25866744 ns
Q9NZU5 LMCD1 102.916867 59.45 24 24 0.592002376 0.00013294 ***
Q03135 CAV1 102.8381137 39.33 2 8 0.098050003 1.1064E-05 ***
P62820 RAB1A 102.1914731 80.98 6 16 1
O00410 IPO5 101.2415268 27.07 27 27 0.84662973 0.00228706 **
P41252 IARS 101.2162381 26.07 34 34 1
O43776 NARS 101.0379478 39.05 24 24 0.941515251 0.37390097 ns
Q8IVF2 AHNAK2 100.9883219 21.1 41 43 1.200649495 0.15315104 ns
P50552 VASP 100.8974239 50.53 18 18 0.632921596 0.00277398 **
Q8IUD2 ERC1 100.4879887 29.21 33 34 0.788846403 0.00107459 **
P05362 ICAM1 100.1500107 37.03 21 22 0.808996052 #DIV/0! #DIV/0!
H0Y2S9 MPRIP 100.0219896 15.66 3 27 1
B5BUB5 SSB 99.99410915 44.61 25 26 0.845392068 0.00918932 **
P02786 TFRC 99.95833945 37.5 2 26 0.644106022 0.02770189 *
O60763 USO1 99.68557072 31.7 31 31 0.907600035 0.09513308 ns
B5BTY4 DDX3X 99.65425193 44.11 10 29 1.007795825 0.88604212 ns
P02533 KRT14 99.6000005 39.62 4 22 1.344832691 0.37216347 ns
E7ETU9 PLOD2 99.58264327 36.27 2 26 1.02204854 0.84344239 ns
P27824 CANX 99.55334008 35.64 17 25 1
P15880 RPS2 99.40856874 56.31 13 18 0.953390957 0.21974664 ns
Q9Y678 COPG1 99.09563303 36.5 26 30 0.817281885 0.06016245 ns
O94973 AP2A2 99.04706872 29.82 15 29 0.448924198 0.00022328 ***
P26641 EEF1G 98.64518356 36.84 20 20 0.870030381 0.2330113 ns
H0YD13 CD44 98.02377772 47.09 9 9 0.226233389 6.4202E-06 ***
Q15365 PCBP1 97.96830523 48.03 8 15 0.983212237 0.37390097 ns
P09619 PDGFRB 97.95063233 22.97 24 26 0.319675337 9.6082E-05 ***
P20700 LMNB1 97.92282057 42.66 23 28 0.810974928 0.01727052 *
P48444 ARCN1 97.77234137 40.9 23 23 0.81765081 0.0416616 *
C9JNG9 COL6A3 97.61256146 30.79 1 21 0.942365326 0.37390097 ns
P54136 RARS 97.54465842 41.52 28 28 0.941634699 0.41479073 ns
258
Q6YHK3 CD109 97.5137459 19.58 28 29 0.982101478 0.23029939 ns
O94979 SEC31A 97.14377224 26.56 32 33 0.901913691 0.16622422 ns
Q12797 ASPH 96.96380341 34.04 28 28 0.42398085 0.00045452 ***
P21796 VDAC1 96.82183814 49.82 11 12 1
B1ANR0 PABPC4 96.78370559 33.98 16 25 0.806116448 0.26764043 ns
P50395 GDI2 96.30039406 50.79 15 22 0.794983057 0.05177516 ns
Q08211 DHX9 96.1631974 24.25 28 28 0.85000148 2.1152E-05 ***
O00151 PDLIM1 96.073645 56.23 16 17 0.604644069 0.00087827 ***
A0A024RB16 FAM62A 95.8872509 31.42 32 32 0.87212994 0.22692896 ns
A0A024RC87 RNH1 95.79523396 46.27 19 20 0.605761762 0.00018909 ***
F5H365 SEC23A 95.70094883 35.73 19 21 1
E9PRU1 EFEMP2 95.63373756 37.84 15 15 1
Q5EC54 HNRPK 95.53801703 42.03 1 21 0.614479689 0.13156432 ns
Q9Y2D5 AKAP2 95.42605007 35.51 1 25 1.440149862 0.15801953 ns
Q92896 GLG1 95.08208466 23.49 33 33 0.760052655 0.021968 *
G3V4W0 HNRNPC 95.05706072 56.87 21 21 0.731491562 0.01684258 *
A0A087WUT6 EIF5B 94.7693392 23.2 29 31 0.757927251 0.00164248 **
P13611 VCAN 94.63353288 6.8 3 26 1.160174235 0.37390097 ns
P09972 ALDOC 94.42240787 36.81 9 15 0.927163511 0.37390097 ns
A0A087WY71 AP2M1 94.39802742 44.01 3 20 0.724516912 0.10328021 ns
O95025 SEMA3D 93.91996622 33.2 29 30 0.883157732 0.19437182 ns
P35998 PSMC2 93.60846174 57.74 26 26 0.948298668 0.36142944 ns
O00469 PLOD2 93.55829906 32.29 1 25 1
P41250 GARS 93.47918344 29.5 25 25 0.95944394 0.45921659 ns
P53618 COPB1 93.44026887 34.52 30 30 0.990932351 0.37390097 ns
Q32Q12 NME1-NME2 93.39006877 56.16 1 12 1.23697253 0.32715043 ns
Q92974 ARHGEF2 93.18259382 30.93 30 30 0.994929124 0.76174362 ns
A0A087WYF1 LAMA2 93.15405285 11.32 33 34 0.539964127 4.1149E-07 ***
P36871 PGM1 93.13989377 45.2 25 25 0.982948903 0.80104402 ns
O00425 IGF2BP3 92.44845319 44.21 23 25 0.787271654 0.00775972 **
O43390 HNRNPR 92.35258353 34.91 14 22 0.640414709 3.8772E-05 ***
Q8NF91 SYNE1 92.31227922 4.21 4 38 1
P05997 COL5A2 92.25800073 21.75 5 28 0.940666246 0.11675213 ns
Q92499 DDX1 92.21397436 35.41 25 25 1
A0A024RAL1 CSPG2 91.88291097 8.76 1 24 7.03103103 0.00322339 **
Q13740 ALCAM 91.7256602 33.45 4 21 0.878599161 0.34165482 ns
P07942 LAMB1 91.10749769 16.41 31 32 0.605233141 0.00342137 **
Q68CZ2 TNS3 90.98682499 22.56 9 28 0.218466195 3.2306E-06 ***
P38159 RBMX 90.72920239 46.29 10 23 0.972675393 0.00029006 ***
B7ZLW0 LPP 90.54315674 35.62 20 21 0.722020684 0.00042708 ***
Q96T46 HBA2 90.5213629 90.79 1 5 0.750604278 0.18648548 ns
O15523 DDX3Y 90.34439766 42.88 7 26 0.906280951 0.1494872 ns
Q05DA4 P4HA2 90.31031001 38.69 21 21 0.952770231 0.45019318 ns
Q15046 KARS 90.01174033 38.02 19 25 0.949837814 0.37390097 ns
Q7Z6Z7 HUWE1 89.8925755 8.89 34 34 1
O60701 UGDH 89.82101965 47.77 22 23 1.216758764 0.12519178 ns
O15031 PLXNB2 89.80431116 18.72 30 31 0.41685841 0.00037142 ***
259
Q8NC51 SERBP1 89.68260503 34.8 18 18 0.974010072 0.52244822 ns
Q02952 AKAP12 89.60472488 20.31 34 34 1
O60565 GREM1 89.48483145 66.3 11 11 1.093498091 0.20867909 ns
E7EQG2 EIF4A2 89.38809741 37.57 3 15 1.04941225 0.40302536 ns
Q96RT1 ERBB2IP 89.12837946 25.28 33 34 0.79504904 0.0488353 *
Q92930 RAB8B 89.06852293 57 4 13 0.679650372 2.1639E-62 ***
Q6IB91 PCK2 89.05075336 38.91 1 24 0.876555812 0.03717616 *
O60568 PLOD3 89.01463592 29.81 23 23 0.964337495 0.37390097 ns
P49411 TUFM 88.90843964 47.57 20 20 0.595511736 0.00082411 ***
P56730 PRSS12 88.44672012 29.94 28 28 3.116451701 0.03857608 *
Q16531 DDB1 87.85899138 28.51 31 32 0.922333851 0.07801155 ns
P49257 LMAN1 87.27707648 34.12 17 18 0.817947393 0.0572444 ns
P35606 COPB2 86.91517138 34.66 29 29 0.907865223 0.27576085 ns
P02461 COL3A1 86.79572105 20.94 24 25 0.980471318 0.37390097 ns
H0Y827 FKBP10 86.61482263 36.79 1 13 3.893330016 0.00139793 **
P61006 RAB8A 86.56513047 53.62 4 13 1
P24593 IGFBP5 86.2776891 47.43 13 13 0.14210488 2.0625E-07 ***
Q6NTA2 HNRNPL 86.10209298 38.64 17 18 0.963229406 0.37390097 ns
M0QYM7 TUBB4A 85.85119724 32.3 1 4 0.941173685 0.80772835 ns
H0Y5N9 COL12A1 85.5184195 36.77 2 24 0.660226888 0.00294661 **
Q9H4B7 TUBB1 84.99465954 13.75 2 8 1
Q15063 POSTN 84.41623485 31.58 3 23 2.358312581 0.03619119 *
P26373 RPL13 84.37564003 48.82 14 15 0.89380645 0.25279493 ns
P23142 FBLN1 84.13848925 17.07 6 14 0.671871453 0.00024252 ***
A0A087X0K9 TJP1 83.92100108 22.49 1 31 0.288507625 0.00017235 ***
Q9H0U4 RAB1B 83.85085106 69.65 5 15 0.607926922 0.00054866 ***
Q15366 PCBP2 83.66461349 41.1 4 13 0.863064051 0.01943424 *
H0YAR2 PABPC1 83.61719143 47.54 1 16 0.37390097 ns
P04899 GNAI2 83.44527876 52.39 8 16 0.791796247 0.0129473 *
A9CQZ8 TJP1 83.40687478 21.29 1 31 0.468555845 0.01928762 *
P12081 HARS 83.28454077 46.56 19 27 0.788165505 0.1574194 ns
Q9Y5S2 CDC42BPB 83.16076016 14.9 24 28 1
Q86UY0 TXNDC5 83.01752412 48.61 17 19 0.95872615 0.44109441 ns
A0A087WUK2 HNRNPDL 83.01145709 34.44 15 17 0.788630327 0.01798671 *
Q7Z2W2 DKFZp686F13142 82.97275841 24.45 23 23 0.513381702 1.0497E-05 ***
P09525 ANXA4 82.90509236 64.89 21 22 0.734599641 0.08384147 ns
P37837 TALDO1 82.85037827 45.1 17 17 0.580420937 0.00232871 **
Q9Y4F1 FARP1 82.81395745 23.35 25 25 0.447806601 9.547E-05 ***
Q9BR63 FARSB 82.75520492 42.22 25 26 0.784415999 0.04632285 *
P06737 PYGL 82.70175958 35.18 23 28 0.991223941 0.37390097 ns
H0YJ34 FERMT2 82.67003191 31.09 2 20 0.646807297 0.07684835 ns
Q16851 UGP2 82.26187646 42.91 22 22 0.937490208 0.49077356 ns
P63000 RAC1 82.22520256 43.75 4 11 0.580050602 0.00120644 **
P06748 NPM1 82.16358101 43.88 15 15 0.764354626 0.02758225 *
P49748 ACADVL 81.71091866 35.11 22 22 0.381036832 0.00010692 ***
P26447 S100A4 81.58446288 45.54 7 7 0.313712447 7.8421E-06 ***
P23381 WARS 81.58242118 37.15 18 18 0.65259694 0.0001593 ***
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P07339 CTSD 81.54867208 41.99 15 15 1
Q9H2G2 SLK 81.53240502 17.89 26 28 1
P53675 CLTCL1 81.48850298 10.73 1 21 1
P21980 TGM2 81.37849486 39.45 24 24 0.260525926 3.9689E-11 ***
Q04695 KRT17 81.3106842 44.91 5 24 1.750480225 0.37390097 ns
P18124 RPL7 81.19908905 54.44 20 20 0.888543439 0.39692999 ns
O43242 PSMD3 80.83635092 42.32 1 24 1
Q5HYL6 DKFZp686E1899 80.83347034 52.56 16 17 0.886655633 0.01455166 *
P17987 TCP1 80.64091802 45.68 24 24 1.008936957 0.85174301 ns
O43854 EDIL3 80.32981241 41.04 20 20 4.429318034 0.00049714 ***
Q14157 UBAP2L 80.31015432 25.85 4 21 0.838956935 0.02298445 *
O15144 ARPC2 80.10173786 44.67 18 18 1.007991908 0.37390097 ns
Q9NZB2 FAM120A 79.91535366 22.81 21 22 0.720026615 0.00719579 **
Q16822 PCK2 79.86744857 39.84 2 25 0.313035898 0.00430273 **
A1JUI8 CCT6A 79.72034955 37.09 1 23 1
A0A087WW66 PSMD1 79.32456446 29.49 26 26 0.748953962 0.03467777 *
Q96D15 RCN3 79.22462451 40.85 11 11 1.08527933 0.37390097 ns
P62277 RPS13 79.21696186 52.98 12 12 0.913607892 0.25524634 ns
H0YDG6 LMO7 79.20644772 58.69 4 17 0.465396883 0.00036798 ***
A0A024RDF4 HNRPD 79.03417635 44.77 3 17 0.875013609 0.43135532 ns
Q9NZN3 EHD3 79.01042902 35.33 9 21 1
Q7RTM4 SYNE1 78.98139596 4.13 1 34 0.37390097 ns
Q99623 PHB2 78.97235096 59.87 19 19 0.857086792 0.33639196 ns
B5BU63 KLC1 78.8706162 38.31 20 24 0.786723861 0.08435921 ns
P54886 ALDH18A1 78.63805079 32.2 24 24 1
P13010 XRCC5 78.43653989 24.73 20 21 0.833490738 0.12811592 ns
Q08378 GOLGA3 78.28965783 19.89 27 28 1
Q6IPH7 RPL14 78.12106919 56.82 2 15 0.96515812 0.44861832 ns
Q53SY7 CAD 78.00145459 11.76 25 25 0.950677366 0.11611652 ns
A8MXP9 MATR3 77.97986555 28.83 26 26 0.934031963 0.13859697 ns
P14868 DARS 77.84264374 45.51 22 22 0.986247668 0.37390097 ns
Q5JRA6 MIA3 77.79105484 15.99 27 28 0.809258143 0.11611652 ns
O75095 MEGF6 77.7278918 18.88 21 21 0.48352994 1.1389E-05 ***
E9PK01 EEF1D 77.65364206 42.91 11 12 0.983580535 0.37390097 ns
P40925 MDH1 77.57122838 44.01 17 17 0.646064196 0.00040756 ***
P09543 CNP 77.49071097 42.76 23 25 0.485419058 0.00079219 ***
C9J9K3 RPSA 77.47466826 58.33 10 12 0.919239724 0.00616967 **
P39023 RPL3 77.45591271 41.44 22 22 0.882294847 0.30358051 ns
B4DDB6 HNRPA3 77.42929542 33.71 11 14 0.906726342 0.11963071 ns
Q66K79 CPZ 77.36748588 33.44 19 19 0.147216208 2.4918E-05 ***
Q14160 SCRIB 77.29639626 18.47 26 28 0.86621786 0.00044628 ***
B9EGA7 CDC42BPA 77.1688813 18.07 26 29 0.520489532 0.00037225 ***
B1ALD9 POSTN 77.08961666 29.7 2 22 1.502755106 0.07328439 ns
P60953 CDC42 77.05334044 49.21 9 10 0.680478662 0.01520216 *
P62333 PSMC6 77.0056448 53.21 23 23 0.801019355 0.02629486 *
E9PSG1 CAST 76.77030838 50 1 13 1
Q13200 PSMD2 76.65857673 31.5 27 27 0.980527557 0.37390097 ns
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P25398 RPS12 76.49056327 60.61 8 8 0.853537405 0.02064141 *
P62701 RPS4X 76.16921496 42.97 9 15 0.919164741 0.14765613 ns
Q63ZY3 KANK2 76.16697848 28.79 20 25 0.422893011 0.00302443 **
Q02878 RPL6 76.04871547 39.58 16 16 0.74370658 0.03960985 *
Q6DEN2 DPYSL3 75.82296443 35.53 16 20 0.323677932 5.7899E-05 ***
H7BZJ3 PDIA3 75.61649358 57.72 1 7 1
Q9H2D6 TRIOBP 75.53974903 9.56 21 24 0.543838111 6.5134E-05 ***
K7EKE6 LONP1 75.34129238 28.99 23 25 0.84526107 0.03812243 *
Q16527 CSRP2 75.21239614 61.14 11 11 0.683170213 8.8237E-05 ***
Q15404 RSU1 75.20766711 46.93 16 16 0.925943968 0.00755262 **
Q14112 NID2 74.75838065 19.71 22 23 0.764852033 0.01830369 *
E9PCT5 CAV1 74.7096051 35.33 1 7 0.424235979 0.04243092 *
Q02790 FKBP4 74.51590455 47.71 20 21 0.999236149 0.37390097 ns
P22102 GART 74.50192559 22.97 24 24 1
P10316 HLA-A 74.15289962 51.51 0 15 0.37390097 ns
P40222 TXLNA 74.12704945 38.1 20 22 0.941350921 0.37390097 ns
B2RMV2 CYTSA 74.02228665 24.17 26 28 0.939126647 0.37390097 ns
P68431 HIST1H3A 73.97794127 47.79 2 12 1
P61224 RAP1B 73.87053144 57.07 4 12 0.656015408 0.0058565 **
Q13214 SEMA3B 73.81213999 28.84 18 19 0.860298276 0.00140206 **
Q9BSQ6 RPL13A 73.6729269 51.24 14 14 0.841988391 0.20204743 ns
Q13561 DCTN2 73.5523715 56.36 22 22 0.801898061 0.0005247 ***
W6I206 LOXL2 73.52433825 23.59 10 19 1.154708064 0.26722153 ns
D5H3T4 HLA-A 73.46855271 52.33 0 15 0.37390097 ns
H0Y6I0 GOLGA4 73.43535221 13.24 26 29 1
A0A087WYX9 COL5A2 73.4335233 23.29 1 23 0.612665454 0.12577202 ns
P49589 CARS 73.41204166 35.16 3 25 0.447772203 0.00056037 ***
H7BXI1 ESYT2 73.35458028 26.36 20 20 0.339148294 2.2319E-07 ***
P62070 RRAS2 73.01520085 54.9 9 11 0.785365378 0.00088271 ***
P62191 PSMC1 72.98040426 54.09 21 23 0.866678205 0.0637064 ns
Q9UQ35 SRRM2 72.62336707 12.5 27 27 1
O15231 ZNF185 72.53855097 40.06 10 26 0.758387103 0.00046511 ***
P31939 ATIC 72.47854352 40.71 21 21 0.819853643 0.00051333 ***
Q9Y6M1 IGF2BP2 72.26998138 32.05 15 17 0.948585943 0.37390097 ns
P61586 RHOA 72.20305073 41.97 3 8 0.857748508 0.0027597 **
B4DLR8 NQO1 72.14329863 50 13 13 0.340067672 0.00046629 ***
P00966 ASS1 72.10724068 32.28 18 18 0.193480969 5.9353E-07 ***
A0A087WUA5 EHD4 72.02006745 43.7 17 25 0.586329595 0.0001957 ***
D6R9P3 HNRNPAB 71.92216802 35.36 10 12 0.961790907 0.26615254 ns
O60361 NME2P1 71.89366126 52.55 1 7 5.582799263 0.00167699 **
P49023 PXN 71.88088143 33.5 12 17 0.640834642 0.00059146 ***
Q32P28 LEPRE1 71.61838961 22.15 15 16 0.619004804 3.2356E-05 ***
P08243 ASNS 71.58539736 36.01 2 20 1.408226388 0.00690705 **
P62195 PSMC5 71.5685401 51.48 18 20 0.891855779 0.3203894 ns
P50479 PDLIM4 71.5455097 53.33 16 16 0.611567699 0.00037624 ***
P50502 ST13 71.43180037 32.79 15 15 0.9259825 0.11916906 ns
Q1KMD3 HNRNPUL2 71.18356752 26.37 22 22 0.818870848 0.01178588 *
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Q13283 G3BP1 71.14020967 34.33 11 12 1
O75116 ROCK2 71.07349658 17.87 22 27 1
Q5VZU9 TPP2 71.04133093 23.61 1 27 0.667712739 0.00940548 **
P29144 TPP2 70.98779261 24.58 1 27 0.37390097 ns
P05787 KRT8 70.77582991 21.95 5 13 1
Q99985 SEMA3C 70.69001579 26.36 22 24 0.247040374 6.3011E-07 ***
Q96TA1 FAM129B 70.66360641 27.21 22 22 0.503264948 0.00112683 **
Q04721 NOTCH2 70.46831775 11.45 22 24 0.876730015 0.09833075 ns
P35052 GPC1 70.45983005 41.4 21 21 0.552182279 1.6229E-06 ***
P05141 SLC25A5 70.23184228 44.3 6 16 0.761596921 0.00477746 **
P54289 CACNA2D1 70.03432679 24.39 26 26 0.36565156 1.9725E-05 ***
P62917 RPL8 69.93753231 46.69 15 16 0.917689495 0.30181605 ns
P05198 EIF2S1 69.47889411 48.89 15 16 0.670484725 0.002763 **
Q15286 RAB35 69.41864502 49.25 7 11 0.609057322 0.00260497 **
O75131 CPNE3 69.3596952 33.71 17 18 0.908563943 0.30425816 ns
O75643 SNRNP200 69.3010844 11.38 24 24 1
Q06210 GFPT1 69.26823092 32.47 17 21 0.913044577 0.19577993 ns
Q6F3I9 HLA-A 69.0502342 60.81 0 14 0.37390097 ns
P28331 NDUFS1 69.02861035 31.77 23 23 0.620701382 0.00148442 **
O75533 SF3B1 68.92889392 19.63 21 21 0.861668947 0.0993146 ns
Q96N67 DOCK7 68.83096552 13.5 27 28 0.985632595 0.37390097 ns
O00299 CLIC1 68.7690469 74.27 14 15 0.699197016 0.00050773 ***
D6R938 CAMK2D 68.72603977 32.73 5 18 0.950051929 0.12345548 ns
R4GN98 S100A6 68.52286184 45.88 6 6 1.06225011 0.5969043 ns
Q9UHB9 SRP68 68.47484922 37.64 23 23 0.846503587 0.00169422 **
P50570 DNM2 68.10611057 24.02 13 23 0.948273165 0.23039944 ns
P60228 EIF3E 68.06295514 39.78 17 17 1
P18084 ITGB5 67.94779813 31.04 22 22 0.613144245 0.00230251 **
H0Y3P2 EIF4G2 67.84367752 27.5 23 23 0.963135005 0.37390097 ns
Q7Z3Z9 L1CAM 67.32185531 20 23 24 0.578276158
B4DJV2 CS 67.26569355 28.04 12 13 0.947057949 0.34302382 ns
P55084 HADHB 67.14619243 36.71 18 20 0.995143657 0.37390097 ns
Q9Y266 NUDC 67.14301801 43.81 18 19 0.839554538 0.17338262 ns
Q9UNA0 ADAMTS5 67.03662348 26.02 26 26 0.191816274 1.0783E-05 ***
O76094 SRP72 67.00478053 31.15 20 21 0.746165818 0.09078653 ns
Q9H792 PEAK1 66.91825724 16.95 26 26 0.664181018 0.00390143 **
O75396 SEC22B 66.80782104 38.6 8 8 0.91644313 0.16533445 ns
Q9Y696 CLIC4 66.72032475 65.22 14 15 0.73878772 0.0051113 **
P08727 KRT19 66.63347101 44.75 12 20 1.112957343 0.37390097 ns
Q969G5 PRKCDBP 66.60435748 34.87 10 10 0.57089739 0.00091929 ***
Q96I99 SUCLG2 66.56942177 40.51 21 21 0.993248715 0.14243384 ns
Q6P2Q9 PRPF8 66.41806674 10.06 26 26 1
M0R210 RPS16 66.39558995 74.42 15 15 0.977882837 0.23533382 ns
P32455 GBP1 66.29369974 28.89 1 20 1
Q96AG4 LRRC59 66.24892199 43.97 17 17 0.678814866 0.00232714 **
Q15389 ANGPT1 66.1647141 40.56 18 18 0.269193162 6.2943E-05 ***
P15531 NME1 65.88900423 57.89 1 8 1.422756669 0.21867926 ns
263
Q54A51 hEMMPRIN 65.8220185 43.49 12 12 0.561574529 0.01295495 *
A7XZY7 ITSN1 65.81623733 21.22 23 26 0.790735346 #DIV/0! #DIV/0!
P28838 LAP3 65.81506443 47.4 20 20 0.681745059 0.0175289 *
Q9Y3I0 RTCB 65.72630847 31.09 15 15 0.866539315 0.19699663 ns
Q99497 PARK7 65.55603647 60.32 13 13 1
Q12841 FSTL1 65.30360937 37.99 14 14 1
P07686 HEXB 65.2985369 31.47 17 19 0.431734502 0.00021767 ***
B5BUB1 RUVBL1 65.21010828 40.13 16 16 1
P01023 A2M 65.12464809 4.88 6 9 1.012615354 0.43533182 ns
Q9Y230 RUVBL2 65.03231502 43.2 18 18 0.905006556 0.1979213 ns
E5KLM2 OPA1 64.83521938 24.17 21 21 0.877120568 0.00246189 **
P45880 VDAC2 64.72336519 40.82 11 11 0.977797895 0.37390097 ns
P35232 PHB 64.60958087 47.06 14 14 0.735644746 0.00868107 **
Q13045 FLII 64.43123937 20.8 25 25 0.98231894 0.37390097 ns
Q6UB35 MTHFD1L 64.30128729 20.14 19 20 0.795218335 0.02492876 *
B4DV79 EIF3B 64.11961722 28.46 21 21 0.929064928 0.42534908 ns
Q8WUP2 FBLIM1 64.04281235 40.48 15 15 0.657383061 0.00342502 **
Q5T985 ITIH2 63.9382621 10.16 11 11 1.111033282 0.11724932 ns
P16152 CBR1 63.83604944 58.48 12 16 0.64098785 0.01368647 *
P10301 RRAS 63.81084752 40.83 5 7 0.421548495 0.0005064 ***
A0A024R7G6 EPS15L1 63.71085966 26.92 22 22 0.820000905 0.01042991 *
P61088 UBE2N 63.69095266 63.82 10 10 0.861278524 0.02511308 *
Q5JTV8 TOR1AIP1 63.40027344 33.1 2 20 0.330421937 0.00280583 **
P07602 PSAP 63.36603212 23.28 15 15 0.508302033 0.0026181 **
A6NHL2 TUBAL3 63.33344781 15.7 2 7 1
A0A024R7L5 UPF1 63.17448473 20.13 20 20 0.813231392 0.02467802 *
O43399 TPD52L2 63.15228915 51.94 2 13 0.93899552 0.78011607 ns
Q9Y3F4 STRAP 63.14752293 44.57 15 15 0.937910407 0.40841452 ns
P09874 PARP1 62.93441987 17.16 20 20 0.774504944 0.04959765 *
P61026 RAB10 62.66679537 44 7 12 0.651670371 0.00642928 **
P31943 HNRNPH1 62.60603952 25.84 3 9 0.900944122 0.03705992 *
Q86W92 PPFIBP1 62.56711578 23.44 18 22 0.898955437 0.00914554 **
Q5JXI2 FHL1 62.41635108 56.67 2 14 0.123672159 5.6473E-06 ***
A0A024R3F4 PHLDB1 62.33774447 20.92 23 24 0.525677474 6.5003E-06 ***
Q13425 SNTB2 62.2586422 33.89 17 20 0.723951252 0.02020509 *
D3DT72 COL11A1 62.20873904 13.97 18 24 0.949761503 0.37390097 ns
Q15293 RCN1 62.16178906 30.82 10 10 0.84175492 0.06894614 ns
Q6NYC8 PPP1R18 61.95135307 36.05 19 19 0.576049929 0.0025835 **
A0A024RDQ0 HSPH1 61.81229413 29.12 17 22 0.949079764 0.12512499 ns
O75955 FLOT1 61.7522763 40.98 18 19 0.68177474 0.00806311 **
Q93008 USP9X 61.6914289 9.03 23 24 1
P04040 CAT 61.59539318 34.54 18 18 0.52466959 2.2234E-05 ***
J3KN66 TOR1AIP1 61.58290303 31.05 1 19 1
B4DVQ5 EIF3C 61.44728482 21.49 23 23 0.97289073 0.52954041 ns
P62753 RPS6 61.17091453 41.77 15 15 0.884876892 0.31676231 ns
A0A087X2D8 SPAG9 60.98467207 17.76 17 22 1.086305005 0.258016 ns
P17858 PFKL 60.95205975 27.56 14 22 1.129961909 0.27245738 ns
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P11387 TOP1 60.92829919 30.85 23 23 0.77630761 0.02622805 *
B5BU83 STMN1 60.89709222 52.35 11 11 0.923242936 0.42526007 ns
H0Y4R1 IMPDH2 60.64984322 37.87 16 17 0.78955077 0.03524461 *
P18085 ARF4 60.61304808 56.11 6 9 1
O00291 HIP1 60.59991705 19.67 21 24 0.716170235 0.02395862 *
A0A024R201 PSMD13 60.58700371 38.83 1 16 1.06205429 0.78453899 ns
P43034 PAFAH1B1 60.49679661 45.61 17 18 0.958774174 0.37390097 ns
P62244 RPS15A 60.46612036 77.69 4 11 0.846722221 0.12584148 ns
A0A024R4X0 CYB5R3 60.3715564 46.74 3 13 0.965819078 0.82861963 ns
Q13177 PAK2 60.3068856 31.3 8 15 0.838250938 0.23747537 ns
A0A024R0K2 CSDE1 60.29484963 27.38 23 23 1.001430752 0.37390097 ns
P62834 RAP1A 60.09408844 53.26 2 10 0.256965569 8.815E-05 ***
P31949 S100A11 59.98114371 61.9 7 7 0.84140123 0.16122117 ns
D3DUG9 USP14 59.97010255 34.4 19 19 1
A4FU11 RPS4Y1 59.86693263 43.51 7 14 0.848344085 0.13102983 ns
O00231 PSMD11 59.82235885 46.45 19 19 0.896890956 0.05306464 ns
E9PBS1 PAICS 59.81817567 31.48 15 15 1
Q12884 FAP 59.79344678 19.47 15 15 0.886698062 0.2730828 ns
D9ZGF8 ROCK1 59.62425613 14.55 18 22 1
P43686 PSMC4 59.62415791 34.69 16 17 1
Q07955 SRSF1 59.45383036 45.56 13 13 0.985217809 0.35545036 ns
B5BU72 PICALM 59.45357454 26.89 1 18 0.708336422 0.24258527 ns
A7E2Y5 DNAJC13 59.4064436 11.23 24 24 0.801727599 0.00082382 ***
Q15599 SLC9A3R2 59.29795432 39.17 16 16 0.720607411 0.000134 ***
G8JLD5 DNM1L 59.19023895 30.9 21 21 0.921931933 0.27380158 ns
P13693 TPT1 59.18363214 48.84 10 10 0.714122948 6.6497E-05 ***
Q96JY6 PDLIM2 59.11489618 39.77 11 12 0.696792847 0.00222351 **
A0A024R5L7 PICALM 59.10163808 26.89 1 18 0.979895359 0.37390097 ns
P51858 HDGF 59.05915499 43.33 10 11 1
P62136 PPP1CA 58.96397531 41.52 4 13 0.641054264 0.0081526 **
O94907 DKK1 58.87902141 34.96 8 10 0.742847424 5.3405E-05 ***
P52907 CAPZA1 58.8471911 53.15 9 12 0.898693309 0.16791789 ns
A0A087WZZ5 SF3B2 58.83767092 23.88 23 23 0.749462761 0.01881178 *
I3L397 EIF5A 58.72944498 57.82 10 10 0.962873815 0.24472649 ns
I3L4X2 ABCC1 58.6937629 16.46 20 22 1
Q12904 AIMP1 58.58567071 42.95 12 13 0.685265358 0.0005564 ***
Q4L180 FILIP1L 58.56663167 19.12 23 24 0.812796756 0.12031685 ns
P51149 RAB7A 58.5619545 74.88 15 15 0.689711843 0.00405381 **
L7UUZ7 ITGB3 58.50377536 26.78 21 21 0.63560438 0.00046759 ***
A0A024R5A3 CAPN1 58.45554948 25.35 20 21 0.899744642 0.33477504 ns
P62826 RAN 58.4547652 40.28 10 10 0.928928593 0.23005839 ns
Q16352 INA 58.39575064 6.81 3 4 1.110564697 0.37390097 ns
P29317 EPHA2 58.38309717 22.03 20 21 0.728252053 0.00046111 ***
P13804 ETFA 58.32438374 52.55 15 15 0.540488805 0.0001125 ***
P12236 SLC25A6 58.31740558 43.96 1 14 0.729516336 0.17800667 ns
P24752 ACAT1 58.30234838 40.28 17 17 0.537459895 0.00304952 **
Q9NZI8 IGF2BP1 58.26649332 28.08 14 15 1.262344544 0.12595377 ns
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X5D2T3 RPL10 58.22658145 52.34 15 15 0.959921727 0.39441679 ns
P46779 RPL28 58.02508044 50.36 10 10 0.897472915 0.05182473 ns
P07954 FH 57.99991751 27.84 15 15 0.387287445 0.00010705 ***
Q27J81 INF2 57.95770109 17.37 20 20 0.923670426 0.37390097 ns
P45974 USP5 57.82712984 30.07 22 22 0.763634225 0.02299221 *
Q1ELT0 HLA-A 57.82702792 44.38 0 12 0.37390097 ns
A0A024QZE7 TGFB1I1 57.68644762 42.34 13 13 0.782860105 0.01130507 *
F5GWP8 KRT17 57.65320528 41.26 1 18 1.022716096 0.74492767 ns
Q9H425 C1orf198 57.63413703 40.06 15 15 0.927673375 0.12488478 ns
Q86UE4 MTDH 57.62437546 32.47 18 18 0.864229692 0.00014635 ***
P62280 RPS11 57.52647066 52.53 12 12 0.971773877 0.30412568 ns
P35658 NUP214 57.48624706 11.39 19 20 1
P05387 RPLP2 57.38726497 77.39 5 7 0.989419102 0.37390097 ns
Q14019 COTL1 57.35347295 54.93 13 13 0.986562434 0.73899742 ns
P38606 ATP6V1A 57.09249818 25.93 15 15 0.914168028 0.22414745 ns
A0A024QZ63 hCG_27198 56.9992125 10.69 11 24 0.569563981 0.00015637 ***
Q9P2B4 CTTNBP2NL 56.98554575 33.02 18 18 1
Q9UNM1 EPFP1 56.95705414 78.35 5 10 0.765053527 0.02223362 *
P62263 RPS14 56.72811103 39.07 7 7 1
K4RH61 MMP14 56.59888959 29.21 15 16 0.994712485 0.82966494 ns
P62750 RPL23A 56.47088742 51.92 15 15 0.978532541 0.37390097 ns
A0A024R5H8 RAB6A 56.45994616 47.12 10 11 0.972932732 0.3596339 ns
Q16777 HIST2H2AC 56.39827549 45.74 1 7 0.731437134 0.0921685 ns
Q9BUZ3 QARS 56.35709143 30.74 18 18 0.902612172 0.17305247 ns
M0R0F0 RPS5 56.31616974 37.5 10 10 0.987672506 0.37390097 ns
A0A024R684 NUMB 56.17478538 24.83 10 16 0.576034597 0.00366492 **
P17301 ITGA2 56.08917999 19.48 5 21 0.885376832 0.17966936 ns
Q5SSJ5 HP1BP3 56.0855484 28.03 19 19 0.552343228 0.00558376 **
P61204 ARF3 56.06589961 50.28 5 9 0.840274726 0.07815589 ns
P60891 PRPS1 55.94533122 38.99 8 13 1.498604167 0.05457185 ns
Q6DD88 ATL3 55.8339932 28.28 15 15 0.783115022 0.04734504 *
P48735 IDH2 55.81786478 38.5 16 17 0.305973009 6.6671E-05 ***
O95340 PAPSS2 55.80414021 34.69 20 23 0.514667339 7.6725E-05 ***
Q96QK1 VPS35 55.80332279 23.49 17 17 1
Q6V0I7 FAT4 55.59420955 5.12 22 23 0.686706235 0.00025936 ***
A6H8X9 CEP170 55.58303642 17.05 18 25 0.95046073 0.33988271 ns
P08754 GNAI3 55.53127551 27.12 4 12 0.692309257 0.01466038 *
A0A087WZK9 EIF3H 55.49313474 30.37 13 13 0.896219047 0.08676461 ns
P23526 AHCY 55.48897183 40.74 17 18 0.98896732 0.37390097 ns
P63092 GNAS 55.36323988 37.82 14 15 0.555096471 0.00232994 **
E9PLY5 MACF1 55.16595662 14.69 1 20 0.37390097 ns
P25786 PSMA1 55.1415844 51.33 15 15 1.096877371 0.34165988 ns
P00441 SOD1 55.13517833 49.35 11 11 1
Q01546 KRT76 54.97707975 12.07 1 10 1.253827433 0.37390097 ns
Q9UBI6 GNG12 54.87138534 69.44 5 5 0.66141336 1.2781E-09 ***
A0A024R6W0 GOT2 54.6871264 30.93 15 15 0.936504956 0.37390097 ns
P32969 RPL9 54.67424583 51.04 11 11 0.949094259 0.34809735 ns
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P24534 EEF1B2 54.64591169 37.78 9 10 0.802457195 0.00019174 ***
P62140 PPP1CB 54.62626195 39.76 4 12 0.633112372 0.0014054 **
P05091 ALDH2 54.6209476 33.66 16 18 1.010752469 0.58766879 ns
Q8NE71 ABCF1 54.55142188 23.08 12 18 1
P49321 NASP 54.50300705 21.07 17 18 1.034289142 0.50904995 ns
Q53EP0 FNDC3B 54.50101805 17.69 18 18 0.840584314 0.05717431 ns
P42766 RPL35 54.44657886 40.65 7 9 0.659464045 0.04537225 *
Q86SQ0 PHLDB2 54.43464601 17.08 21 21 0.699589343 0.01867677 *
A6NKB8 RNPEP 54.38659894 28.81 16 16 0.987150055 0.37644526 ns
Q5JR08 RHOC 54.32960904 36.51 2 7 1
O94874 UFL1 54.32828367 27.08 20 21 0.741361145 0.00862425 **
P30050 RPL12 54.30472004 71.52 11 11 0.967282203 0.58248587 ns
P17252 PRKCA 54.11555743 23.66 17 17 0.889799978 0.19258112 ns
B2ZRD4 HLA-A 54.09150875 64.47 0 12 0.37390097 ns
A0A087X020 SBDS 53.9237231 42.4 14 14 0.850010327 0.11613106 ns
H0Y360 AMPD2 53.72292137 21.6 19 19 0.999910961 0.37390097 ns
P61106 RAB14 53.70713151 46.05 9 11 0.932016996 0.13526888 ns
Q9H2M9 RAB3GAP2 53.52640343 15.22 18 20 0.913252243 0.29749516 ns
V9HW35 HEL-S-55 53.49629104 73.46 9 9 0.977137415 0.37390097 ns
Q149P0 GBF1 53.44842529 10.89 19 20 1
P01024 C3 53.40967751 5.53 11 11 1.021162679 0.37390097 ns
P61221 ABCE1 53.32127237 30.88 17 17 0.740378611 0.01273382 *
E9PCX8 TNS3 53.31205976 18.32 2 18 0.528202585 0.000214 ***
E7EQV9 RPL15 53.28045535 38.51 7 7 0.909866218 0.31059942 ns
P28300 LOX 53.25587809 33.33 12 13 1.345778614 0.14269178 ns
P63313 TMSB10 53.14172328 47.73 4 7 0.910223165 0.26336129 ns
J3QR09 RPL19 53.0921526 43.01 10 11 0.918111758 0.37907824 ns
P60866 RPS20 53.03583384 36.13 5 5 0.910776223 0.22487846 ns
C9JNW5 RPL24 52.76844049 44 11 11 0.943672599 0.37390097 ns
P09211 GSTP1 52.7200886 51.9 6 8 1.009109684 0.53721847 ns
Q7Z4Y4 AK3 52.71543062 58.15 15 15 0.499991326 0.00083642 ***
H0YDQ3 LMO7 52.67328274 48.63 0 13 0.37390097 ns
O00186 STXBP3 52.52977967 25.34 18 18 0.463257106 0.00036113 ***
P62328 TMSB4X 52.49831295 45.45 2 5 1.101906251 0.259777 ns
Q9NY33 DPP3 52.48276854 27 18 18 1
Q02539 HIST1H1A 52.46477926 26.51 2 8 0.493439752 2.0467E-05 ***
Q9H3U1 UNC45A 52.43250048 22.25 19 20 1
Q9NSE4 IARS2 52.40350795 20.95 20 20 0.589934028 0.00291981 **
P62851 RPS25 52.37476993 51.2 9 9 0.981290483 0.37390097 ns
H0Y2W2 ATAD3A 52.36932242 30.42 5 16 0.551491462 0.00846754 **
P22695 UQCRC2 52.20449746 36.64 14 14 0.625844778 0.00097292 ***
Q96I24 FUBP3 52.203619 28.5 12 15 0.821607396 0.0009815 ***
A0A087WXM6 RPL17 52.17033625 49.7 8 9 0.906386516 0.04429842 *
O15020 SPTBN2 52.13056397 5.9 1 15 0.428586346 0.0345944 *
Q15008 PSMD6 52.07730579 39.85 17 17 0.83592011 0.01129006 *
Q00688 FKBP3 52.05521345 56.25 16 16 0.931068094 0.16737128 ns
P10644 PRKAR1A 52.0089519 34.91 16 16 0.690340848 0.02717431 *
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P29590 PML 51.94854689 19.73 20 20 0.68639258 0.00126634 **
P11766 ADH5 51.8630774 41.98 16 16 0.726576124 0.00528083 **
P63096 GNAI1 51.8522656 27.12 4 12 0.270018666 0.00100889 **
C5J3Z8 HLA-B 51.84000421 37.29 0 11 0.37390097 ns
P48047 ATP5O 51.76541245 53.05 11 11 0.439434207 0.00038109 ***
Q6UY14 ADAMTSL4 51.76076448 22.63 17 17 1
P02795 MT2A 51.73393738 83.61 3 5 1.048969882 0.37390097 ns
Q5T123 SH3BGRL3 51.71029365 53.41 6 6 1.011015869 0.37390097 ns
Q15459 SF3A1 51.5820365 24.59 18 19 0.709070837 0.00013575 ***
O95336 PGLS 51.55627906 50 11 11 0.902180869 0.0360574 *
A0A024R4A5 TNRC15 51.54666221 14.87 17 17 1
P08240 SRPR 51.53139424 31.97 20 20 0.972169182 0.37390097 ns
P09486 SPARC 51.496737 37.62 13 14 1.220409573 0.13174141 ns
P60763 RAC3 51.46747923 31.25 1 7 1
Q59EK6 TRAF1 51.37269521 25.75 18 19 0.854529006 0.14329674 ns
X5D2J9 GTF2I 51.36238682 19.96 22 22 0.966053505 0.21276689 ns
Q9UJU6 DBNL 51.33283067 37.21 2 16 0.893948 0.13212081 ns
O43143 DHX15 51.27046573 22.89 18 19 0.892917603 0.37390097 ns
O75822 EIF3J 51.04224706 37.21 13 13 0.849791685 0.05649969 ns
A0A024QZB7 ATXN2L 50.94420493 19.94 15 18 0.673050183 0.026839 *
Q92878 RAD50 50.94334936 13.57 20 21 1
Q9NZ56 FMN2 50.91330028 9.29 14 16 0.907556178 0.38365823 ns
P55795 HNRNPH2 50.91277802 21.38 3 8 0.877092984 0.09065494 ns
P0C0S5 H2AFZ 50.89920628 31.25 2 4 0.956170993 0.24874953 ns
P17812 CTPS1 50.8758738 27.58 13 16 0.903487079 0.38829912 ns
A0A024RBE8 SLC25A3 50.86528456 28.25 12 12 0.612472427 0.01716288 *
P60900 PSMA6 50.72527838 55.69 13 13 1.142107115 0.11686258 ns
O95202 LETM1 50.72227442 24.63 18 18 0.787465784 0.00867771 **
F8WDG7 PTK7 50.69403553 67.52 1 9 0.515829508 0.20475373 ns
Q69EZ8 F2 50.66378284 12.88 5 5 1.591765665 0.10202269 ns
P62888 RPL30 50.65268528 80 10 11 0.985917879 0.23663094 ns
P48059 LIMS1 50.64718771 42.77 8 16 0.677094564 0.00418288 **
H0YH87 ATXN2 50.55248117 15.72 1 14 1
P52926 HMGA2 50.5243094 66.06 7 7 1.038479294 0.25471755 ns
P48163 ME1 50.45949876 28.32 17 18 0.969316904 0.7350765 ns
Q8N1G4 LRRC47 50.33387148 30.53 18 18 0.735996737 0.00620477 **
P09960 LTA4H 50.279814 26.68 17 17 0.942525444 0.21343451 ns
Q70UQ0 IKBIP 50.27283776 41.14 6 16 0.4454613 0.00368744 **
Q12765 SCRN1 50.2549448 28.5 12 13 0.958266598 0.29228111 ns
P30040 ERP29 50.05826211 38.7 10 10 1
Q7L576 CYFIP1 49.91334033 17.24 21 21 0.892555397 0.14680592 ns
P49189 ALDH9A1 49.82505369 32.39 16 16 0.741784192 0.02625832 *
B7ZLP5 SAFB 49.68134356 19.04 11 18 0.650470868 0.00092558 ***
F8WB06 ATXN2 49.67337823 13.14 1 14 1
K7ELP0 TPM4 49.55998516 56.52 1 5 0.309221722 0.00225854 **
C5IWY4 HLA-A 49.55044746 42.19 1 10 1
P62879 GNB2 49.53711009 27.65 3 9 1
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F8WAE5 EIF2A 49.38209867 29.83 15 15 0.92125958 0.11611652 ns
Q14258 TRIM25 49.26485705 20.95 12 12 0.831081253 0.0022622 **
Q9BTM1 H2AFJ 49.20391834 45.74 1 7 0.37390097 ns
Q9UPN1 PPP1CC 49.191239 36.73 2 11 1
P30086 PEBP1 49.18356872 56.15 9 9 0.915134443 0.32651824 ns
H3BN98 H3BN98 49.06933033 30.8 2 9 0.982485564 0.37390097 ns
Q13151 HNRNPA0 48.94784141 39.67 10 12 0.528941327 0.00166506 **
P0C0L4 C4A 48.9421134 5.79 12 12 1.095388728 0.28240709 ns
Q9Y2W1 THRAP3 48.90342772 22.41 20 20 0.566753109 0.00023983 ***
O43237 DYNC1LI2 48.85021091 32.72 14 15 0.700655477 0.00666888 **
Q9NVD7 PARVA 48.78780818 32.8 12 13 0.494327732 0.00577176 **
Q12959 DLG1 48.70225763 16.59 18 18 0.287441636 0.00024088 ***
Q6PKG0 LARP1 48.65929294 16.61 18 18 1.003149287 0.37390097 ns
Q9HCU0 CD248 48.65883672 17.7 15 15 0.624508774 0.00012986 ***
P51148 RAB5C 48.62087655 54.17 6 9 1
P60903 S100A10 48.61609244 40.21 7 7 0.579095157 0.00826001 **
Q9NTK5 OLA1 48.58594465 34.85 15 15 0.726914594 0.06107745 ns
P62241 RPS8 48.57725084 45.67 10 10 1.003464076 0.82023295 ns
A0AVT1 UBA6 48.56148279 17.11 17 17 0.820456395 0.02098819 *
Q13443 ADAM9 48.49519193 17.22 16 16 0.916275866 0.162589 ns
Q16270 IGFBP7 48.43407822 39.01 10 10 0.806752131 3.7919E-06 ***
P30508 HLA-C 48.31305182 40.44 0 11 0.37390097 ns
Q9TP39 HLA-A 48.31213081 55.8 0 10 0.37390097 ns
P13612 ITGA4 48.24296832 14.44 3 15 0.228928286 4.2076E-09 ***
P46781 RPS9 48.2374593 46.39 9 10 0.918144129 0.26532745 ns
P14550 AKR1A1 48.2329427 38.77 12 13 0.983805594 0.23915815 ns
Q9BS26 ERP44 48.09795427 36.95 14 16 0.437114354 0.00118654 **
Q96CS3 FAF2 48.08575749 40 14 14 0.974059398 0.23380388 ns
P51153 RAB13 48.08003449 46.31 7 10 0.807558158 0.0678489 ns
Q96PK6 RBM14 47.98778677 26.16 17 17 0.804912448 0.02092911 *
P55060 CSE1L 47.93527699 19.26 20 20 0.95941512 0.60805337 ns
P40123 CAP2 47.86880088 33.54 14 16 0.945740268 0.23068888 ns
Q53T76 GPD2 47.84735334 28.28 21 21 0.840696366 0.13403209 ns
A0A024R9B9 MATN2 47.82757139 20.61 5 17 1
Q9UNF1 MAGED2 47.76969838 28.38 16 17 1.023739394 0.78355236 ns
G3V1C3 API5 47.73209763 25.88 4 15 0.953563033 0.49239996 ns
O43615 TIMM44 47.67256284 33.85 15 15 0.999024918 0.37390097 ns
P15121 AKR1B1 47.61355615 33.86 11 13 0.566500658 0.00626523 **
A7MD96 SYNPO 47.44941473 22.89 16 16 0.699141779 1.0756E-06 ***
O95831 AIFM1 47.35800362 30.02 15 15 0.868404433 0.09333656 ns
Q13162 PRDX4 47.34021091 31.37 5 8 0.982875991 0.63580852 ns
Q6P1N0 CC2D1A 47.29731548 19.98 11 19 1
Q9Y2A7 NCKAP1 47.24382257 17.02 19 19 0.940268555 0.17462941 ns
Q99988 GDF15 47.20780826 46.43 10 10 1.415212033 8.7181E-05 ***
Q13884 SNTB1 47.08775473 25.65 11 14 0.294456206 6.3251E-05 ***
P59998 ARPC4 47.07351696 46.43 9 9 0.970171995 0.6361694 ns
Q29941 HLA-B 47.00357294 35.36 0 10 0.37390097 ns
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P30084 ECHS1 47.00141549 34.48 12 12 0.870583509 0.13484048 ns
P52565 ARHGDIA 46.94182479 38.73 9 10 1
P04908 HIST1H2AB 46.72073638 45.38 3 7 0.762170275 0.00836016 **
P07205 PGK2 46.68982649 20.86 3 9 1.308111615 0.12983146 ns
P11177 PDHB 46.6073451 31.48 10 10 1
Q9NQW7 XPNPEP1 46.55747342 30.66 17 18 0.954661177 0.25275075 ns
A5PLK9 BMP1 46.53188252 15.52 1 16 1.186191406 0.11722647 ns
A0A024R1X8 JUP 46.52573717 23.09 10 15 1.069938587 0.37390097 ns
O43865 AHCYL1 46.46072161 24.72 6 14 0.614107991 4.3981E-05 ***
P52597 HNRNPF 46.41823602 26.02 7 9 0.587847371 0.00089195 ***
A0A087WT27 PGM3 46.37391996 35.15 15 15 0.880651344 0.21083169 ns
Q16222 UAP1 46.36514473 27.78 15 16 1.652185026 0.06518617 ns
Q9Y570 PPME1 46.31808579 29.02 10 10 0.984982815 0.37390097 ns
P46060 RANGAP1 46.29634714 31.52 16 16 0.975389536 0.14721814 ns
Q32MZ4 LRRFIP1 46.27118349 20.42 9 15 1.15468095 0.50576551 ns
O15143 ARPC1B 46.14720845 35.48 13 13 0.634459459 0.00591369 **
A0A087X142 SEPT8 46.14164221 21.6 5 10 0.910986742 0.17552168 ns
P28074 PSMB5 46.11973429 42.21 11 11 1.021738569 0.37390097 ns
P61254 RPL26 46.10200632 41.38 10 10 0.954737177 0.15947082 ns
Q9BZQ8 FAM129A 46.10091889 14.76 14 15 0.368955807 0.00068762 ***
E9PQN2 BCLAF1 46.08865809 20.8 17 17 0.644371452 0.00024955 ***
Q9UNZ2 NSFL1C 46.06525254 51.08 14 14 0.688664809 0.00197665 **
A0JP02 PLEKHA5 45.88302374 18.99 15 15 0.830350785 0.00155062 **
P16104 H2AFX 45.73803914 27.97 3 6 1
O00203 AP3B1 45.73786879 16.54 9 17 0.975135602 0.24634324 ns
Q86VS8 HOOK3 45.70362043 22.84 16 16 0.871732455 0.18171802 ns
Q99536 VAT1 45.70052016 42.24 13 13 0.732371286 4.3627E-05 ***
Q9NUQ6 SPATS2L 45.6329608 32.62 9 16 0.861299058 0.01040891 *
Q10471 GALNT2 45.57180119 28.72 16 17 1.295719369 0.26836092 ns
Q14554 PDIA5 45.49527025 25.82 14 14 0.690208932 0.03528473 *
P11233 RALA 45.44930482 39.81 6 9 0.489327262 0.0013934 **
B4DXZ6 FXR1 45.42475653 22.53 6 15 0.970619746 0.73013506 ns
Q6FG43 FLOT2 45.34750116 45.91 20 20 0.654202233 0.02678532 *
P35442 THBS2 45.32183862 15.53 13 14 0.695887722 2.6644E-62 ***
Q2VIN3 RBM1 45.23089242 29.43 1 14 0.37390097 ns
Q15393 SF3B3 45.1824857 15.53 17 18 0.817635635 0.09083912 ns
D3DTX6 PPP1R9B 45.15600061 21.79 16 17 0.644558428 0.00113531 **
Q15907 RAB11B 44.96240675 53.67 12 12 0.955838413 0.14052596 ns
P48634 PRRC2A 44.94246209 9.5 16 18 1
A0A024R895 SET 44.88794661 24.55 7 7 0.745977665 0.00862539 **
A0A024R4S2 PPP1R12C 44.85051787 24.55 16 16 0.95474838 0.11611652 ns
Q2NL95 DDX19B 44.81078255 30.07 1 13 0.37390097 ns
B4DMT5 EIF3F 44.72898602 29.97 9 9 1
O14776 TCERG1 44.62925851 14.03 15 16 0.920624249 0.43285563 ns
P51610 HCFC1 44.60116959 8.65 16 16 0.876033559 0.01313073 *
P02765 AHSG 44.5839479 8.72 5 5 1.263322754 0.20772953 ns
Q6MZK8 DKFZp686K06110 44.54119802 5.53 1 14 1
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P49419 ALDH7A1 44.52443981 28.94 14 14 0.827764726 0.15239437 ns
B4DY09 ILF2 44.51126218 24.43 9 9 0.810313647 0.01542413 *
Q9UKS6 PACSIN3 44.51007676 36.56 14 14 0.896677336 0.12607459 ns
Q5QPL9 RALY 44.48062801 52.32 13 13 0.83853914 0.15944481 ns
P10319 HLA-B 44.46111727 34.53 0 9 0.37390097 ns
P27487 DPP4 44.428339 16.19 15 15 0.385818016 0.00035165 ***
Q0VGA5 SARS 44.39580715 26.42 14 14 0.630492744 0.022755 *
A6H8W6 SIPA1L1 44.33826339 10.32 17 17 1
A6NNK5 TP53BP1 44.32428718 11.62 17 17 1
E7EMF1 ITGA2 44.25434208 24.17 1 17 0.885498003 0.12119474 ns
Q15056 EIF4H 44.11675322 38.31 10 10 0.969219566 0.24121388 ns
Q5T9W8 HSP90AB1 44.08511484 38.69 1 8 1
E7EV99 ADD1 44.0591805 26.58 15 15 0.494344044 0.00025027 ***
P17096 HMGA1 44.00474858 33.64 4 4 1.085447869 0.22342511 ns
Q9HDC9 APMAP 43.98139071 23.32 12 12 0.801389211 0.09546914 ns
O75368 SH3BGRL 43.97217572 51.75 8 8 0.869083214 0.09196913 ns
P29536 LMOD1 43.93568313 21.83 16 16 0.969877824 0.37390097 ns
Q29940 HLA-B 43.93099082 29.83 0 8 0.37390097 ns
Q63HN8 RNF213 43.9303956 3.4 17 17 1
O94855 SEC24D 43.90003228 19.77 19 19 0.976707321 0.67920702 ns
Q96CV9 OPTN 43.89511907 24.61 14 14 0.872958381 0.03364671 *
C3VMY8 CRYAB 43.87130475 42.86 9 9 13.61069539 0.00690306 **
A0A087WSV8 DCAF5 43.85815263 32.38 14 14 0.870079517 0.1191283 ns
A0A024RB48 TENC1 43.78991103 15.64 14 17 0.958258431 0.04227135 *
P84085 ARF5 43.72943306 48.33 4 8 0.735519527 0.02893688 *
Q9NZW5 MPP6 43.71386576 30.19 13 15 0.507896671 3.1273E-05 ***
P14735 IDE 43.69811916 15.11 15 15 0.985650805 0.24180094 ns
Q92804 TAF15 43.54660571 30.74 8 12 0.647670815 0.00390974 **
A6NLN1 PTBP1 43.50396001 24.86 10 14 0.434748939 0.00023863 ***
P31930 UQCRC1 43.50361276 28.96 11 12 0.913636236 0.11611652 ns
Q9BR76 CORO1B 43.50304484 31.9 16 16 0.769926582 0.04321456 *
P31153 MAT2A 43.40812063 29.87 13 14 0.969687115 0.14790899 ns
P48637 GSS 43.37692845 29.96 14 14 0.897919274 0.38378011 ns
A0A075B730 EPPK1 43.33674729 7.54 1 9 0.696074947 0.41764485 ns
A0A024R3J7 hCG_2032701 43.24754381 17.64 12 14 0.619120105 0.0201486 *
H0Y5B0 EPB41L2 43.18641162 30.53 2 12 0.848480789 0.10664628 ns
P13073 COX4I1 43.14111805 41.42 9 9 0.617905548 0.00047485 ***
K7EIV0 CAPNS1 43.09474874 35.2 8 8 0.773187848 0.01807536 *
Q13442 PDAP1 43.07516909 49.17 11 11 0.723725532 0.00873176 **
P36957 DLST 43.03335464 24.5 11 11 0.746633554 0.00546615 **
A7E2F7 CLIP2 42.98899627 14.34 10 14 1
Q15155 NOMO1 42.8519845 11.54 13 13 0.574568789 0.00020632 ***
Q14344 GNA13 42.82661653 31.03 9 11 0.773994837 0.00046464 ***
Q2M2I8 AAK1 42.76971245 15.82 12 12 0.922310586 0.26853535 ns
Q06124 PTPN11 42.76725888 26.97 16 17 1
E7EQT4 ACIN1 42.76008403 12.99 6 16 0.833631188 0.31471765 ns
Q13724 MOGS 42.69714975 21.39 16 16 0.966930325 0.1360964 ns
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O95373 IPO7 42.66823649 14.16 11 12 0.90697424 0.14663342 ns
G3XAJ6 RFTN1 42.62381887 25.83 1 15 0.507179489 0.03191806 *
P21964 COMT 42.48347259 34.32 10 10 0.923319621 0.04886261 *
Q9HD26 GOPC 42.47546029 25.32 13 13 0.769439537 0.00170875 **
P10155 TROVE2 42.44148886 24.54 14 14 1.14308157 0.28143729 ns
Q7L1Q6 BZW1 42.43539357 26.01 13 13 0.974053785 0.47021122 ns
Q9BQS8 FYCO1 42.42522144 11.64 15 17 1
E5RHW4 ERLIN2 42.42228079 41.12 10 15 1
Q9UNF0 PACSIN2 42.42099833 27.78 16 16 0.922679033 0.06134363 ns
A6H591 HLA-A 42.4200424 47.99 0 10 0.37390097 ns
Q8TD55 PLEKHO2 42.39681935 23.27 14 14 0.389612885 0.00081104 ***
P51572 BCAP31 42.28150034 32.11 12 13 0.484865653 0.00021317 ***
O43633 CHMP2A 42.271065 38.74 10 11 0.979040941 0.14114463 ns
P13798 APEH 42.22582221 19.67 14 14 0.969897354 0.49091344 ns
D3DUJ0 AFG3L2 42.09403348 17.26 15 16 0.678634032 0.00982639 **
P30493 HLA-B 42.08456528 29.56 0 8 0.37390097 ns
P09496 CLTA 42.04541266 29.03 10 11 0.84136751 0.07485487 ns
P62081 RPS7 42.03246546 34.54 10 10 0.972911717 0.37390097 ns
P28066 PSMA5 41.91897345 39 8 8 0.817141103 0.31227676 ns
E9PNW4 CD59 41.91281176 29.63 4 4 0.967318693 0.37390097 ns
P17174 GOT1 41.76369405 27.12 12 12 0.906131187 0.44274271 ns
Q9ULT8 HECTD1 41.72650981 6.63 15 16 1
Q9NR45 NANS 41.67264307 39 10 14 1
Q9UM54 MYO6 41.66956961 10.12 13 13 1
Q14677 CLINT1 41.50658059 20.48 12 12 1
Q05DH1 PSMA7 41.46153164 42.86 10 10 1
Q8TD16 BICD2 41.39714658 16.14 14 14 1
P12259 F5 41.3907187 5.49 13 13 1
A0A087WXK9 TRIP11 41.38892031 8.8 17 19 1
Q15121 PEA15 41.31657529 47.69 6 6 0.984518684 0.7009085 ns
Q9BWM7 SFXN3 41.28382051 38.15 10 11 0.746003189 0.10636577 ns
Q7Z478 DHX29 41.27651775 14.54 17 19 0.850588178 0.18990992 ns
Q9Y6G9 DYNC1LI1 41.25989652 33.27 13 14 0.911253699 0.2398422 ns
P21266 GSTM3 41.16396642 53.78 11 13 0.501260328 0.00488581 **
G3V0I5 NDUFV1 41.15685606 26.04 14 14 0.6044763 0.00090704 ***
Q99584 S100A13 41.12758946 48.98 6 6 0.915978937 0.34389058 ns
P30479 HLA-B 41.09264648 27.07 0 8 0.37390097 ns
Q9NQR4 NIT2 41.00511265 53.99 14 14 0.72784967 0.0075592 **
Q9H7C4 SYNC 40.94234562 25.31 13 13 1.009549403 0.96030129 ns
Q15113 PCOLCE 40.91448069 36.3 13 13 0.614468659 0.00172301 **
P15153 RAC2 40.82555056 37.5 4 8 0.865814265 0.16156682 ns
P46937 YAP1 40.80094123 34.33 12 12 1
O95865 DDAH2 40.79659462 47.72 12 13 0.838618334 0.06389446 ns
Q9UKY7 CDV3 40.79029465 61.24 9 9 0.801619865 0.10666968 ns
O14980 XPO1 40.75293708 11.11 12 12 0.963075224 0.57239174 ns
Q08209 PPP3CA 40.70726514 22.26 5 11 0.783025666 0.07446716 ns
P29373 CRABP2 40.70422423 64.49 11 11 0.223437339 3.1206E-05 ***
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Q68J68 HLA-B 40.64322758 32.64 0 9 0.37390097 ns
Q68D38 DKFZp686O15119 40.63025892 28.97 5 9 0.840338268 0.11037556 ns
P84095 RHOG 40.56979227 35.6 8 9 0.620320895 0.00116401 **
A0A024R7S3 CLTB 40.56480575 37.44 11 11 0.514759721 0.00631006 **
A0A024R2W4 DAG1 40.54068494 14.64 12 12 0.492040249 8.0214E-05 ***
Q96HI4 NMT1 40.53281403 25.91 10 14 0.819079036 0.00705189 **
J3QL06 HYOU1 40.51090455 53.55 1 11 1
H0UI49 LAMA4 40.50789905 8.7 16 16 0.811504553 #DIV/0! #DIV/0!
P61020 RAB5B 40.50458288 47.91 5 8 0.960493791 0.11611652 ns
Q14978 NOLC1 40.48645091 16.74 14 14 0.759981145 5.941E-07 ***
Q9H6S3 EPS8L2 40.47226071 20.42 14 14 0.818840822 3.2935E-06 ***
Q9UJ70 NAGK 40.46573639 38.66 13 13 0.985325227 0.37390097 ns
Q9ULH1 ASAP1 40.43743002 14.44 15 16 0.887584176 0.12595486 ns
A0A024R172 LTB4DH 40.42788911 30.09 12 12 0.662470134 0.00531329 **
O15173 PGRMC2 40.37809491 33.63 8 10 1
P49207 RPL34 40.37689829 46.15 8 8 1
P49773 HINT1 40.35333216 64.29 7 7 0.679405166 0.00069076 ***
A0A024RAI6 BIN1 40.29622483 28.36 11 13 0.668478256 0.00047291 ***
E4W6B6 RPL27 40.2693069 57.14 8 9 0.978289057 0.82174207 ns
Q04760 GLO1 40.2578696 39.13 11 11 0.864255384 0.00845697 **
P21281 ATP6V1B2 40.23532283 27.59 14 14 0.703633661 0.06945356 ns
P19022 CDH2 40.2272321 18.21 13 13 0.893717719 0.1273368 ns
M0R3D6 RPL18A 40.16166425 46.81 7 7 1.031205363 0.37390097 ns
Q15654 TRIP6 40.15808272 36.13 13 14 0.872584163 0.00027939 ***
Q6IBS0 TWF2 40.13458419 43.84 10 14 0.893674505 0.08901051 ns
P46087 NOP2 40.12695456 16.87 11 15 0.701590796 0.00477721 **
F8W1A4 AK2 40.08463514 43.53 10 10 1
Q9UKK3 PARP4 40.03951192 8.24 14 15 1
O75094 SLIT3 39.97249687 8.6 13 13 0.766565621 2.3504E-06 ***
P62316 SNRPD2 39.9497689 66.95 9 9 1.010830119 0.30759376 ns
P23193 TCEA1 39.89303684 44.52 13 13 1
F5GYN4 OTUB1 39.89160371 46.89 11 11 0.995571491 0.37390097 ns
P09429 HMGB1 39.84018826 46.98 8 11 0.643712782 0.00075937 ***
C9JFR7 CYCS 39.69723105 41.58 6 6 0.748649721
Q7L014 DDX46 39.69667959 13.77 16 16 0.684166959 0.00104065 **
A6NGP5 HN1L 39.69634461 73.03 11 11 0.862320484 0.04290513 *
P48426 PIP4K2A 39.68686366 27.59 5 11 0.567786011 0.01069362 *
O15400 STX7 39.63655674 34.87 8 9 0.666208471 0.00678911 **
G3V3M6 APEX1 39.6107893 35.74 11 11 0.77916485 0.03150574 *
Q13011 ECH1 39.54004049 34.15 11 11 0.943579636 0.1150547 ns
Q9Y5M8 SRPRB 39.52865422 47.97 13 13 0.94790741 0.26737304 ns
Q13347 EIF3I 39.48833692 32.31 11 11 1
Q5T9B9 ENG 39.45841646 21.92 7 12 0.676624957 0.00078892 ***
O75347 TBCA 39.38171625 73.15 12 12 0.99941741 0.9645169 ns
Q9Y680 FKBP7 39.32089436 42.08 11 11 0.617794735 0.00012452 ***
Q15262 PTPRK 39.31468773 12.65 14 14 1
Q92888 ARHGEF1 39.31168079 17.11 14 14 0.624733196 0.03305859 *
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Q01650 SLC7A5 39.30803335 8.09 4 4 0.892966974 0.16777125 ns
Q00169 PITPNA 39.26889062 41.11 10 13 1
B7Z7P8 ETF1 39.24925613 30.5 13 13 0.99980057 0.9990605 ns
O95292 VAPB 39.23873591 37.45 8 9 0.482090166 0.00202431 **
B5BU01 EIF2S2 39.17231631 36.34 11 11 0.919462695 0.18991243 ns
Q13136 PPFIA1 39.12281847 17.14 17 18 0.725334908 0.00120514 **
Q16543 CDC37 39.08455348 38.89 17 17 0.85636781 0.14297658 ns
G0KXI4 HLA-A 39.08005857 47.51 0 9 0.37390097 ns
O94813 SLIT2 39.07223237 10.6 14 14 0.937779019 0.11611652 ns
Q13838 DDX39B 39.03401434 26.4 5 14 0.66346105 0.02472171 *
M4QFU4 HLA-B 38.94090307 28.45 0 8 0.37390097 ns
P10768 ESD 38.94006443 27.66 9 9 0.898928367 0.34661759 ns
P28161 GSTM2 38.92908716 60.55 7 14 1
A5YKK6 CNOT1 38.91231656 5.93 14 14 1
F8VU51 YLPM1 38.85337913 9.79 2 14 1
H3BR35 GSPT1 38.81044698 25.68 8 16 0.590282269 0.00283545 **
P56159 GFRA1 38.78332829 22.15 13 13 0.264565692 0.00019757 ***
O95479 H6PD 38.75012958 20.48 15 15 0.990619882 0.11611652 ns
Q96J84 KIRREL 38.72193217 21.14 11 11 0.995251085 #DIV/0! #DIV/0!
B4DQF6 EIF3L 38.68029928 20.53 12 12 0.740801945 0.08745421 ns
P16989 YBX3 38.64552367 25.27 2 8 1
O75937 DNAJC8 38.53723001 38.74 10 10 0.926590212 0.10195842 ns
P18463 HLA-B 38.51033103 29.83 0 8 0.37390097 ns
Q9NX63 CHCHD3 38.48989534 43.17 13 13 0.675223065 0.00118134 **
Q8IWE2 FAM114A1 38.44893217 24.87 13 13 0.733125838 0.01547153 *
F1T0I1 SEC16A 38.36507297 7.28 14 14 0.71221153 0.00476385 **
Q99733 NAP1L4 38.35773933 23.73 10 11 0.781285838 0.00820579 **
Q7YQB3 HLA-Cw 38.32414222 31.69 0 10 0.37390097 ns
P50148 GNAQ 38.31048357 37.05 8 14 0.638957976 0.0067195 **
P21399 ACO1 38.28525376 16.42 16 16 0.732523919 0.00970213 **
Q5JWQ6 NRP1 38.27474332 20.95 13 13 1
H0Y9J2 CAMK2D 38.26421142 46.7 1 10 0.740811431 0.02341707 *
Q99714 HSD17B10 38.21370554 61.69 11 11 1
B8YBG3 HLA-Cw 38.20128965 30.6 0 10 0.37390097 ns
Q9NRV9 HEBP1 38.18284059 61.9 10 10 0.438676145 1.7998E-05 ***
Q16630 CPSF6 38.17254019 23.41 12 12 0.998199568 0.37390097 ns
B4E1L0 ADSS 38.14500391 24.6 12 12 0.974215666 0.3236772 ns
P49750 YLPM1 38.12407196 8.15 2 14 0.500387595 0.06866765 ns
Q07960 ARHGAP1 38.0465281 25.97 11 11 0.85892186 0.16693356 ns
A0A024RDA1 EXOC1 38.00639331 17.18 16 16 0.702336147 0.02387646 *
Q9Y263 PLAA 37.97602439 21.76 14 14 0.849554763 0.26521282 ns
O75976 CPD 37.96614945 11.81 16 16 0.929556106 0.11611652 ns
Q16698 DECR1 37.93008065 33.43 10 10 0.657683534 0.00421513 **
Q96C19 EFHD2 37.86658776 44.17 9 11 0.875656551 0.31671098 ns
P18754 RCC1 37.82595682 26.84 7 8 0.90314291 0.00037887 ***
P62857 RPS28 37.80447829 52.17 4 4 0.893308247 0.26612473 ns
P30492 HLA-B 37.79426706 27.9 0 7 0.37390097 ns
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Q4LE74 MYO9B 37.72695553 8.58 16 17 1
Q9BPW0 PPP5C 37.70646691 24.59 13 13 1
P61201 COPS2 37.70282662 27.54 13 13 0.820329408 0.00359953 **
Q9HC35 EML4 37.69406378 15.8 14 14 0.870418338 0.05004916 ns
P26440 IVD 37.6847229 26.48 11 11 0.392530781 3.6894E-05 ***
Q3B7X1 TMX3 37.67374766 28.37 11 12 0.723571788 0.06371385 ns
Q01970 PLCB3 37.622365 12.97 14 14 0.829319778 0.00102905 **
O75367 H2AFY 37.54600334 31.18 9 9 0.730032012 0.00242527 **
O75828 CBR3 37.53661132 44.4 8 12 0.94341426 0.52541927 ns
P46063 RECQL 37.44352973 17.87 12 12 0.984564919 0.28647107 ns
Q7Z417 NUFIP2 37.40804482 21.01 11 11 1
P55809 OXCT1 37.2924211 32.69 15 15 0.88738257 0.37142684 ns
E9PHK0 CLEC3B 37.2220782 27.5 3 3 1.013309244 0.60391156 ns
O75935 DCTN3 37.21798253 40.32 11 11 0.858245527 0.11092837 ns
Q6FH24 VBP1 37.06200898 61.25 11 12 1
Q9Y639 NPTN 37.02808011 21.11 9 9 0.685950453 0.00184236 **
B2RNR6 ZFR 37.01314867 14.62 17 17 0.67609775 0.04742109 *
P08237 PFKM 37.00428987 18.21 12 16 1.008633029 0.37390097 ns
P20339 RAB5A 36.9792254 53.95 6 9 0.901467413 0.11023312 ns
D6RD46 LIMCH1 36.91343713 16.12 14 14 0.629240657 5.6502E-06 ***
Q53FA7 TP53I3 36.88733029 34.04 12 12 0.848037451 0.2422022 ns
Q9UDY4 DNAJB4 36.87416172 35.91 9 11 1.06418037 0.37390097 ns
P27361 MAPK3 36.8468678 28.76 7 11 0.828842286 0.15296846 ns
Q9UQN3 CHMP2B 36.83947742 34.27 9 9 0.640200316 2.2115E-05 ***
P50402 EMD 36.82394528 39.37 9 9 0.827954945 0.00268476 **
O76021 RSL1D1 36.79170775 21.84 12 12 0.717829768 0.01437377 *
O15230 LAMA5 36.72321939 5.3 14 14 1
B7ZKY2 CASK 36.71524763 14.94 13 14 0.522711357 0.00016068 ***
Q3B7K3 IKIP 36.65045285 35.96 1 11 3.045974528 0.12130282 ns
Q8NBJ5 COLGALT1 36.59585333 23.15 17 17 0.877969869 0.25559745 ns
A0A087WYK8 NRD1 36.58415294 10.54 11 11 0.944746712 0.54094269 ns
O95747 OXSR1 36.58006597 28.27 12 12 1
P30519 HMOX2 36.55791831 35.13 11 11 0.977521865 0.37390097 ns
Q8IX12 CCAR1 36.4938395 9.83 13 13 0.81250569 0.01219521 *
P00813 ADA 36.46246672 31.68 11 11 0.927270428 0.37390097 ns
P46778 RPL21 36.4509064 40 8 9 0.900450976 0.26298646 ns
H7C597 SND1 36.43320131 46.75 1 10 0.37390097 ns
Q9BXP5 SRRT 36.40180945 15.41 14 14 1
Q15843 NEDD8 36.36421156 40.74 5 5 0.89627649 0.38273167 ns
A0A024RAD5 DDOST 36.33711243 22.81 11 11 1
Q8IWJ2 GCC2 36.32789564 5.82 10 13 0.958728634 0.23438059 ns
J3KQ45 TGOLN2 36.29591405 31.5 15 15 0.454972844 0.00053909 ***
Q02218 OGDH 36.29217255 12.61 13 13 1
P22061 PCMT1 36.28618109 44.93 10 10 0.709472765 0.01351101 *
O76031 CLPX 36.26699138 18.8 11 11 1
P54709 ATP1B3 36.2521255 32.97 12 12 0.553628532 5.7532E-07 ***
Q8IVL6 LEPREL2 36.23539531 16.58 6 12 1.010171071 0.37390097 ns
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Q9H0B6 KLC2 36.23285437 21.06 9 12 1
S4R3N1 HSPE1-MOB4 36.20700622 23.75 3 8 1
O00487 PSMD14 36.19867301 26.13 9 9 0.980911542 0.37390097 ns
P30487 HLA-B 36.16809535 28.18 0 8 0.37390097 ns
P62269 RPS18 36.08852911 53.29 11 11 0.944078943 0.41243668 ns
Q14669 TRIP12 36.01521266 8.48 14 15 0.972802279 4.4169E-06 ***
P61764 STXBP1 35.94871616 25.93 16 16 0.950121291 0.28946605 ns
P61019 RAB2A 35.93903661 41.98 3 9 0.995379034 0.86906191 ns
O94804 STK10 35.92545891 15.19 15 16 0.68111504 0.00016834 ***
P35625 TIMP3 35.89544201 41.71 10 10 0.281881727 0.00042501 ***
D6RAN1 PDLIM7 35.89337945 45.56 1 5 0.818877161 0.47762021 ns
Q9Y277 VDAC3 35.83217454 21.91 6 7 1
A1X283 SH3PXD2B 35.71404493 13.5 11 12 1.506136953 0.1545606 ns
P20674 COX5A 35.68738317 30.67 7 8 0.488815133 0.00014846 ***
P25788 PSMA3 35.68648136 34.9 10 10 1.282467621 0.09300899 ns
P36543 ATP6V1E1 35.65825045 34.96 10 11 1
Q9BRK5 SDF4 35.648579 28.45 10 10 0.689414863 0.00692578 **
P51116 FXR2 35.59006166 20.36 9 12 1.019364904 0.37390097 ns
Q14151 SAFB2 35.58292007 17.21 7 14 0.466738053 0.00025661 ***
Q99961 SH3GL1 35.49360704 30.43 12 12 0.947833342 0.18739332 ns
B3LEU8 TMEM214 35.41569865 15.9 12 12 0.94985529 0.25140792 ns
A0A087WXM8 BCAM 35.38511276 24.66 12 12 1
O75962 TRIO 35.38291037 5.33 13 14 1.063160074 0.13420159 ns
O15511 ARPC5 35.3617177 56.95 8 9 0.791404021 0.065982 ns
H0YN26 ANP32A 35.34737539 51.98 5 11 0.919013135 0.37838107 ns
P52948 NUP98 35.34142947 8.04 15 15 0.930039837 0.31059151 ns
Q9UHX1 PUF60 35.31169331 17.89 6 12 0.826571936 0.00439774 **
Q08397 LOXL1 35.26627958 21.08 11 12 1.0091834 0.87130113 ns
Q71UH4 TOP2B 35.26564455 13.27 16 20 1
P55010 EIF5 35.24485135 27.15 11 11 0.593452066 0.00176889 **
R4GMR5 PSMD8 35.22147179 39.37 11 11 0.922593856 0.30663315 ns
P55036 PSMD4 35.21575117 27.06 9 9 0.803136432 0.04611662 *
Q6LEU0 STX12 35.16597772 31.6 8 8 1
Q5JSH3 WDR44 35.1481694 13.91 12 12 1.288244344 0.2000105 ns
C1ICA6 HLA-B15 35.14748669 49.45 0 8 0.37390097 ns
F8W020 NAP1L1 35.10179806 40.1 6 7 1
Q8IUE6 HIST2H2AB 35.08166587 24.62 1 4 0.758505667 0.02028686 *
Q96AQ6 PBXIP1 34.95911849 18.19 1 12 0.820673095 0.39762042 ns
Q96BS4 FBL 34.95245385 34.23 10 10 0.623181733 0.01887451 *
Q9NQC3 RTN4 34.9193399 11.83 9 9 0.913768699 0.16520517 ns
Q96CT7 CCDC124 34.90507567 47.09 14 14 0.831718559 0.14841177 ns
P83111 LACTB 34.89280462 19.93 9 13 0.55470373 0.01676217 *
A0A087WTA5 EIF2B4 34.88427234 25.19 12 12 0.890435357 0.21140957 ns
P23368 ME2 34.86597073 22.09 11 12 0.987986383 0.37390097 ns
Q9H0A0 NAT10 34.82051051 11.32 11 11 1
P18031 PTPN1 34.81796718 31.03 13 13 1
A0A075B7B1 SYNM 34.796018 11.33 15 15 1
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Q13619 CUL4A 34.71892738 14.89 3 14 0.704483525 0.05152424 ns
Q15717 ELAVL1 34.6656363 38.65 11 11 0.902851825 0.13002695 ns
P12429 ANXA3 34.65826714 35.6 12 12 0.458495623 6.146E-05 ***
O78052 HLA-B 34.62335372 45.05 0 8 0.37390097 ns
Q8N766 EMC1 34.61989522 16.01 14 14 0.859103692 0.30435446 ns
A0A024R588 SF1 34.60271907 17.88 8 10 1
O00161 SNAP23 34.597561 47.87 12 12 0.642858297 0.00023869 ***
O43252 PAPSS1 34.55141354 21.63 10 13 0.702164402 0.003711 **
Q9UHN6 TMEM2 34.54940152 9.62 12 13 1
B5BU25 U2AF2 34.46636939 17.62 9 9 1
O78107 HLA-B 34.43732238 45.86 0 8 0.37390097 ns
P23743 DGKA 34.34795976 21.22 13 14 0.987361571 0.37390097 ns
P20618 PSMB1 34.34557581 45.64 9 9 1.241540747 0.10980009 ns
P19784 CSNK2A2 34.33360767 33.14 8 10 1
Q15435 PPP1R7 34.29205441 39.72 13 13 0.858775977 0.226592 ns
Q9UBU2 DKK2 34.27613211 32.05 6 8 0.329176768 0.00050342 ***
O43765 SGTA 34.24206018 33.87 10 10 0.992477365 0.77131373 ns
Q9H845 ACAD9 34.23251629 18.2 12 12 0.785916437 0.01222538 *
Q9HA77 CARS2 34.21666133 22.34 12 12 0.575974009 0.01047478 *
Q9BXF6 RAB11FIP5 34.20077395 22.36 11 11 0.848807367 0.05303019 ns
P01111 NRAS 34.18649459 46.03 4 8 0.424594712 0.02406746 *
Q8N3D4 EHBP1L1 34.15987122 8.86 10 11 0.901516643 0.11611652 ns
Q8TCS8 PNPT1 34.15618944 16.22 13 13 0.85559594 0.00819027 **
P63167 DYNLL1 34.04350185 51.69 4 5 0.954551845 0.10288631 ns
P62266 RPS23 34.04060912 38.46 7 8 0.99822825 0.57812985 ns
O75964 ATP5L 34.03338981 51.46 6 7 0.702598148 0.04004333 *
I2G9F9 HLA-C 34.01034117 30.38 0 9 0.37390097 ns
A0A024RAV4 CSDA 33.9701587 30.69 1 7 0.917772567 0.37390097 ns
Q9NRX4 PHPT1 33.95712972 58.4 8 8 0.882704001 0.11856589 ns
Q9Y2X3 NOP58 33.92920351 21.17 10 10 0.663828224 0.02488897 *
Q9Y371 SH3GLB1 33.87978542 26.58 8 11 0.599517043 0.00866765 **
I6L9E8 FAM98A 33.86326241 17.57 6 9 0.986342472 0.37390097 ns
Q15185 PTGES3 33.85357583 40 8 8 0.77380957 0.0094423 **
P31937 HIBADH 33.83994567 33.04 9 9 1
Q08379 GOLGA2 33.82613301 13.87 7 13 1.012653685 0.11611652 ns
A0A075B6E5 ENAH 33.75945938 35.21 1 8 0.921213942 0.37390097 ns
E9PKG1 PRMT1 33.73755598 28 10 10 1.120757662 0.27655049 ns
E7EU96 CSNK2A1 33.73114073 29.09 9 11 0.882577327 0.03191678 *
P00568 AK1 33.7161243 56.19 10 11 0.81585049 0.11543259 ns
A0A024R1M8 APOL2 33.69489741 32.05 11 11 0.542382236 0.00282095 **
O15439 ABCC4 33.6687274 8.08 10 12 0.673245366 6.1359E-07 ***
P14543 NID1 33.6431427 13.87 13 14 0.981016628 0.11611652 ns
Q02252 ALDH6A1 33.58657932 25.98 13 14 0.884371608 0.00010801 ***
Q52LJ0 FAM98B 33.55148315 28.48 6 9 1
Q9UG63 ABCF2 33.54568052 18.62 12 12 0.910169018 0.01105055 *
Q15042 RAB3GAP1 33.5342412 13.25 11 11 0.978958076 0.48796064 ns
Q9BQG0 MYBBP1A 33.5319289 10.02 13 13 0.863012665 0.10479325 ns
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Q14161 GIT2 33.52923203 15.15 8 11 0.640873942 0.00218871 **
P31040 SDHA 33.46666574 17.62 11 11 0.608207423 0.00012624 ***
Q8N1N4 KRT78 33.41636229 13.46 5 8 1
B4E2V5 STOM 33.35067201 42.62 9 9 1
O94776 MTA2 33.2452327 19.61 13 14 0.966295692 0.37390097 ns
Q9Y608 LRRFIP2 33.11669898 15.81 9 11 0.696364813 0.00018567 ***
Q16666 IFI16 33.10602188 14.27 7 10 0.905688783 0.08736719 ns
Q9UIW2 PLXNA1 33.09642684 7.07 11 15 0.776945264 3.6227E-06 ***
A0A087WUQ6 GPX1 33.09416986 42.57 8 8 0.479754961 0.00078733 ***
Q9Y3P9 RABGAP1 33.08035707 12.16 9 12 1.063585126 0.43249543 ns
I3L0A0 TMEM189-UBE2V1 33.07650757 27.3 8 12 0.930052091 0.35813776 ns
A0A024R326 RPL29 33.06718278 30.57 7 7 0.75256729 0.00025042 ***
Q8N556 AFAP1 33.06712031 13.84 11 12 0.970047345 0.63465884 ns
D3DVW9 PTPNS1 33.06115675 28.37 12 12 1.48767128 0.04372223 *
E9PHV5 SSFA2 33.05424154 11.48 14 14 1
O75475 PSIP1 32.97928357 18.87 11 12 1
Q5VYK3 ECM29 32.97018158 8.78 14 14 0.94456831 0.13147887 ns
P30038 ALDH4A1 32.92073572 24.33 13 13 0.689143127 0.00041975 ***
J3KN29 PSMD9 32.90214324 40.09 9 9 0.987012691 0.37390097 ns
O95433 AHSA1 32.88024354 33.73 12 12 0.938113323 0.28208584 ns
P10599 TXN 32.80686855 51.43 7 7 0.327078214 0.00088185 ***
Q9BRK3 MXRA8 32.79612005 29.64 12 12 0.882169065 0.20535872 ns
Q6UVY6 MOXD1 32.75838935 17.62 12 12 0.236258518 5.7282E-05 ***
P61587 RND3 32.7560823 27.87 7 7 0.347930678 5.1559E-05 ***
Q53S54 CUL3 32.71317005 14.08 11 12 1
A0A087WUM2 LDHAL6A 32.71101344 10.3 1 3 1.090635128 0.67896062 ns
D6RB85 CANX 32.67939365 51.39 1 9 0.746649124 0.341356 ns
Q08J23 NSUN2 32.65332437 18.38 13 13 1
C5IWY9 HLA-A 32.64860404 33.7 0 9 0.37390097 ns
Q8N3C0 ASCC3 32.63950157 4.59 3 12 0.719155563 0.09376316 ns
F2Z2V0 CPNE1 32.62105513 16.89 10 10 0.716085566 0.06299599 ns
Q13185 CBX3 32.55944419 47.54 9 11 0.664523165 0.02731657 *
Q9NP72 RAB18 32.54373157 47.57 9 10 0.829421068 0.17956002 ns
H0YBJ4 MATN2 32.52951717 18.19 1 13 0.590911263 0.02381204 *
O14737 PDCD5 32.52274561 45.6 8 8 1
Q14444 CAPRIN1 32.48652244 10.58 9 9 0.566600567 0.01967668 *
Q08AF3 SLFN5 32.48587561 15.6 13 14 1
Q15057 ACAP2 32.46284294 14.4 12 12 0.706852538 0.14660452 ns
O43747 AP1G1 32.43104136 12.04 12 13 0.890374755 0.24969801 ns
Q9P2R3 ANKFY1 32.38950658 11.46 11 13 0.983484783 0.37390097 ns
Q6EMK4 VASN 32.38617253 17.38 11 11 0.284373272 0.00015849 ***
Q9BVJ8 HEXA 32.36448812 29.34 11 12 0.611123095 0.00758881 **
Q9UN86 G3BP2 32.34110737 21.99 10 11 0.945303758 0.37390097 ns
P38919 EIF4A3 32.32304907 21.17 7 10 1
P09661 SNRPA1 32.30079579 41.18 11 11 0.595967079 0.00015933 ***
P04424 ASL 32.2383374 27.59 12 12 1.103055587 0.08310969 ns
Q96T51 RUFY1 32.22537482 17.51 11 13 0.962644124 0.37390097 ns
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Q8N4P8 GTPBP4 32.17783678 17.88 11 12 0.983422256 0.16224364 ns
P40763 STAT3 32.16469884 14.16 10 11 0.518918045 0.00099637 ***
O75947 ATP5H 32.14869833 45.96 8 9 0.59773669 0.00046264 ***
Q96RP9 GFM1 32.10989952 16.25 1 13 0.37390097 ns
Q9UPT5 EXOC7 32.08785796 16.19 11 11 1
Q06323 PSME1 32.07900715 48.59 13 13 0.81801183 0.03519762 *
P67775 PPP2CA 32.01972425 41.42 1 10 1
Q6NX51 EXOC4 32.01710808 14.07 13 13 0.777129198 0.02944828 *
A5PLK7 RCC2 31.96793592 23.85 10 10 0.906362651 0.3105979 ns
P50452 SERPINB8 31.94906545 30.48 11 13 0.686308374 2.8921E-05 ***
P25789 PSMA4 31.91953611 34.87 11 11 1.020849141 0.88982121 ns
P54687 BCAT1 31.90304291 17.62 8 8 1.836965354 0.1888629 ns
O00232 PSMD12 31.90297437 26.32 10 12 0.994128869 0.82624084 ns
C1KJK7 HLA-A 31.89236689 38.67 0 7 0.37390097 ns
A0A024R529 DAK 31.78817916 20.7 10 10 1
Q9UJZ1 STOML2 31.78512049 34.27 11 11 0.546917212 0.00359409 **
P30566 ADSL 31.74935651 23.35 11 11 1
Q3B874 STRN 31.70114851 17.09 9 12 1
E9PFR3 PPP2R5D 31.69478858 21.55 9 12 1.008804838 0.37390097 ns
E5KND7 GFM1 31.68201017 16.25 1 13 1
P0CW22 RPS17L 31.67376351 45.93 8 9 0.87073838 0.31329641 ns
B8ZZU8 TCEB2 31.65570021 54.87 6 6 1.048598153 0.25654008 ns
Q9H6X2 ANTXR1 31.64629638 18.97 9 10 0.320884321 0.00030388 ***
Q9BTV4 TMEM43 31.64007545 23.25 9 10 0.588373342 1.4089E-06 ***
G8JLG1 SMC1A 31.63903069 11.73 15 15 0.940391471 0.37134761 ns
P12004 PCNA 31.62953305 42.15 11 11 0.855922985 0.29803026 ns
O75400 PRPF40A 31.6008513 8.67 10 10 0.500427247 4.112E-05 ***
C9J712 PFN2 31.59997463 74.73 4 8 1.071654226 0.14102116 ns
P68036 UBE2L3 31.58882689 42.86 3 8 1.029588763 0.91176802 ns
E9PPJ5 MDK 31.51809144 61.07 9 9 3.645394328 0.07022279 ns
Q96A33 CCDC47 31.42645574 26.5 12 12 0.905886748 0.11867909 ns
Q9H3P7 ACBD3 31.40539253 21.21 9 9 0.992485252 0.37390097 ns
A0PJ92 NOP56 31.39938641 25.5 12 12 0.735338909 0.06730888 ns
Q5QNZ2 ATP5F1 31.2984935 29.23 7 7 0.57086081 0.00014173 ***
Q8N0Y7 PGAM4 31.28821492 26.77 1 6 1.010581787 0.37390097 ns
B7ZKK7 EIF2AK2 31.28203344 18.68 10 10 0.942308157 0.01803925 *
P63173 RPL38 31.23867154 42.86 4 5 0.556591766 0.01613117 *
P17948 FLT1 31.17425239 8.97 12 13 0.707527203 1.1982E-05 ***
B4E043 KHDRBS1 31.14391983 17.87 6 9 1
Q92609 TBC1D5 31.08004093 14.97 10 10 1
Q8TAT6 NPLOC4 31.02178097 17.76 12 12 1.007465948 0.83900693 ns
P61970 NUTF2 30.99466133 34.65 3 4 0.863676552 0.16803894 ns
Q0PHV0 HLA-B 30.99440742 42.54 0 7 0.37390097 ns
P12931 SRC 30.98775291 22.39 5 11 0.931961611 0.25649597 ns
Q13242 SRSF9 30.98380744 42.99 10 10 0.990438761 0.37390097 ns
P30048 PRDX3 30.97947741 31.64 8 8 0.762153448 0.00087419 ***
Q9UNE7 STUB1 30.97360682 35.97 11 12 0.998975499 0.37390097 ns
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P43490 NAMPT 30.95937359 25.87 12 12 0.699095054 0.00218264 **
P16333 NCK1 30.75835848 27.85 8 10 0.986462459 0.37390097 ns
P48739 PITPNB 30.74430537 35.79 6 10 0.855614945 0.31680819 ns
B2RMN7 SPTB 30.69524097 3.7 1 11 0.37390097 ns
Q96G03 PGM2 30.68490744 14.38 7 9 0.635243818 0.00271298 **
Q31612 HLA-B 30.64455676 32.51 0 8 0.37390097 ns
O00148 DDX39A 30.56325734 20.14 1 10 1
Q4KMQ2 ANO6 30.52022672 12.64 13 13 0.353809126 4.0222E-06 ***
P04181 OAT 30.51305664 17.77 10 10 0.556210257 0.01108233 *
C9J0K6 SRI 30.48727942 63.87 9 9 0.663583043 0.00358318 **
Q9NTZ6 RBM12 30.47421467 10.52 9 10 1
B0QYK0 EWSR1 30.46820116 19.09 10 10 1
P02458 COL2A1 30.4675144 5.31 1 6 0.316241918 2.0283E-05 ***
P25685 DNAJB1 30.46667361 32.35 10 11 0.585040106 0.00019591 ***
K7ERI7 RPL22 30.42252755 44.21 5 5 0.628442597 0.00889998 **
Q15181 PPA1 30.41729331 33.56 7 8 1.010624857 0.85402126 ns
A0A024QZJ7 CCDC6 30.40591192 20.04 10 10 0.93316726 0.22477404 ns
O75821 EIF3G 30.40334725 32.19 10 10 0.972958865 0.66676592 ns
G3V203 RPL18 30.40209138 43.9 8 8 0.935450187 0.37390097 ns
P61619 SEC61A1 30.35184717 17.23 10 10 0.879855494 0.3803541 ns
Q07812 BAX 30.34377635 35.94 5 5 1
Q9ULC3 RAB23 30.3030014 40.51 8 8 1
O43290 SART1 30.29833996 15.13 9 11 0.966522626 0.37390097 ns
Q13217 DNAJC3 30.27003872 22.42 11 12 0.743191788 0.1251071 ns
A5PKX5 MAN2A1 30.26864111 10.06 11 11 1.121132772 0.37390097 ns
Q5FYB0 ARSJ 30.26619935 14.86 11 11 3.914305943 0.00802979 **
D3YTB1 RPL32 30.26444745 45.86 8 8 0.910737398 0.49078598 ns
Q14573 ITPR3 30.20138359 3.93 10 11 0.756752679 0.00823942 **
Q9H3N1 TMX1 30.19079351 19.64 7 7 0.494131417 0.00046737 ***
A0A024R258 UBQLN1 30.17786384 16.58 2 7 0.912851989 0.37390097 ns
A4D0Y7 LOC392781 30.14054871 24.48 1 5 1
P49841 GSK3B 30.12739182 29.76 5 9 0.860022487 0.17375697 ns
P16435 POR 30.11532617 17.28 12 12 0.930352353 0.28693065 ns
O15187 TIAL1 30.08958149 24.15 4 9 0.431147667 0.00111274 **
Q9UBE0 SAE1 30.08075833 21.1 9 9 0.805903103 0.17828923 ns
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AAK1 ATP5B CS ENO1 HIP1 MDH2 PCK2 RAB5C RPS3A TJP1
ABCC1 ATP5F1 CSDA EPB41L2 HMGA1 MEGF6 PDAP1 RAB7A RPS4X TLN1
ABCC4 ATP5H CSPG4 EPHA2 HSD17B10 MME PDGFRB RAB8A RPS5 TLN2
ABCF2 ATP5L CSRP2 EPRS HSP90AA1 MMP14 PDHB RAC1 RPS7 TMEM2
ACAT1 ATP5O CTNNA1 ERP29 HSPA5 MOXD1 PDIA3 RAC2 RPS8 TMEM43
ACTA2 BASP1 CTNND1 FAM129B HSPA8 MPRIP PDIA6 RAI14 RPS9 TNC
ACTBL2 C1ORF198 CTSD FAM62A HSPB1 MRC2 PDLIM1 RALA RRAS TNKS1BP1
ACTN1 CACNA2D1 CTTN FAM98A HSPD1 MSN PDLIM4 RAN RRAS2 TNS1
ACTN4 CALD1 CTTNBP2NL FAP HSPG2 MVP PDLIM5 RAP1B RSU1 TNS3
ACTR2 CALU CYB5R3 FARP1 HYOU1 MXRA5 PDLIM7 RDX RTN4 TPD52L2
ACTR3 CANX CYCS FBLIM1 ICAM1 MXRA8 PEBP1 RFTN1 S100A10 TPM1
ADAM9 CAPN1 CYFIP1 FERMT2 IDH2 MYH10 PFN1 RHOA S100A11 TPM2
ADAMTSL4 CAPRIN1 DAG1 FHL1 ILK MYH9 PGK1 RHOG S100A13 TPM3
ADD1 CAPZA1 DBN1 FHL2 INF2 MYL6B PGRMC2 RND3 S100A4 TPM4
AFAP1 CAPZB DDAH2 FLNA IQGAP1 MYL9 PHB RPL10A S100A6 TRIOBP
AGRN CASK DDX1 FLNB ITGA2 MYLK PHB2 RPL12 SCRIB TRIP6
AHNAK CAT DDX3X FLNC ITGA4 MYO1B PHLDB1 RPL13A SCUBE3 TUBB
AKAP12 CAV1 DDX3Y FLOT1 ITGAV MYO1C PICALM RPL18 SERBP1 UACA
ALCAM CC2D1A DECR1 FLOT2 ITGB1 NCKAP1 PKM2 RPL19 SF1 UBAP2L
ALDH7A1 CCDC124 DLG1 FLT1 ITGB3 NDUFV1 PLS3 RPL22 SFPQ UGDH
ALDOA CD109 DNAJC3 FMN2 ITGB5 NES PLXNA1 RPL27 SIPA1L1 UQCRC1
ANO6 CD248 DNAJC8 FXR2 JUP NEXN PLXNB2 RPL3 SLC25A3 UQCRC2
ANPEP CD44 DNM2 G3BP1 KANK2 NME1 PPFIBP1 RPL30 SLC25A5 UTRN
ANXA1 CD59 DOCK7 G3BP2 KIRREL NOTCH2 PPP1CB RPL38 SLC7A5 VAPB
ANXA2 CDC42 DPP4 GANAB KLC1 NPM1 PPP1CC RPL4 SLC9A3R2 VASN
ANXA5 CDC42BPB DST GAPDH L1CAM NPTN PPP1R12C RPL5 SNAP23 VASP
ANXA6 CDH2 DSTN GARS LACTB NQO1 PRDX1 RPL6 SNTB1 VCL
AP2A1 CFL1 DYNC1LI2 GDI2 LAP3 NRP1 PRDX3 RPL7 SNTB2 VDAC1
AP2A2 CKAP4 DYNLL1 GIT2 LASP1 NUFIP2 PRDX4 RPL7A SPTAN1 VDAC2
AP2B1 CLIC1 ECHS1 GNA13 LDHA NUMB PRDX6 RPL8 SPTBN1 VDAC3
AP2M1 CLIC4 EEF1A1 GNAI2 LIMCH1 OGDH PRKCDBP RPL9 STOML2 VIM
ARHGEF2 CLTC EEF2 GNAQ LIMS1 OLA1 PTK7 RPLP2 STX12 WARS
ARPC1B CNN1 EHD1 GNAS LMNA P4HA1 PTRF RPN1 STXBP1 WDR1
ARPC2 CNN2 EHD2 GNB2 LMO7 P4HA2 PXDN RPS10 SYNPO YWHAB
ARPC5 CNN3 EHD3 GNG12 LPP P4HB PXN RPS11 SYNPO2 YWHAE
ASPH CNP EHD4 GOT2 LRP1 PABPC1 RAB10 RPS13 TAGLN YWHAG
ATL3 COMT EIF3B GPC1 LRPPRC PACSIN2 RAB11FIP5 RPS14 TAGLN2 YWHAQ
ATP1A1 CORO1B EIF3E GSTP1 LRRC59 PACSIN3 RAB14 RPS16 TCEB2 YWHAZ
ATP1B3 COTL1 EIF4H HADHB LUZP1 PALLD RAB18 RPS18 TENC1 ZYX
ATP2B1 COX5A ELAVL1 HDLBP MACF1 PARK7 RAB1B RPS19 TFRC
ATP2B4 CPNE1 ENAH HEXB MAP4 PARVA RAB23 RPS2 TGFB1I1
ATP5A1 CPNE3 ENG HIBADH MARCKS PCBP2 RAB35 RPS3 TGM2
Supplementary Table 3:
Adhesion fraction proteins also reproducibly 
detected in adhesions by Kuo et al
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Supplementary Table 4: Proteins matching Naba et al's matrisome
Proteins detected 
matching those 
predicted as core 
matrisome proteins by 
Naba et al
Of which, detected with 
reduced abundance in 
TMEM67
Detected ECM 
glycoproteins
Detected collagens
ECM glycoproteins with 
reduced abundance in 
TMEM67
Collagens with reduced 
abundance in TMEM67
Detected proteins 
matching lung ECM 
(Naba et al )
AGRN COL12A1 AGRN COL11A1 EMILIN2 COL12A1 ADAMTSL1
COL11A1 COL1A1 CYR61 COL12A1 FBLN1 COL1A1 AGRN
COL12A1 COL2A1 EDIL3 COL1A1 FBN1 COL2A1 ANXA1
COL1A1 COL6A1 EFEMP2 COL1A2 FBN2 COL6A1 ANXA2
COL1A2 COL6A2 EMILIN1 COL2A1 FN1 COL6A2 ANXA5
COL2A1 COL6A3 EMILIN2 COL3A1 IGFBP5 COL6A3 ANXA6
COL3A1 EMILIN2 FBLN1 COL5A1 IGFBP7 COL12A1
COL5A1 FBLN1 FBLN2 COL5A2 LAMA2 COL1A1
COL5A2 FBN1 FBN1 COL6A1 LAMB1 COL1A2
COL6A1 FBN2 FBN2 COL6A2 LAMB2 COL3A1
COL6A2 FN1 FN1 COL6A3 LAMC1 COL5A1
COL6A3 HSPG2 IGFBP3 LTBP1 COL5A2
CYR61 IGFBP5 IGFBP5 MATN2 COL6A1
EDIL3 IGFBP7 IGFBP7 MXRA5 COL6A2
EFEMP2 LAMA2 LAMA2 NID2 COL6A3
EMILIN1 LAMB1 LAMA4 PCOLCE CSPG4
EMILIN2 LAMB2 LAMA5 SLIT3 EFEMP2
FBLN1 LAMC1 LAMB1 THBS1 EMILIN1
FBLN2 LTBP1 LAMB2 THBS2 EMILIN2
FBN1 MATN2 LAMC1 FBLN1
FBN2 MXRA5 LTBP1 FBLN2
FN1 NID2 LTBP2 FBN1
HSPG2 PCOLCE LTBP4 FN1
IGFBP3 SLIT3 MATN2 HSPG2
IGFBP5 THBS1 MXRA5 HTRA1
IGFBP7 THBS2 NID1 IGFBP7
LAMA2 NID2 ITIH2
LAMA4 PCOLCE LAMA2
LAMA5 POSTN LAMA4
LAMB1 PXDN LAMA5
LAMB2 SLIT2 LAMB2
LAMC1 SLIT3 LAMC1
LTBP1 SPARC LOX
LTBP2 TGFBI LOXL1
LTBP4 THBS1 LTBP1
MATN2 THBS2 LTBP2
MXRA5 THSD4 LTBP4
NID1 TNC NID1
NID2 PLOD3
PCOLCE PLXNB2
POSTN POSTN
PXDN PXDN
SLIT2 S100A11
SLIT3 S100A13
SPARC SEMA3C
TGFBI SERPINH1
THBS1 TGFBI
THBS2 TGM2
THSD4 THBS1
TNC VCAN
VCAN
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Detected proteins 
matching colon ECM 
(Naba et al )
Proteins matching colon 
ECM (Naba et al ) with 
reduced abundance in 
TMEM67
Proteins matching colon 
ECM (Naba et al ) with 
reduced abundance in 
TMEM67
ADAMTSL1 ANXA1 ANXA1
AGRN COL12A1 COL12A1
ANXA1 COL1A1 COL1A1
ANXA2 COL6A1 COL6A1
ANXA6 COL6A2 COL6A2
COL12A1 COL6A3 COL6A3
COL1A1 CSPG4 CSPG4
COL1A2 EMILIN2 EMILIN2
COL5A1 FBLN1 FBN1
COL5A2 FBN1 FN1
COL6A1 FN1 HCFC1
COL6A2 HSPG2 HSPG2
COL6A3 HTRA1 IGFBP7
CSPG4 IGFBP7 LAMA2
EMILIN1 LAMA2 LAMB2
EMILIN2 LAMB2 LAMC1
FBLN2 LAMC1 LTBP1
FBN1 LTBP1 MATN2
FN1 PLXNB2 PLXNB2
HSPG2 SEMA3C TGM2
IGFBP7 TGM2
ITIH2 THBS1
LAMA2
LAMA4
LAMA5
LAMB2
LAMC1
LOXL1
LTBP1
LTBP4
NID1
PLXNB2
POSTN
PXDN
S100A11
SERPINH1
TGFBI
TGM2
VCAN
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Analysis of high-throughput datasets 
Summary 
The era of high-throughput “-omics” approaches to data acquisition has created an 
environment in which many biologists find themselves “data-rich but knowledge-poor” due 
to the difficulty of extracting meaningful information from vast datasets. This is especially 
true in the case of centriole biology, where there has been a surge in publication of high-
throughput studies. Here, we describe two approaches for analysis of high-throughput 
datasets: functional annotation clustering, which can be used to analyse lists of genes in the 
context of gene annotation databases; and pathway mapping, which can be used to visualise 
expression changes in the context of interactome databases. We approach these from the 
context of differential gene expression, but both are applicable to proteomic or other analyses 
that produce similar datasets. 
Introduction 
Centrioles have been studied since the early era of cell biology in the 19
th
 century due to their 
central role in cell division
1
. The fundamental research questions – how do centrioles 
function in mitosis? What is their molecular structure? How do they replicate? – have 
remained relevant
2
, but the tools used to study them have changed profoundly. Since the 
advent of genomics, proteomics and other high-throughput approaches, many studies have 
applied these tools to the centrioles
3–9
 and generated rich datasets. Analysis of these datasets 
in the context of ever-increasing information about all cellular and biological processes 
requires new approaches. A researcher may be tempted to “eyeball” the data, manually 
searching it for interesting alterations. This can be a productive approach if the dataset is 
small or if only a few transcripts exhibit large changes in expression, but as datasets grow to 
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the hundreds or thousands of transcripts, manual analysis becomes increasingly prone to 
confirmation bias (where the researcher takes note only of changes that are consistent with 
their working hypothesis), and may miss important changes in less obvious molecular 
pathways. Furthermore, when trying to map expression changes onto signalling pathways, the 
complexity of the pathways themselves often precludes manual analysis.  
Fortunately, tools to assist and automate these analyses have been developed. To illustrate the 
use of these analytical tools, we present basic tutorials for functional annotation clustering 
using the online DAVID resource and pathway mapping using the free, open source software 
package Cytoscape. 
Gene set enrichment analysis and functional annotation clustering 
Set enrichment analysis (or category over-representation analysis) is a statistical technique 
designed to identify categorical bias within lists. Gene set enrichment analysis takes as an 
input a list of genes, relates them to annotations in an annotation database (e.g. gene 
ontology), and identifies within the gene list annotations that are overrepresented in 
comparison to what would be expected in a randomly chosen list of genes from the same 
background (see Note 1). 
Functional annotation clustering analysis is a refinement of this technique that identifies 
similar annotations within and across annotation databases and clusters them together, then 
reports an enrichment score for the entire cluster, rather than for each annotation individually 
(see Note 2). This improves human readability of the data and helps reveal underlying 
biology by eliminating the problem of overrepresentation of redundant annotations; for 
example, where a simpler analysis might show enrichment separately for the GO terms 
“centrosome cycle”, “centrosome organization”, and “microtubule organizing center 
organization”, a functional annotation cluster combines all three as essentially equivalent and 
reports an overall enrichment score (Fig. 1). 
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Figure 1: Example functional annoatation clusters 
 This approach is ideal for examining large differential gene expression datasets that are 
difficult to interpret manually. It is possible to quickly identify the overall patterns within the 
data, such as particular molecular pathways that may be altered, and to find the genes of most 
interest. However, basic set enrichment analysis has a number of limitations that result from 
its simplified input: since it takes only a list of genes and no further attributes, the analysis 
cannot take into account information such as whether a particular gene was up- or 
downregulated, or the degree of altered expression (i.e. fold change). Care must therefore be 
taken to consider the biological question being asked when choosing the list of genes to 
submit for set enrichment analysis. It may be appropriate to separately submit lists of up- and 
downregulated genes from a dataset to identify which processes are activated and which are 
suppressed under the experimental conditions; conversely, if you suspect, for example, 
dysregulation of a particular signalling pathway where some of the pathway-associated 
transcripts are upregulated and others are downregulated, submitting the entire list of 
differentially expressed genes may increase the chance of identifying the pathway (see Note 
3). 
Gene set enrichment analysis makes the assumption that, under the null hypothesis, all genes 
are equally likely to be selected by chance as significantly altered in expression. This is a safe 
assumption for datasets such as those from microarray experiments, but due to the technical 
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details of RNA-seq differential expression analysis it is not a safe assumption for these 
datasets, which are more likely to report significant differences in high-abundance transcripts 
and long transcripts. This bias should be corrected for with an additional data processing step; 
for example, the GOseq method
10
. 
DAVID (the Database for Annotation, Visualisation and Integrated Discovery; 
david.ncifcrf.gov) is an online tool for automated gene set enrichment and functional 
annotation clustering analysis. The following is a step-by-step guide to basic analysis of a 
gene list using this tool (written for DAVID version 6.7; be aware that later versions may 
introduce changes in the interface). Much more comprehensive documentation is available 
within the DAVID website’s Help and Tool Manual section, and in Huang et al11. 
Materials 
A computer with at least 1 GHz CPU and 1 GB of memory, running at least Windows 
2000/XP or Mac OS 10. 
A web browser. DAVID recommends Internet Explorer 6.0 or higher, Firefox 1.5 or higher, 
Netscape 8.0 or higher, or Safari. Google Chrome is not officially recommended but appears 
to work without issue (version 49.0). 
An internet connection (broadband recommended).  
A list of gene identifiers in an appropriate format (eg Affymetrix ID, Ensembl gene ID). 
Method 
Submitting a gene list to DAVID 
1. On the DAVID homepage (david.ncifcrf.gov), select “Start Analysis” from the top menu. 
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2. Under “Step 1: Enter Gene List” on 
the left panel (. 2), either paste your gene list 
into box A, or upload a file using the “Choose 
file” button. 
3. Under “Step 2: Select Identifier” on 
the left panel, select the correct identifier for 
your gene list from the drop-down menu. In 
the example image (Fig. 2), a gene list has 
been entered using Ensembl IDs, and 
therefore “Ensembl gene ID” has been 
selected as the identifier. A variety of other 
identifiers can be used with DAVID including 
Affymetrix and Entrez IDs (see Note 4).  
4. Under “Step 3: List Type”, Select 
“gene list”. 
5. Click the “Submit List” button under 
“Step 4: Submit List”. Uploading the list may 
take a few seconds depending on connection 
speed. Once the upload is complete, the Gene 
List Manager will open (. 3, left). In the Gene 
List Manager, select a species to limit your 
analysis to, or opt to use all species, by selecting the option in the list and pressing the 
“Select Species” button. 
Figure 2: Upload a gene list 
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6. In most cases, DAVID will automatically select an appropriate background. If this is not 
already shown, click “Start Analysis” on the top menu, which will display the Analysis 
Wizard and the current background. (Once a gene list has been uploaded, the “Start 
Analysis” button will take you to the Analysis Wizard instead of the upload panel). In the 
example image (Fig. 3), a gene list has been successfully submitted and the background 
correctly recognised as Homo sapiens. If you wish to manually select the background, 
this can be done via the “Background” tab above the Gene List Manager (see Note 5). 
 
Figure 3: Gene List Manager and Analysis Wizard 
Analysing the sequencing-derived gene list 
1. To begin analysing your gene list, select “Functional Annotation Tool” in the 
Analysis Wizard (Fig. 3, right). This will take you to the Annotation Summary 
Results page (Fig. 4). This page contains many options; click the “Help and Tool 
Manual” link at the right for an explanation of what the various options and numbers 
mean. A similar link is available on most of the analysis pages.  
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2. Each line in this list represents a set of annotation categories. To expand one of the 
sets and see the individual categories, click the small grey plus symbol next to it. 
 
Figure 4: Annotation Summary Results 
3. Within an expanded set, click the “Chart” button next to a category to see the detailed 
report, which will open in a new window. This displays the annotation categories that 
are enriched in your gene list for this particular annotation category. This data can be 
downloaded (as a tab-delimited text file) for further analysis by clicking “Download 
File” at the top right of the chart. By default, the chart is sorted by P-value; click the 
column header to sort by another column. 
Functional annotation clustering  
1. So far we have looked only at results within one annotation category. To combine 
information from multiple annotation categories, they must be selected on the 
Annotation Summary Results page (Fig. 4). This is done by clicking the box to the 
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left of the category name so that a tick appears. DAVID has a default set of categories 
which are selected initially; these can be deselected if desired. 
2. To see the functional annotation clustering report on the selected categories, click the 
Functional Annotation Clustering button toward the bottom of the Annotation 
Summary Results page (Fig. 4). It may take a few seconds for the report to display. 
Each cluster represents multiple related annotations, potentially from different 
annotation categories (Fig. 1). The Enrichment Score for each cluster indicates how 
highly the set of proteins matching the cluster annotations are enriched; higher is 
more enriched (see Note 6). The list of proteins associated with a cluster can be 
viewed by clicking on the red “G”. As before, these data can be downloaded in their 
entirety via the link at the top-right of the table for analysis in an external application 
(see Note 7).  
Pathway mapping in Cytoscape 
Cytoscape (www.cytoscape.org) is a free and open source software platform for visualisation 
of networks. Cytoscape has a number of features built-in to allow rapid import and 
visualisation of biological interaction networks, and it is possible to visually overlay 
differential expression data onto these networks. This is a powerful way to put gene 
expression changes in the context of wider biological systems. The quality and completeness 
of information in public interaction databases is variable, however, so interpretation can be 
challenging, especially when investigating less well-studied parts of the interactome. 
The following is a guide to quickly set up Cytoscape to visualise differential expression (see 
Note 8). Cytoscape is a complex program with much more functionality than is described 
here; a complete manual is available at the official Cytoscape wiki (wiki.cytoscape.org). 
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Materials 
A PC or Mac running Windows, Linux, or Mac OS X. Cytoscape will run on most 
computers, but its resource demands scale with the data analysed; even high-performance 
machines may struggle with the memory and processing requirements of very large or highly 
interconnected interaction networks. 
A broadband internet connection 
Cytoscape (free to download from www.cytoscape.org). 
A gene expression dataset, properly formatted for import into Cytoscape (see 
wiki.cytoscape.org/Cytoscape_User_Manual/Expression_Data). 
 
Figure 5: Import Network from Web Service 
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Method 
Loading an interaction network into Cytoscape 
1. Start Cytoscape and select File > Import > Network > Public Databases… 
2. This invokes the “Import Network from Web Service” window (. 5). Type a protein 
name (or official gene symbol; e.g. “centrin 2” or “CETN2”) into the search box and 
click the “Search” button. This will poll a set of online databases; it may take some 
time for all the databases to respond, depending on competing requests and your 
connection speed.  
3. A list of databases containing interactions involving your protein of interest will 
appear. In the example image (Fig. 5), interaction records have been found in eight 
databases, with the most in the “mentha” interactome database.  
4. Select the databases you wish to retrieve interaction networks from by clicking the 
checkboxes in the “Import” column, or press the “Select All” button beneath. 
Databases with no results for your search query will be automatically excluded. You 
may wish to exclude databases that do not contain information relevant to your 
research question even if there were matches for your protein of interest. 
5. If you have selected multiple databases, Cytoscape can automatically merge the 
interaction networks together (see Note 9). Click the checkbox next to “Automatic 
Network Merge” at the bottom of the Import window to toggle this function. 
6. Click “Import”. Cytoscape will retrieve the interactions and build the network, then 
confirm by displaying an “Import Finished” dialog box. Click “close” to dismiss this 
box. 
7. The network will now appear visualised in the largest panel of the Cytoscape interface 
(. 6). Proteins and other entities (such as complexes and functional RNAs) are 
represented by default as rectangles; Cytoscape terms these “nodes”. Interactions 
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between nodes are represented by lines; Cytoscape terms these “edges” (following the 
terminology used in graph theory). 
 
Figure 6: CETN2 network visualised in Cytoscape 
8. Information about nodes and edges can be seen in the Table Panel to the bottom of the 
Cytoscape interface (. 6). Click and drag over the network visualisation to bandbox-
select multiple nodes and edges. Attributes of only the selected nodes will appear in 
the Table Panel. Switch to the “Edge Table” tab at the bottom of the Table Panel to 
see the attributes of the selected edges instead (see Note 10).  
Importing gene expression data into an interaction network 
1. Load an interaction network that contains at least some of the genes in your 
expression dataset (see Note 11).  
2. Prepare a text file with your expression data according to the Cytoscape expression 
data file format (see wiki.cytoscape.org/Cytoscape_User_Manual/Expression_Data). 
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The simplest way to input this data is as a list of genes, each with a single associated 
fold change figure; the rest of these instructions will assume this. 
3. In Cytoscape, select File > Import > Table > File… 
4. In the dialog box, select your expression data file. 
 
Figure 7: Import Columns From Table 
5. The “Import Columns From Table” dialog box should appear (. 7). Under “Key 
Column for Network”, ensure that the correct key is selected. In this case, gene 
symbols have been used as identifiers; the corresponding option in Cytoscape is 
“Human Readable Label”.  
6. Click “OK” (see Note 12).  
7. Verify that the expression data has been imported correctly by selecting a node in the 
interaction network representing one of the differentially expressed genes. A new 
column in the Node Table should have appeared showing the transcript’s expression 
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value. If this does not appear, click the gear icon at the top right of the Table Panel 
and select “show all” to make sure all columns are displayed. 
 
Figure 8: Continuous Mapping Editor 
 Visualising gene expression changes in an interaction network 
1. With an interaction network loaded and a set of expression data imported, right click 
on the network’s entry in the “Network” tab of the “Control Panel” toward the left of 
the Cytoscape window. 
2. Select “Apply Style…” and choose one of the options. Try selecting several different 
options. Observe how the network’s appearance changes – these are “Visual Styles” 
that control the graphical representation of the network without affecting its 
underlying data or its arrangement. To visualise your fold change data, you can edit 
the Visual Style settings so that node colour is controlled by the value of the fold 
change attribute. 
3. Select the “Style” tab at the top of the Control Panel (Fig. 8). 
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4. Either select an existing visual style to modify with the drop-down menu or create a 
new style by clicking the arrow button to the right of the drop-down menu. 
5. In the Style tab, select “Fill Color”  
6. If not already expanded, expand “Fill Color” by clicking the arrow. 
7. Set the default colour to white by clicking the rightmost box next to “Fill Color” and 
choosing white. 
8. To the right of “Column”, select your expression attribute. 
9. To the right of “Mapping Type”, select “Continuous Mapping”. This will apply a 
colour to the nodes that depends on the value of their associated expression attribute. 
By default the colour varies from black (low numbers) to white (high numbers). 
10. Click on the gradient image to the right of “Current Mapping” to open the Continuous 
Mapping Editor (Fig. 8), which allows you to alter the colours used and the way the 
gradient varies with the expression values.  
11. Double-click the arrows at the top of the gradient display to modify their colour. Try 
changing the gradient from black/white to red/green so that upregulated genes and 
downregulated genes are clearly distinguished. You may also want to modify the 
gradient so that “no change” has a neutral colour; new arrows can be placed with the 
“Add” button to create a series of gradients. 
12. To view the expression changes overlaid on a network, go to the Network tab and 
switch the network’s Visual Style to your modified Visual Style. Nodes with no 
associated expression will remain white, while nodes with altered expression will 
become appropriately coloured. 
13. The network can now be analysed visually: for example, if a series of connected 
nodes are all coloured to indicate expression changes, this may suggest disruption of a 
pathway that merits further analysis. To check the actual expression value of an 
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individual node, select the node and find the expression column in the Node Table tab 
of the Data Panel below the main view. 
14. Now that the custom Visual Style is set and the expression data is loaded, any new 
interaction networks you load can have your expression data overlaid onto them by 
setting the Visual Style. This can be used to rapidly examine candidate pathways for 
patterns of altered expression (see Note 13).  
Notes 
Note 1: The background is a list of all the potential genes that could have appeared in the list 
under analysis; for example, the entire human genome, or a list of the genes that were 
detectable in principle in a particular experiment; for example, if your experiment was a 
microarray, it would be appropriate to use as a background the list of all transcripts probed 
for on the array, whereas if it was a whole-transcriptome mRNA-seq experiment, the entire 
genome would be the background. 
Note 2: A functional annotation cluster is therefore a cluster of annotations, not a cluster of 
genes; a cluster may have many associated differentially expressed genes or only one, and the 
annotations may have genes in common – in the extreme case, you may have a cluster with 
many annotations, each of which is associated with a few genes shared between all of them. 
Whether any cluster is biologically meaningful is dependent upon many factors including the 
quality of the underlying data and annotation databases; therefore interpretation may be 
required. 
Note 3: Keep in mind that “enrichment” is not equivalent to upregulation. If analysing a list 
of downregulated genes, the “most enriched” annotations are likely ones for which many 
genes are downregulated. If analysing a list of up- and downregulated genes, the most 
enriched annotations may represent any pattern of alteration to the associated genes; for 
example, half may be upregulated and half downregulated. 
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Note 4: While it is possible to use official gene symbols with DAVID, this is not 
recommended because they require conversion and are sometimes ambiguous. If another 
form of IDs are available for your gene list, those should be used in preference. 
Note 5: As described above (Note 1), the background is a list of all the potential genes that 
could have appeared in the list under analysis, and will depend on the nature of your dataset.  
Note 6: DAVID calculates enrichment scores as the geometric mean of the p-values of all 
members of the cluster, expressed in –log scale, so in technical terms, higher enrichment 
scores indicate lower probability that the observed overrepresentation of genes associated 
with the cluster would occur purely by chance. 
Note 7: Various options are available to fine-tune the results of DAVID’s functional 
annotation clustering. The most prominent is the “Classification Stringency” (controlled by a 
drop-down list found at the top of the Functional Annotation Clustering results list). Higher 
stringency groups annotations into smaller, more closely-related clusters, whereas lower 
stringency will result in clusters with more, less closely-related annotations. Either may be 
appropriate depending on your dataset; if, for example, you find that DAVID is forming 
functional annotation clusters out of groups of annotations that should, for the purposes of 
your analysis, be considered separately, increasing stringency may help. More advanced 
options to fine-tune clustering are available within “Options” next to the Classification 
Stringency drop-down list. 
Note 8: These instructions were written for Cytoscape version 3.3.0. If you are using a future 
version, or an earlier version for legacy or compatibility reasons, the details of some dialog 
boxes and options may differ.  
Note 9: merging networks is useful as it reduces redundancy in the resulting network and 
may indicate the presence of pathways by showing chains of connections not apparent in the 
individual databases. However, due to incompatibilities between different databases, 
302
  
automatic merging is not always completely successful. It may be necessary to manually fix 
errors in a combined network, such as multiple nodes for a single protein. 
Note 10: Understanding what a particular edge represents can be especially important when 
trying to interpret an interaction network, as several very different kinds of relationship are 
represented this way: for example, an “in_same_component” relationship may indicate two 
proteins are part of a complex, whereas a “reacts_with” relationship indicates chemical 
interaction. 
Note 11: In previous versions of Cytoscape, it was necessary to load a network prior to 
importing expression data, because any expression data that did not relate to a node currently 
loaded in Cytoscape would not be imported, resulting in missing values when loading further 
interaction networks. This behaviour was corrected in Cytoscape version 3.1, so expression 
data and interaction networks can now be imported in any order. 
Note 12: Errors at this stage are often due to the delimiter setting, which defines which 
character separates entries in the data file (often tab or space characters, which can be easily 
confused as they are both rendered as whitespace). If your file fails to import, check the 
“Advanced Options…” dialog and ensure that the set delimiter matches the delimiter used in 
your expression data file. 
Note 13: to improve readability of cluttered networks, it may be desirable to delete nodes that 
appear irrelevant; for example, nodes representing non-proteins, or proteins that have no 
expression data in your dataset. This may, however, obscure connections between relevant 
nodes that were linked via the deleted nodes, so should be done with caution. 
Figure legends 
Figure 1 – Examples of functional annotation clusters generated by DAVID. The first 
cluster combines three different Biological Process GO annotations pertaining to the 
centrosome into a single centrosome-related annotation cluster. In the second cluster, five 
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Cellular Component GO annotations and one Protein Information Resource annotation have 
been clustered as they all indicate a similar kinetochore association. The enrichment score for 
each cluster is shown above the list of annotations. 
  
Figure 2 – DAVID’s “Upload Gene List” interface. A list of Ensembl gene IDs has been 
entered (A: Paste a list) and Ensembl gene ID has been selected as the identifier (Step 2: 
Select Identifier). 
 
Figure 3 – DAVID’s Gene List Manager and Analysis Wizard. The Gene List Manager 
(left pane) allows selection of species to limit annotation searches; the Analysis Wizard (right 
pane) shows the assigned background and options to begin analysis. 
 
Figure 4 – DAVID’s Annotation Summary Results page. This page contains multiple 
categories of analysis, only some of which are selected by default (as shown). 
 
Figure 5 – Cytoscape’s “Import Network from Web Service” window, showing search 
results for centrin 2 (CETN2) from multiple online databases. 
Figure 6 – Cytoscape’s network visualisation. The merged CETN2 interaction network has 
been loaded into Cytoscape and is visualised in the large top-right panel. Proteins are 
represented as rectangles (nodes), and interactions as lines (edges). In the Table Panel 
(bottom-right), node details are displayed. 
Figure 7 – Cytoscape’s “Import Columns From Table” window. A list of gene symbols 
with associated fold change values have been selected for import from an external text file 
and are previewed. 
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Figure 8 – Cytoscape’s Style panel (left) and Continuous Mapping Editor (centre). This 
interface allows you to place node colour under the control of your expression attribute. In 
this example, as expression (fold change) reduces, nodes are coloured darker grey; in the 
network visible to the right, white nodes indicate little or no reduction in expression, and 
darker nodes have greatly reduced expression in this dataset. 
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